There O
is O
a O
single O
methionine O
codon O
- O
initiated O
open O
reading O
frame O
of O
1 O
, O
458 O
nt O
in O
frame O
with O
a O
homeobox O
and O
a O
CAX O
repeat O
, O
and O
the O
open O
reading O
frame O
is O
predicted O
to O
encode O
a O
protein O
of O
51 O
, O
659 O
daltons O
. O

When O
the O
homeodomain O
from O
HB24 O
was O
compared O
to O
known O
mammalian O
and O
Drosophila O
homeodomains O
it O
was O
found O
to O
be O
only O
moderately O
conserved O
, O
but O
when O
it O
was O
compared O
to O
a O
highly O
diverged O
Drosophila O
homeodomain O
, O
H2 O
. O
0 O
, O
it O
was O
found O
to O
be O
80 O
% O
identical O
. O

The O
HB24 O
mRNA O
was O
absent O
or O
present O
at O
low O
levels O
in O
normal O
B O
and O
T O
lymphocytes O
; O
however O
, O
with O
the O
appropriate O
activation O
signal O
HB24 O
mRNA O
was O
induced O
within O
several O
hours O
even O
in O
the O
presence O
of O
cycloheximide O
. O

Characterization O
of O
HB24 O
expression O
in O
lymphoid O
and O
select O
developing O
tissues O
was O
performed O
by O
in O
situ O
hybridization O
. O

Positive O
hybridization O
was O
found O
in O
thymus O
, O
tonsil O
, O
bone O
marrow O
, O
developing O
vessels O
, O
and O
in O
fetal O
brain O
. O

HB24 O
is O
likely O
to O
have O
an O
important O
role O
in O
lymphocytes O
as O
well O
as O
in O
certain O
developing O
tissues O
. O

Platelet B-protein
- I-protein
activating I-protein
factor I-protein
induces O
phospholipid O
turnover O
, O
calcium O
flux O
, O
arachidonic O
acid O
liberation O
, O
eicosanoid O
generation O
, O
and O
oncogene O
expression O
in O
a O
human O
B O
cell O
line O
. O

Platelet B-protein
- I-protein
activating I-protein
factor I-protein
is O
a O
potent O
mediator O
of O
the O
inflammatory O
response O
. O

Studies O
of O
the O
actions O
of O
platelet B-protein
- I-protein
activating I-protein
factor I-protein
have O
centered O
mainly O
around O
neutrophils O
, O
monocytes O
, O
and O
platelets O
. O

In O
this O
report O
we O
begin O
to O
uncover O
the O
influence O
of O
platelet B-protein
- I-protein
activating I-protein
factor I-protein
on O
B O
lymphocytes O
. O

Employing O
the O
EBV O
- O
transformed O
human O
B O
cell O
line O
SKW6 O
. O
4 O
, O
we O
demonstrate O
that O
platelet B-protein
- I-protein
activating I-protein
factor I-protein
significantly O
alters O
membrane O
phospholipid O
metabolism O
indicated O
by O
the O
incorporation O
of O
32P O
into O
phosphatidylcholine O
, O
phosphatidylinositol O
, O
and O
phosphatidic O
acid O
but O
not O
significantly O
into O
phosphatidylethanolamine O
at O
concentrations O
ranging O
from O
10 O
( O
- O
9 O
) O
to O
10 O
( O
- O
6 O
) O
M O
. O

The O
inactive O
precursor O
, O
lyso B-protein
- I-protein
platelet I-protein
- I-protein
activating I-protein
factor I-protein
, O
at O
a O
concentration O
as O
high O
as O
10 O
( O
- O
7 O
) O
M O
had O
no O
effect O
on O
any O
of O
the O
membrane O
phospholipids O
. O

We O
also O
show O
that O
platelet B-protein
- I-protein
activating I-protein
factor I-protein
from O
10 O
( O
- O
12 O
) O
to O
10 O
( O
- O
6 O
) O
M O
induced O
rapid O
and O
significant O
elevation O
in O
intracellular O
calcium O
levels O
, O
whereas O
lyso O
- O
platelet B-protein
- I-protein
activating I-protein
factor I-protein
was O
again O
ineffective O
. O

We O
further O
demonstrate O
the O
impact O
of O
platelet B-protein
- I-protein
activating I-protein
factor I-protein
binding O
to O
B O
cells O
by O
measuring O
platelet B-protein
- I-protein
activating I-protein
factor I-protein
induced O
arachidonic O
acid O
release O
and O
5 O
- O
hydroxyeicosatetraenoic O
acid O
production O
. O

Moreover O
, O
platelet B-protein
- I-protein
activating I-protein
factor I-protein
was O
capable O
of O
inducing O
transcription O
of O
the O
nuclear O
proto O
- O
oncogenes O
c O
- O
fos O
and O
c O
- O
jun O
. O

Finally O
we O
explored O
the O
possible O
role O
of O
5 O
- O
hydroxyeicosatetraenoic O
acid O
as O
a O
regulator O
of O
arachidonic O
acid O
liberation O
demonstrating O
that O
endogenous O
5 B-protein
- I-protein
lipoxygenase I-protein
activity O
modulates O
platelet B-protein
- I-protein
activating I-protein
factor I-protein
induced O
arachidonic O
acid O
release O
perhaps O
acting O
at O
the O
level O
of O
phospholipase B-protein
A2 I-protein
. O

In O
summary O
, O
platelet B-protein
- I-protein
activating I-protein
factor I-protein
is O
shown O
here O
to O
have O
a O
direct O
and O
profound O
effect O
on O
a O
pure O
B O
cell O
line O
. O

Positive O
and O
negative O
regulation O
of O
immunoglobulin O
gene O
expression O
by O
a O
novel O
B O
- O
cell O
- O
specific O
enhancer O
element O
. O

A O
new O
B O
- O
cell O
- O
specific O
enhancer O
element O
has O
been O
identified O
3 O
' O
of O
E4 O
and O
the O
octamerlike O
motifs O
in O
the O
human B-protein
immunoglobulin I-protein
heavy I-protein
- I-protein
chain I-protein
gene O
enhancer O
. O

Tandem O
copies O
of O
this O
67 O
- O
bp O
MnlI O
- O
AluI O
fragment O
, O
when O
fused O
to O
the O
chloramphenicol O
acetyltransferase O
gene O
driven O
by O
the O
conalbumin O
promoter O
, O
stimulated O
transcription O
in O
B O
cells O
but O
not O
in O
Jurkat O
T O
cells O
or O
HeLa O
cells O
. O

Footprinting O
analysis O
revealed O
that O
the O
identical O
sequence O
CCGAAACTGAAAAGG O
, O
designated O
E6 O
, O
was O
protected O
by O
nuclear O
extracts O
from O
B O
cells O
, O
T O
cells O
, O
or O
HeLa O
cells O
. O

Gel O
mobility O
shift O
assays O
using O
a O
synthetic O
E6 O
motif O
detected O
a O
B B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
complex I-protein
in O
addition O
to O
a O
ubiquitous O
band O
found O
also O
in O
T O
cells O
and O
HeLa O
cells O
. O

In O
agreement O
with O
the O
results O
of O
gel O
retardation O
assays O
, O
tandem O
copies O
of O
the O
E6 O
motif O
stimulated O
transcription O
in O
ARH77 O
and O
Raji O
cells O
but O
not O
in O
Jurkat O
or O
HeLa O
cells O
. O

Furthermore O
, O
a O
mutant O
E6 O
motif O
lost O
both O
in O
vitro O
binding O
activity O
and O
in O
vivo O
enhancer O
activity O
. O

In O
striking O
contrast O
to O
the O
mouse O
Ig O
heavy O
- O
chain O
enhancer O
, O
in O
which O
the O
octamer O
motif O
acts O
as O
a O
B O
- O
cell O
- O
specific O
enhancer O
element O
, O
the O
human O
enhancer O
contains O
an O
octamerlike O
sequence O
with O
one O
base O
substitution O
which O
bound O
octamer B-protein
- I-protein
binding I-protein
proteins I-protein
with O
only O
very O
low O
affinity O
and O
showed O
no O
enhancer O
activity O
of O
its O
own O
. O

Interestingly O
, O
the O
MnlI O
- O
AluI O
fragment O
could O
suppress O
the O
basal O
- O
level O
activity O
of O
the O
conalbumin O
promoter O
in O
both O
Jurkat O
and O
HeLa O
cells O
. O

Moreover O
, O
simian O
virus O
40 O
enhancer O
activity O
was O
blocked O
by O
the O
MnlI O
- O
AluI O
fragment O
in O
HeLa O
cells O
but O
not O
in O
B O
cells O
. O

Thus O
, O
the O
novel O
enhancer O
element O
identified O
in O
this O
study O
is O
probably O
a O
target O
site O
for O
both O
positive B-protein
and O
negative B-protein
factors I-protein
. O

Charybdotoxin O
- O
sensitive O
, O
Ca O
( O
2 O
+ O
) O
- O
dependent O
membrane O
potential O
changes O
are O
not O
involved O
in O
human O
T O
or O
B O
cell O
activation O
and O
proliferation O
. O

The O
involvement O
of O
ion B-protein
channels I-protein
in O
B O
and O
T O
lymphocyte O
activation O
is O
supported O
by O
many O
reports O
of O
changes O
in O
ion O
fluxes O
and O
membrane O
potential O
after O
mitogen B-protein
binding O
. O

Human O
T O
and O
B O
lymphocytes O
demonstrate O
an O
early O
and O
transient O
hyperpolarization O
after O
ligand O
binding O
. O

Inasmuch O
as O
the O
change O
in O
membrane O
potential O
is O
dependent O
on O
elevation O
of O
free O
cytosolic O
calcium O
, O
the O
hyperpolarization O
is O
presumably O
through O
opening O
of O
Ca O
( O
2 O
+ O
) O
- O
stimulated O
K O
+ O
channels O
. O

We O
have O
used O
charybdotoxin O
, O
a O
known O
inhibitor O
of O
Ca B-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
dependent I-protein
K I-protein
+ I-protein
channels I-protein
, O
to O
study O
the O
role O
of O
these O
channels O
in O
lymphocyte O
activation O
and O
mitogenesis O
. O

We O
demonstrate O
that O
charybdotoxin O
inhibits O
the O
ligand O
- O
induced O
transient O
membrane O
hyperpolarization O
in O
B O
and O
T O
cells O
in O
a O
dose O
- O
dependent O
fashion O
, O
without O
affecting O
changes O
in O
cytosolic O
Ca2 O
+ O
. O

However O
, O
blockade O
of O
the O
Ca B-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
activated I-protein
K I-protein
+ I-protein
channel I-protein
is O
not O
associated O
with O
changes O
in O
cell O
- O
cycle O
gene O
activation O
, O
IL B-protein
- I-protein
2 I-protein
production O
, O
IL B-protein
- I-protein
2R I-protein
expression O
or O
B O
and O
T O
cell O
mitogenesis O
. O

These O
results O
imply O
that O
membrane O
potential O
changes O
secondary O
to O
the O
ligand O
- O
dependent O
opening O
of O
Ca B-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
activated I-protein
K I-protein
+ I-protein
channels I-protein
are O
not O
involved O
in O
B O
and O
T O
lymphocyte O
activation O
and O
mitogenesis O
. O

Activity O
of O
the O
kappa O
B O
enhancer O
of O
the O
interleukin B-protein
- I-protein
2 I-protein
receptor I-protein
alpha I-protein
chain I-protein
in O
somatic O
cell O
hybrids O
is O
accompanied O
by O
the O
nuclear O
localization O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

The O
two B-protein
nuclear I-protein
proteins I-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
( O
consisting O
of O
subunits O
p50 B-protein
an O
dp65 B-protein
) O
and O
the O
DNA B-protein
- I-protein
binding I-protein
subunit I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
( O
p50 B-protein
) O
by O
itself O
, O
also O
called O
KBF1 B-protein
, O
are O
constitutively O
expressed O
and O
localized O
in O
the O
nucleus O
of O
the O
human O
T O
- O
cell O
line O
IARC O
301 O
. O
5 O
. O

In O
order O
to O
define O
the O
roles O
of O
these O
two O
factors B-protein
, O
which O
bind O
to O
the O
same O
kappa O
B O
enhancers O
, O
in O
transcription O
activation O
we O
have O
prepared O
somatic O
cell O
hybrids O
between O
IARC O
301 O
. O
5 O
and O
a O
murine O
myeloma O
. O

Most O
hybrids O
express O
both O
KBF1 B-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
their O
nuclei O
, O
but O
one O
hybrid O
expresses O
only O
KBF1 B-protein
. O

The O
kappa O
B O
enhancer O
of O
the O
gene O
encoding O
the O
interleukin B-protein
- I-protein
2 I-protein
( I-protein
IL I-protein
- I-protein
2 I-protein
) I-protein
receptor I-protein
alpha I-protein
chain I-protein
( O
IL B-protein
- I-protein
2R I-protein
alpha I-protein
) O
is O
functional O
only O
in O
the O
hybrids O
expressing O
nuclear B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
. O

These O
findings O
show O
that O
nuclear B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
is O
necessary O
to O
activate O
the O
kappa O
B O
enhancer O
, O
while O
KBF1 B-protein
by O
itself O
is O
not O
sufficient O
. O

We O
propose O
that O
KBF1 B-protein
is O
a O
competitive O
inhibitor O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
discuss O
how O
these O
factors O
may O
be O
involved O
in O
the O
transient O
expression O
of O
IL B-protein
- I-protein
2 I-protein
and O
IL B-protein
- I-protein
2 I-protein
alpha I-protein
genes O
during O
the O
immune O
response O
. O

T B-protein
- I-protein
helper I-protein
- I-protein
cell I-protein
determinants I-protein
in O
protein B-protein
antigens I-protein
are O
preferentially O
located O
in O
cysteine B-protein
- I-protein
rich I-protein
antigen I-protein
segments I-protein
resistant O
to O
proteolytic O
cleavage O
by O
cathepsin O
B O
, O
L O
, O
and O
D O
. O

We O
report O
on O
a O
computer O
algorithm O
capable O
of O
predicting O
the O
location O
of O
T B-protein
- I-protein
helper I-protein
- I-protein
cell I-protein
epitopes I-protein
in O
protein B-protein
antigen I-protein
( O
Ag B-protein
) O
by O
analysing O
the O
Ag B-protein
amino B-protein
acid I-protein
sequence I-protein
. O

The O
algorithm O
was O
constructed O
with O
the O
aim O
of O
identifying O
segments O
in O
Ag B-protein
which O
are O
resistant O
to O
proteolytic O
degradation O
by O
the O
enzymes O
cathepsin O
B O
, O
L O
, O
and O
D O
. O

These O
are O
prominent O
enzymes B-protein
in O
the O
endocytic O
pathway O
through O
which O
soluble B-protein
protein I-protein
Ag I-protein
enter O
APC B-protein
, O
and O
resistant B-protein
segments I-protein
in O
Ag B-protein
may O
, O
therefore O
, O
be O
expected O
to O
contain O
more O
T B-protein
- I-protein
cell I-protein
determinants I-protein
than O
susceptible B-protein
segments I-protein
. O

From O
information O
available O
in O
the O
literature O
on O
the O
substrate O
specificity O
of O
the O
three O
enzymes B-protein
, O
it O
is O
clear O
that O
a O
cysteine O
is O
not O
accepted O
in O
any O
of O
the O
S2 O
, O
S1 O
, O
S1 O
' O
, O
and O
S2 O
' O
subsites O
of O
cathepsin O
B O
and O
L O
, O
and O
not O
in O
the O
S1 B-protein
and O
S1 B-protein
' I-protein
subsites O
of O
cathepsin B-protein
D I-protein
. O

Moreover O
, O
we O
have O
noticed O
that O
cysteine B-protein
- I-protein
containing I-protein
T I-protein
- I-protein
cell I-protein
determinants I-protein
in O
a O
number O
of O
protein B-protein
Ag I-protein
are O
particularly O
rich O
in O
the O
amino O
acids O
alanine O
, O
glycine O
, O
lysine O
, O
leucine O
, O
serine O
, O
threonine O
, O
and O
valine O
. O

By O
searching O
protein O
Ag B-protein
for O
clusters O
of O
amino O
acids O
containing O
cysteine O
and O
two O
of O
the O
other O
amino O
acids O
we O
were O
able O
to O
predict O
17 O
out O
of O
23 O
empirically O
known O
T B-protein
- I-protein
cell I-protein
determinants I-protein
in O
the O
Ag B-protein
with O
a O
relatively O
low O
number O
of O
false O
( O
positive O
) O
predictions O
. O

Furthermore O
, O
we O
present O
a O
new O
principle O
for O
searching O
Ag B-protein
for O
potential O
amphipatic B-protein
alpha I-protein
- I-protein
helical I-protein
protein I-protein
segments I-protein
. O

Such O
segments O
accord O
well O
with O
empirically O
known O
T B-protein
- I-protein
cell I-protein
determinants I-protein
and O
our O
algorithm O
produces O
a O
lower O
number O
of O
false O
positive O
predictions O
than O
the O
principle O
based O
on O
discrete O
Fourier O
transformations O
previously O
described O
. O

Contribution O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
Sp1 O
binding O
motifs O
to O
the O
replicative O
capacity O
of O
human O
immunodeficiency O
virus O
type O
1 O
: O
distinct O
patterns O
of O
viral O
growth O
are O
determined O
by O
T O
- O
cell O
types O
. O

Starting O
with O
a O
replication O
- O
incompetent O
molecular O
clone O
of O
human O
immunodeficiency O
virus O
type O
1 O
, O
lacking O
all O
the O
NF O
- O
kappa O
B O
and O
Sp1 O
binding O
sites O
present O
in O
the O
native O
long O
terminal O
repeat O
( O
LTR O
) O
, O
proviruses O
containing O
reconstructed O
LTRs O
with O
individual O
or O
combinations O
of O
NF O
- O
kappa O
B O
and O
Sp1 O
elements O
were O
generated O
and O
evaluated O
for O
their O
capacity O
to O
produce O
virus O
progeny O
following O
transfection O
- O
cocultivation O
. O

Virus O
stocks O
obtained O
from O
these O
experiments O
exhibited O
a O
continuum O
of O
replicative O
capacities O
in O
different O
human O
T O
- O
cell O
types O
depending O
on O
which O
element O
( O
s O
) O
was O
present O
in O
the O
LTR O
. O

For O
example O
, O
in O
experiments O
involving O
proviral O
clones O
with O
LTRs O
containing O
one O
or O
two O
NF B-protein
- I-protein
kappa I-protein
B I-protein
elements O
( O
and O
no O
Sp1 O
binding O
sites O
) O
, O
a O
hierarchy O
of O
cellular O
permissivity O
to O
virus O
replication O
( O
peripheral O
blood O
lymphocytes O
= O
MT4 O
greater O
than O
H9 O
greater O
than O
CEM O
greater O
than O
Jurkat O
) O
was O
observed O
. O

Of O
note O
was O
the O
associated O
emergence O
of O
second O
- O
site O
LTR O
revertants O
which O
involved O
an O
alteration O
of O
the O
TATA O
box O
. O

These O
results O
suggest O
that O
the O
human O
immunodeficiency O
virus O
type O
1 O
LTR O
possesses O
functional O
redundancy O
which O
ensures O
virus O
replication O
in O
different O
T O
- O
cell O
types O
and O
is O
capable O
of O
changing O
depending O
on O
the O
particular O
combination O
of O
transcriptional B-protein
factors I-protein
present O
. O

Stimulation O
of O
interferon O
beta O
gene O
transcription O
in O
vitro O
by O
purified O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
a O
novel O
TH B-protein
protein I-protein
. O

The O
human B-protein
interferon I-protein
beta I-protein
( O
IFN B-protein
- I-protein
beta I-protein
) O
regulatory O
element O
consists O
of O
multiple O
enhanson O
domains O
which O
are O
targets O
for O
transcription B-protein
factors I-protein
involved O
in O
inducible O
expression O
of O
the O
promoter O
. O

To O
further O
characterize O
the O
protein O
- O
DNA O
interactions O
mediating O
IFN B-protein
- I-protein
beta I-protein
induction O
, O
positive B-protein
regulatory I-protein
domain I-protein
( I-protein
PRD I-protein
) I-protein
II I-protein
binding I-protein
proteins I-protein
were O
purified O
from O
phorbol O
ester O
induced O
Jurkat O
T O
- O
cells O
and O
from O
IFN B-protein
primed O
, O
cycloheximide O
/ O
polyinosinic O
- O
polycytidylic O
acid O
treated O
HeLa O
S3 O
cells O
. O

From O
HeLa O
cells O
, O
two O
major O
proteins O
of O
52 O
and O
45 O
kilodaltons O
( O
kD O
) O
copurified O
with O
DNA O
binding O
activity O
, O
whereas O
from O
T O
- O
cells O
, O
four O
proteins O
- O
- O
a O
major B-protein
protein I-protein
of O
52 B-protein
kD I-protein
and O
three O
minor B-protein
proteins I-protein
of O
82 B-protein
, O
67 B-protein
, O
and O
43 B-protein
- I-protein
47 I-protein
kD I-protein
- O
- O
were O
purified O
. O

Also O
, O
an O
induction O
specific B-protein
DNA I-protein
binding I-protein
protein I-protein
was O
purified O
from O
HeLa O
cells O
that O
interacted O
with O
the O
( O
AAGTGA O
) O
4 O
tetrahexamer O
sequence O
and O
the O
PRDI O
domain O
. O

This O
protein O
is O
immunologically O
distinct O
from O
IRF B-protein
- I-protein
1 I-protein
/ I-protein
ISGF2 I-protein
. O

Uninduced O
or O
Sendai O
virus O
induced O
HeLa O
extracts O
were O
used O
to O
examine O
transcription O
in O
vitro O
using O
a O
series O
of O
IFN O
beta O
promoter O
deletions O
. O

Deletions O
upstream O
of O
the O
PRDII O
element O
increased O
transcription O
in O
the O
uninduced O
extract O
, O
indicating O
predominantly O
negative O
regulation O
of O
the O
promoter O
. O

A O
2 O
- O
4 O
- O
fold O
increase O
in O
IFN O
- O
beta O
promoter O
transcription O
was O
observed O
in O
Sendai O
virus O
induced O
extracts O
, O
and O
deletion O
of O
PRDI O
and O
PRDII O
elements O
decreased O
this O
induced O
level O
of O
transcription O
. O

When O
purified O
PRDII O
and O
tetrahexamer O
binding O
proteins O
were O
added O
to O
the O
induced O
extract O
, O
a O
4 O
- O
fold O
increase O
in O
transcription O
was O
observed O
. O

These O
experiments O
demonstrate O
that O
it O
is O
possible O
to O
modulate O
IFN O
- O
beta O
transcription O
in O
vitro O
but O
indicate O
that O
additional O
proteins O
may O
be O
required O
to O
fully O
activate O
IFN B-protein
- I-protein
beta I-protein
transcription O
. O

The O
rhombotin O
family O
of O
cysteine O
- O
rich O
LIM O
- O
domain O
oncogenes O
: O
distinct O
members O
are O
involved O
in O
T O
- O
cell O
translocations O
to O
human O
chromosomes O
11p15 O
and O
11p13 O
. O

A O
chromosomal O
translocation O
in O
a O
T O
- O
cell O
leukemia O
involving O
the O
short O
arm O
of O
human O
chromosome O
11 O
at O
band O
11p15 O
disrupts O
the O
rhombotin O
gene O
. O

This O
gene O
encodes O
a O
protein O
with O
duplicated O
cysteine B-protein
- I-protein
rich I-protein
regions I-protein
called O
LIM B-protein
domains I-protein
, O
which O
show O
homology O
to O
zinc B-protein
- I-protein
binding I-protein
proteins I-protein
and O
to O
iron B-protein
- I-protein
sulfur I-protein
centers I-protein
of O
ferredoxins B-protein
. O

Two O
homologues O
of O
the O
rhombotin O
gene O
have O
now O
been O
isolated O
. O

One O
of O
these O
, O
designated O
Rhom O
- O
2 O
, O
is O
located O
on O
human O
chromosome O
11 O
at O
band O
11p13 O
, O
where O
a O
cluster O
of O
T O
- O
cell O
leukemia O
- O
specific O
translocations O
occur O
; O
all O
translocation O
breakpoints O
at O
11p13 O
are O
upstream O
of O
the O
Rhom O
- O
2 O
gene O
. O

Human O
and O
mouse O
Rhom O
- O
2 O
are O
highly O
conserved O
and O
, O
like O
rhombotin O
, O
encode O
two O
tandem O
cysteine O
- O
rich O
LIM B-protein
domains I-protein
. O

Rhom O
- O
2 O
mRNA O
is O
expressed O
in O
early O
mouse O
development O
in O
central O
nervous O
system O
, O
lung O
, O
kidney O
, O
liver O
, O
and O
spleen O
but O
only O
very O
low O
levels O
occur O
in O
thymus O
. O

The O
other O
gene O
, O
designated O
Rhom O
- O
3 O
, O
is O
not O
on O
chromosome O
11 O
but O
also O
retains O
homology O
to O
the O
LIM O
domain O
of O
rhombotin O
. O

Since O
the O
Rhom O
- O
2 O
gene O
is O
such O
a O
common O
site O
of O
chromosomal O
damage O
in O
T O
- O
cell O
tumors O
, O
the O
consistency O
of O
translocations O
near O
the O
rhombotin O
gene O
was O
further O
examined O
. O

A O
second O
translocation O
adjacent O
to O
rhombotin O
was O
found O
and O
at O
the O
same O
position O
as O
in O
the O
previous O
example O
. O

Therefore O
, O
chromosome O
bands O
11p15 O
( O
rhombotin O
) O
and O
11p13 O
( O
Rhom O
- O
2 O
) O
are O
consistent O
sites O
of O
chromosome O
translocation O
in O
T O
- O
cell O
leukemia O
, O
with O
the O
11p15 O
target O
more O
rarely O
involved O
. O

The O
results O
define O
the O
rhombotin O
gene O
family O
as O
a O
class O
of O
T O
- O
cell O
oncogenes O
with O
duplicated O
cysteine O
- O
rich O
LIM B-protein
domains I-protein
. O

NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
by O
tumor B-protein
necrosis I-protein
factor I-protein
alpha I-protein
in O
the O
Jurkat O
T O
cell O
line O
is O
independent O
of O
protein B-protein
kinase I-protein
A I-protein
, O
protein B-protein
kinase I-protein
C I-protein
, O
and O
Ca B-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
regulated I-protein
kinases I-protein
. O

NF B-protein
- I-protein
kappa I-protein
B I-protein
is O
a O
DNA B-protein
- I-protein
binding I-protein
regulatory I-protein
factor I-protein
able O
to O
control O
transcription O
of O
a O
number O
of O
genes O
, O
including O
human O
immunodeficiency O
virus O
( O
HIV O
) O
genes O
. O

In O
T O
cells O
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
is O
activated O
upon O
cellular O
treatment O
by O
phorbol O
esters O
and O
the O
cytokine O
tumor B-protein
necrosis I-protein
factor I-protein
alpha I-protein
( O
TNF B-protein
alpha I-protein
) O
. O

In O
the O
present O
work O
, O
we O
investigated O
the O
molecular O
events O
leading O
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
by O
TNF B-protein
alpha I-protein
in O
a O
human O
T O
cell O
line O
( O
Jurkat O
) O
and O
its O
subclone O
JCT6 O
, O
which O
presents O
a O
deficiency O
in O
the O
PKA B-protein
transduction O
pathway O
. O

We O
found O
that O
in O
both O
cell O
lines O
, O
both O
phorbol O
ester O
and O
TNF B-protein
alpha I-protein
were O
able O
to O
activate O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

Phorbol O
activation O
was O
positively O
modulated O
by O
Ca2 O
+ O
influx O
while O
TNF B-protein
alpha I-protein
activation O
was O
not O
. O

Furthermore O
, O
while O
PMA O
activation O
was O
inhibited O
by O
the O
PKC B-protein
inhibitor O
staurosporin O
, O
the O
TNF B-protein
alpha I-protein
effect O
was O
unchanged O
. O

TNF B-protein
alpha I-protein
did O
not O
activate O
cAMP O
production O
and O
its O
signal O
was O
not O
modulated O
by O
cAMP O
activators O
. O

Moreover O
, O
cAMP O
activators O
did O
not O
activate O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
Jurkat O
cells O
. O

Thus O
, O
TNF B-protein
alpha I-protein
- O
induced O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
was O
found O
to O
be O
mediated O
by O
none O
of O
the O
major O
signal B-protein
- I-protein
mediating I-protein
kinases I-protein
such O
as O
protein B-protein
kinase I-protein
C I-protein
( O
PKC B-protein
) O
, O
protein B-protein
kinase I-protein
A I-protein
, O
or O
Ca B-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
regulated I-protein
kinases I-protein
. O

Furthermore O
, O
we O
found O
that O
cytoplasmic O
acidification O
facilitated O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
by O
both O
TNF B-protein
alpha I-protein
and O
PKC B-protein
, O
by O
a O
mechanism O
that O
increases O
NF B-protein
- I-protein
kappa I-protein
B I-protein
/ B-protein
I I-protein
kappa I-protein
B I-protein
dissociation O
without O
affecting O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
translocation O
step O
. O

The O
functional O
domains O
of O
the O
murine O
Thy O
- O
1 O
gene O
promoter O
. O

The O
Thy O
- O
1 O
gene O
promoter O
resembles O
a O
" O
housekeeping O
" O
promoter O
in O
that O
it O
is O
located O
within O
a O
methylation O
- O
free O
island O
, O
lacks O
a O
canonical O
TATA O
box O
, O
and O
displays O
heterogeneity O
in O
the O
5 O
' O
- O
end O
termini O
of O
the O
mRNA O
. O

Using O
transgenic O
mice O
, O
we O
show O
that O
this O
promoter O
does O
not O
confer O
any O
tissue O
specificity O
and O
is O
active O
only O
in O
a O
position O
- O
dependent O
manner O
. O

It O
can O
only O
be O
activated O
in O
a O
tissue O
- O
specific O
manner O
by O
elements O
that O
lie O
downstream O
of O
the O
initiation O
site O
. O

We O
have O
analyzed O
the O
functional O
domains O
of O
the O
minimal O
Thy O
- O
1 O
promoter O
and O
show O
that O
the O
dominant O
promoter O
elements O
consist O
of O
multiple O
binding O
sites O
for O
the O
transcription B-protein
factor I-protein
Sp1 B-protein
, O
an O
inverted O
CCAAT O
box O
, O
and O
sequences O
proximal O
to O
the O
transcription O
start O
site O
. O

DNase O
I O
and O
gel O
mobility O
shift O
assays O
show O
the O
binding O
of O
a O
number O
of O
nuclear B-protein
factors I-protein
to O
these O
elements O
, O
including O
Sp1 B-protein
and O
CP1 B-protein
. O

Our O
results O
show O
that O
the O
structure O
of O
this O
promoter O
only O
permits O
productive O
interactions O
of O
the O
two O
transcription B-protein
factors I-protein
Sp1 B-protein
and O
CP1 B-protein
with O
the O
basal O
transcription O
machinery O
in O
the O
presence O
of O
enhancer O
sequences O
. O

Nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
activates O
proenkephalin O
transcription O
in O
T O
lymphocytes O
. O

Upon O
activation O
, O
T O
lymphocytes O
accumulate O
high O
levels O
of O
the O
neuropeptide O
enkephalin O
which O
correlate O
with O
high O
levels O
of O
proenkephalin O
mRNA O
in O
the O
cells O
. O

Here O
we O
investigated O
the O
transcriptional O
basis O
for O
these O
changes O
. O

The O
proenkephalin O
promoter O
contains O
a O
sequence O
GGGGACGTCCCC O
, O
named O
B2 O
, O
which O
is O
similar O
to O
the O
kappa O
B O
sequence O
GGGGACTTTCC O
, O
the O
binding O
site O
of O
the O
transcription B-protein
factor I-protein
nuclear B-protein
factor I-protein
( I-protein
NF I-protein
) I-protein
- I-protein
kappa I-protein
B I-protein
. O

Activation O
of O
T O
lymphocytes O
induces O
an O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
like O
binding O
activity O
to O
the O
B2 O
site O
, O
concomitant O
with O
activation O
of O
the O
proenkephalin O
promoter O
. O

Mutations O
at O
the O
B2 O
site O
abolish O
this O
transcriptional O
activation O
. O

The O
purified O
homodimer B-protein
( O
two O
p50s B-protein
) O
of O
the O
DNA B-protein
- I-protein
binding I-protein
subunit I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binds O
the O
B2 O
site O
of O
proenkephalin O
relatively O
better O
than O
does O
the O
heterotetramer B-protein
( O
two O
p65s B-protein
plus O
two O
p50s B-protein
) O
form O
of O
the O
factor O
. O

Thus O
, O
it O
appears O
that O
the O
T O
- O
cell O
- O
specific O
activation O
of O
the O
proenkephalin O
promoter O
is O
mediated O
by O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

However O
, O
as O
NF B-protein
- I-protein
kappa I-protein
B I-protein
is O
ubiquitous O
and O
the O
transcriptional O
activation O
through O
the O
B2 O
site O
is O
T O
cell O
specific O
, O
yet O
another O
T B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
factor I-protein
which O
synergizes O
with O
NF B-protein
- I-protein
kappa I-protein
B I-protein
should O
be O
considered O
. O

Induction O
of O
NF B-protein
- I-protein
KB I-protein
during O
monocyte O
differentiation O
by O
HIV O
type O
1 O
infection O
. O

The O
production O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
progeny O
was O
followed O
in O
the O
U937 O
promonocytic O
cell O
line O
after O
stimulation O
either O
with O
retinoic O
acid O
or O
PMA O
, O
and O
in O
purified O
human O
monocytes O
and O
macrophages O
. O

Electrophoretic O
mobility O
shift O
assays O
and O
Southwestern O
blotting O
experiments O
were O
used O
to O
detect O
the O
binding O
of O
cellular B-protein
transactivation I-protein
factor I-protein
NF B-protein
- I-protein
KB I-protein
to O
the O
double O
repeat O
- O
KB O
enhancer O
sequence O
located O
in O
the O
long O
terminal O
repeat O
. O

PMA O
treatment O
, O
and O
not O
retinoic O
acid O
treatment O
of O
the O
U937 O
cells O
acts O
in O
inducing O
NF B-protein
- I-protein
KB I-protein
expression O
in O
the O
nuclei O
. O

In O
nuclear O
extracts O
from O
monocytes O
or O
macrophages O
, O
induction O
of O
NF B-protein
- I-protein
KB I-protein
occurred O
only O
if O
the O
cells O
were O
previously O
infected O
with O
HIV O
- O
1 O
. O

When O
U937 O
cells O
were O
infected O
with O
HIV O
- O
1 O
, O
no O
induction O
of O
NF B-protein
- I-protein
KB I-protein
factor I-protein
was O
detected O
, O
whereas O
high O
level O
of O
progeny O
virions O
was O
produced O
, O
suggesting O
that O
this O
factor O
was O
not O
required O
for O
viral O
replication O
. O

These O
results O
indicate O
that O
in O
monocytic O
cell O
lineage O
, O
HIV O
- O
1 O
could O
mimic O
some O
differentiation O
/ O
activation O
stimuli O
allowing O
nuclear O
NF B-protein
- I-protein
KB I-protein
expression O
. O

Disruption O
of O
the O
human O
SCL O
locus O
by O
" O
illegitimate O
" O
V O
- O
( O
D O
) O
- O
J O
recombinase O
activity O
. O

A O
fusion O
complementary O
DNA O
in O
the O
T O
cell O
line O
HSB O
- O
2 O
elucidates O
a O
provocative O
mechanism O
for O
the O
disruption O
of O
the O
putative O
hematopoietic B-protein
transcription I-protein
factor I-protein
SCL B-protein
. O

The O
fusion O
cDNA O
results O
from O
an O
interstitial O
deletion O
between O
a O
previously O
unknown O
locus O
, O
SIL O
( O
SCL B-protein
interrupting O
locus O
) O
, O
and O
the O
5 O
' O
untranslated O
region O
of O
SCL B-protein
. O

Similar O
to O
1 O
; O
14 O
translocations O
, O
this O
deletion O
disrupts O
the O
SCL B-protein
5 O
' O
regulatory O
region O
. O

This O
event O
is O
probably O
mediated O
by O
V O
- O
( O
D O
) O
- O
J O
recombinase O
activity O
, O
although O
neither O
locus O
is O
an O
immunoglobulin B-protein
or O
a O
T B-protein
cell I-protein
receptor I-protein
. O

Two O
other O
T O
cell O
lines O
, O
CEM O
and O
RPMI O
8402 O
, O
have O
essentially O
identical O
deletions O
. O

Thus O
, O
in O
lymphocytes O
, O
growth O
- O
affecting O
genes O
other O
than O
immune B-protein
receptors I-protein
risk O
rearrangements O
. O

Thyroid B-protein
hormone I-protein
receptors I-protein
form O
distinct O
nuclear O
protein O
- O
dependent O
and O
independent O
complexes O
with O
a O
thyroid O
hormone O
response O
element O
. O

We O
have O
examined O
the O
binding O
of O
nuclear B-protein
proteins I-protein
and O
recombinant B-protein
thyroid I-protein
hormone I-protein
receptors I-protein
( O
TRs B-protein
) O
to O
the O
palindromic O
thyroid O
hormone O
responsive O
element O
AGGTCATGACCT O
( O
TREp O
) O
using O
a O
gel O
electrophoretic O
mobility O
shift O
assay O
. O

Four O
specific O
protein B-protein
- I-protein
DNA I-protein
complexes I-protein
were O
detected O
after O
incubation O
of O
nuclear O
extracts O
( O
NE O
) O
from O
T3 O
- O
responsive O
pituitary O
( O
GH3 O
) O
cells O
with O
a O
TREp O
- O
containing O
DNA O
fragment O
. O

This O
was O
compared O
with O
the O
TREp O
binding O
of O
reticulocyte B-protein
lysate I-protein
- I-protein
synthesized I-protein
TRs I-protein
. O

TR B-protein
alpha I-protein
1 I-protein
and O
TR B-protein
beta I-protein
2 I-protein
each O
formed O
a O
single O
major O
TR B-protein
: I-protein
TREp I-protein
complex I-protein
which O
comigrated O
with O
the O
least O
retarded O
complex O
formed O
by O
GH3 O
NE O
, O
while O
TR B-protein
beta I-protein
1 I-protein
formed O
multiple O
complexes O
suggesting O
that O
it O
can O
bind O
to O
TREp O
as O
an O
oligomer B-protein
. O

Interestingly O
, O
coincubation O
of O
35S B-protein
- I-protein
TR I-protein
alpha I-protein
1 I-protein
, O
GH3 O
NE O
, O
and O
unlabeled O
TREp O
resulted O
in O
not O
only O
the O
35S B-protein
- I-protein
TR I-protein
: I-protein
TREp I-protein
complex I-protein
, O
but O
in O
two O
additional O
more O
greatly O
retarded O
complexes O
containing O
35S B-protein
- I-protein
TR I-protein
alpha I-protein
1 I-protein
and O
comigrating O
with O
those O
formed O
by O
GH3 O
extract O
alone O
. O

Incubation O
of O
each O
of O
the O
TRs B-protein
with O
NE O
from O
COS O
- O
7 O
cells O
, O
which O
do O
not O
possess O
sufficient O
endogenous O
TRs B-protein
to O
mediate O
T3 O
- O
responses O
, O
resulted O
in O
formation O
of O
a O
new O
, O
more O
greatly B-protein
shifted I-protein
complex I-protein
. O

A O
similar O
, O
heat O
labile O
activity O
which O
altered O
mobility O
of O
the O
TR B-protein
: I-protein
TRE I-protein
complex I-protein
was O
also O
present O
in O
NE O
from O
T3 O
- O
unresponsive O
JEG O
- O
3 O
cells O
. O

At O
high O
concentration O
of O
NE O
, O
all O
of O
the O
TR B-protein
bound O
to O
TREp O
was O
more O
greatly O
retarded O
than O
in O
the O
absence O
of O
NE O
. O

Truncation O
of O
TR B-protein
alpha I-protein
1 I-protein
at O
amino B-protein
acid I-protein
210 I-protein
prevented O
additional O
complex O
formation O
in O
the O
presence O
of O
NE O
without O
affecting O
DNA O
binding O
, O
suggesting O
that O
the O
carboxyl B-protein
- I-protein
terminus I-protein
of O
the O
TRs B-protein
is O
essential O
for O
interaction O
with O
nuclear B-protein
proteins I-protein
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Cell O
- O
specific O
differences O
in O
activation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
regulatory O
elements O
of O
human O
immunodeficiency O
virus O
and O
beta O
interferon O
promoters O
by O
tumor B-protein
necrosis I-protein
factor I-protein
. O

Three O
aspects O
of O
the O
involvement O
of O
tumor B-protein
necrosis I-protein
factor I-protein
in O
human O
immunodeficiency O
virus O
( O
HIV O
) O
pathogenesis O
were O
examined O
. O

Tumor B-protein
necrosis I-protein
factor I-protein
alpha I-protein
( O
TNF B-protein
- I-protein
alpha I-protein
) O
mRNA O
production O
was O
analyzed O
by O
polymerase O
chain O
reaction O
amplification O
in O
monocytic O
U937 O
cells O
and O
in O
a O
chronically O
HIV O
infected O
U937 O
cell O
line O
( O
U9 O
- O
IIIB O
) O
. O

TNF B-protein
- I-protein
alpha I-protein
RNA O
was O
undetectable O
in O
U937 O
cells O
, O
whereas O
a O
low O
constitutive O
level O
was O
detected O
in O
U9 O
- O
IIIB O
cells O
. O

Paramyxovirus O
infection O
induced O
a O
5 O
- O
to O
10 O
- O
fold O
increase O
in O
the O
steady O
- O
state O
level O
of O
TNF B-protein
- I-protein
alpha I-protein
RNA O
in O
U9 O
- O
IIIB O
cells O
compared O
with O
U937 O
cells O
, O
suggesting O
that O
HIV O
- O
infected O
monocytic O
cells O
produced O
higher O
levels O
of O
TNF B-protein
- I-protein
alpha I-protein
than O
did O
normal O
cells O
after O
a O
secondary O
virus O
infection O
. O

The O
effects O
of O
TNF B-protein
- I-protein
alpha I-protein
on O
gene O
expression O
were O
examined O
by O
transient O
expression O
assays O
using O
reporter O
chloramphenicol O
acetyltransferase O
plasmids O
linked O
to O
regulatory O
elements O
from O
the O
HIV O
long O
terminal O
repeat O
( O
LTR O
) O
and O
the O
beta O
interferon O
promoter O
. O

In O
U937 O
and O
Jurkat O
T O
lymphoid O
cells O
, O
the O
inducibility O
of O
the O
different O
hybrid O
promoters O
by O
TNF B-protein
- I-protein
alpha I-protein
or O
phorbol O
ester O
varied O
in O
a O
cell O
type O
- O
and O
promoter O
context O
- O
specific O
manner O
; O
the O
levels O
of O
gene O
activity O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
containing O
plasmids O
correlated O
directly O
with O
induction O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
DNA O
- O
binding O
activity O
. O

Although O
the O
intact O
beta O
interferon O
promoter O
was O
only O
weakly O
stimulated O
by O
phorbol O
ester O
or O
TNF B-protein
- I-protein
alpha I-protein
, O
multimers O
of O
the O
PRDII O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
binding O
domain O
were O
inducible O
by O
both O
agents O
. O

TNF B-protein
- I-protein
alpha I-protein
was O
able O
to O
increase O
expression O
of O
the O
HIV O
LTR O
in O
T O
cells O
, O
but O
in O
monocytic O
cells O
, O
TNF B-protein
- I-protein
alpha I-protein
did O
not O
induce O
the O
HIV O
LTR O
above O
a O
constitutive O
level O
of O
activity O
. O

This O
level O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
independent O
activity O
appears O
to O
be O
sufficient O
for O
virus O
multiplication O
, O
since O
TNF B-protein
- I-protein
alpha I-protein
treatment O
had O
no O
effect O
on O
the O
kinetics O
of O
de O
novo O
HIV O
type O
1 O
( O
HIV O
- O
1 O
) O
infection O
and O
viral O
RNA O
production O
in O
U937 O
cells O
. O

However O
, O
in O
Jurkat O
cells O
, O
TNF B-protein
- I-protein
alpha I-protein
dramatically O
enhanced O
the O
spread O
of O
HIV O
- O
1 O
through O
the O
cell O
population O
and O
increased O
viral O
RNA O
synthesis O
, O
indicating O
that O
in O
T O
cells O
HIV O
- O
1 O
multiplication O
was O
stimulated O
by O
TNF B-protein
- I-protein
alpha I-protein
treatment O
. O

Functional O
analysis O
of O
cis O
- O
linked O
regulatory O
sequences O
in O
the O
HLA O
DRA O
promoter O
by O
transcription O
in O
vitro O
. O

Two O
consensus O
sequences O
, O
called O
X O
and O
Y O
boxes O
, O
capable O
of O
binding O
nuclear B-protein
proteins I-protein
and O
regulating O
expression O
in O
B O
cells O
have O
been O
defined O
within O
the O
immediate O
upstream O
region O
of O
major O
histocompatibility O
complex O
( O
MHC O
) O
class O
II O
promoters O
. O

Unlike O
other O
class O
II O
promoters O
, O
the O
HLA O
- O
DR O
alpha O
( O
DRA O
) O
promoter O
also O
contains O
one O
element O
identical O
to O
the O
" O
octamer O
" O
motif O
of O
immunoglobulin O
variable O
region O
promoters O
that O
is O
responsible O
for O
B O
cell O
- O
specific O
transcription O
. O

This O
" O
octamer O
" O
in O
the O
context O
of O
DRA B-protein
appears O
capable O
of O
binding O
both O
the O
ubiquitous B-protein
( O
OTF B-protein
- I-protein
1 I-protein
) O
and O
lymphoid B-protein
- I-protein
specific I-protein
( I-protein
OTF I-protein
- I-protein
2 I-protein
) I-protein
" I-protein
octamer I-protein
" I-protein
binding I-protein
proteins I-protein
, O
but O
at O
least O
one O
other O
distinct O
" B-protein
octamer I-protein
" I-protein
complex I-protein
was O
found O
. O

In O
order O
to O
characterize O
the O
function O
of O
cis O
- O
acting O
elements O
, O
we O
have O
developed O
an O
in O
vitro O
system O
in O
which O
a O
DRA O
promoter O
construct O
is O
transcribed O
more O
efficiently O
in O
extracts O
from O
B O
cells O
than O
in O
extracts O
from O
class O
II O
- O
negative O
HeLa O
cells O
. O

5 O
' O
deletion O
constructs O
which O
lacked O
the O
Y O
box O
, O
but O
retained O
the O
" O
octamer O
" O
motif O
and O
TATA O
box O
were O
completely O
inactive O
, O
and O
internal O
deletion O
of O
the O
Y O
box O
reduced O
transcription O
by O
95 O
% O
. O

Using O
supercoiled O
, O
but O
not O
linear O
templates O
, O
we O
observed O
differences O
in O
transcription O
efficiencies O
from O
templates O
lacking O
or O
disrupting O
the O
X O
consensus O
element O
that O
reflect O
effects O
of O
random O
replacement O
of O
X O
box O
sequences O
in O
transient O
expression O
assays O
. O

Demonstration O
of O
the O
complete O
dependence O
on O
the O
Y O
box O
in O
this O
system O
suggests O
that O
, O
despite O
its O
demonstrated O
importance O
in O
the O
DRA O
promoter O
, O
the O
DRA O
" O
octamer O
" O
does O
not O
utilize O
OTF B-protein
- I-protein
2 I-protein
in O
a O
manner O
analogous O
to O
immunoglobulin O
promoters O
in O
B O
cells O
. O

Lipopolysaccharide O
is O
a O
potent O
monocyte O
/ O
macrophage O
- O
specific O
stimulator O
of O
human O
immunodeficiency O
virus O
type O
1 O
expression O
. O

Lipopolysaccharide O
( O
LPS O
) O
potently O
stimulates O
human O
immunodeficiency O
virus O
type O
1 O
- O
long O
terminal O
repeat O
( O
HIV O
- O
1 O
- O
LTR O
) O
CAT O
constructs O
transfected O
into O
monocyte O
/ O
macrophage O
- O
like O
cell O
lines O
but O
not O
a O
T O
cell O
line O
. O

This O
effect O
appears O
to O
be O
mediated O
through O
the O
induction O
of O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
( O
NF B-protein
- I-protein
kappa I-protein
B I-protein
) O
. O

Electrophoretic O
mobility O
shift O
assays O
demonstrate O
that O
LPS O
induces O
a O
DNA O
binding O
activity O
indistinguishable O
from O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
U937 O
and O
THP O
- O
1 O
cells O
. O

LPS O
is O
also O
shown O
to O
dramatically O
increase O
HIV O
- O
1 O
production O
from O
a O
chronically O
infected O
monocyte O
/ O
macrophage O
- O
like O
cloned O
cell O
line O
, O
U1 O
, O
which O
produces O
very O
low O
levels O
of O
HIV O
- O
1 O
at O
baseline O
. O

The O
stimulation O
of O
viral O
production O
from O
this O
cell O
line O
occurs O
only O
if O
these O
cells O
are O
treated O
with O
granulocyte B-protein
/ I-protein
macrophage I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
( O
GM B-protein
- I-protein
CSF I-protein
) O
before O
treatment O
with O
LPS O
. O

This O
stimulation O
of O
HIV O
- O
1 O
production O
is O
correlated O
with O
an O
increase O
in O
the O
level O
of O
HIV O
- O
1 O
RNA O
and O
and O
activation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

LPS O
is O
not O
able O
to O
induce O
HIV O
- O
1 O
production O
in O
a O
cloned O
T O
cell O
line O
. O

The O
effect O
of O
LPS O
on O
HIV O
- O
1 O
replication O
occurs O
at O
picogram O
per O
milliliter O
concentrations O
and O
may O
be O
clinically O
significant O
in O
understanding O
the O
variability O
of O
the O
natural O
history O
of O
HIV O
- O
1 O
infection O
. O

Steroid O
dose O
sparing O
: O
pharmacodynamic O
responses O
to O
single O
versus O
divided O
doses O
of O
methylprednisolone O
in O
man O
. O

Inhibitory O
drug O
interactions O
affecting O
the O
metabolism O
of O
methylprednisolone O
( O
MP O
) O
may O
produce O
either O
steroid O
sparing O
or O
adverse O
effects O
partly O
by O
increasing O
the O
exposure O
time O
to O
the O
steroid O
. O

This O
phenomenon O
can O
be O
mimicked O
by O
administering O
MP O
in O
divided O
doses O
. O

Two O
types O
of O
responses O
were O
compared O
after O
a O
single O
MP O
dose O
( O
40 O
mg O
bolus O
) O
and O
a O
divided O
regimen O
( O
20 O
mg O
bolus O
and O
a O
5 O
mg O
bolus O
8 O
hours O
later O
) O
in O
six O
healthy O
male O
volunteers O
. O

The O
suppression O
of O
basophils O
measured O
as O
whole O
blood O
histamine O
and O
plasma O
cortisol O
concentrations O
was O
assessed O
during O
32 O
hours O
. O

The O
37 O
. O
5 O
% O
reduction O
in O
dose O
produced O
a O
23 O
% O
overall O
decreased O
blood O
histamine O
response O
. O

A O
pharmacodynamic O
model O
for O
basophil O
cell O
distribution O
to O
and O
from O
an O
extravascular O
compartment O
describes O
the O
effects O
of O
MP O
after O
both O
regimens O
. O

A O
slower O
initial O
decline O
in O
blood O
histamine O
after O
the O
divided O
regimen O
may O
be O
related O
to O
incomplete O
suppression O
of O
basophil O
cell O
return O
to O
blood O
. O

The O
50 O
% O
inhibitory O
concentrations O
of O
MP O
of O
about O
5 O
ng O
/ O
ml O
were O
similar O
for O
both O
regimens O
. O

The O
decline O
and O
return O
of O
cortisol O
concentrations O
were O
similar O
between O
MP O
treatments O
with O
suppression O
continuing O
for O
24 O
hours O
. O

The O
50 O
% O
inhibitory O
concentrations O
of O
MP O
values O
for O
adrenal O
suppression O
were O
about O
1 O
ng O
/ O
ml O
. O

Pharmacodynamic O
modeling O
is O
useful O
in O
quantitating O
corticosteroid O
responses O
and O
generally O
predicted O
the O
" O
dose O
- O
sparing O
" O
effects O
that O
were O
achieved O
by O
prolonging O
MP O
plasma O
concentrations O
. O

This O
study O
supports O
previous O
clinical O
observations O
that O
patients O
may O
require O
morning O
through O
evening O
exposure O
to O
MP O
to O
optimize O
efficacy O
while O
adrenal O
suppression O
is O
being O
minimized O
. O

1 O
, O
25 O
( O
OH O
) O
2D2 O
production O
by O
T O
lymphocytes O
and O
alveolar O
macrophages O
recovered O
by O
lavage O
from O
normocalcemic O
patients O
with O
tuberculosis O
. O

To O
compare O
extra O
- O
renal O
1 O
, O
25 O
( O
OH O
) O
2D3 O
production O
in O
different O
types O
of O
granulomatous O
disease O
, O
and O
to O
identify O
the O
cell O
types O
responsible O
, O
we O
have O
evaluated O
the O
conversion O
of O
25 O
( O
OH O
) O
D3 O
in O
1 O
, O
25 O
( O
OH O
) O
2D3 O
by O
uncultured O
cells O
recovered O
by O
bronchoalveolar O
lavage O
and O
blood O
mononuclear O
cells O
from O
normocalcemic O
patients O
with O
sarcoidosis O
and O
tuberculosis O
. O

1 O
, O
25 O
( O
OH O
) O
2D3 O
was O
produced O
both O
by O
lavage O
cells O
( O
12 O
/ O
12 O
tuberculosis O
patients O
, O
2 O
/ O
6 O
sarcoidosis O
patients O
) O
and O
blood O
mononuclear O
cells O
( O
3 O
/ O
5 O
tuberculosis O
patients O
, O
0 O
/ O
3 O
sarcoidosis O
patients O
) O
from O
patients O
but O
not O
controls O
, O
but O
significantly O
greater O
amounts O
were O
produced O
by O
lavage O
cells O
from O
tuberculosis O
patients O
than O
those O
of O
sarcoidosis O
patients O
( O
P O
less O
than O
0 O
. O
001 O
) O
. O

1 O
, O
25 O
( O
OH O
) O
2D3 O
production O
by O
lavage O
cells O
from O
tuberculosis O
patients O
correlated O
with O
the O
number O
of O
CD8 O
+ O
T O
lymphocytes O
present O
but O
not O
other O
cell O
types O
. O

T O
lymphocytes O
appeared O
to O
be O
an O
important O
source O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
production O
, O
since O
purified O
T O
lymphocytes O
from O
all O
patients O
with O
tuberculosis O
produced O
1 O
, O
25 O
( O
OH O
) O
2D3 O
, O
and O
1 O
, O
25 O
( O
OH O
) O
2D3 O
production O
by O
these O
cells O
correlated O
closely O
with O
that O
produced O
by O
unseparated O
lavage O
cells O
. O

Because O
1 O
, O
25 O
( O
OH O
) O
2D3 O
can O
improve O
the O
capacity O
of O
macrophages O
to O
kill O
mycobacteria O
, O
our O
results O
support O
the O
conclusion O
that O
macrophage O
- O
lymphocyte O
interactions O
, O
mediated O
at O
least O
in O
part O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
, O
may O
be O
an O
important O
component O
of O
a O
successful O
antituberculous O
immune O
response O
. O

Megakaryocytic O
and O
erythrocytic O
lineages O
share O
specific O
transcription B-protein
factors I-protein
. O

Erythroid O
- O
specific O
genes O
contain O
binding O
sites O
for O
NF B-protein
- I-protein
E1 I-protein
( O
also O
called O
GF B-protein
- I-protein
1 I-protein
and O
Eryf B-protein
- I-protein
1 I-protein
; O
refs O
1 O
- O
3 O
respectively O
) O
, O
the O
principal O
DNA B-protein
- I-protein
binding I-protein
protein I-protein
of O
the O
erythrocytic O
lineage O
. O

NF B-protein
- I-protein
E1 I-protein
expression O
seems O
to O
be O
restricted O
to O
the O
erythrocytic O
lineage O
. O

A O
closely O
related O
( O
if O
not O
identical O
) O
protein O
is O
found O
in O
both O
a O
human O
megakaryocytic O
cell O
line O
and O
purified O
human O
megakaryocytes O
; O
it O
binds O
to O
promoter O
regions O
of O
two O
megakaryocytic O
- O
specific O
genes O
. O

The O
binding O
sites O
and O
partial O
proteolysis O
profile O
of O
this O
protein O
are O
indistinguishable O
from O
those O
of O
the O
erythroid B-protein
protein I-protein
; O
also O
, O
NF B-protein
- I-protein
E1 I-protein
messenger O
RNA O
is O
the O
same O
size O
in O
both O
the O
megakaryocytic O
and O
erythroid O
cell O
lines O
. O

Furthermore O
, O
point O
mutations O
that O
abolish O
binding O
of O
NF B-protein
- I-protein
E1 I-protein
result O
in O
a O
70 O
% O
decrease O
in O
the O
transcriptional O
activity O
of O
a O
megakaryocytic O
- O
specific O
promoter O
. O

We O
also O
find O
that O
NF B-protein
- I-protein
E2 I-protein
, O
another O
trans B-protein
- I-protein
acting I-protein
factor I-protein
of O
the O
erythrocytic O
lineage O
, O
is O
present O
in O
megakaryocytes O
. O

Transcriptional O
effects O
in O
both O
lineages O
might O
then O
be O
mediated O
in O
part O
by O
the O
same O
specific O
trans B-protein
- I-protein
acting I-protein
factors I-protein
. O

Our O
data O
strengthen O
the O
idea O
of O
a O
close O
association O
between O
the O
erythrocytic O
and O
the O
megakaryocytic O
lineages O
and O
could O
also O
explain O
the O
expression O
of O
markers O
specific O
to O
the O
erythrocytic O
and O
megakaryocytic O
lineages O
in O
most O
erythroblastic O
and O
megakaryoblastic O
permanent O
cell O
lines O
. O

Transcriptional O
down O
- O
regulation O
of O
c O
- O
myc O
expression O
by O
protein O
synthesis O
- O
dependent O
and O
- O
independent O
pathways O
in O
a O
human O
T O
lymphoblastic O
tumor O
cell O
line O
. O

We O
show O
that O
in O
the O
human O
T O
lymphoblastic O
tumor O
cell O
line O
Molt4 O
c O
- O
myc O
mRNA O
and O
protein O
expression O
is O
down O
- O
regulated O
after O
exposure O
to O
dimethyl O
sulfoxide O
, O
to O
phorbol O
myristate O
acetate O
, O
or O
to O
the O
calcium O
ionophore O
A23187 O
, O
which O
raises O
the O
intracellular O
calcium O
concentration O
. O

A O
block O
to O
RNA O
elongation O
is O
largely O
responsible O
for O
decreased O
c O
- O
myc O
transcription O
. O

Although O
negative O
regulation O
by O
dimethyl O
sulfoxide O
takes O
place O
even O
when O
protein O
synthesis O
is O
inhibited O
by O
cycloheximide O
, O
the O
phorbol O
myristate O
acetate O
effect O
is O
blocked O
to O
some O
extent O
only O
by O
cycloheximide O
. O

The O
calcium O
ionophore O
- O
induced O
c O
- O
myc O
suppression O
, O
however O
, O
strictly O
requires O
de O
novo O
protein O
synthesis O
. O

Therefore O
, O
two O
different O
negative O
regulatory O
pathways O
are O
involved O
in O
c O
- O
myc O
regulation O
: O
one O
which O
is O
independent O
and O
one O
which O
depends O
on O
de O
novo O
protein O
synthesis O
. O

The O
latter O
one O
appears O
to O
be O
mediated O
by O
a O
rapidly O
calcium B-protein
- I-protein
dependent I-protein
induced I-protein
gene I-protein
product I-protein
. O

Oestrogen B-protein
receptor I-protein
( O
ER B-protein
) O
analysis O
in O
B O
- O
cell O
chronic O
lymphocytic O
leukemia O
: O
correlation O
of O
biochemical O
and O
immunocytochemical O
methods O
. O

Oestrogen B-protein
receptors I-protein
( O
ER B-protein
) O
are O
present O
in O
neoplastic O
lymphoid O
cells O
and O
have O
been O
considered O
a O
physiological O
marker O
of O
growth O
rate O
or O
differentiation O
. O

Tamoxifen O
, O
an O
oestrogen O
antagonist O
, O
has O
been O
given O
in O
some O
patients O
with O
CLL O
and O
Hodgkin O
' O
s O
disease O
, O
with O
dramatic O
response O
in O
single O
cases O
. O

Until O
now O
, O
ER B-protein
status O
has O
been O
assessed O
using O
a O
steroid O
binding O
assay O
( O
SBA O
) O
which O
has O
many O
inherent O
problems O
. O

Recently O
, O
the O
development O
of O
monoclonal O
antibodies O
directed O
against O
ER B-protein
has O
been O
applied O
to O
the O
study O
of O
breast O
carcinomas O
and O
results O
obtained O
show O
good O
correlation O
with O
the O
quantitative O
SBA O
. O

We O
studied O
49 O
cases O
of O
B O
- O
cell O
chronic O
lymphocytic O
leukemia O
( O
CLL O
) O
using O
immunostaining O
of O
cytospin O
preparations O
. O

In O
30 O
of O
these O
cases O
ER B-protein
enzyme O
immunoassay O
( O
ER B-protein
- O
EIA O
) O
was O
also O
performed O
. O

Cultured O
MCF O
- O
7 O
cells O
, O
derived O
from O
a O
pleural O
effusion O
of O
a O
breast O
cancer O
patient O
, O
known O
to O
contain O
high O
levels O
of O
ER B-protein
were O
used O
as O
a O
positive O
control O
( O
40 O
- O
48 O
% O
ER B-protein
positive O
cells O
by O
immunocytochemistry O
; O
200 O
fmol O
/ O
mg O
protein O
by O
EIA O
) O
. O

All O
of O
the O
CLL O
cases O
except O
two O
( O
96 O
% O
) O
were O
negative O
for O
ER B-protein
( O
less O
than O
1 O
% O
staining O
; O
less O
than O
4 O
fmol O
/ O
mg O
protein O
) O
. O

The O
two O
positive O
cases O
expressed O
granular O
ER B-protein
staining O
over O
the O
nucleus O
( O
9 O
. O
2 O
and O
12 O
. O
1 O
% O
positive O
cells O
) O
and O
were O
positive O
by O
EIA O
and O
SBA O
. O

It O
is O
concluded O
that O
( O
i O
) O
patients O
with O
CLL O
rarely O
express O
ER B-protein
and O
( O
ii O
) O
immunocytochemical O
staining O
of O
cytospin O
preparations O
is O
a O
valid O
technique O
for O
the O
measurement O
of O
ER B-protein
. O

It O
is O
of O
interest O
that O
one O
of O
the O
positive O
cases O
was O
diagnosed O
as O
CLL O
with O
Richter O
' O
s O
transformation O
confirming O
earlier O
findings O
. O

Type B-protein
- I-protein
II I-protein
estrogen I-protein
binding I-protein
sites I-protein
in O
a O
lymphoblastoid O
cell O
line O
and O
growth O
- O
inhibitory O
effect O
of O
estrogen O
, O
anti O
- O
estrogen O
and O
bioflavonoids O
. O

Type B-protein
- I-protein
II I-protein
estrogen I-protein
- I-protein
binding I-protein
sites I-protein
( O
type B-protein
- I-protein
II I-protein
EBS I-protein
) O
have O
been O
demonstrated O
in O
the O
human O
lymphoblastoid O
cell O
line O
IM O
- O
9 O
using O
a O
whole O
- O
cell O
assay O
with O
( O
6 O
, O
7 O
- O
3H O
) O
estradiol O
( O
3H O
- O
E2 O
) O
as O
tracer O
. O

Competition O
analysis O
showed O
that O
the O
anti O
- O
estrogen O
tamoxifen O
and O
the O
flavonoids O
quercetin O
and O
rutin O
competed O
for O
( O
3H O
) O
- O
E2 O
binding O
to O
type B-protein
- I-protein
II I-protein
EBS I-protein
. O

Growth O
experiments O
demonstrated O
that O
diethylstilbestrol O
( O
DES O
) O
tamoxifen O
( O
TAM O
) O
, O
quercetin O
and O
rutin O
exerted O
a O
reversible O
dose O
- O
dependent O
inhibition O
of O
cell O
proliferation O
in O
the O
range O
of O
concentrations O
between O
10 O
nM O
and O
10 O
microM O
. O

The O
relative O
binding O
affinity O
of O
quercetin O
, O
rutin O
, O
DES O
and O
TAM O
for O
type B-protein
- I-protein
II I-protein
EBS I-protein
correlated O
well O
with O
their O
potency O
as O
cell O
growth O
inhibitors O
. O

Moreover O
, O
hesperidin O
, O
a O
flavonoid O
which O
does O
not O
bind O
to O
type B-protein
- I-protein
II I-protein
EBS I-protein
, O
was O
ineffective O
in O
inhibiting O
cell O
growth O
. O

Cell O
- O
cycle O
analysis O
showed O
that O
the O
growth O
- O
inhibitory O
effect O
of O
DES O
, O
TAM O
or O
quercetin O
was O
due O
to O
a O
blocking O
effect O
in O
the O
G0 O
- O
G1 O
phases O
. O

Our O
results O
suggest O
that O
high O
estrogen O
and O
anti O
- O
estrogen O
concentrations O
and O
flavonoids O
may O
regulate O
IM O
- O
9 O
cell O
growth O
through O
a O
common O
mechanism O
involving O
a O
binding O
interaction O
with O
type B-protein
- I-protein
II I-protein
EBS I-protein
. O

[ O
Glucocorticoid B-protein
receptors I-protein
in O
peripheral O
blood O
lymphocytes O
of O
patients O
with O
bronchial O
asthma O
] O
. O

Quantitation O
of O
glucocorticoid B-protein
receptors I-protein
( O
GCR B-protein
) O
and O
the O
study O
of O
their O
affinity O
for O
glucocorticosteroids O
( O
GCS O
) O
were O
made O
in O
peripheral O
blood O
lymphocytes O
of O
bronchial O
asthma O
( O
BA O
) O
patients O
in O
consideration O
of O
GCR B-protein
treatment O
and O
serum O
levels O
of O
endogenous O
cortisol O
. O

It O
is O
stated O
that O
GCR B-protein
of O
healthy O
controls O
and O
GCS O
- O
untreated O
patients O
outnumbered O
those O
of O
cortisol O
- O
dependent O
BA O
patients O
on O
hormone O
therapy O
. O

Following O
discontinuation O
of O
glucocorticoid O
drugs O
GCR B-protein
count O
in O
cortisol O
- O
dependent O
BA O
tends O
to O
rise O
. O

Endogenous O
cortisol O
has O
no O
effect O
on O
GCR B-protein
level O
estimated O
by O
3H O
- O
triamcinolone O
acetonide O
. O

Two O
glucocorticoid B-protein
binding I-protein
sites I-protein
on O
the O
human B-protein
glucocorticoid I-protein
receptor I-protein
. O

Glucocorticoids O
are O
known O
to O
have O
a O
lytic O
effect O
in O
leukemic O
cells O
via O
interactions O
with O
the O
glucocorticoid B-protein
receptor I-protein
( O
GR B-protein
) O
. O

Cortisol O
and O
various O
synthetic O
glucocorticoids O
bind O
to O
the O
GR B-protein
with O
one O
- O
site O
kinetics O
. O

Cortivazol O
( O
CVZ O
) O
is O
a O
unique O
, O
high O
potency O
synthetic O
glucocorticoid O
, O
which O
has O
a O
phenylpyrazol O
fused O
to O
the O
A O
- O
ring O
of O
the O
steroid O
nucleus O
and O
displays O
binding O
consistent O
with O
two O
or O
more O
sites O
in O
the O
cytosol O
from O
CEM O
C7 O
cells O
( O
a O
human O
acute O
lymphoblastic O
T O
- O
cell O
line O
) O
. O

It O
has O
previously O
been O
shown O
that O
the O
lower O
affinity O
class O
of O
sites O
are O
similar O
in O
affinity O
and O
site O
molarity O
to O
those O
recognized O
by O
dexamethasone O
. O

The O
higher O
affinity O
sites O
bind O
CVZ O
with O
20 O
- O
to O
50 O
- O
fold O
greater O
affinity O
, O
consistent O
with O
CVZ O
' O
s O
enhanced O
biological O
effects O
. O

In O
mutant O
leukemic O
cells O
resistant O
to O
the O
lytic O
effects O
of O
dexamethasone O
, O
CVZ O
both O
lyses O
the O
cells O
and O
recognizes O
a O
single O
class O
of O
sites O
similar O
to O
the O
high O
affinity O
site O
in O
CEM O
C7 O
cells O
. O

We O
have O
carried O
out O
experiments O
to O
define O
the O
nature O
of O
the O
higher B-protein
affinity I-protein
CVZ I-protein
binding I-protein
site I-protein
. O

We O
now O
show O
that O
: O
1 O
) O
CVZ O
has O
more O
than O
one O
binding O
site O
in O
a O
second O
, O
independent O
, O
B O
- O
cell O
line O
, O
IM O
- O
9 O
; O
2 O
) O
the O
antiglucocorticoid O
RU O
38486 O
is O
able O
to O
block O
both O
CVZ O
' O
s O
higher O
and O
lower O
affinity O
sites O
; O
3 O
) O
all O
of O
CVZ B-protein
' I-protein
s I-protein
binding I-protein
sites I-protein
are O
on O
a O
protein O
immunologically O
indistinguishable O
from O
the O
human O
GR B-protein
; O
and O
4 O
) O
freshly O
isolated O
clones O
of O
CVZ O
- O
resistant O
cells O
have O
lost O
all O
binding O
sites O
for O
CVZ O
. O

These O
data O
indicate O
that O
CVZ O
is O
recognizing O
two O
glucocorticoid B-protein
binding I-protein
sites I-protein
on O
the O
human O
GR B-protein
or O
a O
protein O
very O
similar O
to O
it O
. O

Retroviral O
mediated O
transfer O
and O
expression O
of O
exogenous O
genes O
in O
primary O
lymphoid O
cells O
: O
assaying O
for O
a O
viral O
transactivator B-protein
activity O
in O
normal O
and O
malignant O
cells O
. O

In O
this O
report O
we O
describe O
the O
use O
of O
recombinant O
retroviruses O
to O
characterize O
the O
activity O
of O
an O
exogenous O
promoter O
in O
primary O
cells O
obtained O
from O
patients O
with O
lymphoproliferative O
disorders O
. O

The O
infection O
of O
a O
variety O
of O
cultured O
and O
primary O
lymphoid O
cells O
with O
a O
recombinant O
retrovirus O
containing O
a O
histone B-protein
promoter I-protein
- I-protein
driven I-protein
beta I-protein
- I-protein
galactosidase I-protein
gene O
is O
shown O
to O
result O
in O
the O
expression O
of O
beta B-protein
- I-protein
galactosidase I-protein
in O
50 O
% O
to O
100 O
% O
of O
the O
cells O
. O

A O
similar O
infection O
with O
a O
recombinant O
retrovirus O
containing O
the O
beta B-protein
- I-protein
galactosidase I-protein
gene O
with O
an O
adenovirus O
E2 O
promoter O
, O
results O
in O
beta B-protein
- I-protein
galactosidase I-protein
activity O
in O
a O
limited O
number O
of O
cultured O
and O
primary O
cells O
. O

Since O
the O
adenovirus O
E2 O
promoter O
has O
been O
well O
characterized O
and O
is O
known O
to O
be O
regulated O
by O
transactivators B-protein
encoded O
by O
many O
viruses O
, O
the O
activity O
of O
this O
promoter O
in O
specific O
cell O
types O
is O
discussed O
in O
reference O
to O
both O
the O
biology O
of O
the O
cell O
and O
the O
possible O
presence O
of O
as O
yet O
undetected O
viral B-protein
gene I-protein
products I-protein
. O

[ O
The O
effect O
of O
24 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
dioxyvit O
) O
on O
Ca O
metabolism O
and O
immune O
status O
during O
chronic O
kidney O
failure O
] O
. O

Active O
metabolite O
of O
vitamin O
D3 O
, O
24R O
, O
25 O
( O
OH O
) O
2D3 O
( O
dioxyvit O
) O
was O
used O
at O
a O
daily O
dose O
of O
100 O
micrograms O
in O
treatment O
of O
children O
affected O
with O
tubulointerstitial O
disease O
of O
kidney O
and O
with O
chronic O
glomerulonephritis O
under O
conditions O
of O
kidney O
insufficiency O
. O

The O
drug O
exhibited O
distinct O
normalizing O
effect O
on O
patterns O
of O
calcium O
metabolism O
: O
increase O
of O
total O
and O
ionized O
Ca2 O
+ O
and O
of O
25 O
- O
OHD O
, O
decrease O
in O
concentration O
of O
parath O
hormone O
and O
osteocalcine O
in O
blood O
serum O
as O
well O
as O
on O
immunological O
parameters O
: O
restoration O
of O
decreased O
content O
of O
T O
- O
and O
0 O
- O
lymphocytes O
. O

Concentration O
of O
receptors O
of O
hormonal O
form O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
was O
found O
to O
be O
minimal O
in O
lymphocytes O
under O
conditions O
of O
chronic O
kidney O
insufficiency O
, O
while O
their O
expression O
, O
after O
the O
dioxyvit O
action O
, O
was O
detected O
only O
in O
patients O
with O
glomerulonephritis O
. O

Specific O
calcitropic O
effect O
of O
dioxyvit O
with O
simultaneous O
correction O
of O
vitamin O
D O
deficiency O
were O
apparently O
responsible O
for O
high O
efficacy O
of O
the O
drug O
in O
treatment O
of O
calcium O
metabolism O
and O
immunity O
impairments O
in O
children O
with O
renal O
deteriorations O
at O
the O
step O
of O
chronic O
kidney O
insufficiency O
. O

[ O
The O
role O
of O
glucocorticoid B-protein
receptors I-protein
and O
HLA B-protein
antigens I-protein
in O
the O
pathogenesis O
of O
Cushing B-protein
' I-protein
s I-protein
syndrome I-protein
] O
. O

Lymphocytic O
levels O
of O
glucocorticoid B-protein
receptors I-protein
were O
evaluated O
in O
114 O
patients O
suffering O
from O
Icenko O
- O
Cushing B-protein
' I-protein
s I-protein
syndrome I-protein
. O

Incidence O
of O
HLA B-protein
antigens I-protein
was O
determined O
in O
94 O
of O
them O
. O

A O
significant O
rise O
of O
A10 B-protein
and O
B27 B-protein
antigen I-protein
incidence O
compared O
to O
that O
in O
normal O
subjects O
allows O
these O
antigens O
to O
be O
considered O
genetic O
markers O
of O
Icenko O
- O
Cushing B-protein
' I-protein
s I-protein
syndrome I-protein
. O

The O
levels O
of O
glucocorticoid B-protein
receptors I-protein
in O
lymphocytes O
of O
the O
patients O
are O
lower O
than O
in O
normal O
subjects O
both O
in O
the O
active O
stage O
of O
the O
disease O
and O
following O
bilateral O
total O
adrenalectomy O
. O

The O
patients O
carrying O
B27 B-protein
antigen I-protein
had O
lymphocytic O
receptor O
concentrations O
under O
the O
levels O
of O
such O
in O
patients O
free O
of O
the O
antigen O
carriage O
. O

Antigen B-protein
B27 I-protein
seems O
to O
be O
a O
cause O
of O
lower O
levels O
of O
glucocorticoid B-protein
receptors I-protein
in O
blood O
lymphocytes O
. O

Effects O
of O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
on O
the O
human O
chronic O
myelogenous O
leukemia O
cell O
line O
RWLeu O
- O
4 O
. O

The O
effects O
of O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
VD3 O
) O
on O
proliferation O
, O
differentiation O
, O
and O
macromolecular O
synthesis O
in O
the O
new O
Philadelphia O
chromosome O
- O
positive O
chronic O
myelogenous O
leukemia O
cell O
line O
, O
RWLeu O
- O
4 O
, O
were O
investigated O
. O

Binding O
of O
[ O
3H O
] O
VD3 O
was O
saturable O
, O
with O
approximately O
2000 O
- O
3000 O
sites O
/ O
cell O
, O
and O
half O
- O
maximal O
binding O
occurring O
at O
0 O
. O
21 O
- O
0 O
. O
33 O
nM O
. O

Treatment O
of O
RWLeu O
- O
4 O
cells O
with O
VD3 O
induced O
24R B-protein
- I-protein
hydroxylase I-protein
activity O
, O
a O
marker O
of O
vitamin O
D3 O
responsiveness O
in O
many O
tissues O
. O

Exposure O
of O
RWLeu O
- O
4 O
cells O
to O
VD3 O
also O
inhibited O
proliferation O
and O
DNA O
synthesis O
with O
a O
50 O
% O
effective O
dose O
of O
3 O
. O
5 O
- O
10 O
nM O
within O
72 O
h O
; O
in O
addition O
, O
protein O
and O
RNA O
synthesis O
were O
inhibited O
by O
VD3 O
treatment O
. O

Exposure O
of O
RWLeu O
- O
4 O
cells O
to O
5 O
nM O
VD3 O
for O
72 O
h O
caused O
50 O
% O
of O
the O
cells O
to O
differentiate O
into O
macrophage O
/ O
monocyte O
type O
cells O
as O
judged O
by O
nitroblue O
tetrazolium O
staining O
and O
adherence O
to O
plastic O
. O

Progressive O
expression O
of O
cell B-protein
surface I-protein
maturation I-protein
- I-protein
specific I-protein
antigens I-protein
of O
the O
monocyte O
/ O
macrophage O
lineage O
was O
induced O
by O
treatment O
of O
RWLeu O
- O
4 O
cells O
with O
VD3 O
for O
24 O
to O
72 O
h O
at O
doses O
that O
inhibited O
cellular O
proliferation O
. O

c O
- O
myc O
RNA O
, O
which O
is O
constitutively O
expressed O
in O
RWLeu O
- O
4 O
cells O
, O
increased O
after O
0 O
. O
5 O
h O
of O
treatment O
with O
50 O
nM O
VD3 O
and O
then O
rapidly O
decreased O
to O
barely O
detectable O
levels O
after O
4 O
h O
of O
treatment O
. O

Finally O
, O
the O
in O
vitro O
tyrosine O
kinase O
activity O
associated O
with O
the O
p210bcr B-protein
- I-protein
abl I-protein
oncogene I-protein
product I-protein
was O
decreased O
approximately O
50 O
% O
by O
VD3 O
treatment O
. O

Because O
of O
the O
presence O
of O
a O
functional O
receptor O
- O
effector O
system O
for O
VD3 O
and O
multiple O
biological O
responses O
to O
the O
hormone O
, O
these O
cells O
provide O
a O
unique O
model O
system O
with O
which O
to O
probe O
the O
specific O
effects O
of O
VD3 O
on O
cell O
growth O
and O
differentiation O
in O
chronic O
myelogenous O
leukemia O
. O

A O
new O
member O
of O
the O
leucine B-protein
zipper I-protein
class I-protein
of O
proteins O
that O
binds O
to O
the O
HLA O
DR O
alpha O
promoter O
. O

Several O
mutants O
derived O
from O
transformed O
human O
B O
cell O
lines O
are O
defective O
in O
expressing O
major O
histocompatibility O
complex O
( O
MHC O
) O
class O
II O
genes O
. O

The O
failure O
to O
express O
a O
class O
II O
gene O
in O
at O
least O
one O
such O
mutant O
line O
has O
been O
mapped O
to O
the O
MHC O
class O
II O
X O
box O
, O
a O
conserved O
transcriptional O
element O
in O
the O
promoter O
region O
. O

A O
complementary O
DNA O
encoding O
a O
DNA B-protein
- I-protein
binding I-protein
protein I-protein
( O
human B-protein
X I-protein
box I-protein
binding I-protein
protein I-protein
, O
hXBP B-protein
- I-protein
1 I-protein
) O
whose O
target O
is O
the O
human O
DR O
alpha O
X O
box O
and O
the O
3 O
' O
flanking O
region O
has O
now O
been O
cloned O
. O

This O
complementary O
DNA O
encoded O
a O
protein O
with O
structural O
similarities O
to O
the O
c B-protein
- I-protein
jun I-protein
proto I-protein
- I-protein
oncogene I-protein
product I-protein
, O
and O
its O
target O
sequence O
was O
closely O
related O
to O
the O
palindromic O
target O
sequence O
of O
c O
- O
jun O
. O

Mutation O
of O
the O
hXBP B-protein
- I-protein
1 I-protein
DNA O
target O
sequence O
decreased O
DR O
alpha O
promoter O
activity O
in O
vivo O
. O

These O
studies O
suggest O
that O
the O
hXBP B-protein
- I-protein
1 I-protein
protein I-protein
acts O
as O
a O
transcription B-protein
factor I-protein
in O
B O
cells O
. O

Pseudohypoaldosteronism O
in O
eight O
families O
: O
different O
forms O
of O
inheritance O
are O
evidence O
for O
various O
genetic O
defects O
. O

Pseudohypoaldosteronism O
is O
a O
rare O
hereditary O
disorder O
presenting O
in O
early O
infancy O
with O
renal O
salt O
loss O
leading O
to O
hyponatremia O
and O
hyperkalemia O
despite O
high O
levels O
of O
plasma O
aldosterone O
. O

The O
patients O
are O
insensitive O
to O
mineralocorticoids O
; O
however O
, O
sodium O
supplementation O
is O
able O
to O
correct O
electrolyte O
abnormalities O
. O

Absent O
or O
greatly O
diminished O
type O
I B-protein
aldosterone I-protein
receptors I-protein
in O
peripheral O
mononuclear O
leucocytes O
have O
been O
recently O
demonstrated O
and O
explain O
the O
lack O
of O
response O
to O
mineralocorticoids O
. O

We O
have O
studied O
the O
mode O
of O
inheritance O
in O
eight O
families O
with O
a O
total O
of O
nine O
patients O
. O

There O
was O
evidence O
for O
an O
autosomal O
recessive O
form O
of O
inheritance O
in O
four O
families O
, O
while O
the O
other O
four O
families O
appeared O
to O
have O
an O
autosomal O
dominant O
mode O
of O
transmission O
. O

In O
three O
families O
the O
autosomal O
recessive O
form O
was O
characterized O
by O
normal B-protein
receptor I-protein
as O
well O
as O
hormone O
data O
in O
both O
parents O
, O
while O
in O
one O
family O
receptor O
levels O
in O
both O
parents O
were O
greatly O
reduced O
, O
but O
hormone O
levels O
were O
normal O
. O

In O
the O
four O
families O
with O
an O
autosomal O
dominant O
mode O
of O
transmission O
there O
was O
always O
one O
parent O
with O
reduced O
receptor O
binding O
in O
peripheral O
mononuclear O
leucocytes O
and O
elevated O
serum O
hormone O
levels O
. O

These O
parents O
were O
entirely O
asymptomatic O
. O

In O
an O
extended O
family O
we O
were O
able O
to O
study O
an O
aunt O
and O
her O
newborn O
daughter O
, O
who O
were O
both O
also O
biochemically O
affected O
but O
clinically O
asymptomatic O
. O

It O
, O
therefore O
, O
appears O
that O
this O
dual O
pattern O
of O
genetic O
transmission O
may O
indicate O
differing O
genetic O
defects O
which O
cause O
the O
same O
clinical O
picture O
of O
pseudohypoaldosteronism O
. O

Perceived O
social O
support O
and O
tumor O
estrogen B-protein
/ I-protein
progesterone I-protein
receptor I-protein
status O
as O
predictors O
of O
natural B-protein
killer I-protein
cell I-protein
activity I-protein
in O
breast O
cancer O
patients O
. O

This O
report O
is O
concerned O
with O
the O
prediction O
of O
natural O
killer O
( O
NK O
) O
cell O
activity O
in O
61 O
Stage O
I O
and O
II O
breast O
cancer O
patients O
, O
between O
the O
ages O
of O
25 O
and O
70 O
, O
who O
were O
accrued O
to O
this O
project O
. O

All O
baseline O
interview O
and O
testing O
data O
were O
obtained O
either O
just O
before O
patients O
were O
discharged O
from O
the O
hospital O
, O
or O
at O
their O
first O
outpatient O
visit O
, O
within O
two O
weeks O
of O
discharge O
. O

A O
major O
interest O
of O
this O
project O
is O
the O
predictive O
value O
of O
perceived O
social O
support O
, O
as O
a O
potential O
" O
stress O
" O
buffer O
, O
related O
to O
NK O
activity O
. O

In O
the O
main O
model O
reported O
here O
, O
we O
found O
that O
a O
significant O
amount O
of O
NK O
activity O
variance O
could O
be O
explained O
by O
five O
variables O
. O

Higher O
NK O
activity O
could O
be O
predicted O
by O
the O
perception O
of O
high O
quality O
emotional O
support O
from O
a O
spouse O
or O
intimate O
other O
, O
perceived O
social O
support O
from O
the O
patient O
' O
s O
physician O
, O
estrogen B-protein
receptor I-protein
- O
negative O
tumor O
status O
, O
having O
an O
excisional B-protein
biopsy I-protein
as O
surgical B-protein
treatment I-protein
, O
and O
actively O
seeking O
social B-protein
support I-protein
as O
a O
major O
coping O
strategy O
( O
R2 O
= O
0 O
. O
33 O
, O
F O
( O
5 O
, O
55 O
) O
= O
5 O
. O
5 O
, O
p O
less O
than O
0 O
. O
0004 O
) O
. O

Findings O
are O
discussed O
in O
terms O
of O
host O
interaction O
with O
tumor B-protein
endocrine I-protein
status I-protein
, O
and O
the O
role O
that O
social B-protein
support I-protein
might O
play O
in O
modulating O
such O
activity O
. O

[ O
Estrogen B-protein
receptor I-protein
content O
of O
peripheral O
blood O
lymphocytes O
in O
patients O
with O
systemic O
lupus O
erythematosus O
] O
. O

ER O
content O
in O
lymphocytes O
of O
peripheral O
blood O
from O
27 O
SLE O
patients O
and O
20 O
healthy O
controls O
were O
determined O
by O
dextran O
- O
coated O
charcoal O
assay O
. O

ER B-protein
content O
in O
lymphocytes O
of O
each O
sample O
was O
expressed O
by O
both O
fmol O
/ O
mg O
of O
lymphocyte B-protein
cytosolic I-protein
protein I-protein
and O
fmol O
/ O
micrograms O
of O
lymphocyte O
DNA O
. O

The O
results O
showed O
that O
there O
was O
no O
significant O
difference O
between O
the O
ER B-protein
content O
of O
lymphocytes O
from O
the O
controls O
and O
that O
from O
patients O
with O
SLE O
. O

But O
the O
logarithmic O
mean O
of O
ER B-protein
content O
in O
lymphocytes O
, O
expressed O
by O
fmol O
/ O
mg O
of O
cytosolic B-protein
protein I-protein
, O
in O
14 O
patients O
with O
active O
SLE O
( O
0 O
. O
9356 O
+ O
/ O
- O
0 O
. O
31 O
) O
was O
significantly O
higher O
than O
that O
in O
13 O
patients O
with O
inactive O
SLE O
( O
0 O
. O
2979 O
+ O
/ O
- O
0 O
. O
23 O
, O
P O
less O
than O
0 O
. O
001 O
) O
and O
in O
the O
controls O
( O
0 O
. O
6204 O
+ O
/ O
- O
0 O
. O
52 O
, O
P O
less O
than O
0 O
. O
001 O
) O
. O

The O
normal O
upper O
limit O
of O
ER B-protein
content O
in O
lymphocytes O
, O
expressed O
by O
fmol O
/ O
micrograms O
of O
DNA O
, O
was O
0 O
. O
136 O
. O

The O
elevated O
rate O
of O
ER B-protein
content O
in O
lymphocytes O
in O
14 O
active O
SLE O
( O
92 O
. O
9 O
% O
) O
was O
also O
higher O
than O
that O
in O
quieiescent O
patients O
( O
23 O
. O
1 O
% O
, O
P O
less O
than O
0 O
. O
001 O
) O
and O
in O
the O
controls O
( O
10 O
% O
, O
P O
less O
than O
0 O
. O
001 O
) O
. O

Moreover O
, O
the O
elevated O
level O
of O
ER B-protein
content O
was O
found O
to O
be O
related O
to O
the O
positive O
antidsDNA B-protein
antibody I-protein
and O
hypocomplementemia O
. O

An O
in O
vitro O
globin O
gene O
switching O
model O
based O
on O
differentiated O
embryonic O
stem O
cells O
. O

We O
used O
mouse O
embryonic O
stem O
( O
ES O
) O
cells O
to O
study O
globin O
gene O
expression O
and O
switching O
in O
vitro O
. O

We O
show O
that O
ES O
- O
derived O
embryoid O
bodies O
express O
the O
full O
complement O
of O
mouse O
embryonic O
globin O
genes O
in O
the O
correct O
temporal O
order O
and O
that O
on O
further O
differentiation O
, O
a O
switch O
occurs O
to O
the O
fetal O
/ O
adult O
genes O
. O

In O
addition O
, O
the O
erythroid B-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
NF B-protein
- I-protein
E1 I-protein
was O
shown O
to O
be O
expressed O
coordinately O
with O
that O
of O
globin B-protein
in O
embryoid O
bodies O
. O

We O
conclude O
from O
these O
experiments O
that O
the O
ES O
cell O
system O
provides O
a O
good O
model O
to O
study O
hematopoietic O
development O
. O

When O
the O
human O
epsilon O
- O
or O
beta O
- O
globin O
genes O
driven O
by O
the O
dominant O
control O
region O
( O
DCR O
) O
are O
introduced O
into O
this O
system O
, O
the O
human O
epsilon O
- O
globin O
gene O
, O
in O
contrast O
to O
the O
beta O
- O
globin O
gene O
, O
is O
not O
deregulated O
by O
the O
presence O
of O
the O
DCR O
and O
is O
expressed O
strictly O
as O
an O
embryonic O
gene O
. O

We O
conclude O
from O
this O
that O
the O
epsilon O
- O
globin O
gene O
is O
not O
regulated O
by O
competition O
with O
other O
genes O
in O
the O
human O
beta O
- O
globin O
locus O
. O

Cloning O
of O
a O
mitogen O
- O
inducible O
gene O
encoding O
a O
kappa B-protein
B I-protein
DNA I-protein
- I-protein
binding I-protein
protein I-protein
with O
homology O
to O
the O
rel O
oncogene O
and O
to O
cell O
- O
cycle O
motifs O
. O

We O
have O
cloned O
and O
characterized O
a O
mitogen O
- O
inducible O
gene O
isolated O
from O
human O
T O
cells O
that O
predicts O
a O
protein O
of O
968 B-protein
amino I-protein
acids I-protein
. O

The O
amino B-protein
- I-protein
terminal I-protein
domain I-protein
has O
regions O
homologous O
to O
the O
oncogene O
rel O
and O
to O
the O
developmentally O
important O
gene O
dorsal O
of O
Drosophila O
. O

The O
carboxy B-protein
- I-protein
terminal I-protein
domain I-protein
contains O
repeat O
structures O
found O
in O
a O
variety O
of O
proteins O
that O
are O
involved O
in O
cell O
- O
cycle O
control O
of O
yeast O
and O
in O
tissue O
differentiation O
in O
Drosophila O
and O
Ceanorhabditis O
elegans O
, O
as O
well O
as O
in O
the O
putative O
human O
oncogene O
bcl O
- O
3 O
and O
in O
the O
ankyrin B-protein
protein I-protein
. O

A O
truncated O
form O
of O
the O
product O
of O
this O
gene O
translated O
in O
vitro O
is O
a O
DNA B-protein
- I-protein
binding I-protein
protein I-protein
which O
interacts O
specifically O
with O
the O
kappa O
B O
binding O
site O
found O
in O
many O
inducible O
genes O
, O
including O
the O
enhancer O
in O
human O
immunodeficiency O
virus O
. O

This O
gene O
is O
yet O
another O
in O
a O
growing O
list O
of O
important O
regulatory O
molecules O
whose O
expression O
is O
transcriptionally O
induced O
upon O
cellular O
activation O
. O

Extrarenal O
receptor O
- O
effector O
- O
mechanisms O
for O
aldosterone O
: O
the O
sequence O
of O
effects O
on O
the O
cellular O
electrolyte O
transport O
in O
human O
lymphocytes O
and O
their O
implications O
for O
disorders O
of O
the O
water O
and O
electrolyte O
balances O
. O

High O
affinity O
aldosterone O
binding O
sites O
have O
not O
only O
been O
described O
in O
the O
classic O
target O
tissues O
such O
as O
the O
renal O
tubules O
, O
but O
also O
in O
non O
- O
classic O
target O
tissues O
such O
as O
the O
hippocampus O
, O
mammary O
gland O
, O
endothelial O
cells O
and O
, O
recently O
, O
human O
mononuclear O
leukocytes O
. O

An O
in O
vitro O
effect O
of O
aldosterone O
on O
intracellular O
sodium O
, O
potassium O
and O
calcium O
concentrations O
and O
cell O
volume O
was O
shown O
in O
human O
mononuclear O
leukocytes O
. O

In O
the O
absence O
of O
aldosterone O
, O
the O
intracellular O
Na O
+ O
, O
K O
+ O
and O
Ca2 O
+ O
concentrations O
and O
the O
cell O
volume O
decreased O
significantly O
, O
but O
remained O
constant O
when O
aldosterone O
( O
1 O
. O
4 O
nmol O
/ O
l O
) O
was O
added O
to O
the O
incubation O
medium O
. O

These O
effects O
of O
aldosterone O
were O
blocked O
by O
the O
aldosterone O
antagonist O
canrenone O
( O
140 O
nmol O
/ O
l O
) O
. O

The O
sodium B-protein
/ I-protein
proton I-protein
exchanger I-protein
of O
the O
cell O
membrane O
could O
be O
identified O
as O
the O
primary O
target O
of O
the O
aldosterone O
action O
, O
possibly O
non O
- O
genomically O
mediated O
through O
membrane B-protein
receptors I-protein
. O

The O
clinical O
significance O
of O
this O
model O
was O
underlined O
by O
the O
demonstration O
of O
absent O
or O
a O
decreased O
number O
of O
mineralocorticoid B-protein
receptors I-protein
and O
the O
lack O
of O
electrolyte O
response O
to O
aldosterone O
in O
human O
mononuclear O
leukocytes O
of O
patients O
with O
pseudohypoaldosteronism O
and O
aldosteronism O
. O

Additionally O
, O
an O
abnormal O
effector O
mechanism O
could O
be O
demonstrated O
in O
human O
mononuclear O
leukocytes O
from O
essential O
hypertensives O
. O

These O
studies O
are O
the O
first O
to O
demonstrate O
the O
significance O
of O
extrarenal B-protein
, I-protein
nonepithelial I-protein
mineralocorticoid I-protein
receptors I-protein
and O
the O
related O
effector O
mechanism O
in O
different O
disorders O
of O
the O
water O
and O
electrolyte O
balance O
in O
man O
. O

Immunohistochemical O
study O
of O
steroid O
hormones O
and O
an O
estrogen O
binding O
assay O
in O
malignant O
soft O
tissue O
tumors O
. O

Immunohistochemically O
, O
the O
immunoreaction O
against O
5 O
steroid O
hormone O
anti O
- O
sera O
( O
estradiol O
, O
estriol O
, O
cortisol O
, O
progesterone O
and O
testosterone O
) O
was O
examined O
in O
39 O
cases O
with O
the O
malignant O
soft O
tissue O
tumors O
( O
fibrosarcoma O
: O
8 O
, O
malignant O
fibrous O
histiocytoma O
: O
6 O
, O
rhabdomyosarcoma O
: O
10 O
, O
leiomyosarcoma O
: O
10 O
, O
liposarcoma O
: O
5 O
) O
. O

Seventeen O
cases O
revealed O
distinct O
immunostaining O
against O
at O
least O
1 O
of O
the O
5 O
steroid O
hormones O
. O

Immunostained O
tumor O
cells O
were O
more O
frequently O
distributed O
in O
the O
area O
where O
tumor O
cell O
infiltration O
was O
more O
invasive O
. O

The O
majority O
of O
the O
positive O
cases O
occurred O
in O
female O
cases O
. O

Furthermore O
, O
the O
existence O
of O
estrogen B-protein
receptor I-protein
( O
estrogen O
binding O
activity O
) O
was O
examined O
histochemically O
in O
39 O
cases O
and O
it O
was O
detected O
in O
8 O
. O

We O
concluded O
that O
steroid O
hormones O
might O
be O
closely O
related O
to O
tumor O
cell O
infiltration O
of O
some O
malignant O
soft O
tissue O
tumors O
. O

Involvement O
of O
cyclic B-protein
AMP I-protein
- I-protein
dependent I-protein
protein I-protein
kinases I-protein
in O
the O
signal O
transduction O
pathway O
for O
interleukin B-protein
- I-protein
1 I-protein
. O

Expression O
of O
a O
highly O
specific O
protein O
inhibitor O
for O
cyclic B-protein
AMP I-protein
- I-protein
dependent I-protein
protein I-protein
kinases I-protein
in O
interleukin B-protein
- I-protein
1 I-protein
( O
IL O
- O
1 O
) O
- O
responsive O
cells O
blocked O
IL O
- O
1 O
- O
induced O
gene O
transcription O
that O
was O
driven O
by O
the O
kappa O
immunoglobulin O
enhancer O
or O
the O
human O
immunodeficiency O
virus O
long O
terminal O
repeat O
. O

This O
inhibitor O
did O
not O
affect O
protein B-protein
kinase I-protein
C I-protein
- O
mediated O
gene O
transcription O
, O
suggesting O
that O
cyclic B-protein
AMP I-protein
- I-protein
dependent I-protein
protein I-protein
kinases I-protein
are O
involved O
in O
the O
signal O
transduction O
pathway O
for O
IL B-protein
- I-protein
1 I-protein
in O
a O
number O
of O
responsive O
cell O
types O
. O

The O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
ORI1yt O
enhancer O
is O
not O
B O
- O
cell O
specific O
and O
does O
not O
respond O
synergistically O
to O
the O
EBV O
transcription O
factors O
R O
and O
Z O
. O

The O
Epstein O
- O
Barr O
virus O
DR O
promoter O
is O
located O
upstream O
of O
the O
PstI O
repeats O
, O
and O
in O
addition O
to O
the O
TATA O
box O
, O
it O
contains O
an O
upstream O
region O
( O
positions O
- O
69 O
to O
- O
220 O
) O
responsive O
to O
EB1 B-protein
( I-protein
Z I-protein
) I-protein
( O
the O
BZLF1 B-protein
- I-protein
encoded I-protein
transcription I-protein
factor I-protein
) O
and O
an O
enhancer O
with O
two O
functionally O
distinct O
domains O
, O
A O
and O
B O
. O

Domain O
B O
has O
been O
described O
as O
a O
B O
- O
cell O
- O
specific O
EB1 B-protein
- O
responsive O
element O
( O
P O
. O
M O
. O
Lieberman O
, O
J O
. O
M O
. O
Hardwick O
, O
and O
S O
. O
D O
. O
Hayward O
, O
J O
. O
Virol O
. O
63 O
: O
3040 O
- O
3050 O
, O
1989 O
) O
activated O
synergistically O
by O
EB1 B-protein
and O
R B-protein
, O
an O
EBV B-protein
early I-protein
product I-protein
encoded O
by O
the O
open O
reading O
frame O
BRLF1 O
( O
M O
. O
A O
. O
Cox O
, O
J O
. O
Leahy O
, O
and O
J O
. O
M O
. O
Hardwick O
, O
J O
. O
Virol O
. O
64 O
: O
313 O
- O
321 O
, O
1990 O
) O
. O

We O
show O
here O
that O
domain O
B O
is O
an O
R O
- O
responsive O
element O
in O
HeLa O
cells O
and O
is O
therefore O
not O
an O
EB1 B-protein
- O
responsive O
B O
- O
cell O
- O
specific O
element O
. O

However O
, O
there O
is O
an O
EB1 B-protein
- O
binding O
site O
( O
ZRE O
- O
B O
) O
located O
within O
the O
R O
- O
responsive O
enhancer O
region O
. O

ZRE O
- O
B O
can O
be O
deleted O
without O
affecting O
the O
R O
- O
dependent O
enhancer O
activity O
. O

Moreover O
, O
there O
is O
no O
cooperation O
or O
synergy O
between O
R B-protein
and O
EB1 B-protein
when O
activating O
the O
B O
domain O
( O
ZRE O
- O
B O
plus O
the O
R O
- O
responsive O
element O
) O
positioned O
as O
an O
enhancer O
. O

ZRE O
- O
B O
is O
therefore O
not O
part O
of O
the O
R O
- O
inducible O
enhancer O
. O

We O
have O
tested O
several O
subregions O
of O
the O
DR O
enhancer O
B O
domain O
, O
either O
alone O
or O
in O
combination O
, O
for O
their O
capacity O
to O
transmit O
the O
R O
- O
activating O
signal O
to O
the O
rabbit O
beta O
- O
globin O
promoter O
. O

We O
found O
that O
the O
R O
- O
responsive O
element O
is O
composed O
of O
four O
protoenhancers O
that O
span O
the O
whole O
B O
domain O
. O

These O
protoenhancers O
alone O
are O
weakly O
or O
not O
responsive O
to O
R B-protein
. O

One O
of O
the O
protoenhancers O
contains O
the O
overlapping O
palindromes O
5 O
' O
- O
TTGTCCcgtGGACAAaTGTCC O
- O
3 O
' O
. O

However O
, O
one O
palindrome O
, O
either O
alone O
or O
duplicated O
, O
or O
the O
overlapping O
palindromes O
did O
not O
respond O
to O
R O
. O

Nuclear O
3 B-protein
, I-protein
5 I-protein
, I-protein
3 I-protein
' I-protein
- I-protein
triiodothyronine I-protein
receptors I-protein
( O
T3R B-protein
) O
of O
circulating O
human O
lymphocytes O
in O
hyper O
- O
and O
hypothyroidism O
and O
nonthyroidal O
diseases O
. O

The O
clinical O
implications O
of O
nuclear O
T3R B-protein
alterations O
of O
circulating O
lymphocytes O
in O
hyperthyroidism O
, O
hypothyroidism O
and O
nonthyroidal O
diseases O
were O
investigated O
. O

Nuclear O
T3R B-protein
in O
lymphocytes O
was O
determined O
by O
radio O
- O
ligand O
binding O
analysis O
. O

The O
results O
showed O
that O
in O
hyper O
- O
and O
hypothyroid O
patients O
the O
nuclear O
affinity O
( O
Ka O
) O
for O
T3 O
was O
similar O
to O
that O
of O
normal O
subjects O
. O

In O
hyperthyroidism O
nuclear O
T3 O
maximal O
binding O
capacity O
( O
MBC O
) O
was O
unaltered O
, O
whereas O
in O
hypothyroidism O
the O
MBC O
was O
significantly O
increased O
. O

In O
the O
patients O
with O
diabetes O
mellitus O
, O
chronic O
renal O
failure O
and O
hepatic O
cirrhosis O
, O
the O
nuclear B-protein
T3R I-protein
MBC O
of O
lymphocytes O
was O
about O
1 O
. O
5 O
- O
1 O
. O
6 O
times O
of O
the O
normal O
controls O
. O

It O
was O
concluded O
that O
there O
existed O
hormonal O
regulation O
of O
nuclear B-protein
T3R I-protein
, O
and O
up O
- O
regulation O
was O
seen O
in O
hypothyroidism O
and O
low O
T3 O
syndrome O
. O

Lymphocyte O
cell O
lines O
from O
vitamin O
D O
- O
dependent O
rickets O
type O
II O
show O
functional O
defects O
in O
the O
1 B-protein
alpha I-protein
, I-protein
25 I-protein
- I-protein
dihydroxyvitamin I-protein
D3 I-protein
receptor I-protein
. O

Lymphocyte O
cell O
lines O
were O
established O
from O
five O
patients O
with O
vitamin O
D O
- O
dependent O
rickets O
, O
type O
II O
( O
VDDR O
- O
II O
) O
. O

These O
lines O
were O
established O
by O
infection O
with O
human O
T O
- O
lymphotrophic O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
. O

Binding O
of O
[ O
3H O
] O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
( O
OH O
) O
2D3 O
) O
to O
its O
receptor O
in O
these O
cell O
lines O
was O
compared O
to O
binding O
studies O
using O
a O
T O
- O
lymphocyte O
cell O
line O
( O
S O
- O
LB1 O
) O
from O
a O
normal O
individual O
. O

The O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptor O
of O
S O
- O
LB1 O
was O
comparable O
to O
the O
well O
- O
characterized O
chick B-protein
intestinal I-protein
1 I-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
in O
terms O
of O
its O
ligand O
binding O
affinity O
and O
capacity O
, O
its O
mobility O
on O
5 O
- O
20 O
% O
sucrose O
gradients O
, O
and O
its O
adsorption O
to O
and O
elution O
properties O
from O
DNA O
- O
cellulose O
. O

Three O
cell O
lines O
established O
from O
patients O
with O
VDDR O
- O
II O
( O
Rh O
- O
VDR B-protein
, O
Sh O
- O
VDR B-protein
, O
and O
Ab O
- O
VDR B-protein
) O
showed O
no O
specific O
binding O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
to O
a O
receptor B-protein
and O
treatment O
of O
the O
cultured O
cells O
with O
1 O
, O
25 O
( O
OH O
) O
2D3 O
did O
not O
stimulate O
production O
of O
24 O
, O
25 O
- O
dihydroxy O
- O
vitamin O
D3 O
( O
24 O
, O
25 O
( O
OH O
) O
2D3 O
) O
, O
a O
response O
which O
is O
diagnostic O
of O
the O
presence O
of O
a O
functional B-protein
1 I-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
. O

In O
a O
fourth O
cell O
line O
, O
A1 O
- O
VDR O
, O
the O
receptor O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
had O
a O
low O
binding O
capacity O
and O
25 B-protein
( I-protein
OH I-protein
) I-protein
D3 I-protein
- I-protein
24 I-protein
- I-protein
hydroxylase I-protein
activity O
was O
not O
detectable O
. O

Induction O
of O
24 O
, O
25 O
- O
( O
OH O
) O
2D3 O
synthesis O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
was O
observed O
in O
the O
fifth O
cell O
line O
, O
designated O
Ro O
- O
VDR O
, O
although O
the O
sensitivity O
to O
hormone O
treatment O
was O
lower O
than O
in O
the O
control O
cell O
line O
from O
a O
normal O
donor O
. O

The O
capacity O
of O
the O
receptor B-protein
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
was O
low O
in O
Ro O
- O
VDR O
. O

In O
all O
cell O
lines O
where O
1 O
, O
25 O
( O
OH O
) O
2D3 O
binding O
to O
a O
receptor B-protein
was O
detectable O
, O
the O
receptor B-protein
had O
the O
typical O
sedimentation O
coefficient O
of O
3 O
. O
7 O
S O
on O
sucrose O
density O
gradient O
analysis O
. O

Binding O
and O
elution O
properties O
to O
DNA O
- O
cellulose O
, O
however O
, O
differed O
from O
normal O
in O
both O
Ro O
- O
VDR O
and O
A1 O
- O
VDR O
cells O
where O
elution O
from O
DNA O
- O
cellulose O
occurred O
at O
a O
lower O
salt O
concentration O
than O
is O
typical O
of O
the O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptor B-protein
. O

While O
Ro O
- O
VDR O
cells O
showed O
typical O
nuclear O
localization O
of O
the O
unoccupied B-protein
1 I-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
, O
neither O
the O
unoccupied O
nor O
the O
occupied O
receptor B-protein
from O
A1 O
- O
VDR O
cells O
was O
completely O
localized O
in O
the O
nucleus O
. O

In O
a O
series O
of O
functional O
studies O
we O
found O
that O
modulation O
of O
the O
level O
of O
the O
mRNAs O
coding O
for O
both O
the O
c O
- O
myc O
oncogene O
and O
the O
growth O
factor O
known O
as O
granulocyte O
- O
monocyte O
colony O
stimulating O
activity O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
correlated O
with O
the O
1 O
, O
25 O
( O
OH O
) O
2D3 O
receptor B-protein
status O
of O
these O
cells O
. O

Use O
of O
these O
cell O
lines O
will O
facilitate O
further O
study O
of O
the O
molecular O
defect O
( O
s O
) O
in O
the O
receptor B-protein
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
in O
vitamin O
D O
- O
dependent O
rickets O
type O
II O
and O
will O
allow O
a O
correlation O
with O
impairment O
of O
cellular O
functions O
. O

Transcriptional O
and O
post O
- O
transcriptional O
regulation O
of O
c O
- O
jun O
expression O
during O
monocytic O
differentiation O
of O
human O
myeloid O
leukemic O
cells O
. O

AP B-protein
- I-protein
1 I-protein
, O
the O
polypeptide O
product O
of O
c O
- O
jun O
, O
recognizes O
and O
binds O
to O
specific O
DNA O
sequences O
and O
stimulates O
transcription O
of O
genes O
responsive O
to O
certain O
growth O
factors O
and O
phorbol O
esters O
such O
as O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
. O

We O
studied O
the O
effects O
of O
TPA O
on O
the O
regulation O
of O
c O
- O
jun O
gene O
expression O
in O
HL O
- O
60 O
cells O
during O
monocytic O
differentiation O
. O

Low O
levels O
of O
c O
- O
jun O
transcripts O
were O
detectable O
in O
untreated O
HL O
- O
60 O
leukemic O
cells O
, O
increased O
significantly O
by O
6 O
h O
, O
and O
reached O
near O
maximal O
levels O
by O
24 O
h O
of O
exposure O
to O
32 O
nM O
TPA O
. O

Similar O
kinetics O
of O
c O
- O
jun O
induction O
by O
TPA O
were O
observed O
in O
human O
U O
- O
937 O
and O
THP O
- O
1 O
monocytic O
leukemia O
cells O
. O

Similar O
findings O
were O
obtained O
with O
bryostatin O
1 O
( O
10 O
nM O
) O
, O
another O
activator O
of O
protein B-protein
kinase I-protein
C I-protein
and O
inducer O
of O
monocytic O
differentiation O
. O

Furthermore O
, O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
0 O
. O
5 O
microM O
) O
, O
a O
structurally O
distinct O
agent O
which O
also O
induces O
HL O
- O
60 O
monocytic O
differentiation O
, O
increased O
c O
- O
jun O
expression O
. O

TPA O
treatment O
of O
HL O
- O
60 O
cells O
in O
the O
presence O
of O
cycloheximide O
was O
associated O
with O
superinduction O
of O
c O
- O
jun O
transcripts O
. O

Run O
- O
on O
analysis O
demonstrated O
detectable O
levels O
of O
c O
- O
jun O
gene O
transcription O
in O
untreated O
HL O
- O
60 O
cells O
, O
and O
that O
exposure O
to O
TPA O
increases O
this O
rate O
3 O
. O
3 O
- O
fold O
. O

Treatment O
of O
HL O
- O
60 O
cells O
with O
both O
TPA O
and O
cycloheximide O
had O
no O
effect O
on O
the O
rates O
of O
c O
- O
jun O
transcription O
. O

The O
half O
- O
life O
of O
c O
- O
jun O
RNA O
as O
determined O
by O
treating O
HL O
- O
60 O
cells O
with O
TPA O
and O
actinomycin O
D O
was O
30 O
min O
. O

In O
contrast O
, O
the O
half O
- O
life O
of O
c O
- O
jun O
RNA O
in O
TPA O
- O
treated O
HL O
- O
60 O
cells O
exposed O
to O
cycloheximide O
and O
actinomycin O
D O
was O
greater O
than O
2 O
h O
. O

These O
findings O
suggested O
that O
the O
increase O
in O
c O
- O
jun O
RNA O
observed O
during O
TPA O
- O
induced O
monocytic O
differentiation O
is O
mediated O
by O
both O
transcriptional O
and O
post O
- O
transcriptional O
mechanisms O
. O

[ O
Hormonal O
interactions O
and O
glucocorticoid B-protein
receptors I-protein
in O
patients O
with O
the O
nephrotic O
syndrome O
] O
. O

As O
many O
as O
27 O
children O
aged O
6 O
to O
15 O
years O
with O
morphologically O
verified O
nephropathies O
were O
examined O
. O

Four O
variants O
of O
changes O
in O
the O
thyroid O
status O
, O
characteristic O
of O
children O
with O
different O
variants O
of O
nephrotic O
syndrome O
were O
distinguished O
: O
1 O
) O
biochemical O
signs O
of O
primary O
hypothyroidism O
, O
2 O
) O
biochemical O
signs O
of O
secondary O
hypothyroidism O
, O
3 O
) O
low O
content O
of O
T3 O
, O
4 O
) O
dysfunction O
of O
the O
hypophyseal O
and O
thyroid O
system O
. O

It O
is O
shown O
that O
the O
low O
level O
of O
steroid B-protein
receptors I-protein
, O
thyroid O
hormones O
that O
the O
low O
level O
of O
steroid B-protein
receptors I-protein
, O
thyroid O
hormones O
( O
T3 O
and O
T4 O
) O
and O
cortisol O
is O
typical O
of O
children O
with O
the O
signs O
of O
renal O
dysplasia O
. O

It O
is O
assumed O
that O
superaddition O
under O
such O
conditions O
of O
immune O
glomerulopathy O
( O
glomerulonephritis O
and O
nephrotic O
syndrome O
) O
gives O
rise O
to O
the O
resistance O
to O
the O
treatment O
with O
glucocorticoids O
. O

Lymphoid O
specific O
gene O
expression O
of O
the O
adenovirus O
early O
region O
3 O
promoter O
is O
mediated O
by O
NF O
- O
kappa O
B O
binding O
motifs O
. O

A O
primary O
site O
of O
infection O
by O
human O
adenoviruses O
is O
lymphoid O
cells O
. O

However O
, O
analysis O
of O
the O
viral O
control O
elements O
and O
the O
cellular B-protein
factors I-protein
that O
regulate O
adenoviral O
gene O
expression O
in O
lymphocytes O
has O
not O
been O
reported O
. O

The O
adenovirus B-protein
early I-protein
region I-protein
3 I-protein
( I-protein
ES I-protein
) I-protein
gene I-protein
products I-protein
are O
involved O
in O
the O
maintenance O
of O
viral O
persistence O
by O
complexing O
with O
the O
class B-protein
I I-protein
MHC I-protein
antigens I-protein
, O
thus O
preventing O
their O
cell O
surface O
expression O
with O
a O
resultant O
decrease O
in O
host O
immunologic O
destruction O
. O

To O
determine O
whether O
different O
cellular B-protein
factors I-protein
were O
involved O
in O
E3 O
regulation O
in O
lymphocytes O
as O
compared O
with O
HeLa O
cells O
, O
both O
DNA O
binding O
and O
transfection O
analysis O
with O
the O
E3 O
promoter O
in O
both O
cell O
types O
were O
performed O
. O

These O
studies O
detected O
two O
novel O
domains O
referred O
to O
as O
L1 O
and O
L2 O
with O
a O
variety O
of O
lymphoid O
but O
not O
HeLa O
extracts O
. O

Each O
of O
these O
domains O
possessed O
strong O
homology O
to O
motifs O
previously O
found O
to O
bind O
the O
cellular B-protein
factor I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
. O

Transfections O
of O
E3 O
constructs O
linked O
to O
the O
chloramphenicol O
acetyltransferase O
gene O
revealed O
that O
mutagenesis O
of O
the O
distal O
NF B-protein
- I-protein
kappa I-protein
B I-protein
motif O
( O
L2 O
) O
had O
minimal O
effects O
on O
promoter O
expression O
in O
HeLa O
cells O
, O
but O
resulted O
in O
dramatic O
decreases O
in O
expression O
by O
lymphoid O
cells O
. O

In O
contrast O
, O
mutagenesis O
of O
proximal O
NF O
- O
kappa O
B O
motif O
( O
L1 O
) O
had O
minimal O
effects O
on O
gene O
expression O
in O
both O
HeLa O
cells O
and O
lymphoid O
cells O
but O
resulted O
in O
a O
small O
, O
but O
reproducible O
, O
increase O
in O
gene O
expression O
in O
lymphoid O
cells O
when O
coupled O
to O
the O
L2 O
mutation O
. O

Reversing O
the O
position O
and O
subsequent O
mutagenesis O
of O
the O
L1 O
and O
L2 O
domains O
indicated O
that O
the O
primary O
sequence O
of O
these O
motifs O
rather O
than O
their O
position O
in O
the O
E3 O
promoter O
was O
critical O
for O
regulating O
gene O
expression O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Characterization O
of O
defensin B-protein
resistance O
phenotypes O
associated O
with O
mutations O
in O
the O
phoP O
virulence O
regulon O
of O
Salmonella O
typhimurium O
. O

The O
defensin B-protein
sensitivities O
of O
Salmonella O
typhimurium O
strains O
with O
mutations O
in O
the O
phoP O
/ O
phoQ O
two O
- O
component O
virulence O
regulon O
were O
tested O
by O
using O
purified B-protein
defensins I-protein
NP B-protein
- I-protein
1 I-protein
and O
NP B-protein
- I-protein
2 I-protein
. O

Strains O
with O
mutations O
in O
either O
gene O
of O
the O
regulatory O
pair O
( O
phoP O
[ O
transcriptional O
activator O
] O
or O
phoQ O
[ O
membrane B-protein
sensor I-protein
kinase I-protein
] O
) O
had O
increased O
sensitivities O
to O
defensin B-protein
. O

The O
predicted O
periplasmic B-protein
domain I-protein
of O
the O
PhoQ B-protein
protein I-protein
contained O
a O
markedly O
anionic O
domain O
that O
could O
interact O
with O
cationic B-protein
proteins I-protein
and O
that O
could O
be O
responsible O
for O
resistance O
to O
defensin B-protein
. O

Because O
insertion O
mutations O
in O
phoP O
are O
polar O
on O
phoQ O
, O
we O
constructed O
strains O
that O
expressed O
the O
PhoQ B-protein
protein I-protein
in O
the O
absence O
of O
PhoP B-protein
to O
test O
whether O
resistance O
to O
defensin O
requires O
only O
the O
phoQ B-protein
gene I-protein
product I-protein
. O

We O
found O
that O
resistance O
to O
defensin O
requires O
the O
function O
of O
both O
components O
of O
this O
regulatory O
system O
, O
because O
strains O
expressing O
PhoQ B-protein
without O
PhoP B-protein
were O
still O
markedly O
sensitive O
to O
defensins B-protein
. O

This O
implied O
that O
a O
pag B-protein
( I-protein
phoP I-protein
- I-protein
activated I-protein
gene I-protein
) I-protein
product I-protein
is O
responsible O
for O
defensin B-protein
resistance O
. O

We O
also O
tested O
for O
the O
ability O
of O
defensins B-protein
NP B-protein
- I-protein
1 I-protein
, O
NP B-protein
- I-protein
5 I-protein
, O
and O
HNP B-protein
- I-protein
1 I-protein
to O
activate O
pag O
expression O
and O
found O
that O
these O
peptides O
have O
no O
effect O
. O

Defensin O
resistance O
is O
not O
the O
only O
virulence O
characteristic O
controlled O
by O
the O
PhoP B-protein
- I-protein
PhoQ I-protein
regulon I-protein
because O
mutations O
in O
pagC O
, O
as O
well O
as O
ones O
in O
the O
phoP O
locus O
that O
resulted O
in O
constitutive O
pag O
activation O
( O
phenotype O
PhoPc B-protein
) O
, O
had O
no O
effect O
on O
defensin B-protein
resistance O
, O
even O
though O
they O
rendered O
the O
organism O
avirulent O
and O
deficient O
in O
survival O
within O
macrophages O
. O

The O
virulence O
defect O
conferred O
by O
mutations O
in O
the O
phoP O
- O
phoQ O
two O
- O
component O
regulatory O
system O
is O
not O
completely O
explained O
by O
alterations O
in O
resistance O
to O
cationic B-protein
proteins I-protein
and O
involves O
the O
control O
of O
other O
proteins O
necessary O
for O
S O
. O
typhimurium O
survival O
within O
macrophages O
. O

Stimulation O
of O
a O
human O
T O
- O
cell O
clone O
with O
anti B-protein
- I-protein
CD3 I-protein
or O
tumor B-protein
necrosis I-protein
factor I-protein
induces O
NF B-protein
- I-protein
kappa I-protein
B I-protein
translocation O
but O
not O
human O
immunodeficiency O
virus O
1 O
enhancer O
- O
dependent O
transcription O
. O

The O
expression O
of O
transiently O
transfected O
expression O
vectors O
under O
the O
control O
of O
the O
long O
terminal O
repeat O
( O
LTR O
) O
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
or O
its O
enhancer O
sequence O
and O
the O
translocation O
of O
the O
HIV B-protein
enhancer I-protein
- I-protein
binding I-protein
protein I-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
were O
analyzed O
in O
two O
human O
T O
- O
cell O
clones O
stimulated O
through O
their O
T B-protein
- I-protein
cell I-protein
receptor I-protein
complex I-protein
or O
by O
tumor B-protein
necrosis I-protein
factor I-protein
or O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
. O

We O
found O
a O
dissociation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
translocation O
from O
transactivation O
of O
either O
the O
HIV O
LTR O
or O
the O
HIV O
enhancer O
. O

Interleukin B-protein
2 I-protein
induced O
proliferation O
but O
not O
NF B-protein
- I-protein
kappa I-protein
B I-protein
translocation O
or O
LTR O
transactivation O
. O

Phorbol O
ester O
or O
specific O
antigen O
recognition O
induced O
HIV O
LTR O
transactivation O
, O
whereas O
stimulation O
with O
tumor B-protein
necrosis I-protein
factor I-protein
or O
antibody O
to O
CD3 B-protein
did O
not O
. O

The O
two O
latter O
signals O
were O
nevertheless O
able O
to O
induce O
NF B-protein
- I-protein
kappa I-protein
B I-protein
translocation O
with O
a O
pattern O
in O
the O
band O
- O
shift O
assay O
indistinguishable O
from O
that O
observed O
using O
phorbol O
ester O
. O

Our O
finding O
that O
induction O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
by O
tumor B-protein
necrosis I-protein
factor I-protein
or O
antibody B-protein
to I-protein
CD3 I-protein
is O
not O
sufficient O
to O
induce O
HIV O
enhancer O
- O
dependent O
transcription O
in O
cloned O
T O
cells O
contrasts O
with O
results O
obtained O
in O
most O
lymphoblastoid O
T O
- O
cell O
lines O
and O
indicates O
that O
normal O
T O
lymphocytes O
differ O
from O
tumoral O
T O
cells O
in O
terms O
of O
requirements O
for O
HIV O
LTR O
activation O
. O

Furthermore O
, O
our O
results O
suggest O
that O
events O
linked O
to O
T O
- O
cell O
activation O
, O
in O
addition O
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
translocation O
per O
se O
, O
induce O
functional O
interactions O
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
complex I-protein
with O
the O
HIV O
enhancer O
. O

Decreased O
concentration O
of O
1 B-protein
, I-protein
25 I-protein
- I-protein
dihydroxyvitamin I-protein
D3 I-protein
receptors I-protein
in O
peripheral O
mononuclear O
cells O
of O
patients O
with O
X O
- O
linked O
hypophosphatemic O
rickets O
: O
effect O
of O
phosphate O
supplementation O
. O

Abnormal O
renal O
tubular O
phosphate O
transport O
is O
considered O
to O
be O
the O
primary O
defect O
in O
X O
- O
linked O
hypophosphatemic O
rickets O
( O
XLH O
) O
. O

However O
, O
the O
resistance O
to O
vitamin O
D O
treatment O
in O
XLH O
cannot O
be O
explained O
by O
hypophosphatemia O
alone O
. O

Since O
most O
of O
the O
actions O
of O
vitamin O
D O
are O
mediated O
by O
its O
receptors O
( O
VDR B-protein
) O
, O
abnormalities O
of O
VDR B-protein
have O
been O
postulated O
in O
XLH O
. O

In O
order O
to O
investigate O
this O
possibility O
, O
we O
measured O
the O
concentration O
of O
VDR B-protein
in O
PHA O
- O
activated O
peripheral O
mononuclear O
cells O
from O
10 O
XLH O
patients O
. O

Patients O
without O
phosphate O
supplementation O
showed O
significantly O
lower O
concentration O
( O
21 O
. O
7 O
+ O
/ O
- O
5 O
. O
1 O
fmol O
/ O
mg O
protein O
, O
mean O
+ O
/ O
- O
SEM O
) O
compared O
to O
the O
normal O
controls O
( O
60 O
. O
7 O
+ O
/ O
- O
4 O
. O
0 O
) O
. O

On O
the O
contrary O
, O
there O
was O
no O
significant O
difference O
between O
the O
phosphate O
- O
supplemented O
patients O
( O
58 O
. O
3 O
+ O
/ O
- O
2 O
. O
7 O
) O
and O
controls O
. O

There O
was O
a O
significant O
positive O
correlation O
between O
VDR B-protein
concentration O
and O
serum O
phosphate O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

In O
two O
patients O
, O
VDR B-protein
was O
increased O
after O
daily O
phosphate O
supplementation O
was O
started O
. O

These O
results O
indicate O
that O
a O
decreased O
concentration O
of O
VDR B-protein
secondary O
to O
persistent O
hypophosphatemia O
is O
one O
of O
the O
causes O
of O
vitamin O
D O
resistance O
in O
XLH O
. O

Two O
distinct O
forms O
of O
active B-protein
transcription I-protein
factor I-protein
CREB I-protein
( O
cAMP B-protein
response I-protein
element I-protein
binding I-protein
protein I-protein
) O
. O

Mammalian O
cells O
express O
two O
distinct O
forms O
of O
transcription B-protein
factor I-protein
CREB I-protein
( O
cAMP B-protein
response I-protein
element I-protein
binding I-protein
protein I-protein
) O
that O
are O
apparently O
the O
products O
of O
alternative O
splicing O
of O
the O
CREB B-protein
gene O
transcript O
. O

The O
two O
proteins O
differ O
by O
a O
14 B-protein
- I-protein
amino I-protein
acid I-protein
serine I-protein
- I-protein
rich I-protein
insertion I-protein
present O
in O
one O
of O
the O
CREB B-protein
isoforms I-protein
. O

We O
show O
that O
both O
CREB B-protein
isoforms I-protein
are O
expressed O
in O
many O
cell O
types O
and O
mammalian O
species O
. O

Both O
encode O
proteins O
that O
bind O
specifically O
to O
a O
cAMP O
response O
element O
in O
vitro O
. O

As O
expected O
for O
proteins O
of O
this O
class O
, O
the O
CREB B-protein
proteins I-protein
bind O
DNA O
as O
dimers O
. O

Both O
proteins O
impart O
cAMP O
- O
regulated O
transcriptional O
activity O
to O
a O
heterologous O
DNA O
- O
binding O
domain O
, O
showing O
that O
cAMP O
directly O
modulates O
the O
transcriptional O
stimulatory O
activity O
of O
CREB B-protein
. O

The O
presence O
of O
multiple O
CREB B-protein
isoforms I-protein
with O
identical O
DNA O
- O
binding O
specificities O
but O
differences O
in O
the O
presumed O
regulatory B-protein
domain I-protein
raises O
the O
possibility O
that O
CREB B-protein
proteins I-protein
may O
be O
able O
to O
integrate O
distinct O
regulatory O
signals O
at O
the O
level O
of O
gene O
transcription O
. O

Human B-protein
immunodeficiency I-protein
virus I-protein
vpr I-protein
product I-protein
is O
a O
virion B-protein
- I-protein
associated I-protein
regulatory I-protein
protein I-protein
. O

The O
vpr B-protein
product I-protein
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
acts O
in O
trans O
to O
accelerate O
virus O
replication O
and O
cytopathic O
effect O
in O
T O
cells O
. O

Here O
it O
is O
shown O
that O
the O
HIV O
- O
1 O
viral O
particle O
contains O
multiple O
copies O
of O
the O
vpr B-protein
protein I-protein
. O

The O
vpr B-protein
product I-protein
is O
the O
first O
regulatory O
protein O
of O
HIV O
- O
1 O
to O
be O
found O
in O
the O
virus O
particle O
. O

This O
observation O
raises O
the O
possibility O
that O
vpr O
acts O
to O
facilitate O
the O
early O
steps O
of O
infection O
before O
de O
novo O
viral O
protein O
synthesis O
occurs O
. O

A O
novel O
B B-protein
- I-protein
cell I-protein
lineage I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
present O
at O
early O
but O
not O
late O
stages O
of O
differentiation B-protein
. O

A O
novel O
B B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
, O
BSAP B-protein
, O
was O
identified O
as O
a O
mammalian B-protein
homolog I-protein
of O
the O
sea B-protein
urchin I-protein
protein I-protein
TSAP B-protein
, O
which O
interacts O
with O
the O
promoters O
of O
four O
tissue O
- O
specific O
late O
histone O
H2A O
- O
2 O
and O
H2B O
- O
2 O
genes O
. O

As O
shown O
by O
mobility O
- O
shift O
, O
methylation O
interference O
, O
and O
mutational O
analyses O
, O
the O
mammalian B-protein
protein I-protein
BSAP B-protein
recognizes O
all O
four O
sea O
urchin O
binding O
sites O
in O
a O
manner O
indistinguishable O
from O
TSAP B-protein
; O
however O
, O
the O
two O
proteins O
differ O
in O
molecular O
weight O
. O

BSAP B-protein
is O
exclusively O
restricted O
to O
the O
B O
- O
cell O
lineage O
of O
lymphoid O
differentiation O
. O

Its O
expression O
appears O
to O
be O
activated O
during O
pro O
- O
B O
- O
cell O
development O
, O
is O
abundant O
at O
the O
pre O
- O
B O
- O
and O
mature O
B O
- O
cell O
stages O
, O
but O
is O
absent O
in O
terminally O
differentiated O
plasma O
cells O
. O

Moreover O
, O
BSAP B-protein
is O
clearly O
a O
B B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
, O
as O
a O
wild O
- O
type O
but O
not O
a O
mutant O
TSAP B-protein
- O
binding O
site O
of O
the O
sea O
urchin O
functions O
only O
in O
transfected O
B O
cells O
as O
an O
upstream O
promoter O
element O
. O

Competition O
experiments O
did O
not O
reveal O
any O
high O
- O
affinity O
binding O
site O
for O
BSAP B-protein
in O
known O
regulatory O
regions O
of O
immunoglobulin O
and O
class O
II O
major O
histocompatibility O
( O
MHC O
) O
genes O
, O
suggesting O
that O
BSAP B-protein
is O
a O
regulator O
of O
a O
different O
set O
of O
B O
- O
lymphoid O
- O
specific O
genes O
. O

Octamer B-protein
transcription I-protein
factors I-protein
and O
the O
cell O
type O
- O
specificity O
of O
immunoglobulin O
gene O
expression O
. O

Antibodies B-protein
are O
produced O
exclusively O
in O
B O
lymphocytes O
. O

The O
expression O
of O
the O
antibody O
- O
encoding O
genes O
, O
the O
immunoglobulin O
( O
Ig O
) O
genes O
, O
is O
also O
restricted O
to O
B O
cells O
. O

The O
octamer O
sequence O
ATGCAAAT O
is O
present O
in O
the O
promoter O
and O
the O
enhancer O
of O
Ig O
genes O
, O
and O
plays O
an O
important O
role O
in O
its O
tissue O
- O
specific O
expression O
. O

This O
sequence O
motif O
is O
a O
binding O
site O
for O
nuclear B-protein
proteins I-protein
, O
the O
so O
- O
called O
octamer B-protein
transcription I-protein
factors I-protein
( O
Oct B-protein
or O
OTF B-protein
factors I-protein
) O
. O

The O
Oct B-protein
- I-protein
1 I-protein
protein I-protein
is O
present O
in O
all O
cell O
types O
analyzed O
so O
far O
, O
whereas O
Oct B-protein
- I-protein
2A I-protein
and O
Oct B-protein
- I-protein
2B I-protein
are O
found O
mainly O
in O
B O
lymphocytes O
. O

All O
three O
proteins O
show O
the O
same O
sequence O
specificity O
and O
binding O
affinity O
. O

It O
appears O
that O
the O
B O
cell O
- O
specific O
expression O
of O
Ig O
genes O
is O
mediated O
at O
least O
in O
part O
by O
cell O
type B-protein
- I-protein
specific I-protein
Oct I-protein
factors I-protein
, O
and O
that O
there O
are O
both O
quantitative O
and O
qualitative O
differences O
between O
Oct B-protein
- I-protein
1 I-protein
and O
Oct B-protein
- I-protein
2 I-protein
factors I-protein
. O

Recently O
, O
a O
number O
of O
other O
octamer B-protein
factor I-protein
variants I-protein
were O
identified O
. O

Many O
of O
these O
may O
be O
created O
by O
alternative O
splicing O
of O
a O
primary O
transcript O
of O
one O
Oct O
factor O
gene O
and O
may O
serve O
a O
specific O
function O
in O
the O
fine O
tuning O
of O
gene O
expression O
. O

A O
factor O
known O
to O
bind O
to O
endogenous O
Ig O
heavy O
chain O
enhancer O
only O
in O
lymphocytes O
is O
a O
ubiquitously B-protein
active I-protein
transcription I-protein
factor I-protein
. O

The O
transcriptional O
enhancer O
located O
in O
the O
first O
intron O
of O
the O
immunoglobulin O
heavy O
chain O
constant O
region O
is O
a O
major O
determinant O
of O
B O
- O
cell O
- O
specific O
expression O
of O
immunoglobulin O
genes O
. O

Like O
other O
enhancers O
, O
the O
Ig O
heavy O
chain O
enhancer O
contains O
several O
short O
sequence O
motifs O
that O
bind O
specific B-protein
transcription I-protein
factors I-protein
. O

Each O
binding O
site O
contributes O
to O
the O
overall O
activity O
of O
the O
enhancer O
, O
however O
no O
single O
element O
seems O
absolutely O
required O
for O
activity O
. O

For O
a O
better O
understanding O
of O
the O
Ig O
heavy O
chain O
enhancer O
components O
, O
we O
have O
cloned O
and O
analyzed O
individual O
sequence O
elements O
. O

We O
find O
that O
the O
factor O
that O
binds O
to O
the O
E3 O
enhancer O
motif O
, O
CATGTGGC O
, O
is O
a O
ubiquitous B-protein
transcription I-protein
factor I-protein
. O

It O
is O
present O
in O
an O
active O
form O
in O
both O
B O
cells O
and O
non O
- O
B O
cells O
, O
where O
it O
can O
mediate O
transcriptional O
activation O
in O
vitro O
and O
in O
vivo O
. O

However O
, O
despite O
its O
ability O
to O
activate O
transcription O
of O
a O
transfected O
reporter O
gene O
, O
the O
factor O
is O
apparently O
unable O
to O
bind O
to O
the O
endogenous O
Ig O
heavy O
chain O
enhancer O
in O
non O
- O
lymphoid O
cells O
: O
In O
previous O
experiments O
by O
others O
, O
the O
characteristic O
in O
vivo O
footprint O
of O
this O
factor O
, O
designated O
NF B-protein
- I-protein
muE3 I-protein
, O
was O
detected O
in O
B O
cells O
but O
not O
in O
non O
- O
B O
cells O
. O

From O
this O
and O
other O
findings O
the O
picture O
emerges O
that O
there O
are O
at O
least O
three O
categories O
of O
factors O
which O
mediate O
cell O
- O
type O
- O
specific O
transcription O
in O
B O
lymphocytes O
: O
( O
a O
) O
cell B-protein
- I-protein
specific I-protein
factors I-protein
such O
as O
Oct B-protein
- I-protein
2A I-protein
and O
Oct B-protein
- I-protein
2B I-protein
that O
are O
not O
expressed O
in O
most O
other O
cell O
types O
: O
( O
b O
) O
ubiquitous B-protein
factors I-protein
such O
as O
NF B-protein
- I-protein
kappa I-protein
B I-protein
that O
are O
constitutively O
active O
in O
B O
cells O
but O
are O
sequestered O
in O
an O
inactive O
form O
in O
other O
cells O
; O
( O
c O
) O
ubiquitously B-protein
active I-protein
factors I-protein
, O
exemplified O
by O
the O
one O
binding O
to O
the O
E3 O
sequence O
motif O
. O

This O
factor O
is O
present O
in O
an O
active O
form O
in O
a O
variety O
of O
cell O
types O
but O
is O
apparently O
unable O
to O
bind O
to O
the O
endogenous O
Ig O
heavy O
chain O
enhancer O
in O
non O
- O
B O
cells O
, O
perhaps O
due O
to O
a O
non O
- O
permissive O
chromatin O
structure O
of O
the O
Ig O
heavy O
chain O
locus O
. O

[ O
Endocrine O
status O
changes O
in O
children O
with O
bronchial O
asthma O
] O
. O

A O
study O
was O
made O
of O
adrenocortical O
function O
by O
measuring O
blood O
plasma O
cortisol O
concentration O
and O
amount O
of O
glucocorticoid B-protein
receptors I-protein
in O
lymphocytes O
as O
well O
as O
thyroid O
function O
by O
measuring O
blood O
plasma O
triidothyronine O
and O
thyroxine O
concentration O
in O
58 O
bronchial O
asthma O
children O
aged O
1 O
to O
14 O
years O
. O

The O
authors O
revealed O
alterations O
in O
the O
functional O
activity O
of O
the O
indicated O
endocrine O
glands O
depending O
on O
the O
intensity O
of O
bronchial O
patency O
disorders O
and O
the O
nature O
of O
the O
therapeutic O
measures O
carried O
out O
. O

TAR O
independent O
activation O
of O
the O
human O
immunodeficiency O
virus O
in O
phorbol O
ester O
stimulated O
T O
lymphocytes O
. O

Multiple O
regulatory O
elements O
in O
the O
human O
immunodeficiency O
virus O
long O
terminal O
repeat O
( O
HIV O
LTR O
) O
are O
required O
for O
activation O
of O
HIV O
gene O
expression O
. O

Previous O
transfection O
studies O
of O
HIV O
LTR O
constructs O
linked O
to O
the O
chloramphenicol O
acetyltransferase O
gene O
indicated O
that O
multiple O
regulatory O
regions O
including O
the O
enhancer O
, O
SP1 O
, O
TATA O
and O
TAR O
regions O
were O
important O
for O
HIV O
gene O
expression O
. O

To O
characterize O
these O
regulatory O
elements O
further O
, O
mutations O
in O
these O
regions O
were O
inserted O
into O
both O
the O
5 O
' O
and O
3 O
' O
HIV O
LTRs O
and O
infectious O
proviral O
constructs O
were O
assembled O
. O

These O
constructs O
were O
transfected O
into O
either O
HeLa O
cells O
, O
Jurkat O
cells O
or O
U937 O
cells O
in O
both O
the O
presence O
and O
absence O
of O
phorbol O
esters O
which O
have O
previously O
been O
demonstrated O
to O
activate O
HIV O
gene O
expression O
. O

Viral O
gene O
expression O
was O
assayed O
by O
the O
level O
of O
p24 B-protein
gag I-protein
protein I-protein
released O
from O
cultures O
transfected O
with O
the O
proviral O
constructs O
. O

Results O
in O
all O
cell O
lines O
indicated O
that O
mutations O
of O
the O
SP1 O
, O
TATA O
and O
the O
TAR O
loop O
and O
stem O
secondary O
structure O
resulted O
in O
marked O
decreases O
in O
gene O
expression O
while O
mutations O
of O
the O
enhancer O
motif O
or O
TAR O
primary O
sequence O
resulted O
in O
only O
slight O
decreases O
. O

However O
, O
viruses O
containing O
mutations O
in O
either O
the O
TAR O
loop O
sequences O
or O
stem O
secondary O
structure O
which O
were O
very O
defective O
for O
gene O
expression O
in O
untreated O
Jurkat O
cells O
, O
gave O
nearly O
wild O
- O
type O
levels O
of O
gene O
expression O
in O
phorbol O
ester O
- O
treated O
Jurkat O
cells O
but O
not O
in O
phorbol O
ester O
- O
treated O
HeLa O
or O
U937 O
cells O
. O

High O
level O
gene O
expression O
of O
these O
TAR O
mutant O
constructs O
in O
phorbol O
ester O
- O
treated O
Jurkat O
cells O
was O
eliminated O
by O
second O
site O
mutations O
in O
the O
enhancer O
region O
or O
by O
disruption O
of O
the O
tat O
gene O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

A O
case O
of O
hypersensitivity O
to O
thyroid O
hormones O
with O
normally O
functioning O
thyroid O
gland O
and O
increased O
nuclear O
triiodothyronine B-protein
receptors I-protein
. O

A O
52 O
- O
year O
- O
old O
male O
presented O
himself O
with O
tachycardia O
crises O
which O
appeared O
first O
during O
childhood O
, O
increased O
in O
frequency O
without O
goiter O
or O
exophthalmos O
. O

Cardiac O
and O
adrenergic O
diseases O
were O
excluded O
. O

The O
thyroid O
function O
was O
normal O
regarding O
T4 O
, O
free O
T4 O
and O
T3 O
, O
TBG O
, O
radioiodine O
uptake O
, O
TSH O
and O
T3 O
suppressibility O
; O
however O
the O
TSH O
response O
to O
TRH O
was O
decreased O
. O

The O
lymphocyte B-protein
nuclear I-protein
T3 I-protein
receptor I-protein
was O
found O
with O
an O
affinity O
close O
to O
that O
of O
normal O
volunteers O
( O
Ka O
: O
1 O
. O
42 O
x O
10 O
( O
10 O
) O
M O
- O
1 O
vs O
1 O
. O
95 O
+ O
/ O
- O
0 O
. O
35 O
x O
10 O
( O
10 O
) O
M O
- O
1 O
) O
and O
a O
binding O
capacity O
markedly O
increased O
( O
9 O
. O
9 O
vs O
3 O
. O
7 O
+ O
/ O
- O
0 O
. O
4 O
fmol O
T3 O
/ O
100 O
micrograms O
DNA O
) O
. O

Pindolol O
was O
inefficient O
on O
the O
dysrhythmia O
which O
disappeared O
with O
carbimazole O
and O
relapsed O
after O
withdrawal O
of O
the O
antithyroid O
drug O
. O

Under O
carbimazole O
, O
the O
plasma O
T4 O
markedly O
decreased O
( O
27 O
. O
7 O
+ O
/ O
- O
3 O
. O
6 O
nmol O
/ O
l O
) O
but O
the O
patient O
remained O
euthyroid O
. O

The O
clinical O
course O
and O
the O
laboratory O
data O
suggest O
that O
the O
tachycardia O
crises O
are O
the O
consequence O
of O
a O
hypersensitivity O
of O
the O
heart O
to O
thyroid O
hormones O
, O
associated O
with O
an O
increased O
number O
of O
T3 B-protein
nuclear I-protein
receptor I-protein
sites O
in O
lymphocytes O
. O

Induction O
of O
immediate O
early O
response O
genes O
by O
macrophage B-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
in O
normal O
human O
monocytes O
. O

A O
group O
of O
coordinately O
induced O
protooncogenes O
, O
cytoskeletal O
, O
and O
extracellular O
matrix O
genes O
have O
been O
termed O
immediate O
early O
response O
genes O
, O
and O
their O
induction O
has O
been O
associated O
with O
growth B-protein
factor I-protein
- O
stimulated O
cell O
proliferation O
. O

We O
have O
investigated O
the O
induction O
of O
these O
genes O
by O
macrophage B-protein
- I-protein
CSF I-protein
( O
M B-protein
- I-protein
CSF I-protein
) O
in O
human O
monocytes O
that O
do O
not O
proliferate O
in O
response O
to O
M B-protein
- I-protein
CSF I-protein
but O
require O
the O
factor O
for O
optimal O
cell O
differentiation O
. O

Normal O
human O
monocytes O
were O
isolated O
, O
carefully O
washed O
, O
and O
incubated O
for O
36 O
to O
48 O
h O
in O
fetal O
bovine O
serum O
- O
containing O
medium O
. O

At O
the O
end O
of O
this O
incubation O
the O
resting O
cells O
were O
stimulated O
with O
M B-protein
- I-protein
CSF I-protein
, O
and O
RNA O
was O
isolated O
for O
analysis O
by O
Northern O
blotting O
. O

RNA O
from O
control O
resting O
cells O
contained O
low O
to O
undetectable O
levels O
of O
c O
- O
jun O
, O
fibronectin O
receptor O
, O
and O
actin O
mRNA O
. O

Within O
15 O
to O
30 O
min O
of O
addition O
of O
M B-protein
- I-protein
CSF I-protein
, O
however O
, O
there O
was O
a O
dramatic O
coordinate O
induction O
of O
these O
genes O
. O

The O
c O
- O
jun O
gene O
expression O
was O
very O
transient O
and O
was O
not O
detectable O
by O
60 O
min O
after O
M B-protein
- I-protein
CSF I-protein
addition O
. O

In O
contrast O
, O
the O
expression O
of O
actin O
and O
fibronectin O
receptor O
mRNA O
was O
more O
sustained O
, O
and O
the O
expression O
of O
these O
genes O
remained O
elevated O
at O
24 O
to O
48 O
h O
after O
M B-protein
- I-protein
CSF I-protein
addition O
. O

We O
also O
observed O
the O
induction O
of O
the O
myelomonocytic B-protein
specific I-protein
tyrosine I-protein
kinase I-protein
hck O
gene O
simultaneously O
with O
the O
other O
immediate O
early O
response O
genes O
. O

The O
protein O
synthesis O
inhibitor O
cycloheximide O
did O
not O
block O
the O
induction O
of O
any O
of O
these O
genes O
, O
and O
in O
fact O
, O
super O
- O
induced O
the O
expression O
of O
c O
- O
jun O
and O
hck O
. O

Nuclear O
run O
on O
transcription O
of O
the O
c O
- O
jun O
, O
hck O
, O
and O
actin O
genes O
. O

Therefore O
, O
in O
normal O
human O
monocytes O
M B-protein
- I-protein
CSF I-protein
induces O
immediate O
early O
response O
genes O
without O
inducing O
cell O
proliferation O
. O

These O
genes O
may O
then O
play O
a O
role O
in O
altering O
the O
physiologic O
status O
of O
the O
cells O
in O
response O
to O
CSF B-protein
. O

Inducible O
nuclear B-protein
factor I-protein
binding O
to O
the O
kappa O
B O
elements O
of O
the O
human O
immunodeficiency O
virus O
enhancer O
in O
T O
cells O
can O
be O
blocked O
by O
cyclosporin O
A O
in O
a O
signal O
- O
dependent O
manner O
. O

Cyclosporin O
A O
( O
CsA O
) O
is O
thought O
to O
exert O
its O
immunosuppressive O
effects O
by O
inhibiting O
the O
expression O
of O
a O
distinct O
set O
of O
lymphokine O
genes O
which O
are O
induced O
upon O
T O
- O
cell O
activation O
, O
among O
them O
the O
gene O
coding O
for O
interleukin B-protein
- I-protein
2 I-protein
. O

In O
addition O
, O
the O
activation O
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
is O
partially O
suppressed O
. O

To O
better O
understand O
the O
molecular O
mechanisms O
underlying O
suppression O
by O
CsA O
, O
we O
have O
investigated O
the O
effects O
of O
this O
drug O
on O
transcription B-protein
factors I-protein
in O
T O
cells O
. O

Here O
we O
report O
that O
the O
formation O
of O
two O
distinct O
mitogen B-protein
- I-protein
inducible I-protein
DNA I-protein
- I-protein
binding I-protein
complexes I-protein
, O
the O
kappa B-protein
B I-protein
complex I-protein
within O
the O
HIV O
enhancer O
and O
the O
NFAT B-protein
- I-protein
1 I-protein
complex I-protein
within O
the O
interleukin B-protein
- I-protein
2 I-protein
enhancer O
, O
is O
inhibited O
in O
the O
presence O
of O
CsA O
. O

The O
kappa O
B O
- O
binding O
activity O
with O
the O
HIV O
enhancer O
is O
inhibited O
only O
if O
it O
is O
activated O
via O
the O
mitogen B-protein
phytohemagglutinin B-protein
whereas O
phorbol O
myristate O
acetate O
- O
mediated O
activation O
is O
completely O
insensitive O
to O
the O
drug O
. O

This O
suggests O
a O
model O
in O
which O
functionally O
indistinguishable O
kappa B-protein
B I-protein
complexes I-protein
can O
be O
activated O
via O
two O
separate O
pathways O
of O
signal O
transduction O
distinguishable O
by O
CsA O
. O

Purification O
of O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
, O
a O
T B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
that O
activates O
the O
T O
- O
cell O
receptor O
C O
alpha O
gene O
enhancer O
in O
a O
context O
- O
dependent O
manner O
. O

The O
differentiation O
of O
T O
cells O
into O
functionally O
diverse O
subpopulations O
is O
controlled O
in O
part O
, O
by O
transcriptional O
activation O
and O
silencing O
; O
however O
, O
little O
is O
known O
in O
detail O
about O
the O
proteins O
that O
influence O
this O
developmental O
process O
. O

We O
have O
purified O
a O
new O
T B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
factor I-protein
, O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
, O
that O
is O
implicated O
in O
the O
activation O
of O
genes O
encoding O
a O
major O
component O
of O
the O
human B-protein
T I-protein
- I-protein
cell I-protein
receptor I-protein
( O
TCR B-protein
) O
. O

TCF B-protein
- I-protein
1 I-protein
alpha I-protein
, O
originally O
identified O
and O
purified O
through O
its O
binding O
sites O
on O
the O
HIV O
- O
1 O
promoter O
, O
was O
found O
to O
bind O
to O
the O
TCR B-protein
alpha O
enhancer O
and O
to O
promoters O
for O
several O
genes O
expressed O
at O
significantly O
earlier O
stages O
of O
T O
- O
cell O
development O
than O
the O
TCR B-protein
alpha O
gene O
( O
e O
. O
g O
. O
, O
p56lck O
and O
CD3 O
delta O
) O
. O

Sequences O
related O
to O
the O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
binding O
motif O
( O
5 O
' O
- O
GGCACCCTTTGA O
- O
3 O
' O
) O
are O
also O
found O
in O
the O
human O
TCR B-protein
delta O
( O
and O
possibly O
TCR B-protein
beta O
) O
enhancers O
. O

Southwestern O
and O
gel O
renaturation O
experiments O
with O
the O
use O
of O
purified O
protein O
fractions O
revealed O
that O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
activity O
is O
derived O
from O
a O
family O
of O
57 B-protein
- I-protein
to I-protein
53 I-protein
- I-protein
kD I-protein
proteins I-protein
that O
are O
abundantly O
expressed O
in O
mature O
and O
immature O
T O
- O
cell O
lines O
( O
Jurkat O
, O
CCRF O
- O
CEM O
) O
and O
not O
in O
mature O
B O
cells O
( O
JY O
, O
Namalwa O
) O
or O
nonlymphoid O
( O
HeLa O
) O
cell O
lines O
. O

A O
small O
95 O
- O
bp O
fragment O
of O
the O
TCR B-protein
alpha O
control O
region O
that O
contains O
the O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
binding O
site O
juxtaposed O
between O
a O
cAMP O
- O
response O
element O
( O
the O
CRE O
or O
T O
alpha O
1 O
motif O
) O
and O
the O
binding O
site O
for O
a O
distinct O
lymphoid B-protein
- I-protein
specific I-protein
protein I-protein
( O
TCF B-protein
- I-protein
2 I-protein
alpha I-protein
) O
behaved O
as O
a O
potent O
T O
- O
cell O
- O
specific O
enhancer O
in O
vivo O
. O

Tandem O
copies O
of O
this O
enhancer O
functioned O
synergistically O
in O
mature O
( O
Jurkat O
) O
T O
- O
cell O
lines O
as O
well O
as O
resting O
and O
activated O
immature O
( O
CCRF O
- O
CEM O
) O
T O
- O
cell O
lines O
. O

Mutation O
of O
the O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
binding O
site O
diminished O
enhancer O
activity O
and O
disrupted O
the O
synergism O
observed O
in O
vivo O
between O
tandem O
enhancer O
repeats O
. O

The O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
binding O
site O
was O
also O
required O
for O
TCR B-protein
alpha O
enhancer O
activity O
in O
transcriptionally O
active O
extracts O
from O
Jurkat O
but O
not O
HeLa O
cells O
, O
confirming O
that O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
is O
a O
T B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
. O

Curiously O
, O
the O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
binding O
element O
was O
inactive O
in O
vivo O
when O
removed O
from O
its O
neighboring O
elements O
on O
the O
TCR B-protein
alpha O
enhancer O
and O
positioned O
in O
one O
or O
more O
copies O
upstream O
of O
a O
heterologous O
promoter O
. O

Thus O
, O
the O
transcriptional O
activity O
of O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
appears O
to O
depend O
on O
the O
TCF B-protein
- I-protein
2 I-protein
alpha I-protein
and O
T B-protein
alpha I-protein
1 I-protein
( O
CREB B-protein
) O
transcription B-protein
factors I-protein
and O
the O
context O
of O
its O
binding O
site O
within O
the O
TCR B-protein
alpha O
enhancer O
. O

Tandem O
AP O
- O
1 O
- O
binding O
sites O
within O
the O
human O
beta O
- O
globin O
dominant O
control O
region O
function O
as O
an O
inducible O
enhancer O
in O
erythroid O
cells O
. O

A O
powerful O
enhancer O
has O
been O
mapped O
to O
an O
18 O
- O
bp O
DNA O
segment O
located O
11 O
kb O
5 O
' O
to O
the O
human O
epsilon O
- O
globin O
gene O
within O
the O
dominant O
control O
or O
locus O
- O
activating O
region O
. O

This O
enhancer O
is O
inducible O
in O
K562 O
human O
erythroleukemia O
cells O
, O
increasing O
linked O
gamma O
- O
globin O
promoter O
/ B-protein
luciferase I-protein
gene O
expression O
to O
170 O
- O
fold O
over O
an O
enhancerless O
construct O
. O

The O
enhancer O
consists O
of O
tandem O
AP O
- O
1 O
- O
binding O
sites O
, O
phased O
10 O
bp O
apart O
, O
which O
are O
both O
required O
for O
full O
activity O
. O

DNA O
- O
protein O
binding O
assays O
with O
nuclear O
extracts O
from O
induced O
cells O
demonstrate O
a O
high B-protein
molecular I-protein
weight I-protein
complex I-protein
on O
the O
enhancer O
. O

The O
formation O
of O
this O
complex O
also O
requires O
both O
AP O
- O
1 O
sites O
and O
correlates O
with O
maximal O
enhancer O
activity O
. O

Induction O
of O
the O
enhancer O
may O
have O
a O
role O
in O
the O
increase O
in O
globin O
gene O
transcription O
that O
characterizes O
erythroid O
maturation O
. O

Enhancer O
activity O
appears O
to O
be O
mediated O
by O
the O
binding O
of O
a O
complex O
of O
proteins O
from O
the O
jun O
and O
fos O
families O
to O
tandem O
AP O
- O
1 O
consensus O
sequences O
. O

Identification O
of O
a O
novel B-protein
factor I-protein
that O
interacts O
with O
an O
immunoglobulin O
heavy O
- O
chain O
promoter O
and O
stimulates O
transcription O
in O
conjunction O
with O
the O
lymphoid B-protein
cell I-protein
- I-protein
specific I-protein
factor I-protein
OTF2 B-protein
. O

The O
tissue O
- O
specific O
expression O
of O
the O
MOPC O
141 O
immunoglobulin O
heavy O
- O
chain O
gene O
was O
studied O
by O
using O
in O
vitro O
transcription O
. O

B O
- O
cell O
- O
specific O
transcription O
of O
this O
gene O
was O
dependent O
on O
the O
octamer O
element O
5 O
' O
- O
ATGCAAAG O
- O
3 O
' O
, O
located O
in O
the O
upstream O
region O
of O
this O
promoter O
and O
in O
the O
promoters O
of O
all O
other O
immunoglobulin O
heavy O
- O
and O
light O
- O
chain O
genes O
. O

The O
interaction O
of O
purified O
octamer B-protein
transcription I-protein
factors I-protein
1 O
and O
2 O
( O
OTF1 B-protein
and O
OTF2 B-protein
) O
with O
the O
MOPC O
141 O
promoter O
was O
studied O
by O
using O
electrophoretic O
mobility O
shift O
assays O
and O
DNase B-protein
I I-protein
footprinting O
. O

Purified O
OTF1 B-protein
from O
HeLa O
cells O
and O
OTF1 B-protein
and O
OTF2 B-protein
from O
B O
cells O
bound O
to O
identical O
sequences O
within O
the O
heavy O
- O
chain O
promoter O
. O

The O
OTF O
interactions O
we O
observed O
extended O
over O
the O
heptamer O
element O
5 O
' O
- O
CTCAGGA O
- O
3 O
' O
, O
and O
it O
seems O
likely O
that O
the O
binding O
of O
the O
purified B-protein
factors I-protein
involves O
cooperation O
between O
octamer O
and O
heptamer O
sites O
in O
this O
promoter O
. O

In O
addition O
to O
these O
elements O
, O
we O
identified O
a O
second O
regulatory O
element O
, O
the O
N O
element O
with O
the O
sequence O
5 O
' O
- O
GGAACCTCCCCC O
- O
3 O
' O
. O

The O
N O
element O
could O
independently O
mediate O
low O
levels O
of O
transcription O
in O
both O
B O
- O
cell O
and O
HeLa O
- O
cell O
extracts O
, O
and O
, O
in O
conjunction O
with O
the O
octamer O
element O
, O
it O
can O
promote O
high O
levels O
of O
transcription O
in O
B O
- O
cell O
extracts O
. O

The O
N O
element O
bound O
a O
transcription B-protein
factor I-protein
, O
NTF B-protein
, O
that O
is O
ubiquitous O
in O
cell B-protein
- I-protein
type I-protein
distribution I-protein
, O
and O
NTF B-protein
was O
distinct O
from O
any O
of O
the O
previously B-protein
described I-protein
proteins I-protein
that O
bind O
to O
similar O
sequences O
. O

Based O
on O
these O
results O
, O
we O
propose O
that O
NTF B-protein
and O
OTF2 B-protein
interactions O
( O
both O
with O
their O
cognate O
DNA O
elements O
and O
possibly O
at O
the O
protein O
- O
protein O
level O
) O
may O
be O
critical O
to O
B O
- O
cell O
- O
specific O
expression O
and O
that O
these O
interactions O
provide O
additional O
pathways O
for O
regulating O
gene O
expression O
. O

NF B-protein
- I-protein
kappa I-protein
B I-protein
as O
inducible O
transcriptional B-protein
activator I-protein
of O
the O
granulocyte O
- O
macrophage O
colony O
- O
stimulating O
factor O
gene O
. O

The O
expression O
of O
the O
gene O
encoding O
the O
granulocyte B-protein
- I-protein
macrophage I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
( O
GM B-protein
- I-protein
CSF I-protein
) O
is O
induced O
upon O
activation O
of O
T O
cells O
with O
phytohemagglutinin B-protein
and O
active O
phorbolester O
and O
upon O
expression O
of O
tax1 B-protein
, O
a O
transactivating B-protein
protein I-protein
of O
the O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
. O

The O
same O
agents O
induce O
transcription O
from O
the O
interleukin O
- O
2 O
receptor O
alpha O
- O
chain O
and O
interleukin O
- O
2 O
genes O
, O
depending O
on O
promoter O
elements O
that O
bind O
the O
inducible B-protein
transcription I-protein
factor I-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
( O
or O
an O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- I-protein
like I-protein
factor I-protein
) O
. O

We O
therefore O
tested O
the O
possibility O
that O
the O
GM B-protein
- I-protein
CSF I-protein
gene O
is O
also O
regulated O
by O
a O
cognate O
motif O
for O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
transcription I-protein
factor I-protein
. O

A O
recent O
functional O
analysis O
by O
Miyatake O
et O
al O
. O
( O
S O
. O
Miyatake O
, O
M O
. O
Seiki O
, O
M O
. O
Yoshida O
, O
and O
K O
. O
Arai O
, O
Mol O
. O
Cell O
. O
Biol O
. O
8 O
: O
5581 O
- O
5587 O
, O
1988 O
) O
described O
a O
short O
promoter O
region O
in O
the O
GM B-protein
- I-protein
CSF I-protein
gene O
that O
conferred O
strong O
inducibility O
by O
T O
- O
cell O
- O
activating O
signals O
and O
tax1 B-protein
, O
but O
no O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
binding O
motifs O
were O
identified O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
, O
we O
showed O
binding O
of O
purified O
human B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
and O
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activated O
in O
Jurkat O
T O
cells O
to O
an O
oligonucleotide O
comprising O
the O
GM B-protein
- I-protein
CSF I-protein
promoter O
element O
responsible O
for O
mediating O
responsiveness O
to O
T O
- O
cell O
- O
activating O
signals O
and O
tax1 B-protein
. O

As O
shown O
by O
a O
methylation O
interference O
analysis O
and O
oligonucleotide O
competition O
experiments O
, O
purified O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binds O
at O
positions O
- O
82 O
to O
- O
91 O
( O
GGGAACTACC O
) O
of O
the O
GM B-protein
- I-protein
CSF I-protein
promoter O
sequence O
with O
an O
affinity O
similar O
to O
that O
with O
which O
it O
binds O
to O
the O
biologically O
functional O
kappa O
B O
motif O
in O
the O
beta O
interferon O
promoter O
( O
GGGAAATTCC O
) O
. O

Two O
kappa O
B O
- O
like O
motifs O
at O
positions O
- O
98 O
to O
- O
108 O
of O
the O
GM B-protein
- I-protein
CSF I-protein
promoter O
were O
also O
recognized O
but O
with O
much O
lower O
affinities O
. O

Our O
data O
provide O
strong O
evidence O
that O
the O
expression O
of O
the O
GM B-protein
- I-protein
CSF I-protein
gene O
following O
T O
- O
cell O
activation O
is O
controlled O
by O
binding O
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
transcription I-protein
factor I-protein
to O
a O
high O
- O
affinity O
binding O
site O
in O
the O
GM B-protein
- I-protein
CSF I-protein
promoter O
. O

Effects O
of O
mitogenic O
agents O
upon O
glucocorticoid O
action O
in O
human O
tonsillar O
T O
- O
lymphocytes O
. O

The O
treatment O
of O
human O
tonsillar O
T O
- O
lymphocytes O
with O
4 O
- O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
, O
resulted O
in O
about O
two O
fold O
increase O
in O
glucocorticoid B-protein
receptor I-protein
( O
GR B-protein
) O
number O
, O
without O
any O
significant O
change O
in O
the O
receptor O
affinity O
. O

This O
increase O
disappeared O
in O
the O
presence O
of O
cycloheximide O
. O

Alone O
, O
PMA O
and O
calcium O
ionophore O
A23187 O
did O
not O
affect O
, O
but O
together O
stimulated O
, O
like O
phytohaemagglutinin B-protein
( O
PHA B-protein
) O
, O
leucine O
and O
, O
in O
particular O
, O
thymidine O
incorporation O
. O

PMA O
enhanced O
slightly O
the O
stimulatory O
effect O
of O
PHA B-protein
. O

Alone O
, O
these O
agents O
failed O
to O
alter O
the O
suppressive O
effect O
of O
dexamethasone O
on O
thymidine O
and O
leucine O
incorporation O
; O
however O
, O
PMA O
- O
A23187 O
and O
PMA O
- B-protein
PHA I-protein
combinations O
appeared O
to O
antagonize O
the O
suppression O
by O
dexamethasone O
. O

To O
be O
or O
not O
to O
be O
a O
responder O
in O
T O
- O
cell O
responses O
: O
ubiquitous O
oligopeptides O
in O
all O
proteins O
. O

Amino O
acid O
sequences O
of O
all O
proteins O
are O
essays O
written O
in O
the O
same O
language O
. O

Accordingly O
, O
the O
same O
set O
of O
words O
and O
phrases O
( O
oligopeptides O
) O
appear O
in O
totally O
unrelated B-protein
proteins I-protein
. O

The O
reason O
that O
only O
certain O
individuals O
of O
particular O
major B-protein
histocompatibility I-protein
complex I-protein
( I-protein
MHC I-protein
) I-protein
haplotypes I-protein
can O
mount O
T O
- O
cell O
responses O
against O
a O
given O
antigen O
of O
pathogens O
is O
found O
in O
the O
fact O
that O
T B-protein
- I-protein
cell I-protein
receptors I-protein
are O
designed O
to O
recognize O
18 O
- O
20 O
residue O
- O
long O
peptide O
fragments O
sandwiched O
between O
two O
alpha B-protein
- I-protein
helices I-protein
of O
class B-protein
I I-protein
or O
class B-protein
II I-protein
MHC I-protein
molecules I-protein
. O

At O
this O
range O
of O
peptide O
lengths O
, O
most O
would O
appear O
as O
self O
, O
while O
nonselfness O
of O
the O
remainders O
are O
destined O
to O
be O
quite O
ambiguous O
, O
hence O
creating O
responders O
and O
nonresponders O
. O

Two O
distinct O
signal O
transmission O
pathways O
in O
T O
lymphocytes O
are O
inhibited O
by O
complexes O
formed O
between O
an O
immunophilin B-protein
and O
either O
FK506 O
or O
rapamycin O
. O

Proliferation O
and O
immunologic O
function O
of O
T O
lymphocytes O
are O
initiated O
by O
signals O
from O
the O
antigen B-protein
receptor I-protein
that O
are O
inhibited O
by O
the O
immunosuppressant O
FK506 O
but O
not O
by O
its O
structural O
analog O
, O
rapamycin O
. O

On O
the O
other O
hand O
, O
interleukin B-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
- O
induced O
signals O
are O
blocked O
by O
rapamycin O
but O
not O
by O
FK506 O
. O

Remarkably O
, O
these O
two O
drugs O
inhibit O
each O
other O
' O
s O
actions O
, O
raising O
the O
possibility O
that O
both O
act O
by O
means O
of O
a O
common O
immunophilin B-protein
( O
immunosuppressant B-protein
binding I-protein
protein I-protein
) O
. O

We O
find O
that O
the O
dissociation O
constant O
of O
rapamycin O
to O
the O
FK506 B-protein
binding I-protein
protein I-protein
FKBP B-protein
( O
Kd O
= O
0 O
. O
2 O
nM O
) O
is O
close O
to O
the O
dissociation O
constant O
of O
FK506 O
to O
FKBP B-protein
( O
Kd O
= O
0 O
. O
4 O
nM O
) O
and O
to O
their O
effective O
biologic O
inhibitory O
concentrations O
. O

However O
, O
an O
excess O
of O
rapamycin O
is O
needed O
to O
revert O
FK506 O
- O
mediated O
inhibition O
of O
IL B-protein
- I-protein
2 I-protein
production O
, O
apoptosis O
, O
and O
transcriptional O
activation O
of O
NF B-protein
- I-protein
AT I-protein
, O
a O
T B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
necessary O
for O
IL B-protein
- I-protein
2 I-protein
gene O
activation O
. O

Similarly O
, O
an O
excess O
of O
FK506 O
is O
needed O
to O
revert O
rapamycin O
- O
mediated O
inhibition O
of O
IL B-protein
- I-protein
2 I-protein
- O
induced O
proliferation O
. O

The O
drug O
concentrations O
required O
for O
antagonism O
may O
be O
explained O
by O
the O
relative O
affinity O
of O
the O
drugs O
to O
, O
and O
by O
the O
abundance O
of O
, O
the O
immunophilin B-protein
FKBP B-protein
. O

FKBP B-protein
has O
been O
shown O
to O
catalyze O
the O
interconversion O
of O
the O
cis O
- O
and O
trans O
- O
rotamers O
of O
the O
peptidyl B-protein
- I-protein
prolyl I-protein
amide I-protein
bond I-protein
of O
peptide O
substrates O
; O
here O
we O
show O
that O
rapamycin O
, O
like O
FK506 O
, O
is O
a O
potent O
inhibitor O
of O
the O
rotamase O
activity O
of O
FKBP B-protein
( O
Ki O
= O
0 O
. O
2 O
nM O
) O
. O

Neither O
FKBP B-protein
binding O
nor O
inhibition O
of O
rotamase O
activity O
of O
FKBP B-protein
alone O
is O
sufficient O
to O
explain O
the O
biologic O
actions O
of O
these O
drugs O
. O

Rather O
, O
these O
findings O
suggest O
that O
immunophilin B-protein
bound O
to O
FK506 O
interferes O
with O
antigen B-protein
receptor I-protein
- O
induced O
signals O
, O
while O
rapamycin O
bound O
to O
the O
immunophilin B-protein
interferes O
with O
IL B-protein
- I-protein
2 I-protein
- O
induced O
signals O
. O

Adherence O
- O
dependent O
increase O
in O
human O
monocyte O
PDGF O
( O
B O
) O
mRNA O
is O
associated O
with O
increases O
in O
c O
- O
fos O
, O
c O
- O
jun O
, O
and O
EGR2 O
mRNA O
. O

Adherence O
is O
an O
important O
initial O
step O
in O
the O
transition O
of O
a O
circulating O
monocyte O
to O
a O
tissue O
macrophage O
. O

This O
differentiation O
is O
accompanied O
by O
an O
augmented O
capacity O
to O
generate O
growth B-protein
factors I-protein
. O

We O
hypothesized O
that O
adherence O
itself O
might O
be O
an O
important O
trigger O
for O
a O
sequence O
of O
gene O
activation O
culminating O
in O
cells O
with O
increased O
mRNA O
encoding O
profibrotic O
growth B-protein
factors I-protein
such O
as O
platelet B-protein
- I-protein
derived I-protein
growth I-protein
factor I-protein
B I-protein
subunit I-protein
( O
PDGF B-protein
[ I-protein
B I-protein
] I-protein
) O
and O
transforming B-protein
growth I-protein
factor I-protein
- I-protein
beta I-protein
( O
TGF B-protein
- I-protein
beta I-protein
) O
. O

After O
in O
vitro O
adherence O
, O
human O
monocytes O
had O
a O
biphasic O
increase O
in O
PDGF B-protein
( I-protein
B I-protein
) I-protein
mRNA O
with O
peaks O
at O
6 O
h O
and O
13 O
d O
. O

No O
increase O
in O
TGF B-protein
- I-protein
beta I-protein
mRNA O
was O
observed O
. O

The O
6 O
- O
h O
increase O
in O
PDGF B-protein
( I-protein
B I-protein
) I-protein
mRNA O
was O
adherence O
dependent O
, O
and O
in O
addition O
, O
was O
abrogated O
when O
the O
cytoskeletal O
integrity O
was O
compromised O
by O
cytochalasin O
D O
. O

The O
6 O
- O
h O
increase O
in O
PDGF B-protein
( I-protein
B I-protein
) I-protein
mRNA O
was O
unaltered O
by O
adherence O
in O
the O
presence O
of O
the O
monocyte O
stimulus O
lipopolysaccharide O
. O

Adherence O
to O
either O
fibronectin O
or O
collagen O
- O
coated O
plastic O
had O
little O
consistent O
effect O
on O
PDGF B-protein
( I-protein
B I-protein
) I-protein
mRNA O
accumulation O
. O

The O
increased O
PDGF B-protein
( I-protein
B I-protein
) I-protein
mRNA O
observed O
in O
adherent O
monocytes O
was O
accompanied O
by O
increases O
in O
mRNAs O
of O
the O
early O
growth O
response O
genes O
c O
- O
fos O
( O
maximal O
at O
20 O
min O
) O
, O
c O
- O
jun O
, O
and O
EGR2 O
( O
maximal O
at O
6 O
- O
24 O
h O
) O
. O

The O
increase O
in O
c O
- O
jun O
and O
EGR2 O
, O
but O
not O
c O
- O
fos O
, O
mRNA O
was O
also O
abrogated O
by O
cytochalasin O
D O
. O

These O
observations O
suggest O
that O
adherence O
results O
in O
increases O
of O
c O
- O
fos O
, O
c O
- O
jun O
, O
EGR2 O
, O
and O
PDGF O
( O
B O
) O
mRNA O
. O

In O
addition O
, O
the O
increases O
in O
c O
- O
jun O
, O
EGR2 O
, O
and O
PDGF B-protein
( I-protein
B I-protein
) I-protein
may O
depend O
on O
cytoskeletal O
rearrangement O
. O

Modulation O
of O
these O
events O
at O
the O
time O
of O
adherence O
offers O
a O
mechanism O
by O
which O
differential O
priming O
of O
the O
cells O
may O
be O
accomplished O
. O

Single O
cell O
assay O
of O
a O
transcription B-protein
factor I-protein
reveals O
a O
threshold O
in O
transcription O
activated O
by O
signals O
emanating O
from O
the O
T B-protein
- I-protein
cell I-protein
antigen I-protein
receptor I-protein
. O

Stimulation O
of O
T O
lymphocytes O
through O
their O
antigen B-protein
receptor I-protein
leads O
to O
the O
appearance O
of O
several O
transcription B-protein
factors I-protein
, O
including O
NF B-protein
- I-protein
AT I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
which O
are O
involved O
in O
regulating O
genes O
required O
for O
immunologic O
activation O
. O

To O
investigate O
the O
activity O
of O
a O
single O
transcription B-protein
factor I-protein
in O
individual O
viable O
cells O
, O
we O
have O
applied O
an O
assay O
that O
uses O
the O
fluorescence O
- O
activated O
cell O
sorter O
to O
quantitate O
beta B-protein
- I-protein
galactosidase I-protein
( O
beta B-protein
- I-protein
gal I-protein
) O
. O

We O
have O
analyzed O
the O
distribution O
of O
NF B-protein
- I-protein
AT I-protein
transcriptional O
activity O
among O
T O
cells O
undergoing O
activation O
by O
using O
a O
construct O
in O
which O
three O
tandem O
copies O
of O
the O
NF B-protein
- I-protein
AT I-protein
- O
binding O
site O
directs O
transcription O
of O
the O
lacZ O
gene O
. O

Unexpectedly O
, O
stimulation O
of O
cloned O
stably O
transfected O
Jurkat O
T O
cells O
leads O
to O
a O
bimodal O
pattern O
of O
beta O
- O
gal O
expression O
in O
which O
some O
cells O
express O
no O
beta B-protein
- I-protein
gal I-protein
and O
others O
express O
high O
levels O
. O

This O
expression O
pattern O
cannot O
be O
accounted O
for O
by O
cell O
- O
cycle O
position O
or O
heritable O
variation O
. O

Further O
results O
, O
in O
which O
beta B-protein
- I-protein
gal I-protein
activity O
is O
correlated O
with O
NF B-protein
- I-protein
AT I-protein
- O
binding O
activity O
, O
indicate O
that O
the O
concentration O
of O
NF B-protein
- I-protein
AT I-protein
must O
exceed O
a O
critical O
threshold O
before O
transcription O
initiates O
. O

This O
threshold O
likely O
reflects O
the O
NF B-protein
- I-protein
AT I-protein
concentration O
- O
dependent O
assembly O
of O
transcription B-protein
complexes I-protein
at O
the O
promoter O
. O

Similar O
constructs O
controlled O
by O
NF B-protein
- I-protein
kappa I-protein
B I-protein
or O
the O
entire O
interleukin O
- O
2 O
enhancer O
show O
bimodal O
expression O
patterns O
during O
induction O
, O
suggesting O
that O
thresholds O
set O
by O
the O
concentration O
of O
transcription B-protein
factors I-protein
may O
be O
a O
common O
property O
of O
inducible O
genes O
. O

The O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
BMRF1 O
promoter O
for O
early B-protein
antigen I-protein
( O
EA B-protein
- I-protein
D I-protein
) O
is O
regulated O
by O
the O
EBV B-protein
transactivators I-protein
, O
BRLF1 B-protein
and O
BZLF1 B-protein
, O
in O
a O
cell O
- O
specific O
manner O
. O

The O
Epstein B-protein
- I-protein
Barr I-protein
virus I-protein
early I-protein
antigen I-protein
diffuse I-protein
component I-protein
( O
EA B-protein
- I-protein
D I-protein
) O
is O
essential O
for O
Epstein O
- O
Barr O
virus O
DNA O
polymerase O
activity O
, O
and O
its O
activity O
is O
suppressed O
during O
latent O
infection O
. O

We O
investigated O
the O
regulation O
of O
the O
promoter O
( O
BMRF1 O
) O
for O
this O
early O
gene O
by O
studying O
its O
responsiveness O
in O
vitro O
to O
two O
immediate B-protein
- I-protein
early I-protein
viral I-protein
transactivators I-protein
, O
BZLF1 B-protein
( O
Z B-protein
) O
and O
BRLF1 B-protein
( O
R B-protein
) O
, O
focusing O
on O
the O
differences O
in O
response O
in O
lymphoid O
cells O
and O
epithelial O
cells O
. O

In O
lymphoid O
cells O
, O
Z B-protein
or O
R B-protein
alone O
produced O
only O
small O
increases O
in O
EA B-protein
- I-protein
D I-protein
promoter O
activity O
, O
whereas O
both O
transactivators B-protein
together O
produced O
a O
large O
stimulatory O
effect O
. O

In O
epithelial O
cells O
, O
the O
Z B-protein
transactivator I-protein
alone O
produced O
maximal O
stimulation O
of O
the O
EA B-protein
- I-protein
D I-protein
promoter O
; O
the O
effect O
of O
R B-protein
and O
Z B-protein
together O
was O
no O
greater O
than O
that O
of O
Z B-protein
alone O
. O

Deletional O
analysis O
and O
site O
- O
directed O
mutagenesis O
of O
the O
EA B-protein
- I-protein
D I-protein
promoter O
demonstrated O
that O
in O
epithelial O
cells O
the O
potential O
AP O
- O
1 O
binding O
site O
plays O
an O
essential O
role O
in O
Z B-protein
responsiveness O
, O
although O
sequences O
further O
upstream O
are O
also O
important O
. O

In O
lymphoid O
cells O
, O
only O
the O
upstream O
sequences O
are O
required O
for O
transactivation O
by O
the O
Z B-protein
/ I-protein
R I-protein
combination O
, O
and O
the O
AP B-protein
- I-protein
1 I-protein
site I-protein
is O
dispensable O
. O

These O
data O
suggest O
that O
EA B-protein
- I-protein
D I-protein
( O
BMRF1 O
) O
promoter O
regulation O
by O
Z B-protein
and O
R B-protein
is O
cell O
type O
specific O
and O
appears O
to O
involve O
different O
mechanisms O
in O
each O
cell O
type O
. O

Complementary O
DNA O
encoding O
the O
human B-protein
T I-protein
- I-protein
cell I-protein
FK506 I-protein
- I-protein
binding I-protein
protein I-protein
, O
a O
peptidylprolyl B-protein
cis I-protein
- I-protein
trans I-protein
isomerase I-protein
distinct O
from O
cyclophilin B-protein
. O

The O
recently O
discovered O
macrolide O
FK506 O
has O
been O
demonstrated O
to O
have O
potent O
immunosuppressive O
activity O
at O
concentrations O
100 O
- O
fold O
lower O
than O
cyclosporin O
A O
, O
a O
cyclic O
undecapeptide O
that O
is O
used O
to O
prevent O
rejection O
after O
transplantation O
of O
bone O
marrow O
and O
organs O
, O
such O
as O
kidney O
, O
heart O
, O
and O
liver O
. O

After O
the O
recent O
discovery O
that O
the O
cyclosporin B-protein
A I-protein
- I-protein
binding I-protein
protein I-protein
cyclophilin B-protein
is O
identical O
to O
peptidylprolyl B-protein
cis I-protein
- I-protein
trans I-protein
isomerase I-protein
, O
a O
cellular B-protein
binding I-protein
protein I-protein
for O
FK506 O
was O
found O
to O
be O
distinct O
from O
cyclophilin B-protein
but O
to O
have O
the O
same O
enzymatic O
activity O
. O

In O
this O
study O
, O
we O
isolated O
a O
cDNA O
coding O
for O
FK506 O
- O
binding O
protein O
( O
FKBP B-protein
) O
from O
human O
peripheral O
blood O
T O
cells O
by O
using O
mixed O
20 O
- O
mer O
oligonucleotide O
probes O
synthesized O
on O
the O
basis O
of O
the O
sequence O
, O
Glu O
- O
Asp O
- O
Gly O
- O
Lys O
- O
Lys O
- O
Phe O
- O
Asp O
, O
reported O
for O
bovine B-protein
FKBP I-protein
. O

The O
DNA O
isolated O
contained O
an O
open O
reading O
frame O
encoding O
108 O
amino O
acid O
residues O
. O

The O
first O
40 O
residues O
of O
the O
deduced O
amino B-protein
acid I-protein
sequence I-protein
were O
identical O
to O
those O
of O
the O
reported O
amino O
- O
terminal O
sequence O
of O
bovine O
FKBP B-protein
, O
indicating O
that O
the O
DNA O
sequence O
isolated O
represents O
the O
gene O
coding O
for O
FKBP B-protein
. O

Computer O
- O
assisted O
analysis O
of O
the O
deduced O
amino O
acid O
sequence O
indicates O
that O
FKBP B-protein
exhibits O
no O
internal O
homology O
and O
does O
not O
have O
significant O
sequence O
similarity O
to O
any O
other O
amino O
acid O
sequences O
of O
known O
proteins O
, O
including O
cyclophilin B-protein
. O

This O
result O
suggests O
that O
two O
catalytically O
similar O
proteins O
, O
cyclophilin B-protein
and O
FKBP B-protein
, O
evolved O
independently O
. O

In O
Northern O
blot O
analysis O
, O
mRNA O
species O
of O
approximately O
1 O
. O
8 O
kilobases O
that O
hybridized O
with O
human O
FKBP B-protein
cDNA O
were O
detected O
in O
poly O
( O
A O
) O
+ O
RNAs O
from O
brain O
, O
lung O
, O
liver O
, O
and O
placental O
cells O
and O
leukocytes O
. O

Induction O
of O
Jurkat O
leukemic O
T O
cells O
with O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
and O
ionomycin O
did O
not O
affect O
the O
level O
of O
FKBP B-protein
mRNA O
. O

Southern O
blot O
analysis O
of O
human O
genomic O
DNA O
digested O
with O
different O
restriction B-protein
enzymes I-protein
suggests O
the O
existence O
of O
only O
a O
few O
copies O
of O
the O
DNA O
sequence O
encoding O
FKBP B-protein
. O

This O
is O
in O
contrast O
to O
the O
result O
that O
as O
many O
as O
20 O
copies O
of O
the O
cyclophilin B-protein
gene O
and O
possible O
pseudogenes O
may O
be O
present O
in O
the O
mammalian O
genome O
. O

Involvement O
of O
a O
second O
lymphoid O
- O
specific O
enhancer O
element O
in O
the O
regulation O
of O
immunoglobulin O
heavy O
- O
chain O
gene O
expression O
. O

To O
determine O
whether O
enhancer O
elements O
in O
addition O
to O
the O
highly O
conserved O
octamer O
( O
OCTA O
) O
- O
nucleotide O
motif O
are O
important O
for O
lymphoid O
- O
specific O
expression O
of O
the O
immunoglobulin O
heavy O
- O
chain O
( O
IgH O
) O
gene O
, O
we O
have O
investigated O
the O
effect O
of O
mutating O
the O
binding O
site O
for O
a O
putative B-protein
additional I-protein
lymphoid I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
, O
designated O
NF B-protein
- I-protein
microB I-protein
, O
in O
the O
murine O
IgH O
enhancer O
. O

We O
demonstrate O
that O
the O
NF O
- O
microB O
- O
binding O
site O
plays O
a O
critical O
role O
in O
the O
IgH O
enhancer O
, O
because O
mutation O
of O
the O
microB O
DNA O
motif O
decreased O
transcriptional O
activity O
of O
the O
IgH O
enhancer O
in O
cells O
of O
the O
B O
- O
cell O
lineage O
but O
not O
in O
nonlymphoid O
cells O
. O

This O
effect O
was O
comparable O
to O
or O
even O
stronger O
than O
the O
effect O
of O
a O
mutation O
in O
the O
OCTA O
site O
. O

Moreover O
, O
combined O
mutation O
of O
both O
microB O
and O
OCTA O
sites O
further O
reduced O
enhancer O
activity O
in O
lymphoid O
cells O
. O

Interestingly O
, O
alteration O
of O
either O
the O
microB O
or O
E3 O
site O
in O
a O
70 O
- O
base O
- O
pair O
fragment O
of O
the O
IgH O
enhancer O
that O
lacks O
the O
binding O
site O
for O
OCTA O
abolished O
enhancer O
activity O
in O
lymphoid O
cells O
completely O
. O

Nevertheless O
, O
a O
multimer O
of O
the O
microB O
motif O
alone O
showed O
no O
enhancer O
activity O
. O

DNase O
footprinting O
analysis O
corroborated O
the O
functional O
data O
showing O
that O
a O
lymphoid B-protein
- I-protein
specific I-protein
protein I-protein
binds O
to O
the O
microB O
DNA O
motif O
. O

Our O
results O
suggest O
that O
the O
microB O
element O
is O
a O
new O
crucial O
element O
important O
for O
lymphoid O
- O
specific O
expression O
of O
the O
IgH O
gene O
but O
that O
interaction O
with O
another O
enhancer O
element O
is O
essential O
for O
its O
activity O
. O

Stimulation O
of O
the O
human O
immunodeficiency O
virus O
type O
2 O
( O
HIV O
- O
2 O
) O
gene O
expression O
by O
the O
cytomegalovirus O
and O
HIV O
- O
2 O
transactivator O
gene O
. O

Human O
immunodeficiency O
virus O
( O
HIV O
) O
often O
causes O
latent O
infection O
. O

Transactivation O
by O
some O
DNA O
viruses O
has O
been O
implicated O
in O
inducing O
HIV O
- O
1 O
replication O
and O
pathogenesis O
. O

The O
transactivator O
( O
IE O
- O
2 O
) O
gene O
of O
the O
human O
cytomegalovirus O
( O
CMV O
) O
can O
enhance O
HIV O
- O
2 O
as O
well O
as O
HIV O
- O
1 O
gene O
expression O
in O
vitro O
. O

This O
inducer O
can O
act O
in O
concert O
with O
the O
HIV O
- O
2 O
tat O
gene O
and O
T O
- O
cell O
activation O
in O
enhancing O
gene O
expression O
in O
human O
CD4 O
+ O
lymphocytes O
. O

While O
the O
HIV O
- O
2 O
and O
HIV O
- O
1 O
tat O
genes O
and O
T B-protein
- I-protein
cell I-protein
activators I-protein
apparently O
employ O
independent O
modes O
of O
action O
, O
the O
CMV O
transactivator O
in O
combination O
with O
the O
HIV O
- O
2 O
tat O
or O
T B-protein
- I-protein
cell I-protein
activators I-protein
may O
employ O
a O
gene O
activation O
pathway O
with O
some O
common O
and O
some O
distinct O
components O
. O

Both O
HIV O
- O
2 O
and O
CMV O
transactivators B-protein
enhance O
HIV O
- O
2 O
gene O
expression O
by O
transcriptional O
activation O
involving O
transcript O
initiation O
as O
well O
as O
elongation O
, O
with O
CMV O
transactivator B-protein
affecting O
elongation O
more O
than O
the O
initiation O
. O

A O
significant O
proportion O
of O
transcripts O
appear O
to O
terminate O
prematurely O
in O
the O
absence O
of O
transactivators B-protein
. O

Deletion O
mutation O
analysis O
of O
the O
HIV O
- O
2 O
long O
terminal O
repeat O
( O
LTR O
) O
suggests O
that O
the O
element O
that O
responds O
to O
CMV O
transactivation O
in O
human O
CD4 O
+ O
lymphocytes O
is O
either O
a O
diffuse O
one O
or O
located O
downstream O
of O
the O
HIV O
- O
2 O
enhancer O
element O
. O

Quantitative O
immunohistochemical O
analysis O
of O
mononuclear O
infiltrates O
in O
breast O
carcinomas O
- O
- O
correlation O
with O
tumour O
differentiation O
. O

Inflammatory O
infiltrates O
were O
analysed O
in O
tissue O
sections O
of O
76 O
breast O
carcinomas O
by O
counting O
the O
percentage O
of O
macrophages O
, O
IgA O
+ O
and O
IgG O
+ O
plasma O
cells O
, O
T O
cells O
with O
their O
subpopulations O
, O
and O
natural O
killer O
cells O
, O
and O
by O
measuring O
postcapillary O
venules O
( O
PCVs O
, O
found O
in O
12 O
cases O
) O
within O
the O
infiltrates O
. O

These O
parameters O
were O
correlated O
with O
nuclear O
grade O
and O
biochemically O
determined O
hormone O
receptor O
status O
, O
known O
markers O
of O
tumour O
differentiation O
. O

A O
direct O
correlation O
was O
found O
between O
the O
extent O
of O
inflammation O
and O
nuclear O
grade O
( O
P O
less O
than O
0 O
. O
0001 O
) O
, O
and O
an O
inverse O
correlation O
between O
inflammation O
and O
oestrogen B-protein
receptor I-protein
( O
OR B-protein
) O
positivity O
( O
P O
less O
than O
0 O
. O
05 O
) O
as O
well O
as O
inflammation O
and O
progesterone B-protein
receptor I-protein
( O
PR B-protein
) O
positivity O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

The O
percentage O
of O
the O
OKT8 O
+ O
suppressor O
/ O
cytotoxic O
T O
cells O
increased O
when O
the O
inflammation O
expanded O
from O
scanty O
to O
moderate O
( O
P O
less O
than O
0 O
. O
02 O
) O
. O

The O
diameter O
of O
the O
PCVs O
also O
increased O
with O
increasing O
inflammatory O
infiltrate O
( O
P O
less O
than O
0 O
. O
02 O
) O
. O

In O
addition O
, O
a O
direct O
correlation O
exists O
between O
the O
diameter O
of O
the O
PCVs O
and O
both O
the O
percentage O
of O
the O
OKT8 O
+ O
T O
cells O
( O
P O
less O
than O
0 O
. O
04 O
) O
and O
the O
Leu O
- O
7 O
+ O
natural O
killer O
cells O
( O
P O
less O
than O
0 O
. O
03 O
) O
. O

Reactivity O
of O
lymphocytes O
to O
a O
progesterone B-protein
receptor I-protein
- I-protein
specific I-protein
monoclonal I-protein
antibody I-protein
. O

In O
this O
study O
we O
present O
evidence O
for O
reactivity O
of O
pregnancy O
lymphocytes O
, O
but O
not O
nonpregnancy O
lymphocytes O
, O
with O
the O
progesterone B-protein
receptor I-protein
- I-protein
specific I-protein
monoclonal I-protein
antibody I-protein
mPRI B-protein
. O

Using O
an O
avidin B-protein
- B-protein
biotin I-protein
peroxidase I-protein
detection O
system O
, O
we O
found O
a O
nuclear O
staining O
in O
14 O
. O
6 O
+ O
/ O
- O
3 O
. O
7 O
% O
( O
mean O
+ O
/ O
- O
SEM O
, O
N O
= O
27 O
) O
of O
pregnancy O
lymphocytes O
, O
while O
only O
0 O
. O
47 O
+ O
/ O
- O
0 O
. O
33 O
% O
( O
mean O
+ O
/ O
- O
SEM O
, O
N O
= O
15 O
) O
of O
nonpregnancy O
lymphocytes O
reacted O
with O
the O
antibody O
. O

To O
characterize O
the O
receptor O
- O
bearing O
subset O
, O
CD8 O
+ O
and O
CD4 O
+ O
cells O
were O
depleted O
by O
complement O
- O
dependent O
lysis O
. O

Depletion O
of O
CD8 O
+ O
cells O
was O
accompanied O
by O
62 O
+ O
/ O
- O
18 O
% O
loss O
of O
progesterone B-protein
receptor I-protein
- O
bearing O
cells O
, O
while O
depletion O
of O
CD4 O
+ O
cells O
resulted O
in O
a O
twofold O
increase O
in O
the O
number O
of O
positively O
staining O
lymphocytes O
. O

In O
nonpregnancy O
lymphocytes O
a O
3 O
- O
day O
PHA B-protein
treatment O
, O
as O
well O
as O
allogeneic O
stimulation O
, O
resulted O
in O
a O
significant O
increase O
in O
the O
number O
of O
receptor O
- O
containing O
cells O
. O

These O
results O
suggest O
that O
pregnancy O
, O
but O
not O
nonpregnancy O
, O
lymphocytes O
contain O
progesterone B-protein
binding I-protein
structures I-protein
, O
and O
that O
these O
are O
inducible O
by O
mitogenic O
or O
alloantigenic O
stimuli O
. O

Activation O
of O
human O
CD4 O
T O
lymphocytes O
. O

Interaction O
of O
fibronectin B-protein
with O
VLA B-protein
- I-protein
5 I-protein
receptor I-protein
on O
CD4 O
cells O
induces O
the O
AP B-protein
- I-protein
1 I-protein
transcription I-protein
factor I-protein
. O

Fibronectin B-protein
synergized O
with O
anti B-protein
- I-protein
CD3 I-protein
antibody I-protein
to O
promote O
CD4 B-protein
cell O
proliferation O
in O
a O
serum O
- O
free O
culture O
system O
whereas O
no O
proliferation O
was O
observed O
when O
CD4 O
cells O
were O
cultured O
with O
anti B-protein
- I-protein
CD3 I-protein
alone O
or O
fibronectin B-protein
alone O
. O

In O
addition O
, O
anti B-protein
- I-protein
CD29 I-protein
( O
integrin B-protein
beta I-protein
1 I-protein
) O
as O
well O
as O
anti B-protein
- I-protein
VLA I-protein
- I-protein
5 I-protein
( O
human B-protein
fibronectin I-protein
receptor I-protein
) O
antibodies O
blocked O
this O
CD4 O
cell O
activation O
in O
this O
system O
. O

Although O
anti B-protein
- I-protein
CD3 I-protein
alone O
or O
fibronectin B-protein
alone O
cannot O
induce O
IL B-protein
- I-protein
2 I-protein
message O
by O
CD4 O
cells O
, O
the O
combination O
of O
anti B-protein
- I-protein
CD3 I-protein
plus O
fibronectin B-protein
induced O
IL B-protein
- I-protein
2 I-protein
message O
by O
CD4 O
cells O
. O

In O
an O
analysis O
of O
the O
molecular O
mechanism O
by O
which O
IL B-protein
- I-protein
2 I-protein
message O
was O
generated O
, O
we O
showed O
that O
a O
fibronectin B-protein
- O
VLA O
- O
5 O
fibronectin B-protein
receptor I-protein
interaction O
may O
contribute O
an O
independent O
signal O
distinct O
from O
the O
CD3 B-protein
pathway O
of O
activation O
by O
the O
induction O
of O
an O
AP B-protein
- I-protein
1 I-protein
transcriptional I-protein
factor I-protein
. O

Thus O
the O
VLA B-protein
- I-protein
5 I-protein
fibronectin I-protein
receptor I-protein
on O
CD4 O
cells O
can O
play O
a O
complementary O
role O
in O
CD3 B-protein
- O
TCR B-protein
- O
mediated O
signal O
transduction O
through O
its O
interaction O
with O
fibronectin B-protein
. O

Glucocorticoid B-protein
receptors I-protein
on O
mononuclear O
leukocytes O
in O
Alzheimer O
' O
s O
disease O
. O

Several O
lines O
of O
evidence O
suggest O
disturbances O
of O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
system O
in O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
. O

In O
an O
exploration O
of O
the O
potential O
role O
of O
the O
glucocorticoid O
receptor O
( O
GR O
) O
in O
AD O
, O
GR O
density O
and O
affinity O
were O
assessed O
on O
mononuclear O
leukocytes O
of O
12 O
AD O
patients O
and O
12 O
healthy O
controls O
. O

GR O
binding O
characteristics O
did O
not O
differ O
between O
patients O
and O
controls O
or O
between O
patients O
subdivided O
according O
to O
diagnosis O
or O
associated O
clinical O
features O
. O

These O
data O
suggest O
that O
the O
abnormalities O
of O
the O
HPA O
system O
in O
AD O
are O
not O
related O
to O
a O
GR B-protein
deficiency O
. O

Oncogene O
amplification O
correlates O
with O
dense O
lymphocyte O
infiltration O
in O
human O
breast O
cancers O
: O
a O
role O
for O
hematopoietic B-protein
growth I-protein
factor I-protein
release O
by O
tumor O
cells O
? O
. O

One O
hundred O
six O
primary O
breast O
cancer O
samples O
were O
analysed O
for O
c O
- O
erbB2 O
, O
int O
- O
2 O
, O
and O
c O
- O
myc O
gene O
amplification O
. O

Surgically O
confirmed O
nodal O
involvement O
was O
observed O
in O
42 O
% O
. O

Level O
of O
gene O
amplification O
was O
studied O
by O
Southern O
and O
/ O
or O
slot O
blot O
techniques O
. O

Amplified O
c O
- O
erbB2 O
gene O
sequences O
were O
present O
in O
21 O
. O
5 O
% O
of O
all O
samples O
. O

Int O
- O
2 O
was O
amplified O
in O
13 O
. O
1 O
% O
and O
c O
- O
myc O
was O
amplified O
in O
10 O
. O
3 O
% O
. O

In O
a O
non O
- O
parametric O
test O
( O
Kruskal O
- O
Wallis O
) O
a O
strong O
negative O
association O
was O
found O
between O
high O
levels O
of O
c O
- O
erbB2 O
amplification O
and O
absence O
of O
estrogen O
receptor O
( O
ER O
) O
( O
P O
= O
. O
0009 O
) O
or O
progesterone B-protein
receptor I-protein
( O
PR B-protein
) O
( O
P O
= O
. O
011 O
) O
expression O
. O

No O
correlations O
were O
found O
between O
all O
or O
high O
levels O
of O
amplification O
of O
each O
oncogene O
separately O
or O
combined O
with O
T O
, O
N O
, O
grade O
, O
multifocality O
of O
tumor O
, O
or O
associated O
carcinoma O
in O
situ O
. O

There O
was O
a O
trend O
approaching O
statistical O
significance O
for O
patients O
with O
c O
- O
erbB2 O
amplifications O
to O
have O
positive O
lymph O
nodes O
at O
surgery O
( O
P O
= O
0 O
. O
09 O
) O
. O

A O
somewhat O
surprising O
finding O
however O
was O
a O
very O
strong O
association O
between O
oncogene O
amplification O
and O
dense O
lymphocyte O
infiltration O
of O
the O
tumor O
( O
P O
= O
. O
05 O
) O
. O
This O
correlation O
is O
even O
stronger O
when O
only O
high O
levels O
of O
amplification O
are O
considered O
, O
either O
for O
each O
oncogene O
separately O
( O
P O
= O
. O
0048 O
) O
or O
in O
combination O
( O
P O
= O
. O
0007 O
) O
. O

We O
propose O
that O
malignant O
cell O
cytokine B-protein
production O
may O
help O
explain O
this O
observation O
. O

Suppression O
of O
signals O
required O
for O
activation O
of O
transcription B-protein
factor I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
in O
cells O
constitutively O
expressing O
the O
HTLV B-protein
- I-protein
I I-protein
Tax I-protein
protein I-protein
. O

Transient O
short O
- O
term O
expression O
of O
the O
Tax B-protein
protein I-protein
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
- O
I O
( O
HTLV O
- O
I O
) O
leads O
to O
activation O
of O
the O
pleiotropic O
transcription B-protein
factor I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
. O

Consistent O
with O
findings O
obtained O
with O
transient O
expression O
assays O
, O
we O
observed O
marked O
accumulation O
of O
the O
transcription B-protein
factor I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
in O
the O
nucleus O
of O
Namalwa O
B O
lymphoid O
cells O
, O
which O
constitutively O
express O
Tax B-protein
. O

In O
contrast O
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
was O
not O
detected O
in O
the O
nucleus O
following O
long O
- O
term O
expression O
of O
Tax B-protein
in O
Jurkat O
T O
lymphocytes O
. O

The O
ability O
of O
both O
mitogens O
and O
cytokines B-protein
to O
activate O
NF B-protein
- I-protein
kappa I-protein
B I-protein
was O
also O
blocked O
in O
Jurkat O
cells O
constitutively O
expressing O
Tax B-protein
. O

However O
, O
the O
activation O
of O
other O
mitogen B-protein
- I-protein
inducible I-protein
transcription I-protein
factors I-protein
, O
such O
as O
Fos B-protein
and O
Jun B-protein
, O
was O
unaffected O
. O

Thus O
, O
depending O
on O
the O
cellular O
environment O
, O
the O
short O
- O
and O
long O
- O
term O
effects O
of O
Tax B-protein
expression O
can O
be O
quite O
different O
. O

Consequently O
, O
one O
function O
of O
Tax B-protein
in O
cells O
infected O
with O
HTLV O
- O
I O
might O
involve O
cell O
- O
type O
- O
specific O
suppression O
, O
as O
opposed O
to O
activation O
, O
of O
distinct O
signal O
pathways O
. O

The O
cells O
lines O
described O
here O
should O
be O
useful O
for O
the O
delineation O
of O
signaling O
pathways O
utilized O
in O
the O
selective O
regulation O
of O
gene O
expression O
. O

Interferon B-protein
- I-protein
gamma I-protein
and O
the O
sexual O
dimorphism O
of O
autoimmunity O
. O

The O
sexual O
difference O
in O
the O
incidence O
of O
autoimmune O
diseases O
has O
remained O
an O
enigma O
for O
many O
years O
. O

In O
the O
examination O
of O
the O
induction O
of O
autoimmunity O
in O
transgenic O
mice O
, O
evidence O
has O
been O
obtained O
further O
implicating O
the O
lymphokine B-protein
interferon B-protein
- I-protein
gamma I-protein
in O
the O
etiology O
of O
autoimmunity O
. O

Sex O
steroid O
regulation O
of O
the O
production O
of O
this O
molecule O
, O
as O
well O
as O
other O
cytokines B-protein
, O
may O
help O
explain O
the O
gender O
- O
specific O
differences O
in O
the O
immune O
system O
, O
including O
autoimmunity O
. O

Cloning O
of O
a O
transcriptionally B-protein
active I-protein
human I-protein
TATA I-protein
binding I-protein
factor I-protein
. O

Transcription B-protein
factor I-protein
IID I-protein
( O
TFIID B-protein
) O
binds O
to O
the O
TATA O
box O
promoter O
element O
and O
regulates O
the O
expression O
of O
most O
eukaryotic O
genes O
transcribed O
by O
RNA B-protein
polymerase I-protein
II I-protein
. O

Complementary O
DNA O
( O
cDNA O
) O
encoding O
a O
human B-protein
TFIID I-protein
protein I-protein
has O
been O
cloned O
. O

The O
human B-protein
TFIID I-protein
polypeptide I-protein
has O
339 O
amino O
acids O
and O
a O
molecular O
size O
of O
37 O
, O
745 O
daltons O
. O

The O
carboxyl B-protein
- I-protein
terminal I-protein
181 I-protein
amino I-protein
acids I-protein
of O
the O
human B-protein
TFIID I-protein
protein I-protein
shares O
80 O
% O
identity O
with O
the O
TFIID B-protein
protein O
from O
Saccharomyces O
cerevisiae O
. O

The O
amino B-protein
terminus I-protein
contains O
an O
unusual O
repeat O
of O
38 O
consecutive O
glutamine O
residues O
and O
an O
X B-protein
- I-protein
Thr I-protein
- I-protein
Pro I-protein
repeat I-protein
. O

Expression O
of O
DNA O
in O
reticulocyte O
lysates O
or O
in O
Escherichia O
coli O
yielded O
a O
protein O
that O
was O
competent O
for O
both O
DNA O
binding O
and O
transcription O
activation O
. O

A O
novel O
T B-protein
- I-protein
cell I-protein
trans I-protein
- I-protein
activator I-protein
that O
recognizes O
a O
phorbol O
ester O
- O
inducible O
element O
of O
the O
interleukin B-protein
- I-protein
2 I-protein
promoter O
. O

The O
interleukin B-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
gene O
promoter O
is O
recognized O
by O
several O
cell O
- O
type O
- O
specific O
and O
ubiquitous O
transcriptional O
regulators O
that O
integrate O
information O
transmitted O
by O
various O
signaling O
systems O
leading O
to O
IL B-protein
- I-protein
2 I-protein
production O
and O
T O
- O
cell O
activation O
. O

Using O
a O
combination O
of O
transfection O
, O
protein O
- O
DNA O
binding O
, O
and O
in O
vitro O
transcription O
methods O
, O
we O
have O
discovered O
the O
novel B-protein
T I-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcriptional I-protein
activator I-protein
TCF B-protein
- I-protein
1 I-protein
( O
for O
T B-protein
- I-protein
Cell I-protein
Factor I-protein
- I-protein
1 I-protein
) O
, O
which O
recognizes O
a O
T O
- O
cell O
- O
specific O
response O
element O
( O
TCE O
) O
located O
within O
the O
IL B-protein
- I-protein
2 I-protein
promoter O
. O

Although O
the O
TCE O
is O
similar O
in O
sequence O
to O
a O
consensus O
NF B-protein
kappa I-protein
B I-protein
site O
, O
several O
criteria O
indicate O
that O
TCF B-protein
- I-protein
1 I-protein
is O
distinct O
from O
NF B-protein
kappa I-protein
B I-protein
. O

However O
, O
like O
NF B-protein
kappa I-protein
B I-protein
, O
TCF B-protein
- I-protein
1 I-protein
activity O
is O
induced O
by O
phorbol O
esters O
and O
other O
T O
- O
cell O
activators O
. O

Risk O
factors O
for O
breast O
recurrence O
in O
premenopausal O
and O
postmenopausal O
patients O
with O
ductal O
cancers O
treated O
by O
conservation O
therapy O
. O

Risk O
factors O
for O
local O
failure O
were O
evaluated O
for O
496 O
clinical O
Stage O
I O
- O
II O
patients O
with O
infiltrating O
ductal O
carcinomas O
( O
median O
follow O
- O
up O
, O
71 O
months O
) O
treated O
by O
conservative O
surgery O
and O
radiotherapy O
. O

Monofactorial O
analysis O
identified O
the O
following O
factors O
to O
be O
correlated O
with O
increased O
risk O
: O
moderate O
/ O
marked O
mononuclear O
cell O
reaction O
( O
MCR O
) O
, O
high O
histologic O
grade O
( O
G O
) O
, O
extensive O
intraductal O
component O
( O
EIC O
) O
, O
tumor O
necrosis O
, O
macroscopic O
multiplicity O
, O
estrogen B-protein
receptor I-protein
negativity O
, O
anatomic O
tumor O
size O
, O
age O
younger O
than O
40 O
years O
, O
and O
vascular O
invasion O
. O

Only O
MCR O
, O
G O
, O
and O
EIC O
proved O
significant O
in O
Cox O
multivariate O
analysis O
. O

These O
risk O
factors O
were O
highly O
age O
dependent O
, O
with O
EIC O
markedly O
more O
prevalent O
in O
women O
younger O
than O
50 O
, O
MCR O
and O
G O
in O
women O
younger O
than O
40 O
. O

Separate O
Cox O
analysis O
for O
premenopausal O
patients O
showed O
that O
MCR O
/ O
EIC O
determined O
risk O
independent O
of O
resection O
margins O
: O
tumors O
with O
MCR O
had O
a O
28 O
% O
, O
and O
with O
EIC O
a O
22 O
% O
probability O
of O
recurring O
locally O
by O
5 O
years O
. O

Premenopausal O
patients O
with O
neither O
risk O
factor O
had O
a O
very O
low O
failure O
rate O
( O
2 O
. O
6 O
% O
at O
5 O
years O
) O
, O
regardless O
of O
age O
. O

For O
postmenopausal O
patients O
risk O
of O
breast O
recurrence O
was O
determined O
both O
by O
adequacy O
of O
resection O
margins O
and O
grade O
, O
with O
a O
high O
local O
failure O
rate O
for O
patients O
having O
G3 O
tumors O
with O
positive O
or O
indeterminate O
margins O
( O
31 O
% O
at O
5 O
years O
) O
. O

The O
authors O
conclude O
that O
the O
microscopic O
examination O
is O
the O
only O
useful O
tool O
for O
assessing O
the O
risk O
of O
local O
failure O
, O
which O
is O
quite O
low O
for O
the O
majority O
of O
patients O
treated O
with O
breast O
conservation O
. O

High O
- O
risk O
patients O
can O
be O
recognized O
morphologically O
. O

The O
age O
dependence O
of O
morphologic O
risk O
factors O
appears O
to O
explain O
the O
high O
local O
failure O
rate O
seen O
in O
patients O
younger O
than O
40 O
. O

Tax B-protein
- O
independent O
binding O
of O
multiple O
cellular B-protein
factors I-protein
to O
Tax B-protein
- O
response O
element O
DNA O
of O
HTLV O
- O
I O
. O

The O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
promoter O
contains O
three O
copies O
of O
imperfect O
repeats O
of O
a O
21 O
- O
base O
pair O
sequence O
designated O
here O
as O
TRE O
( O
Tax B-protein
- O
response O
element O
) O
that O
is O
responsive O
to O
the O
virally B-protein
encoded I-protein
transactivator I-protein
protein I-protein
Tax B-protein
. O

We O
have O
identified O
and O
separated O
four O
nuclear B-protein
proteins I-protein
from O
C81 O
- O
66 O
- O
45 O
cells O
, O
an O
HTLV O
- O
I O
immortalized O
Tax B-protein
- O
expressing O
human O
T O
- O
lymphocyte O
line O
( O
Salahuddin O
et O
al O
. O
, O
1983 O
) O
, O
that O
interact O
with O
the O
TRE O
- O
DNA O
, O
none O
of O
which O
are O
identical O
with O
the O
Tax B-protein
- I-protein
protein I-protein
. O

The O
proteins O
identified O
have O
molecular O
weights O
of O
about O
32 O
, O
36 O
to O
42 O
, O
50 O
and O
110 O
kD O
. O

Four O
different O
methods O
were O
used O
to O
identify O
the O
proteins O
. O

First O
, O
from O
different O
cell O
lines O
three O
or O
all O
four O
of O
the O
nuclear B-protein
proteins I-protein
were O
specifically O
cross O
- O
linked O
by O
UV O
irradiation O
to O
the O
radioactively O
labeled O
TRE O
- O
DNA O
fragment O
. O

Second O
, O
TRE B-protein
- I-protein
DNA I-protein
binding I-protein
proteins I-protein
sedimented O
through O
a O
glycerol O
density O
gradient O
at O
rates O
corresponding O
to O
proteins O
of O
native O
molecular O
weights O
of O
35 O
to O
50 O
kD O
and O
110 O
kD O
. O

Third O
, O
only O
the O
50 B-protein
kD I-protein
protein I-protein
was O
retained O
on O
a O
biotinylated O
DNA O
- O
streptavidin O
matrix O
when O
the O
DNA O
fragment O
contained O
the O
TRE O
- O
DNA O
. O

Fourth O
, O
extensive O
purification O
by O
several O
cycles O
of O
TRE O
- O
DNA O
affinity O
chromatography O
resulted O
in O
the O
32 O
, O
36 O
to O
42 O
and O
110 O
kD O
proteins O
and O
to O
less O
extent O
the O
50 B-protein
kD I-protein
factor I-protein
. O

Two O
abundant O
proteins O
of O
75 O
and O
80 O
kD O
were O
competed O
out O
by O
poly O
[ O
d O
( O
I O
- O
C O
) O
] O
in O
all O
reactions O
. O

The O
cAMP O
- O
response O
element O
CRE O
, O
TGACGTCA O
, O
present O
in O
the O
21 O
base O
- O
pair O
sequence O
, O
appears O
to O
be O
essential O
for O
specific O
protein O
- O
TRE O
- O
DNA O
interactions O
because O
mutation O
of O
the O
two O
G O
' O
s O
destroys O
this O
complex O
. O

This O
result O
suggests O
that O
the O
cAMP B-protein
response I-protein
element I-protein
binding I-protein
protein I-protein
, O
CREB B-protein
, O
is O
involved O
in O
the O
protein B-protein
- I-protein
TRE I-protein
- I-protein
DNA I-protein
complex I-protein
and O
in O
mediating O
the O
Tax B-protein
response O
. O

Two O
distinct O
transcription B-protein
factors I-protein
that O
bind O
the O
immunoglobulin O
enhancer O
microE5 O
/ O
kappa O
2 O
motif O
. O

Activity O
of O
the O
immunoglobulin O
heavy O
and O
kappa O
light O
chain O
gene O
enhancers O
depends O
on O
a O
complex O
interplay O
of O
ubiquitous B-protein
and O
developmentally B-protein
regulated I-protein
proteins I-protein
. O

Two O
complementary O
DNAs O
were O
isolated O
that O
encode O
proteins O
, O
denoted O
ITF B-protein
- I-protein
1 I-protein
and O
ITF B-protein
- I-protein
2 I-protein
, O
that O
are O
expressed O
in O
a O
variety O
of O
cell O
types O
and O
bind O
the O
microE5 O
/ O
kappa O
2 O
motif O
found O
in O
both O
heavy O
and O
kappa O
light O
chain O
enhancers O
. O

The O
complementary O
DNAs O
are O
the O
products O
of O
distinct O
genes O
, O
yet O
both O
ITF B-protein
- I-protein
1 I-protein
and O
ITF B-protein
- I-protein
2 I-protein
are O
structurally O
and O
functionally O
similar O
. O

The O
two O
proteins O
interact O
with O
one O
another O
through O
their O
putative O
helix B-protein
- I-protein
loop I-protein
- I-protein
helix I-protein
motifs I-protein
and O
each O
possesses O
a O
distinct O
domain O
that O
dictates O
transcription O
activation O
. O

Elevated O
glucocorticoid B-protein
receptor I-protein
concentrations O
before O
and O
after O
glucocorticoid O
therapy O
in O
peripheral O
mononuclear O
leukocytes O
of O
patients O
with O
atopic O
dermatitis O
. O

The O
number O
and O
affinity O
of O
glucocorticoid O
binding O
sites O
in O
peripheral O
mononuclear O
leukocytes O
of O
patients O
with O
atopic O
dermatitis O
( O
AD O
) O
and O
healthy O
controls O
were O
determined O
under O
baseline O
conditions O
and O
after O
a O
defined O
oral O
glucocorticoid O
treatment O
. O

Patients O
with O
AD O
( O
n O
= O
15 O
) O
exhibited O
significantly O
more O
glucocorticoid B-protein
receptors I-protein
( O
GR B-protein
) O
per O
cell O
than O
the O
control O
group O
( O
n O
= O
22 O
) O
, O
while O
the O
GR B-protein
affinity O
did O
not O
differ O
. O

Methylprednisolone O
treatment O
resulted O
in O
a O
significant O
reduction O
of O
the O
GR B-protein
sites O
per O
cell O
in O
the O
steroid O
- O
treated O
control O
group O
( O
n O
= O
10 O
) O
in O
contrast O
to O
the O
patients O
. O

The O
dissociation O
constant O
was O
not O
affected O
by O
methylprednisolone O
treatment O
in O
either O
group O
. O

In O
view O
of O
the O
therapeutic O
efficiency O
of O
glucocorticoids O
in O
AD O
and O
findings O
of O
abnormal O
cAMP O
and O
cAMP O
- O
phosphodiesterase O
activity O
, O
the O
elevated O
GR B-protein
concentrations O
in O
AD O
lend O
support O
to O
the O
hypothesis O
of O
a O
compensatory O
GR B-protein
upregulation O
due O
to O
an O
insufficient O
action O
of O
endogenous O
cortisol O
or O
to O
altered O
cAMP O
- O
induced O
GR B-protein
expression O
. O

The O
actions O
of O
cyclosporin O
A O
and O
FK506 O
suggest O
a O
novel O
step O
in O
the O
activation O
of O
T O
lymphocytes O
. O

Cyclosporin O
A O
and O
FK506 O
are O
immunosuppressive O
compounds O
that O
have O
similar O
inhibitory O
effects O
on O
the O
expression O
of O
several O
lymphokines B-protein
produced O
by O
T O
lymphocytes O
. O

Despite O
their O
similar O
effects O
the O
drugs O
bind O
to O
two O
different O
cytosolic B-protein
protein I-protein
, O
cyclophilin B-protein
and O
FKBP B-protein
respectively O
, O
which O
raises O
the O
possibility O
that O
they O
have O
different O
modes O
of O
action O
. O

Using O
constructs O
in O
which O
mRNA O
production O
controlled O
by O
a O
specific O
transcription B-protein
factor I-protein
could O
be O
readily O
measured O
we O
found O
that O
both O
cyclosporin O
A O
and O
FK506 O
completely O
inhibited O
transcription O
activated O
by O
NF B-protein
- I-protein
AT I-protein
, O
NFIL2 B-protein
A I-protein
, O
NFIL2 B-protein
B I-protein
and O
partially O
inhibited O
transcription O
activated O
by O
NF B-protein
kappa I-protein
B I-protein
. O

Cyclosporin O
A O
and O
FK506 O
inhibited O
only O
transcriptional O
activation O
that O
was O
dependent O
on O
Ca2 O
+ O
mobilization O
. O

However O
, O
cyclosporin O
A O
and O
FK506 O
did O
not O
inhibit O
Ca2 O
+ O
mobilization O
dependent O
expression O
of O
c O
- O
fos O
mRNA O
indicating O
that O
only O
a O
subset O
of O
signalling O
pathways O
regulated O
by O
Ca2 O
+ O
is O
sensitive O
to O
these O
drugs O
. O

Furthermore O
, O
we O
did O
not O
observe O
any O
qualitative O
differences O
between O
the O
effect O
of O
cyclosporin O
A O
and O
FK506 O
on O
six O
different O
transcription B-protein
factors I-protein
which O
suggests O
that O
these O
drugs O
may O
interfere O
with O
the O
activity O
of O
a O
novel O
Ca2 O
+ O
dependent O
step O
that O
regulates O
several O
transcription B-protein
factors I-protein
. O

The O
internal O
methionine O
codons O
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
II O
rex O
gene O
are O
not O
required O
for O
p24rex B-protein
production O
or O
virus O
replication O
and O
transformation O
. O

Human O
T O
- O
cell O
leukemia O
virus O
types O
I O
( O
HTLV O
- O
I O
) O
and O
II O
( O
HTLV O
- O
II O
) O
have O
two O
nonstructural O
trans O
- O
acting O
regulatory O
genes O
, O
tax O
and O
rex O
, O
located O
in O
the O
3 O
' O
region O
of O
the O
viral O
genome O
. O

The O
tax B-protein
gene I-protein
product I-protein
( O
HTLV O
- O
I O
p40tax O
and O
HTLV O
- O
II O
p37tax O
) O
is O
the O
transcriptional O
activator O
of O
the O
viral O
long O
terminal O
repeat O
. O

The O
rex O
gene O
encodes O
two O
protein O
products O
, O
p27rex B-protein
/ B-protein
p21rex I-protein
and O
p26rex B-protein
/ B-protein
p24rex I-protein
in O
HTLV O
- O
I O
and O
HTLV O
- O
II O
, O
respectively O
. O

Rex B-protein
acts O
posttranscriptionally O
to O
facilitate O
accumulation O
of O
full O
- O
length O
gag B-protein
/ I-protein
pol I-protein
and O
singly O
spliced O
env O
mRNA O
in O
the O
cytoplasm O
of O
HTLV O
- O
infected O
cells O
. O

Previous O
studies O
showed O
that O
the O
first O
ATG O
of O
the O
rex O
gene O
is O
critical O
for O
Rex B-protein
production O
and O
function O
. O

The O
importance O
of O
the O
internal O
ATGs O
to O
Rex B-protein
function O
is O
not O
known O
. O

However O
, O
in O
vitro O
mutagenesis O
of O
the O
HTLV O
- O
I O
rex O
gene O
has O
provided O
indirect O
evidence O
which O
suggests O
that O
p21rex B-protein
, O
and O
by O
analogy O
HTLV O
- O
II O
p24rex B-protein
, O
results O
from O
initiation O
at O
an O
internal O
AUG O
of O
the O
tax O
/ O
rex O
mRNA O
. O

By O
using O
an O
infectious O
molecular O
clone O
of O
HTLV O
- O
II O
, O
we O
investigated O
the O
importance O
of O
the O
internal O
ATGs O
of O
the O
rex O
gene O
on O
Rex B-protein
protein O
production O
and O
function O
. O

Our O
results O
indicate O
that O
p24rex B-protein
of O
HTLV O
- O
II O
is O
not O
initiated O
at O
an O
internal O
AUG O
and O
that O
the O
internal O
methionine O
codons O
are O
not O
crucial O
to O
the O
function O
of O
the O
rex O
gene O
and O
, O
ultimately O
, O
the O
transforming O
properties O
of O
the O
virus O
. O

Astrocytes O
and O
glioblastoma O
cells O
express O
novel O
octamer B-protein
- I-protein
DNA I-protein
binding I-protein
proteins I-protein
distinct O
from O
the O
ubiquitous B-protein
Oct I-protein
- I-protein
1 I-protein
and O
B B-protein
cell I-protein
type I-protein
Oct I-protein
- I-protein
2 I-protein
proteins I-protein
. O

The O
' O
octamer O
' O
sequence O
, O
ATGCAAAT O
or O
its O
complement O
ATTTGCAT O
, O
is O
a O
key O
element O
for O
the O
transcriptional O
regulation O
of O
immunoglobulin O
genes O
in O
B O
- O
lymphocytes O
as O
well O
as O
a O
number O
of O
housekeeping O
genes O
in O
all O
cell O
types O
. O

In O
lymphocytes O
, O
the O
octamer B-protein
- I-protein
binding I-protein
protein I-protein
Oct B-protein
- I-protein
2A I-protein
and O
variants O
thereof O
are O
thought O
to O
contribute O
to O
the O
B O
- O
cell O
specific O
gene O
expression O
, O
while O
the O
ubiquitous O
protein O
Oct O
- O
1 O
seems O
to O
control O
general O
octamer O
site O
- O
dependent O
transcription O
. O

Various O
other O
genes O
, O
for O
example O
interleukin O
- O
1 O
and O
MHC O
class O
II O
genes O
, O
contain O
an O
octamer O
sequence O
in O
the O
promoter O
and O
are O
expressed O
in O
cells O
of O
both O
the O
immune O
and O
nervous O
systems O
. O

This O
prompted O
us O
to O
analyze O
the O
octamer B-protein
- I-protein
binding I-protein
proteins I-protein
in O
the O
latter O
cells O
. O

Using O
the O
electrophoretic O
mobility O
shift O
assay O
, O
at O
least O
six O
novel O
octamer B-protein
binding I-protein
proteins I-protein
were O
detected O
in O
nuclear O
extracts O
of O
cultured O
mouse O
astrocytes O
. O

These O
proteins O
are O
differentially O
expressed O
in O
human O
glioblastoma O
and O
neuroblastoma O
cell O
lines O
. O

The O
nervous B-protein
system I-protein
- I-protein
derived I-protein
( I-protein
N I-protein
- I-protein
Oct I-protein
) I-protein
proteins I-protein
bound O
to O
the O
octamer O
DNA O
sequence O
in O
a O
manner O
which O
is O
indistinguishable O
from O
the O
Oct B-protein
- I-protein
1 I-protein
and O
Oct B-protein
- I-protein
2A I-protein
proteins I-protein
. O

The O
relationship O
of O
the O
N B-protein
- I-protein
Oct I-protein
proteins I-protein
to O
Oct B-protein
- I-protein
1 I-protein
and O
Oct B-protein
- I-protein
2A I-protein
was O
analyzed O
by O
proteolytic O
clipping O
bandshift O
assays O
and O
by O
their O
reactivity O
towards O
antisera O
raised O
against O
recombinant O
Oct B-protein
- I-protein
1 I-protein
and O
Oct B-protein
- I-protein
2A I-protein
proteins O
. O

On O
the O
basis O
of O
these O
assays O
, O
all O
N B-protein
- I-protein
Oct I-protein
- I-protein
factors I-protein
were O
found O
to O
be O
distinct O
from O
the O
ubiquitous B-protein
Oct I-protein
- I-protein
1 I-protein
and O
the O
lymphoid B-protein
- I-protein
specific I-protein
Oct I-protein
- I-protein
2A I-protein
proteins O
. O

In O
melanoma O
cells O
that O
contain O
the O
N B-protein
- I-protein
Oct I-protein
- I-protein
3 I-protein
factor I-protein
, O
a O
transfected O
lymphocyte O
- O
specific O
promoter O
was O
neither O
activated O
nor O
was O
it O
repressed O
upon O
contransfection O
with O
an O
Oct B-protein
- I-protein
2A I-protein
expression O
vector O
. O

We O
therefore O
speculate O
that O
N B-protein
- I-protein
Oct I-protein
- I-protein
3 I-protein
and O
other O
N B-protein
- I-protein
Oct I-protein
factors I-protein
have O
a O
specific O
role O
in O
gene O
expression O
in O
cells O
of O
the O
nervous O
system O
. O

Detection O
in O
non O
- O
erythroid O
cells O
of O
a O
factor O
with O
the O
binding O
characteristics O
of O
the O
erythroid B-protein
cell I-protein
transcription I-protein
factor I-protein
EF1 B-protein
. O

The O
erythroid B-protein
transcription I-protein
factor I-protein
erythroid B-protein
factor I-protein
- I-protein
1 I-protein
( O
EF1 B-protein
) O
plays O
a O
critical O
role O
in O
the O
transcription O
of O
erythroid O
- O
specific O
genes O
. O

Here O
we O
report O
the O
presence O
of O
a O
factor O
with O
the O
mobility O
and O
sequence O
- O
specific O
DNA O
- O
binding O
characteristics O
of O
EF1 B-protein
at O
low O
abundance O
in O
a O
wide O
variety O
of O
non O
- O
erythroid O
cell O
types O
. O

This O
is O
the O
first O
report O
of O
an O
EF1 B-protein
- O
like O
activity O
in O
non O
- O
erythroid O
cells O
and O
indicates O
that O
this O
factor O
may O
play O
a O
role O
in O
the O
regulation O
of O
genes O
expressed O
in O
such O
cells O
. O

Protein O
kinase O
inhibitor O
H O
- O
7 O
blocks O
accumulation O
of O
unspliced O
mRNA O
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
. O

Rex B-protein
, O
the O
post B-protein
- I-protein
transcriptional I-protein
regulator I-protein
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
, O
is O
known O
to O
induce O
accumulation O
of O
the O
unspliced O
viral O
gag O
- O
pol O
mRNA O
. O

Rex B-protein
is O
a O
phosphoprotein B-protein
found O
in O
the O
cell O
nucleolus O
, O
whose O
function O
may O
be O
regulated O
by O
its O
localization O
and O
phosphorylation O
. O

We O
have O
examined O
the O
role O
of O
phosphorylation O
on O
Rex B-protein
function O
by O
using O
a O
protein O
kinase O
inhibitor O
, O
H O
- O
7 O
[ O
1 O
- O
( O
5 O
- O
isoquinolinyl O
- O
sulfonyl O
) O
- O
2 O
- O
methylpiperazine O
] O
. O

Treatment O
of O
an O
HTLV O
- O
I O
infected O
human O
T O
- O
cell O
line O
with O
H O
- O
7 O
blocked O
specifically O
accumulation O
of O
the O
unspliced O
gag O
- O
pol O
mRNA O
, O
resulting O
in O
the O
decreased O
Gag B-protein
protein I-protein
synthesis O
that O
corresponds O
with O
the O
decreased O
in O
vivo O
phosphorylation O
of O
Rex B-protein
. O

In O
contrast O
, O
other O
viral O
and O
cellular O
products O
have O
not O
been O
influenced O
by O
the O
level O
of O
H O
- O
7 O
used O
. O

Therefore O
, O
the O
phosphorylation O
of O
Rex B-protein
is O
required O
for O
the O
viral O
RNA O
partition O
of O
HTLV O
- O
I O
. O

Increased O
glucocorticoid O
responsiveness O
of O
CD4 O
+ O
T O
- O
cell O
clonal O
lines O
grown O
in O
serum O
- O
free O
media O
. O

CEM O
- O
C7 O
, O
a O
human O
leukemic O
CD4 O
+ O
T O
- O
lymphocyte O
cell O
line O
and O
three O
of O
its O
subclones O
, O
CEM O
- O
4R4 O
, O
CEM O
- O
3R43 O
, O
and O
ICR O
- O
27 O
, O
previously O
cultured O
in O
a O
medium O
supplemented O
with O
5 O
to O
10 O
% O
fetal O
bovine O
serum O
, O
have O
been O
adapted O
to O
serum O
- O
free O
media O
. O

The O
best O
medium O
of O
those O
tested O
was O
RPMI O
1640 O
supplemented O
with O
5 O
micrograms O
/ O
ml O
each O
transferrin B-protein
and O
insulin B-protein
+ O
5 O
ng O
/ O
ml O
sodium O
selenite O
+ O
/ O
- O
0 O
. O
1 O
% O
bovine B-protein
serum I-protein
albumin I-protein
. O

While O
growing O
either O
with O
or O
without O
albumin O
, O
the O
several O
clonal O
lines O
of O
CEM O
cells O
displayed O
growth O
similar O
to O
serum O
- O
supplemented O
cultures O
. O

Cell O
proliferation O
of O
CEM O
- O
C7 O
cells O
cultured O
in O
both O
serum O
- O
free O
media O
has O
been O
sustained O
for O
3 O
mo O
. O

with O
culture O
doubling O
times O
of O
about O
25 O
h O
for O
both O
serum O
- O
supplemented O
and O
serum O
- O
free O
cultures O
( O
viability O
greater O
than O
or O
equal O
to O
90 O
% O
) O
. O

Cell O
morphology O
remained O
essentially O
the O
same O
in O
serum O
- O
free O
or O
serum O
containing O
media O
. O

The O
expression O
of O
CD4 B-protein
, O
a O
marker O
for O
T O
- O
derived O
lymphoid O
cells O
, O
was O
not O
significantly O
different O
in O
serum O
- O
free O
medium O
. O

When O
grown O
in O
serum O
- O
free O
medium O
, O
CEM O
- O
C7 O
cells O
exhibited O
increased O
steroid O
responsiveness O
as O
evidenced O
by O
increased O
glucocorticoid B-protein
receptor I-protein
binding O
sites O
, O
increased O
induction O
of O
glutamine B-protein
synthetase I-protein
, O
and O
cell O
lysis O
at O
lower O
concentrations O
of O
steroid O
. O

Receptor O
mutant O
subclones O
of O
CEM O
- O
C7 O
, O
which O
are O
proven O
to O
be O
completely O
unresponsive O
to O
micromolar O
concentrations O
of O
dexamethasone O
when O
grown O
in O
serum O
- O
supplemented O
medium O
, O
become O
partially O
sensitive O
to O
the O
hormone O
after O
growth O
in O
defined O
medium O
. O

The O
increased O
sensitivity O
of O
CEM O
- O
C7 O
cells O
and O
its O
subclones O
to O
dexamethasone O
in O
serum O
- O
free O
medium O
returned O
to O
previous O
levels O
when O
these O
cells O
were O
recultured O
in O
serum O
- O
containing O
medium O
. O

Our O
results O
suggest O
that O
substances O
in O
serum O
influence O
steroid O
effects O
on O
these O
cells O
and O
that O
the O
molecular O
details O
of O
glucocorticoid O
hormone O
action O
may O
be O
pursued O
more O
precisely O
in O
a O
clearly O
defined O
culture O
medium O
. O

[ O
Glucocorticoid B-protein
receptors I-protein
on O
human O
peripheral O
mononuclear O
and O
polymorphonuclear O
leucocytes O
: O
changes O
in O
patients O
with O
yang O
- O
deficiency O
] O
. O

It O
was O
found O
that O
, O
in O
former O
works O
, O
the O
glucocorticoid B-protein
receptors I-protein
( O
GCR B-protein
) O
on O
peripheral O
mixed O
leucocytes O
in O
patients O
with O
Yang O
- O
deficiency O
were O
decreased O
. O

In O
this O
work O
, O
the O
mixed O
leucocytes O
were O
further O
separated O
into O
mononuclear O
( O
MNL O
) O
and O
polymorphonuclear O
( O
PML O
) O
leucocytes O
, O
and O
GCR B-protein
were O
determined O
in O
each O
part O
of O
leucocytes O
. O

GCR B-protein
on O
MNL O
and O
PML O
in O
6 O
Yang O
deficient O
patients O
were O
3473 O
+ O
/ O
- O
413 O
and O
4433 O
+ O
/ O
- O
651 O
sites O
/ O
cell O
respectively O
, O
statistically O
significant O
from O
the O
normal O
control O
group O
( O
4462 O
+ O
/ O
- O
962 O
and O
5622 O
+ O
/ O
- O
782 O
sites O
/ O
cell O
respectively O
, O
P O
less O
than O
0 O
. O
05 O
) O
. O

GCR B-protein
on O
MNL O
, O
PML O
and O
mixed O
leucocytes O
in O
5 O
patients O
were O
determined O
simultaneously O
, O
and O
all O
lowered O
from O
the O
control O
group O
. O

The O
results O
were O
3369 O
+ O
/ O
- O
370 O
, O
4986 O
+ O
/ O
- O
419 O
and O
4524 O
+ O
/ O
- O
852 O
sites O
/ O
cell O
respectively O
, O
with O
the O
lowest O
GCR B-protein
on O
MNL O
and O
highest O
on O
PML O
. O

The O
ubiquitous B-protein
octamer I-protein
- I-protein
binding I-protein
protein I-protein
( O
s O
) O
is O
sufficient O
for O
transcription O
of O
immunoglobulin O
genes O
. O

All O
immunoglobulin O
genes O
contain O
a O
conserved O
octanucleotide O
promoter O
element O
, O
ATGCAAAT O
, O
which O
has O
been O
shown O
to O
be O
required O
for O
their O
normal O
B O
- O
cell O
- O
specific O
transcription O
. O

Proteins O
that O
bind O
this O
octamer O
have O
been O
purified O
, O
and O
cDNAs O
encoding O
octamer B-protein
- I-protein
binding I-protein
proteins I-protein
have O
been O
cloned O
. O

Some O
of O
these O
proteins O
( O
referred O
to O
as O
OTF B-protein
- I-protein
2 I-protein
) O
are O
lymphoid O
specific O
, O
whereas O
at O
least O
one O
other O
, O
and O
possibly O
more O
( O
referred O
to O
as O
OTF B-protein
- I-protein
1 I-protein
) O
, O
is O
found O
ubiquitously O
in O
all O
cell O
types O
. O

The O
exact O
role O
of O
these O
different O
proteins O
in O
directing O
the O
tissue O
- O
specific O
expression O
of O
immunoglobulin O
genes O
is O
unclear O
. O

We O
have O
identified O
two O
human O
pre O
- O
B O
- O
cell O
lines O
that O
contain O
extremely O
low O
levels O
of O
OTF B-protein
- I-protein
2 I-protein
yet O
still O
express O
high O
levels O
of O
steady O
- O
state O
immunoglobulin B-protein
heavy I-protein
- I-protein
chain I-protein
mRNA O
in O
vivo O
and O
efficiently O
transcribe O
an O
immunoglobulin O
gene O
in O
vitro O
. O

Addition O
of O
a O
highly O
enriched O
preparation O
of O
OTF B-protein
- I-protein
1 I-protein
made O
from O
one O
of O
these O
pre O
- O
B O
cells O
or O
from O
HeLa O
cells O
specifically O
stimulated O
in O
vitro O
transcription O
of O
an O
immunoglobulin O
gene O
. O

Furthermore O
, O
OFT O
- O
1 O
appeared O
to O
have O
approximately O
the O
same O
transactivation O
ability O
as O
OTF B-protein
- I-protein
2 I-protein
when O
normalized O
for O
binding O
activity O
. O

These O
results O
suggest O
that O
OTF B-protein
- I-protein
1 I-protein
, O
without O
OTF B-protein
- I-protein
2 I-protein
, O
is O
sufficient O
for O
transcription O
of O
immunoglobulin O
genes O
and O
that O
OTF B-protein
- I-protein
2 I-protein
alone O
is O
not O
responsible O
for O
the O
B O
- O
cell O
- O
specific O
regulation O
of O
immunoglobulin O
gene O
expression O
. O

Effects O
of O
aldosterone O
on O
intralymphocytic O
sodium O
and O
potassium O
in O
patients O
with O
essential O
hypertension O
. O

In O
vitro O
binding O
of O
aldosterone O
to O
mineralocorticoid B-protein
receptors I-protein
on O
human O
mononuclear O
leukocytes O
( O
HML O
) O
and O
its O
effects O
on O
the O
intracellular O
sodium O
and O
potassium O
concentrations O
of O
HML O
have O
already O
been O
described O
. O

In O
the O
present O
paper O
this O
easily O
accessible O
human O
cell O
model O
was O
investigated O
in O
13 O
patients O
with O
essential O
hypertension O
. O

In O
only O
four O
patients O
sodium O
in O
HML O
without O
incubation O
was O
elevated O
compared O
with O
the O
range O
for O
normal O
persons O
. O

A O
decrease O
of O
intracellular O
sodium O
or O
potassium O
occurred O
during O
incubation O
without O
aldosterone O
( O
P O
less O
than O
0 O
. O
02 O
) O
. O

The O
addition O
of O
1 O
. O
4 O
nM O
aldosterone O
did O
not O
prevent O
this O
loss O
of O
electrolytes O
as O
observed O
in O
normal O
persons O
. O

Plasma B-protein
renin I-protein
activity O
and O
aldosterone O
were O
not O
correlated O
with O
the O
electrolyte O
response O
and O
were O
within O
the O
normal O
limits O
. O

The O
number O
of O
mineralocorticoid B-protein
receptors I-protein
/ O
cell O
were O
within O
or O
close O
to O
the O
normal O
range O
( O
n O
= O
9 O
) O
. O

The O
independence O
of O
intracellular O
electrolytes O
from O
aldosterone O
despite O
a O
normal O
number O
of O
mineralocorticoid B-protein
receptors I-protein
may O
reflect O
an O
impairment O
of O
the O
mineralocorticoid O
effector O
mechanism O
in O
the O
HML O
of O
patients O
with O
essential O
hypertension O
. O

[ O
Differential O
diagnostic O
value O
of O
receptors O
of O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
calcitriol O
) O
determination O
in O
lymphocytes O
of O
children O
with O
rickets O
and O
rickets O
- O
like O
diseases O
] O
. O

The O
authors O
provide O
the O
results O
of O
studying O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
calcitriol O
) O
in O
lymphocytes O
of O
children O
with O
rickets O
and O
rickets O
- O
like O
diseases O
. O

It O
is O
proposed O
that O
the O
character O
of O
their O
expression O
under O
the O
influence O
of O
vitamin O
D O
may O
be O
used O
with O
differential O
diagnostic O
purposes O
in O
view O
. O

Regulation O
of O
gene O
expression O
with O
double O
- O
stranded O
phosphorothioate O
oligonucleotides O
. O

Alteration O
of O
gene O
transcription O
by O
inhibition O
of O
specific O
transcriptional B-protein
regulatory I-protein
proteins I-protein
is O
necessary O
for O
determining O
how O
these O
factors O
participate O
in O
cellular O
differentiation O
. O

The O
functions O
of O
these O
proteins O
can O
be O
antagonized O
by O
several O
methods O
, O
each O
with O
specific O
limitations O
. O

Inhibition O
of O
sequence B-protein
- I-protein
specific I-protein
DNA I-protein
- I-protein
binding I-protein
proteins I-protein
was O
achieved O
with O
double O
- O
stranded O
( O
ds O
) O
phosphorothioate O
oligonucleotides O
that O
contained O
octamer O
or O
kappa O
B O
consensus O
sequences O
. O

The O
phosphorothioate O
oligonucleotides O
specifically O
bound O
either O
octamer B-protein
transcription I-protein
factor I-protein
or O
nuclear B-protein
factor I-protein
( I-protein
NF I-protein
) I-protein
- I-protein
kappa I-protein
B I-protein
. O

The O
modified O
oligonucleotides O
accumulated O
in O
cells O
more O
effectively O
than O
standard O
ds O
oligonucleotides O
and O
modulated O
gene O
expression O
in O
a O
specific O
manner O
. O

Octamer O
- O
dependent O
activation O
of O
a O
reporter O
plasmid O
or O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
dependent O
activation O
of O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
enhancer O
was O
inhibited O
when O
the O
appropriate O
phosphorothioate O
oligonucleotide O
was O
added O
to O
a O
transiently O
transfected O
B O
cell O
line O
. O

Addition O
of O
phosphorothioate O
oligonucleotides O
that O
contained O
the O
octamer O
consensus O
to O
Jurkat O
T O
leukemia O
cells O
inhibited O
interleukin B-protein
- I-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
secretion O
to O
a O
degree O
similar O
to O
that O
observed O
with O
a O
mutated O
octamer O
site O
in O
the O
IL O
- O
2 O
enhancer O
. O

The O
ds O
phosphorothioate O
oligonucleotides O
probably O
compete O
for O
binding O
of O
specific O
transcription O
factors O
and O
may O
provide O
anti O
- O
viral O
, O
immunosuppressive O
, O
or O
other O
therapeutic O
effects O
. O

[ O
Effect O
of O
the O
regimen O
of O
kidney O
- O
tonifying O
and O
qi O
- O
invigorating O
on O
aging O
changes O
of O
glucocorticoid B-protein
receptor I-protein
] O
. O

The O
plasma O
cortisol O
concentration O
and O
the O
sites O
of O
glucocorticoid B-protein
receptor I-protein
( O
GCR B-protein
) O
in O
the O
peripheral O
lymphocytes O
were O
measured O
in O
32 O
healthy O
aged O
persons O
and O
13 O
young O
adults O
. O

In O
animal O
experiment O
, O
GCR B-protein
of O
spleen O
lymphocytic O
cell O
was O
also O
measured O
in O
18 O
aged O
rats O
and O
9 O
young O
rats O
. O

The O
results O
showed O
that O
GCR B-protein
was O
significantly O
lower O
in O
the O
aged O
persons O
or O
rats O
than O
that O
in O
the O
young O
while O
the O
plasma O
cortisol O
level O
didn O
' O
t O
change O
with O
aging O
. O

So O
we O
think O
that O
GCR B-protein
is O
more O
sensitive O
than O
the O
plasma O
cortisol O
level O
to O
reflect O
the O
aging O
change O
of O
the O
adrenal O
cortex O
function O
. O

After O
the O
treatment O
with O
the O
regimen O
of O
Kidney O
- O
tonifying O
and O
Qi O
- O
invigorating O
, O
the O
GCR B-protein
of O
the O
aged O
persons O
and O
rats O
was O
enhanced O
, O
and O
in O
this O
way O
, O
the O
function O
of O
the O
aged O
adrenal O
cortex O
was O
improved O
. O

Interferon O
affects O
nuclear B-protein
proteins I-protein
in O
cells O
of O
clinically O
sensitive O
chronic O
myelogenous O
leukemia O
patients O
. O

Cytoplasmic O
protein O
extracts O
from O
chronic O
myelogenous O
leukemia O
( O
CML O
) O
cells O
contained O
an O
activity O
that O
altered O
the O
electrophoretic O
mobility O
of O
complexes O
formed O
between O
nuclear B-protein
proteins I-protein
and O
the O
transcriptional O
enhancers O
of O
interferon O
( O
IFN O
) O
- O
inducible O
genes O
. O

Exposure O
of O
CML O
cells O
to O
IFN B-protein
- I-protein
alpha I-protein
diminished O
the O
effect O
of O
the O
CML B-protein
cytoplasmic I-protein
proteins I-protein
on O
these O
nuclear B-protein
protein I-protein
- I-protein
DNA I-protein
complexes I-protein
. O

The O
presence O
of O
clinical O
responsiveness O
to O
IFN B-protein
- I-protein
alpha I-protein
correlated O
with O
the O
sensitivity O
to O
the O
IFN B-protein
- O
induced O
change O
in O
the O
electrophoretic O
mobility O
of O
nuclear B-protein
protein I-protein
- I-protein
DNA I-protein
complexes I-protein
. O

These O
data O
suggest O
that O
the O
action O
of O
IFN B-protein
- I-protein
alpha I-protein
in O
CML O
may O
be O
linked O
to O
a O
pathway O
that O
can O
result O
in O
posttranslational O
modification O
of O
nuclear B-protein
proteins I-protein
. O

Epstein B-protein
- I-protein
Barr I-protein
virus I-protein
nuclear I-protein
antigen I-protein
2 I-protein
transactivates O
latent B-protein
membrane I-protein
protein I-protein
LMP1 B-protein
. O

Several O
lines O
of O
evidence O
are O
compatible O
with O
the O
hypothesis O
that O
Epstein B-protein
- I-protein
Barr I-protein
virus I-protein
( I-protein
EBV I-protein
) I-protein
nuclear I-protein
antigen I-protein
2 I-protein
( O
EBNA B-protein
- I-protein
2 I-protein
) O
or O
leader B-protein
protein I-protein
( O
EBNA B-protein
- I-protein
LP I-protein
) O
affects O
expression O
of O
the O
EBV B-protein
latent I-protein
infection I-protein
membrane I-protein
protein I-protein
LMP1 B-protein
. O

We O
now O
demonstrate O
the O
following O
. O

( O
i O
) O
Acute O
transfection O
and O
expression O
of O
EBNA B-protein
- I-protein
2 I-protein
under O
control O
of O
simian O
virus O
40 O
or O
Moloney O
murine O
leukemia O
virus O
promoters O
resulted O
in O
increased O
LMP1 B-protein
expression O
in O
P3HR O
- O
1 O
- O
infected O
Burkitt O
' O
s O
lymphoma O
cells O
and O
the O
P3HR O
- O
1 O
or O
Daudi O
cell O
line O
. O

( O
ii O
) O
Transfection O
and O
expression O
of O
EBNA B-protein
- I-protein
LP I-protein
alone O
had O
no O
effect O
on O
LMP1 B-protein
expression O
and O
did O
not O
act O
synergistically O
with O
EBNA B-protein
- I-protein
2 I-protein
to O
affect O
LMP1 B-protein
expression O
. O

( O
iii O
) O
LMP1 B-protein
expression O
in O
Daudi O
and O
P3HR O
- O
1 O
- O
infected O
cells O
was O
controlled O
at O
the O
mRNA O
level O
, O
and O
EBNA B-protein
- I-protein
2 I-protein
expression O
in O
Daudi O
cells O
increased O
LMP1 B-protein
mRNA O
. O

( O
iv O
) O
No O
other O
EBV O
genes O
were O
required O
for O
EBNA B-protein
- I-protein
2 I-protein
transactivation O
of O
LMP1 B-protein
since O
cotransfection O
of O
recombinant O
EBNA B-protein
- I-protein
2 I-protein
expression O
vectors O
and O
genomic O
LMP1 B-protein
DNA O
fragments O
enhanced O
LMP1 B-protein
expression O
in O
the O
EBV O
- O
negative O
B O
- O
lymphoma O
cell O
lines O
BJAB O
, O
Louckes O
, O
and O
BL30 O
. O

( O
v O
) O
An O
EBNA B-protein
- I-protein
2 I-protein
- O
responsive O
element O
was O
found O
within O
the O
- O
512 O
to O
+ O
40 O
LMP1 B-protein
DNA O
since O
this O
DNA O
linked O
to O
a O
chloramphenicol B-protein
acetyltransferase I-protein
reporter O
gene O
was O
transactivated O
by O
cotransfection O
with O
an O
EBNA B-protein
- I-protein
2 I-protein
expression O
vector O
. O

( O
vi O
) O
The O
EBV O
type O
2 O
EBNA B-protein
- I-protein
2 I-protein
transactivated O
LMP1 B-protein
as O
well O
as O
the O
EBV O
type O
1 O
EBNA B-protein
- I-protein
2 I-protein
. O

( O
vii O
) O
Two O
deletions O
within O
the O
EBNA B-protein
- I-protein
2 I-protein
gene O
which O
rendered O
EBV O
transformation O
incompetent O
did O
not O
transactivate O
LMP1 B-protein
, O
whereas O
a O
transformation O
- O
competent O
EBNA B-protein
- I-protein
2 I-protein
deletion O
mutant O
did O
transactivate O
LMP1 B-protein
. O

LMP1 B-protein
is O
a O
potent O
effector O
of O
B O
- O
lymphocyte O
activation O
and O
can O
act O
synergistically O
with O
EBNA B-protein
- I-protein
2 I-protein
to O
induce O
cellular O
CD23 O
gene O
expression O
. O

Thus O
, O
EBNA B-protein
- I-protein
2 I-protein
transactivation O
of O
LMP1 B-protein
amplifies O
the O
biological O
impact O
of O
EBNA B-protein
- I-protein
2 I-protein
and O
underscores O
its O
central O
role O
in O
EBV O
- O
induced O
growth O
transformation O
. O

The O
expression O
of O
c O
- O
fos O
, O
c O
- O
jun O
, O
and O
c O
- O
myc O
genes O
is O
regulated O
by O
heat O
shock O
in O
human O
lymphoid O
cells O
. O

The O
effect O
of O
heat O
shock O
on O
the O
expression O
of O
the O
nuclear O
protooncogenes O
c O
- O
fos O
, O
c O
- O
jun O
, O
and O
c O
- O
myc O
was O
studied O
in O
human O
lymphoid O
cells O
. O

Heat O
shock O
caused O
an O
increase O
in O
c O
- O
fos O
and O
c O
- O
jun O
mRNA O
levels O
and O
a O
decrease O
in O
c O
- O
myc O
mRNA O
levels O
in O
pre O
- O
B O
( O
Hyon O
) O
and O
T O
( O
DND O
- O
41 O
) O
cell O
lines O
as O
well O
as O
in O
freshly O
isolated O
normal O
human O
thymocytes O
. O

The O
changes O
in O
the O
mRNA O
levels O
of O
these O
protooncogenes O
in O
Hyon O
cells O
were O
most O
pronounced O
at O
42 O
and O
43 O
degrees O
C O
; O
kinetic O
analysis O
demonstrated O
that O
the O
changes O
could O
be O
detected O
within O
30 O
min O
of O
heat O
shock O
. O

Altered O
transcription O
of O
c O
- O
fos O
and O
c O
- O
myc O
genes O
was O
the O
primary O
effect O
of O
heat O
shock O
. O

Secondarily O
, O
heat O
shock O
of O
Hyon O
cells O
stabilized O
the O
c O
- O
myc O
mRNA O
level O
by O
increasing O
its O
half O
- O
life O
from O
24 O
to O
45 O
min O
. O

The O
overall O
effect O
of O
heat O
shock O
on O
c O
- O
myc O
mRNA O
level O
, O
however O
, O
was O
a O
marked O
inhibition O
of O
its O
transcription O
. O

These O
results O
demonstrate O
that O
the O
transcription O
of O
nuclear O
protooncogenes O
is O
regulated O
by O
heat O
shock O
indicating O
a O
role O
for O
nuclear O
protooncogenes O
in O
the O
stress O
response O
of O
lymphoid O
cells O
. O

Mapping O
of O
B B-protein
- I-protein
cell I-protein
epitopes I-protein
of O
the O
human B-protein
hepatitis I-protein
B I-protein
virus I-protein
X I-protein
protein I-protein
. O

The O
immune O
response O
to O
the O
X B-protein
protein I-protein
of O
human O
hepatitis O
B O
virus O
( O
HBV O
) O
was O
studied O
by O
epitope O
mapping O
by O
using O
a O
set O
of O
MS2 B-protein
- I-protein
HBx I-protein
fusion I-protein
proteins I-protein
and O
synthetic O
peptides O
. O

Antibodies O
in O
sera O
of O
patients O
with O
acute O
and O
chronic O
HBV O
infection O
showed O
a O
multispecific O
immune O
response O
. O

Each O
serum O
contained O
antibodies B-protein
to O
a O
different O
set O
of O
epitopes B-protein
, O
which O
taken O
together O
cover O
most O
of O
the O
HBx B-protein
sequence I-protein
. O

Some O
of O
the O
epitopes O
were O
detectable O
only O
by O
immunoblotting O
with O
fusion B-protein
proteins I-protein
; O
others O
were O
detectable O
only O
by O
an O
enzyme O
- O
linked O
immunosorbent O
assay O
( O
ELISA O
) O
with O
synthetic O
peptides O
. O

The O
carboxy B-protein
- I-protein
terminal I-protein
half I-protein
of O
the O
HBx B-protein
protein I-protein
was O
preferentially O
recognized O
by O
antibodies B-protein
from O
patients O
with O
chronic O
hepatitis O
and O
contained O
a O
short O
immunodominant B-protein
antigenic I-protein
region I-protein
with O
at O
least O
two O
major O
nonoverlapping B-protein
epitopes I-protein
. O

Anti O
- O
HBx B-protein
antibody O
titers O
as O
revealed O
by O
peptide O
ELISAs O
were O
highest O
and O
most O
frequent O
in O
patients O
with O
chronic O
hepatitis O
and O
usually O
low O
in O
acutely O
infected O
patients O
and O
asymptomatic O
carriers O
. O

The O
data O
demonstrate O
a O
remarkable O
qualitative O
and O
quantitative O
heterogeneity O
of O
the O
humoral O
HBx B-protein
immune O
response O
which O
can O
be O
monitored O
by O
HBx B-protein
- O
specific O
peptide O
ELISAs O
. O

Such O
tests O
may O
become O
useful O
diagnostic O
tools O
. O

[ O
The O
inhibitory O
effect O
of O
hydrocortisone O
on O
the O
chemotactic O
migration O
of O
human O
leukocytes O
] O
. O

Random O
migration O
( O
RM O
) O
and O
chemotactic O
migration O
( O
ChtM O
) O
of O
human O
leukocytes O
to O
yeast O
activated O
serum O
were O
studied O
with O
the O
modified O
Boyden O
chamber O
method O
. O

Both O
RM O
and O
ChtM O
showed O
circadian O
rhythm O
. O

Leukocytes O
migrated O
most O
rapidly O
at O
night O
. O

The O
difference O
between O
the O
peak O
( O
0 O
: O
00 O
) O
and O
trough O
values O
( O
8 O
: O
00 O
) O
of O
RM O
and O
ChtM O
was O
significant O
statistically O
( O
P O
less O
than O
0 O
. O
01 O
) O
. O

ChtM O
was O
inhibited O
by O
hydrocortisone O
( O
F O
) O
of O
physiological O
concentration O
( O
10 O
( O
- O
9 O
) O
- O
10 O
( O
- O
7 O
) O
mol O
/ O
L O
) O
which O
was O
dose O
- O
dependent O
and O
completely O
antagonized O
by O
the O
competitive O
antagonist O
, O
RU38486 O
. O

The O
inhibitory O
effect O
was O
much O
more O
evident O
with O
higher O
dose O
( O
more O
than O
10 O
( O
- O
5 O
) O
mol O
/ O
L O
) O
and O
it O
was O
also O
reversed O
by O
RU38486 O
, O
but O
only O
partially O
. O

It O
is O
suggested O
that O
glucocorticoids O
( O
GC O
) O
may O
be O
a O
physiological O
regulator O
of O
the O
activity O
of O
leukocytes O
and O
its O
inhibitory O
action O
on O
ChtM O
may O
be O
involved O
in O
antiinflammatory O
mechanisms O
of O
GC O
of O
pharmacological O
doses O
. O

The O
action O
of O
physiological O
and O
pharmacological O
concentration O
of O
GC O
may O
be O
mediated O
by O
low B-protein
affinity I-protein
specific I-protein
binding I-protein
sites I-protein
of O
glucocorticoid B-protein
receptors I-protein
. O

Heterogeneity O
of O
antigen B-protein
molecules I-protein
recognized O
by O
anti B-protein
- I-protein
tax1 I-protein
monoclonal I-protein
antibody I-protein
Lt B-protein
- I-protein
4 I-protein
in O
cell O
lines O
bearing O
human O
T O
cell O
leukemia O
virus O
type O
I O
and O
related O
retroviruses O
. O

Using O
a O
monoclonal B-protein
antibody I-protein
, O
Lt B-protein
- I-protein
4 I-protein
, O
directed O
against O
human B-protein
T I-protein
cell I-protein
leukemia I-protein
virus I-protein
type I-protein
I I-protein
( I-protein
HTLV I-protein
- I-protein
I I-protein
) I-protein
trans I-protein
- I-protein
activator I-protein
( I-protein
tax1 I-protein
) I-protein
antigen I-protein
, O
we O
examined O
the O
expression O
of O
tax1 B-protein
and O
related O
antigens B-protein
in O
a O
variety O
of O
T O
cell O
lines O
bearing O
HTLV O
- O
I O
and O
related O
retroviruses O
, O
simian O
T O
cell O
leukemia O
virus O
type O
I O
( O
STLV O
- O
I O
) O
and O
HTLV O
- O
II O
, O
by O
immunofluorescence O
and O
immunoblot O
assays O
. O

Lt B-protein
- I-protein
4 I-protein
reacted O
with O
all O
HTLV O
- O
I O
- O
bearing O
cell O
lines O
tested O
and O
five O
out O
of O
eight O
simian O
cell O
lines O
bearing O
STLV O
- O
I O
, O
but O
not O
with O
an O
HTLV O
- O
II O
- O
bearing O
cell O
line O
. O

Lt B-protein
- I-protein
4 I-protein
detected O
40 O
kd O
tax1 B-protein
antigen I-protein
molecules I-protein
in O
most O
HTLV O
- O
I O
- O
bearing O
cell O
lines O
except O
one O
cell O
line O
that O
expressed O
39 B-protein
kd I-protein
tax1 I-protein
antigen I-protein
. O

In O
the O
STLV O
- O
I O
- O
bearing O
T O
cell O
lines O
, O
tax1 B-protein
- I-protein
related I-protein
antigen I-protein
molecules I-protein
detected O
by O
Lt B-protein
- I-protein
4 I-protein
were O
heterogeneous O
, O
having O
molecular O
weights O
in O
the O
range O
of O
36 O
- O
41 O
kd O
. O

Characterization O
of O
the O
human B-protein
immunodeficiency I-protein
virus I-protein
type I-protein
1 I-protein
enhancer I-protein
- I-protein
binding I-protein
proteins I-protein
from O
the O
human O
T O
- O
cell O
line O
Jurkat O
. O

The O
transcription O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
is O
under O
the O
control O
of O
cellular B-protein
proteins I-protein
that O
bind O
to O
the O
viral O
long O
terminal O
repeat O
( O
LTR O
) O
. O

Among O
the O
protein O
- O
binding O
regions O
of O
the O
HIV O
- O
1 O
LTR O
is O
the O
transcription O
- O
enhancer O
region O
. O

We O
show O
that O
at O
least O
one O
inducible B-protein
, O
C1 B-protein
, O
and O
one O
constitutive B-protein
, I-protein
C2 I-protein
, I-protein
protein I-protein
can O
bind O
to O
the O
HIV O
enhancer O
in O
Jurkat O
cells O
. O

The O
two O
proteins O
differ O
in O
their O
surface O
charge O
, O
since O
they O
are O
separable O
by O
anion O
- O
exchange O
chromatography O
. O

Bivalent O
cations O
such O
as O
Mg2 O
+ O
and O
Zn2 O
+ O
differentially O
affect O
their O
binding O
to O
oligonucleotides O
which O
contain O
the O
HIV O
- O
enhancer O
domain O
. O

Both O
C1 B-protein
and O
C2 B-protein
proteins I-protein
also O
bind O
to O
a O
similar O
sequence O
found O
in O
the O
interleukin B-protein
- I-protein
2 I-protein
- I-protein
receptor I-protein
alpha I-protein
- I-protein
subunit I-protein
enhancer O
. O

The O
inducible B-protein
C1 I-protein
protein I-protein
was O
partially O
purified O
by O
three O
chromatographic O
steps O
and O
characterized O
by O
u O
. O
v O
. O
cross O
- O
linking O
as O
a O
47 B-protein
kDa I-protein
protein I-protein
. O

Differences O
in O
transcriptional O
enhancers O
of O
HIV O
- O
1 O
and O
HIV O
- O
2 O
. O

Response O
to O
T O
cell O
activation O
signals O
. O

T O
cell O
activation O
results O
in O
high O
levels O
of O
HIV O
replication O
and O
is O
thought O
to O
be O
one O
mechanism O
leading O
to O
the O
conversion O
from O
latent O
to O
active O
viral O
infection O
. O

In O
HIV O
- O
1 O
, O
the O
sequences O
that O
respond O
to O
these O
signaling O
events O
are O
found O
in O
the O
long O
terminal O
repeat O
( O
LTR O
) O
and O
comprise O
the O
transcriptional O
enhancer O
, O
which O
contains O
two O
conserved O
binding O
sites O
for O
the O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
( O
NF B-protein
kappa I-protein
B I-protein
) O
. O

The O
corresponding O
region O
in O
the O
second O
AIDS O
retrovirus O
, O
HIV O
- O
2 O
, O
contains O
a O
conserved O
and O
a O
divergent O
NF B-protein
kappa I-protein
B I-protein
binding O
site O
. O

We O
demonstrate O
that O
the O
HIV O
- O
1 O
LTR O
responds O
better O
than O
the O
HIV O
- O
2 O
LTR O
to O
T O
cell O
activation O
signals O
. O

These O
qualitative O
differences O
in O
the O
response O
to O
T O
cell O
activation O
are O
reproduced O
not O
only O
when O
HIV O
- O
1 O
or O
HIV O
- O
2 O
enhancers O
are O
placed O
upstream O
of O
a O
heterologous O
promoter O
but O
also O
when O
these O
enhancers O
are O
switched O
between O
their O
respective O
LTR O
. O

In O
electrophoretic O
mobility O
shift O
assays O
, O
NF B-protein
kappa I-protein
B I-protein
binds O
to O
both O
conserved O
sites O
in O
the O
HIV O
- O
1 O
transcriptional O
enhancer O
and O
only O
to O
the O
single O
conserved O
site O
in O
the O
HIV O
- O
2 O
transcriptional O
enhancer O
. O

Instead O
of O
NF B-protein
kappa I-protein
B I-protein
, O
the O
activator B-protein
protein I-protein
3 I-protein
binds O
to O
the O
divergent O
site O
in O
HIV O
- O
2 O
. O

In O
conclusion O
, O
HIV O
- O
1 O
and O
HIV O
- O
2 O
are O
differentially O
regulated O
by O
T O
cell O
activation O
signals O
, O
and O
this O
difference O
may O
account O
for O
the O
longer O
period O
of O
viral O
latency O
observed O
with O
HIV O
- O
2 O
than O
with O
HIV O
- O
1 O
infection O
. O

NF B-protein
- I-protein
X2 I-protein
that O
binds O
to O
the O
DRA O
X2 O
- O
box O
is O
activator B-protein
protein I-protein
1 I-protein
. O

Expression O
cloning O
of O
c B-protein
- I-protein
Jun I-protein
. O

Human B-protein
class I-protein
II I-protein
MHC I-protein
Ag I-protein
are O
a O
family O
of O
cell B-protein
surface I-protein
glycoproteins I-protein
. O

Their O
constitutive O
expression O
is O
limited O
to O
B O
lymphocytes O
and O
thymic O
epithelial O
cells O
. O

In O
many O
other O
cells O
their O
expression O
can O
be O
induced O
by O
IFN B-protein
- I-protein
gamma I-protein
. O

Conserved O
upstream O
promoter O
sequences O
regulate O
this O
tissue O
- O
specific O
expression O
of O
class O
II O
genes O
. O

In O
the O
DRA O
promoter O
, O
one O
of O
these O
cis O
- O
acting O
regulatory O
motifs O
is O
the O
X2 O
- O
box O
to O
which O
nuclear B-protein
factor I-protein
X2 I-protein
( O
NF B-protein
- I-protein
X2 I-protein
) O
binds O
. O

Here O
, O
we O
present O
the O
isolation O
and O
characterization O
of O
the O
full O
- O
length O
cDNA O
clone O
encoding O
NF B-protein
- I-protein
X2 I-protein
. O

This O
cDNA O
clone O
was O
isolated O
by O
expression O
cDNA O
cloning O
, O
and O
encodes O
the O
human B-protein
c I-protein
- I-protein
Jun I-protein
protein I-protein
, O
which O
together O
with O
c B-protein
- I-protein
Fos I-protein
forms O
the O
heterodimeric B-protein
activator I-protein
protein I-protein
- I-protein
1 I-protein
transcription I-protein
complex I-protein
. O

Whereas O
c B-protein
- I-protein
Fos I-protein
/ I-protein
c I-protein
- I-protein
Jun I-protein
heterodimers I-protein
do O
not O
exist O
in O
B O
cells O
, O
they O
form O
and O
bind O
to O
the O
X2 O
- O
box O
in O
class O
II O
nonexpressing O
cells O
. O

Thus O
, O
c B-protein
- I-protein
Fos I-protein
/ I-protein
c I-protein
- I-protein
Jun I-protein
heterodimers I-protein
might O
contribute O
to O
the O
repression O
of O
DRA O
gene O
expression O
. O

Synthesis O
of O
4 O
, O
19 O
- O
disubstituted O
derivatives O
of O
DOC O
. O

Radioreceptor O
assay O
of O
some O
corticosteroid O
derivatives O
in O
human O
mononuclear O
leukocytes O
. O

Several O
new O
4 O
, O
19 O
- O
substituted O
steroids O
and O
previously O
synthesized O
corticosteroids O
were O
assayed O
for O
affinity O
to O
type B-protein
1 I-protein
receptors I-protein
in O
human O
mononuclear O
leukocytes O
. O

11 O
beta O
, O
19 O
- O
epoxy O
- O
4 O
, O
21 O
- O
dihydroxypregn O
- O
4 O
- O
ene O
- O
3 O
, O
20 O
- O
dione O
( O
2 O
) O
was O
hydrogenated O
with O
Pd O
- O
C O
to O
yield O
a O
mixture O
of O
all O
four O
dihydro O
derivatives O
5 O
, O
accompanied O
by O
4 O
, O
21 O
- O
diacetoxy O
- O
11 O
beta O
, O
19 O
- O
epoxy O
- O
3 O
- O
hydroxypregnan O
- O
20 O
- O
one O
( O
6 O
) O
and O
21 O
- O
acetoxy O
- O
11 O
beta O
, O
19 O
- O
epoxy O
- O
4 O
- O
hydroxypregnane O
- O
3 O
, O
20 O
- O
dione O
( O
7 O
) O
. O

With O
hot O
acetic O
+ O
p O
- O
toluenesulfonic O
acid O
5 O
underwent O
rearrangement O
to O
21 O
- O
acetoxy O
- O
11 O
beta O
, O
19 O
- O
epoxypregn O
- O
5 O
- O
ene O
- O
4 O
, O
20 O
- O
dione O
( O
8 O
) O
Pd O
- O
C O
hydrogenation O
of O
3 O
, O
21 O
- O
diacetoxy O
- O
5 O
beta O
, O
19 O
- O
cyclopregna O
- O
2 O
, O
9 O
( O
11 O
) O
- O
diene O
- O
4 O
, O
20 O
- O
dione O
( O
10 O
) O
gave O
3 O
, O
21 O
- O
diacetoxy O
- O
5 O
beta O
, O
19 O
- O
cyclopregn O
- O
5 O
- O
ene O
- O
4 O
, O
20 O
- O
dione O
( O
11 O
) O
and O
the O
9 O
, O
11 O
- O
dihydro O
derivative O
of O
the O
latter O
. O

Treatment O
of O
10 O
with O
warm O
HCl O
furnished O
19 O
- O
chloro O
- O
4 O
, O
21 O
- O
dihydroxypregna O
- O
4 O
, O
9 O
( O
11 O
) O
- O
diene O
- O
3 O
, O
20 O
- O
dione O
( O
13 O
) O
. O

Pd O
- O
C O
hydrogenation O
of O
its O
diacetate O
14 O
afforded O
the O
4 O
, O
5 O
- O
dihydro O
derivative O
18 O
, O
19 O
- O
chloro O
- O
21 O
- O
acetoxypregn O
- O
9 O
( O
11 O
) O
- O
en O
- O
20 O
- O
one O
( O
15 O
) O
, O
its O
4 O
- O
acetoxy O
derivative O
16 O
and O
the O
3 O
, O
4 O
- O
diacetoxy O
derivative O
17 O
. O

When O
tested O
in O
a O
radioreceptor O
assay O
in O
human O
mononuclear O
leukocytes O
the O
synthesized O
compounds O
showed O
only O
low O
relative O
binding O
affinities O
( O
RBA O
) O
to O
type B-protein
1 I-protein
receptor I-protein
, O
the O
highest O
being O
0 O
. O
72 O
% O
for O
13 O
( O
aldosterone O
= O
100 O
% O
) O
. O

For O
comparison O
, O
other O
RBA O
in O
this O
system O
were O
: O
19 O
- O
noraldosterone O
, O
20 O
% O
; O
18 O
- O
deoxyaldosterone O
, O
5 O
. O
8 O
% O
; O
18 O
- O
deoxy O
- O
19 O
- O
noraldosterone O
, O
4 O
. O
7 O
% O
; O
18 O
, O
21 O
- O
anhydroaldosterone O
, O
0 O
. O
37 O
% O
; O
17 O
- O
isoaldosterone O
, O
7 O
. O
6 O
% O
and O
apoaldosterone O
, O
4 O
. O
3 O
% O
. O

Cell O
type O
specificity O
and O
activation O
requirements O
for O
NFAT B-protein
- I-protein
1 I-protein
( O
nuclear B-protein
factor I-protein
of O
activated O
T O
- O
cells O
) O
transcriptional O
activity O
determined O
by O
a O
new O
method O
using O
transgenic O
mice O
to O
assay O
transcriptional O
activity O
of O
an O
individual O
nuclear B-protein
factor I-protein
. O

Nuclear B-protein
factor I-protein
of O
activated O
T O
- O
cells O
( O
NFAT B-protein
- I-protein
1 I-protein
) O
is O
a O
transcription B-protein
factor I-protein
which O
is O
considered O
to O
be O
an O
important O
regulator O
in O
early O
T O
- O
cell O
activation O
. O

We O
have O
developed O
a O
system O
to O
monitor O
the O
transcriptional O
activity O
of O
NFAT B-protein
- I-protein
1 I-protein
at O
the O
single O
cell O
level O
in O
whole O
animals O
. O

The O
system O
is O
based O
on O
the O
use O
of O
an O
oligomerized O
NFAT B-protein
- I-protein
1 I-protein
binding O
motif O
that O
directs O
transcription B-protein
of I-protein
SV40 I-protein
T I-protein
- I-protein
antigen I-protein
in O
transgenic O
mice O
. O

This O
report O
represents O
the O
first O
demonstration O
that O
a O
multimerized O
short O
binding O
motif O
can O
function O
appropriately O
in O
transgenic O
mice O
. O

NFAT B-protein
- I-protein
1 I-protein
activity O
had O
previously O
been O
thought O
to O
be O
confined O
to O
activated O
T O
- O
lymphocytes O
upon O
release O
of O
intracellular O
calcium O
. O

By O
targeting O
NFAT B-protein
- I-protein
1 I-protein
- O
dependent O
gene O
expression O
in O
transgenic O
mice O
we O
discovered O
new O
sites O
of O
NFAT B-protein
- I-protein
1 I-protein
activity O
. O

Besides O
in O
T O
- O
lymphocytes O
NFAT B-protein
- I-protein
1 I-protein
activity O
could O
also O
be O
induced O
in O
T O
- O
lymphocyte O
- O
depleted O
spleen O
cells O
and O
purified O
B O
- O
lymphocytes O
and O
requires O
agents O
that O
both O
release O
intracellular O
calcium O
and O
activate O
protein B-protein
kinase I-protein
C I-protein
. O

A O
difference O
in O
the O
time O
course O
of O
appearance O
of O
NFAT B-protein
- I-protein
1 I-protein
activity O
between O
T O
- O
lymphocytes O
and O
non O
- O
T O
- O
lymphocytes O
was O
revealed O
. O

Constitutive O
expression O
was O
observed O
in O
a O
small O
population O
of O
cells O
in O
the O
dermis O
and O
some O
mice O
have O
developed O
skin O
lesions O
. O

Interestingly O
, O
the O
tissue O
pattern O
of O
expression O
of O
the O
NFAT B-protein
- I-protein
1 I-protein
activity O
resembles O
the O
expression O
pattern O
described O
for O
HIV O
- O
LTR O
/ O
tat O
transgenic O
mice O
( O
Vogel O
, O
J O
. O
, O
Hinrichs O
, O
S O
. O
H O
. O
, O
Reynolds O
, O
R O
. O
K O
. O
, O
Luciw O
, O
P O
. O
A O
. O
, O
and O
Jay O
, O
G O
. O
( O
1988 O
) O
Nature O
335 O
, O
606 O
- O
611 O
) O
. O

This O
similarity O
in O
expression O
and O
the O
fact O
that O
NFAT B-protein
- I-protein
1 I-protein
has O
been O
shown O
to O
bind O
functional O
sequences O
in O
HIV O
- O
LTR O
suggest O
a O
role O
for O
NFAT B-protein
- I-protein
1 I-protein
in O
dermal O
activation O
of O
the O
HIV O
- O
LTR O
. O

A O
novel O
T B-protein
- I-protein
cell I-protein
protein I-protein
which O
recognizes O
a O
palindromic O
sequence O
in O
the O
negative O
regulatory O
element O
of O
the O
human O
immunodeficiency O
virus O
long O
terminal O
repeat O
. O

Two O
major O
protein O
- O
binding O
sites O
within O
the O
negative O
regulatory O
element O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
long O
terminal O
repeat O
have O
been O
identified O
. O

One O
( O
site O
B O
) O
contained O
a O
palindromic O
sequence O
with O
homology O
to O
steroid O
/ O
thyroid O
hormone O
response O
elements O
but O
was O
distinct O
from O
previously O
described O
binding O
sites O
of O
this O
class O
. O

A O
novel O
T B-protein
- I-protein
cell I-protein
protein I-protein
recognized O
the O
palindromic O
sequence O
within O
site O
B O
and O
also O
bound O
estrogen O
- O
or O
thyroid O
hormone O
- O
response O
elements O
with O
lower O
affinity O
. O

A O
7 O
- O
base O
- O
pair O
mutation O
in O
the O
site O
B O
palindrome O
, O
which O
destroyed O
protein O
binding O
, O
resulted O
in O
increased O
expression O
from O
the O
human O
immunodeficiency O
virus O
type O
1 O
long O
terminal O
repeat O
in O
T O
cells O
. O

Progesterone O
suppression O
of O
pregnancy O
lymphocytes O
is O
not O
mediated O
by O
glucocorticoid O
effect O
. O

This O
study O
investigated O
whether O
the O
suppressive O
effect O
of O
progesterone O
on O
pregnancy O
lymphocytes O
is O
mediated O
by O
specific O
progesterone B-protein
receptors I-protein
. O

The O
effects O
of O
a O
competitive O
progesterone O
antagonist O
( O
RU486 O
) O
and O
a O
specific O
glucocorticoid B-protein
receptor I-protein
blocker O
( O
RU43044 O
) O
were O
tested O
on O
the O
release O
of O
a O
blocking B-protein
factor I-protein
by O
progesterone O
- O
treated O
pregnancy O
lymphocytes O
. O

RU O
486 O
tested O
at O
an O
equal O
concentration O
as O
progesterone O
significantly O
inhibited O
the O
production O
of O
the O
blocking B-protein
factor I-protein
, O
while O
RU O
43044 O
was O
without O
effect O
. O

These O
data O
suggest O
that O
in O
pregnancy O
, O
lymphocyte O
progesterone O
acts O
on O
specific O
progesterone B-protein
receptors I-protein
and O
glucocorticoid B-protein
binding I-protein
sites I-protein
are O
not O
involved O
. O

The O
56 B-protein
- I-protein
59 I-protein
- I-protein
kilodalton I-protein
protein I-protein
identified O
in O
untransformed B-protein
steroid I-protein
receptor I-protein
complexes I-protein
is O
a O
unique B-protein
protein I-protein
that O
exists O
in O
cytosol O
in O
a O
complex O
with O
both O
the O
70 O
- O
and O
90 O
- O
kilodalton O
heat O
shock O
proteins O
. O

It O
has O
previously O
been O
shown O
that O
9S B-protein
, O
untransformed O
progestin O
, O
estrogen O
, O
androgen O
, O
and O
glucocorticoid O
receptor O
complexes O
in O
rabbit O
uterine O
and O
liver O
cytosols O
contain O
a O
59 B-protein
- I-protein
kDa I-protein
protein I-protein
[ O
Tai O
, O
P O
. O
K O
. O
, O
Maeda O
, O
Y O
. O
, O
Nakao O
, O
K O
. O
, O
Wakim O
, O
N O
. O
G O
. O
, O
Duhring O
, O
J O
. O
L O
. O
, O
& O
Faber O
, O
L O
. O
E O
. O
( O
1986 O
) O
Biochemistry O
25 O
, O
5269 O
- O
5275 O
] O
. O

In O
this O
work O
we O
show O
that O
the O
monoclonal B-protein
antibody I-protein
KN I-protein
382 I-protein
/ I-protein
EC1 I-protein
raised O
against O
the O
rabbit B-protein
59 I-protein
- I-protein
kDa I-protein
protein I-protein
reacts O
with O
9S B-protein
, O
untransformed B-protein
glucocorticoid I-protein
receptor I-protein
complexes I-protein
in O
cytosol O
prepared O
from O
human O
IM O
- O
9 O
lymphocytes O
but O
not O
with O
4S B-protein
salt I-protein
- I-protein
transformed I-protein
receptors I-protein
. O

The O
human O
protein O
recognized O
by O
the O
EC1 B-protein
antibody I-protein
is O
a O
56 B-protein
- I-protein
kDa I-protein
protein I-protein
( O
p56 B-protein
) O
of O
moderate O
abundance O
located O
predominantly O
in O
the O
cytoplasm O
by O
indirect O
immunofluorescence O
. O

There O
are O
at O
least O
six O
isomorphs B-protein
of O
p56 B-protein
by O
two O
- O
dimensional O
gel O
analysis O
. O

N O
- O
Terminal O
sequencing O
( O
20 O
amino O
acids O
) O
shows O
that O
p56 B-protein
is O
a O
unique B-protein
human I-protein
protein I-protein
. O

When O
p56 B-protein
is O
immunoadsorbed O
from O
IM O
- O
9 O
cell O
cytosol O
, O
both O
the O
70 O
- O
and O
90 O
- O
kDa O
heat O
shock O
proteins O
are O
coadsorbed O
in O
an O
immune O
- O
specific O
manner O
. O

Neither O
heat B-protein
shock I-protein
protein I-protein
reacts O
directly O
with O
the O
EC1 B-protein
antibody I-protein
. O

We O
conclude O
that O
p56 B-protein
exists O
in O
cytosol O
in O
a O
higher O
order O
complex O
containing O
hsp70 B-protein
and O
hsp90 B-protein
, O
both O
of O
which O
in O
turn O
have O
been O
found O
to O
be O
associated O
with O
untransformed B-protein
steroid I-protein
receptors I-protein
. O

Sequence O
- O
specific O
DNA O
binding O
of O
the O
proto B-protein
- I-protein
oncoprotein I-protein
ets B-protein
- I-protein
1 I-protein
defines O
a O
transcriptional O
activator O
sequence O
within O
the O
long O
terminal O
repeat O
of O
the O
Moloney O
murine O
sarcoma O
virus O
. O

The O
ets O
proto O
- O
oncogene O
family O
is O
a O
group O
of O
sequence O
- O
related O
genes O
whose O
normal O
cellular O
function O
is O
unknown O
. O

In O
a O
study O
of O
cellular B-protein
proteins I-protein
involved O
in O
the O
transcriptional O
regulation O
of O
murine O
retroviruses O
in O
T O
lymphocytes O
, O
we O
have O
discovered O
that O
a O
member O
of O
the O
ets O
gene O
family O
encodes O
a O
sequence B-protein
- I-protein
specific I-protein
DNA I-protein
- I-protein
binding I-protein
protein I-protein
. O

A O
mouse O
ets B-protein
- I-protein
1 I-protein
cDNA O
clone O
was O
obtained O
by O
screening O
a O
mouse O
thymus O
cDNA O
expression O
library O
with O
a O
double O
- O
stranded O
oligonucleotide O
probe O
representing O
20 O
bp O
of O
the O
Moloney O
murine O
sarcoma O
virus O
( O
MSV O
) O
long O
terminal O
repeat O
( O
LTR O
) O
. O

The O
cDNA O
sequence O
has O
an O
813 O
- O
bp O
open O
reading O
frame O
( O
ORF O
) O
whose O
predicted O
amino B-protein
acid I-protein
sequence I-protein
is O
97 O
. O
6 O
% O
identical O
to O
the O
272 B-protein
carboxy I-protein
- I-protein
terminal I-protein
amino I-protein
acids I-protein
of O
the O
human B-protein
ets I-protein
- I-protein
1 I-protein
protein I-protein
. O

The O
ORF O
was O
expressed O
in O
bacteria O
, O
and O
the O
30 B-protein
- I-protein
kD I-protein
protein I-protein
product I-protein
was O
shown O
to O
bind O
DNA O
in O
a O
sequence O
- O
specific O
manner O
by O
mobility O
- O
shift O
assays O
, O
Southwestern O
blot O
analysis O
, O
and O
methylation O
interference O
. O

A O
mutant O
LTR O
containing O
four O
base O
pair O
substitutions O
in O
the O
ets B-protein
- I-protein
1 I-protein
binding O
site O
was O
constructed O
and O
was O
shown O
to O
have O
reduced O
binding O
in O
vitro O
. O

Transcriptional O
efficiency O
of O
the O
MSV O
LTR O
promoter O
containing O
this O
disrupted O
ets B-protein
- I-protein
1 I-protein
binding O
site O
was O
compared O
to O
the O
activity O
of O
a O
wild O
- O
type O
promoter O
in O
mouse O
T O
lymphocytes O
in O
culture O
, O
and O
15 O
- O
to O
20 O
- O
fold O
reduction O
in O
expression O
of O
a O
reporter O
gene O
was O
observed O
. O

We O
propose O
that O
ets B-protein
- I-protein
1 I-protein
functions O
as O
a O
transcriptional O
activator O
of O
mammalian O
type O
- O
C O
retroviruses O
and O
speculate O
that O
ets O
- O
related O
genes O
constitute O
a O
new O
group O
of O
eukaryotic B-protein
DNA I-protein
- I-protein
binding I-protein
proteins I-protein
. O

Type B-protein
II I-protein
estrogen I-protein
binding I-protein
sites I-protein
in O
human O
peripheral O
blood O
mononuclear O
cells O
: O
variations O
during O
the O
menstrual O
cycle O
. O

We O
have O
previously O
reported O
that O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
contain O
type O
II B-protein
estrogen I-protein
binding I-protein
sites I-protein
( O
type B-protein
II I-protein
EBS I-protein
) O
. O

In O
this O
study O
, O
the O
fluctuations O
of O
type B-protein
II I-protein
EBS I-protein
during O
the O
menstrual O
cycle O
were O
analyzed O
in O
6 O
normally O
menstruating O
women O
. O

Approximately O
3 O
times O
higher O
levels O
of O
type B-protein
II I-protein
EBS I-protein
were O
found O
in O
the O
periovulatory O
period O
with O
respect O
to O
both O
follicular O
and O
luteal O
phases O
. O

In O
postmenopausal O
women O
the O
mean O
type B-protein
II I-protein
EBS I-protein
levels O
were O
similar O
to O
those O
observed O
in O
the O
follicular O
phase O
of O
the O
cycle O
. O

However O
, O
in O
3 O
postmenopausal O
patients O
a O
short O
course O
of O
estrogen O
or O
tamoxifen O
resulted O
in O
a O
marked O
increase O
of O
type B-protein
II I-protein
EBS I-protein
levels O
. O

Tamoxifen O
was O
also O
found O
to O
compete O
with O
17 O
beta O
- O
estradiol O
for O
type B-protein
II I-protein
EBS I-protein
in O
PBMC O
, O
although O
to O
a O
lesser O
extent O
than O
diethylstilbestrol O
. O

Mononuclear O
leukocyte O
glucocorticoid B-protein
receptor I-protein
binding O
characteristics O
and O
down O
- O
regulation O
in O
major O
depression O
. O

Some O
patients O
with O
major O
depressive O
disorder O
( O
MDD O
) O
have O
elevated O
plasma O
cortisol O
concentrations O
and O
show O
failure O
to O
suppress O
cortisol O
secretion O
upon O
administration O
of O
dexamethasone O
( O
DEX O
) O
, O
yet O
they O
do O
not O
have O
Cushingoid O
features O
. O

To O
study O
whether O
this O
represents O
glucocorticoid O
( O
GC O
) O
resistance O
, O
[ O
3H O
] O
- O
DEX O
- O
binding O
assays O
were O
used O
to O
measure O
, O
in O
vitro O
, O
the O
GC B-protein
receptor I-protein
affinity O
( O
1 O
/ O
Kd O
) O
and O
number O
( O
Bmax O
) O
in O
mononuclear O
leukocytes O
of O
11 O
MDD O
patients O
and O
15 O
control O
subjects O
. O

No O
receptor O
abnormalities O
were O
detected O
in O
the O
MDD O
group O
; O
thus O
any O
cellular O
defect O
leading O
to O
a O
lack O
of O
responsiveness O
to O
GC O
in O
the O
MDD O
patients O
, O
if O
present O
, O
probably O
lies O
beyond O
the O
initial O
receptor O
binding O
. O

DEX O
( O
1 O
. O
0 O
mg O
orally O
) O
was O
administered O
to O
study O
in O
vivo B-protein
GC I-protein
receptor I-protein
down O
- O
regulation O
. O

Compared O
to O
the O
control O
group O
, O
fewer O
depressed O
subjects O
down O
- O
regulated O
Bmax O
after O
DEX O
. O

By O
paired O
t O
- O
test O
, O
Bmax O
decreased O
significantly O
in O
the O
control O
group O
but O
not O
in O
the O
depressed O
group O
. O

Receptor O
number O
on O
the O
control O
day O
did O
not O
correlate O
significantly O
with O
the O
degree O
of O
receptor O
down O
- O
regulation O
, O
severity O
of O
depression O
or O
cortisol O
concentrations O
across O
all O
the O
subjects O
. O

These O
results O
do O
not O
lend O
support O
to O
previous O
reports O
suggesting O
that O
GC O
resistance O
in O
MDD O
results O
from O
a O
GC O
receptor O
- O
binding O
abnormality O
, O
and O
they O
emphasize O
the O
importance O
of O
considering O
receptor O
studies O
in O
the O
context O
of O
GC O
- O
mediated O
cell O
processes O
in O
order O
to O
identify O
the O
exact O
cellular O
defect O
( O
s O
) O
leading O
to O
GC O
resistance O
. O

Ras B-protein
- I-protein
related I-protein
GTP I-protein
- I-protein
binding I-protein
proteins I-protein
and O
leukocyte O
signal O
transduction O
. O

Many O
aspects O
of O
leukocyte O
function O
are O
regulated O
by O
both O
heterotrimeric B-protein
and O
Ras B-protein
- I-protein
related I-protein
GTP I-protein
- I-protein
binding I-protein
proteins I-protein
, O
but O
there O
is O
little O
definite O
information O
about O
their O
roles O
in O
the O
specialized O
processes O
utilized O
by O
leukocytes O
for O
cell O
killing O
. O

Recent O
progress O
in O
understanding O
the O
regulation O
of O
the O
phagocyte B-protein
NADPH I-protein
oxidase I-protein
by O
the O
Rac B-protein
GTP I-protein
- I-protein
binding I-protein
proteins I-protein
provides O
a O
basis O
for O
defining O
the O
operational O
characteristics O
of O
one O
such O
phagocyte O
system O
. O

It O
is O
clear O
from O
various O
studies O
that O
the O
activity O
of O
the O
NADPH B-protein
oxidase I-protein
can O
be O
modulated O
through O
the O
regulation O
of O
the O
GTP B-protein
- I-protein
GDP I-protein
state I-protein
of O
Rac B-protein
. O

Proteins O
exist O
in O
leukocytes O
able O
to O
modify O
GTP B-protein
- I-protein
binding I-protein
protein I-protein
function O
in O
this O
manner O
, O
and O
their O
activity O
may O
be O
regulated O
by O
signals O
generated O
on O
phagocyte O
stimulation O
. O

Proteins O
of O
the O
Ras B-protein
superfamily I-protein
are O
likely O
to O
be O
involved O
in O
a O
variety O
of O
normal O
phagocyte O
functions O
through O
their O
ability O
to O
modulate O
the O
assembly O
of O
actin B-protein
filaments I-protein
, O
direct O
vesicle O
trafficking O
and O
fusion O
, O
and O
so O
forth O
. O

BSAP B-protein
: O
a O
key O
regulator O
of O
B O
- O
cell O
development O
and O
differentiation O
. O

B B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
activator I-protein
protein I-protein
( O
BSAP B-protein
) O
is O
a O
recently O
identified O
member O
of O
the O
Pax O
- O
gene O
family O
of O
transcription B-protein
factors I-protein
; O
in O
the O
lymphoid O
system O
, O
BSAP B-protein
is O
produced O
only O
in O
B O
cells O
. O

Here O
, O
Markus O
Neurath O
, O
Eckhard O
Stuber O
and O
Warren O
Strober O
describe O
the O
molecular O
structure O
of O
BSAP B-protein
and O
focus O
on O
the O
ability O
of O
this O
protein O
to O
regulate O
the O
expression O
of O
B O
- O
cell O
- O
specific O
genes O
. O

They O
propose O
that O
BSAP B-protein
is O
a O
key B-protein
protein I-protein
of O
B O
cells O
and O
that O
it O
not O
only O
influence O
B O
- O
cell O
development O
but O
also O
influences O
the O
balance O
between O
B O
- O
cell O
proliferation O
and O
immunoglobulin B-protein
secretion O
at O
later O
stages O
of O
B O
- O
cell O
differentiation O
. O

Down O
- O
regulation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
protein I-protein
levels O
in O
activated O
human O
lymphocytes O
by O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
[ O
published O
erratum O
appears O
in O
Proc O
Natl O
Acad O
Sci O
U O
S O
A O
1996 O
Jan O
9 O
; O
93 O
( O
1 O
) O
: O
524 O
] O
. O

The O
effect O
of O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
[ O
1 O
, O
25 O
( O
OH O
) O
2 O
) O
D3 O
] O
, O
a O
steroid O
hormone O
with O
immunomodulating O
properties O
, O
on O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
( O
NF B-protein
- I-protein
kappa I-protein
B I-protein
) O
proteins O
was O
examined O
in O
in O
vitro O
activated O
normal O
human O
lymphocytes O
by O
Western O
blot O
analysis O
. O

Over O
a O
72 O
- O
hr O
period O
of O
activation O
, O
the O
expression O
of O
the O
50 B-protein
- I-protein
kDa I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
, O
p50 B-protein
, O
and O
its O
precursor O
, O
p105 B-protein
, O
was O
increased O
progressively O
. O

When O
cells O
were O
activated O
in O
the O
presence O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
, O
the O
levels O
of O
the O
mature O
protein O
as O
well O
as O
its O
precursor O
were O
decreased O
. O

The O
effect O
of O
the O
hormone O
on O
the O
levels O
of O
p50 B-protein
was O
demonstrable O
in O
the O
cytosolic O
and O
nuclear O
compartments O
; O
it O
required O
between O
4 O
and O
8 O
hr O
and O
was O
specific O
, O
as O
25 O
- O
hydroxyvitamin O
D3 O
and O
24 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
were O
ineffective O
. O

Besides O
p50 B-protein
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
decreased O
the O
levels O
of O
another O
NF B-protein
- I-protein
kappa I-protein
B I-protein
protein I-protein
, O
namely O
c B-protein
- I-protein
rel I-protein
. O

In O
addition O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
decreased O
the O
abundance O
of O
a O
specific B-protein
DNA I-protein
- I-protein
protein I-protein
complex I-protein
formed O
upon O
incubation O
of O
nuclear O
extracts O
from O
activated O
lymphocytes O
with O
a O
labeled O
NF B-protein
- I-protein
kappa I-protein
B I-protein
DNA I-protein
binding I-protein
motif I-protein
. O

Further O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
inhibited O
the O
transcriptional O
activity O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
Jurkat O
cells O
transiently O
transfected O
with O
a O
construct O
containing O
four O
tandem O
repeats O
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
sequence O
of O
the O
immunoglobulin O
kappa O
light O
chain O
gene O
linked O
to O
the O
chloramphenicol B-protein
acetyltransferase I-protein
reporter O
gene O
. O

These O
observations O
demonstrate O
directly O
that O
there O
is O
de O
novo O
synthesis O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
during O
human O
lymphocyte O
activation O
and O
suggest O
that O
this O
process O
is O
hormonally O
regulated O
. O

The O
myeloid O
zinc O
finger O
gene O
, O
MZF O
- O
1 O
, O
regulates O
the O
CD34 O
promoter O
in O
vitro O
. O

MZF O
- O
1 O
is O
a O
C2H2 O
zinc O
finger O
gene O
encoding O
a O
putative B-protein
transcriptional I-protein
regulator I-protein
of O
myeloid O
differentiation O
. O

The O
MZF O
- O
1 O
protein O
contains O
13 O
C2H2 B-protein
zinc I-protein
fingers I-protein
arranged O
in O
bipartite O
DNA B-protein
binding I-protein
domains I-protein
containing O
zinc B-protein
fingers I-protein
through O
4 O
and O
, O
in O
the O
carboxy B-protein
- I-protein
terminus I-protein
, O
5 O
through O
13 O
. O

We O
previously O
identified O
the O
DNA O
consensus O
binding O
site O
recognized O
by O
the O
two O
DNA B-protein
binding I-protein
domains I-protein
. O

To O
assess O
the O
transcription O
regulatory O
function O
of O
MZF O
- O
1 O
, O
the O
full O
- O
length O
MZF O
- O
1 O
coding O
region O
was O
fused O
to O
the O
DNA B-protein
binding I-protein
domain I-protein
of O
the O
yeast B-protein
transactivator I-protein
GAL4 I-protein
. O

The O
expression O
vector O
was O
cotransfected O
with O
the O
chloramphenicol B-protein
acetyl I-protein
transferase I-protein
( O
CAT O
) O
reporter O
gene O
regulated O
by O
the O
thymidine B-protein
kinase I-protein
promoter O
containing O
GAL4 B-protein
DNA O
binding O
sites O
into O
NIH O
3T3 O
, O
293 O
, O
K562 O
, O
and O
Jurkat O
cell O
lines O
. O

MZF O
- O
1 O
represses O
CAT O
reporter O
gene O
expression O
via O
GAL4 B-protein
binding O
sites O
in O
the O
nonhematopoietic O
cell O
lines O
NIH O
3T3 O
and O
293 O
. O

In O
contrast O
, O
MZF O
- O
1 O
activates O
CAT O
reporter O
gene O
expression O
in O
the O
hematopoietic O
cell O
lines O
K562 O
and O
Jurkat O
. O

The O
MZF O
- O
1 O
binding O
sites O
are O
present O
in O
the O
promoters O
of O
several O
genes O
expressed O
during O
myeloid O
differentiation O
, O
including O
the O
CD34 O
promoter O
. O

MZF O
- O
1 O
transcriptional O
regulation O
of O
this O
physiologically O
relevant O
promoter O
was O
assessed O
in O
both O
hematopoietic O
and O
nonhematopoietic O
cell O
lines O
. O

Recombinant B-protein
MZF I-protein
- I-protein
1 I-protein
protein I-protein
specifically O
binds O
to O
the O
consensus O
binding O
sites O
in O
the O
CD34 O
promoter O
in O
mobility O
shift O
assays O
. O

MZF O
- O
1 O
expression O
vectors O
were O
cotransfected O
with O
the O
luciferase O
reporter O
plasmids O
regulated O
by O
the O
CD34 O
promoter O
into O
both O
nonhematopoietic O
and O
hematopoietic O
cell O
lines O
. O

As O
with O
the O
heterologous O
DNA B-protein
binding I-protein
domain I-protein
, O
MZF O
- O
1 O
represses O
reporter O
gene O
expression O
in O
nonhematopoietic O
cell O
lines O
and O
activates O
expression O
in O
hematopoietic O
cell O
lines O
. O

Activation O
of O
CD34 B-protein
expression O
in O
hematopoietic O
cell O
lines O
is O
dependent O
on O
the O
presence O
of O
intact O
MZF O
- O
1 O
binding O
sites O
. O

The O
cell O
type O
- O
specific O
regulation O
of O
the O
CD34 O
promoter O
by O
MZF O
- O
1 O
suggests O
the O
presence O
of O
tissue O
- O
specific O
regulators O
/ O
adapters O
or O
differential O
MZF O
- O
1 O
modifications O
that O
determine O
MZF O
- O
1 O
transcriptional O
regulatory O
function O
. O

The O
murine O
BCL6 O
gene O
is O
induced O
in O
activated O
lymphocytes O
as O
an O
immediate O
early O
gene O
. O

The O
chromosomal O
translocation O
involving O
3q27 O
is O
often O
detected O
in O
human O
B O
- O
cell O
lymphomas O
, O
especially O
diffuse O
lymphomas O
with O
a O
large O
- O
cell O
component O
. O

The O
BCL6 O
gene O
has O
been O
isolated O
from O
the O
chromosomal O
breakpoint O
in O
these O
lymphomas O
. O

Here O
we O
cloned O
the O
murine B-protein
BCL6 I-protein
( O
mBCL6 O
) O
cDNA O
from O
the O
muscle O
cDNA O
library O
using O
the O
human B-protein
BCL6 I-protein
( O
hBCL6 O
) O
cDNA O
as O
a O
probe O
. O

The O
predicted O
amino O
acid O
sequence O
was O
95 O
% O
identical O
to O
that O
of O
hBCL6 B-protein
. O

It O
contains O
six O
repeats O
of O
the O
Kruppel B-protein
- I-protein
like I-protein
zinc I-protein
- I-protein
finger I-protein
motif I-protein
that O
are O
completely O
identical O
to O
those O
of O
hBCL6 B-protein
, O
indicating O
that O
the O
BCL6 O
gene O
is O
well O
conserved O
between O
humans O
and O
mice O
. O

Expression O
of O
the O
mBCL6 O
gene O
was O
ubiquitously O
detected O
in O
adult O
mouse O
tissues O
including O
lymphatic O
organs O
. O

Furthermore O
, O
it O
was O
induced O
in O
lymphocytes O
activated O
with O
phorbol O
ester O
and O
Ca2 O
+ O
ionophore O
within O
30 O
min O
after O
stimulation O
. O

This O
induction O
was O
not O
inhibited O
by O
treatment O
of O
the O
cells O
with O
a O
protein O
synthesis O
inhibitor O
, O
cycloheximide O
. O

These O
results O
suggest O
that O
BCL6 B-protein
plays O
a O
role O
in O
activated O
lymphocytes O
as O
an O
immediate O
early O
gene O
. O

The O
role O
of O
BSAP B-protein
( O
Pax B-protein
- I-protein
5 I-protein
) O
in O
B O
- O
cell O
development O
. O

The O
hierarchy O
of O
transcriptional O
control O
in O
B O
- O
cell O
development O
has O
recently O
been O
analyzed O
by O
targeted O
gene O
inactivation O
in O
the O
mouse O
. O

In O
this O
manner O
, O
the O
paired O
box O
containing O
gene O
Pax O
- O
5 O
, O
encoding O
the O
B B-protein
cell I-protein
specific I-protein
transcription I-protein
factor I-protein
BSAP B-protein
, O
has O
been O
shown O
to O
play O
a O
key O
role O
in O
early O
B O
lymphopoiesis O
. O

Other O
experimental O
strategies O
have O
implicated O
BSAP B-protein
in O
the O
control O
of O
cell O
proliferation O
, O
isotype O
switching O
and O
transcription O
of O
the O
immunoglobulin B-protein
heavy I-protein
- I-protein
chain I-protein
gene O
at O
late O
stages O
of O
B O
- O
cell O
differentiation O
. O

The O
DNA O
- O
binding O
properties O
of O
two B-protein
heat I-protein
shock I-protein
factors I-protein
, O
HSF1 B-protein
and O
HSF3 B-protein
, O
are O
induced O
in O
the O
avian O
erythroblast O
cell O
line O
HD6 O
. O

Avian O
cells O
express O
three O
heat B-protein
shock I-protein
transcription I-protein
factor I-protein
( O
HSF B-protein
) O
genes O
corresponding O
to O
a O
novel B-protein
factor I-protein
, O
HSF3 B-protein
, O
and O
homologs O
of O
mouse O
and O
human O
HSF1 B-protein
and O
HSF2 B-protein
. O

Analysis O
of O
the O
biochemical O
and O
cell O
biological O
properties O
of O
these O
HSFs B-protein
reveals O
that O
HSF3 B-protein
has O
properties O
in O
common O
with O
both O
HSF1 B-protein
and O
HSF2 B-protein
and O
yet O
has O
features O
which O
are O
distinct O
from O
both O
. O

HSF3 B-protein
is O
constitutively O
expressed O
in O
the O
erythroblast O
cell O
line O
HD6 O
, O
the O
lymphoblast O
cell O
line O
MSB O
, O
and O
embryo O
fibroblasts O
, O
and O
yet O
its O
DNA O
- O
binding O
activity O
is O
induced O
only O
upon O
exposure O
of O
HD6 O
cells O
to O
heat O
shock O
. O

Acquisition O
of O
HSF3 B-protein
DNA O
- O
binding O
activity O
in O
HD6 O
cells O
is O
accompanied O
by O
oligomerization O
from O
a O
non B-protein
- I-protein
DNA I-protein
- I-protein
binding I-protein
dimer I-protein
to O
a O
DNA B-protein
- I-protein
binding I-protein
trimer I-protein
, O
whereas O
the O
effect O
of O
heat O
shock O
on O
HSF1 B-protein
is O
oligomerization O
of O
an O
inert B-protein
monomer I-protein
to O
a O
DNA B-protein
- I-protein
binding I-protein
trimer I-protein
. O

Induction O
of O
HSF3 B-protein
DNA O
- O
binding O
activity O
is O
delayed O
compared O
with O
that O
of O
HSF1 B-protein
. O

As O
occurs O
for O
HSF1 B-protein
, O
heat O
shock O
leads O
to O
the O
translocation O
of O
HSF3 B-protein
to O
the O
nucleus O
. O

HSF O
exhibits O
the O
properties O
of O
a O
transcriptional B-protein
activator I-protein
, O
as O
judged O
from O
the O
stimulatory O
activity O
of O
transiently B-protein
overexpressed I-protein
HSF3 I-protein
measured O
by O
using O
a O
heat O
shock O
element O
- O
containing O
reporter O
construct O
and O
as O
independently O
assayed O
by O
the O
activity O
of O
a O
chimeric B-protein
GAL4 I-protein
- I-protein
HSF3 I-protein
protein I-protein
on O
a O
GAL4 B-protein
reporter O
construct O
. O

These O
results O
reveal O
that O
HSF3 B-protein
is O
negatively O
regulated O
in O
avian O
cells O
and O
acquires O
DNA O
- O
binding O
activity O
in O
certain O
cells O
upon O
heat O
shock O
. O

Direct O
demonstration O
of O
NFATp B-protein
dephosphorylation O
and O
nuclear O
localization O
in O
activated O
HT O
- O
2 O
cells O
using O
a O
specific O
NFATp B-protein
polyclonal I-protein
antibody I-protein
. O

Nuclear B-protein
factor I-protein
of I-protein
activated I-protein
T I-protein
cells I-protein
( O
NFAT B-protein
) O
regulates O
transcription O
of O
a O
number O
of O
cytokine B-protein
genes I-protein
, O
and O
NFAT B-protein
DNA O
binding O
activity O
is O
stimulated O
following O
T O
cell O
activation O
. O

Several O
lines O
of O
evidence O
have O
suggested O
that O
NFAT B-protein
is O
a O
substrate O
for O
calcineurin B-protein
, O
a O
serine B-protein
/ I-protein
threonine I-protein
phosphatase I-protein
. O

Using O
a O
polyclonal O
antibody O
to O
murine B-protein
NFATp I-protein
, O
Western O
blot O
analysis O
of O
various O
mouse O
tissues O
demonstrated O
that O
the O
110 O
- O
130 O
- O
kDa O
NFATp B-protein
protein I-protein
was O
highly O
expressed O
in O
thymus O
and O
spleen O
. O

Treatment O
of O
immunoprecipitated O
NFATp B-protein
from O
untreated O
HT O
- O
2 O
cells O
with O
calcineurin B-protein
resulted O
in O
the O
dephosphorylation O
of O
NFATp B-protein
, O
demonstrating O
that O
NFATp B-protein
is O
an O
in O
vitro O
substrate O
for O
calcineurin B-protein
. O

NFATp B-protein
immunoprecipitated O
from O
32P O
- O
labeled O
HT O
- O
2 O
cells O
migrated O
as O
an O
approximately O
120 O
- O
kDa O
protein O
that O
was O
localized O
to O
the O
cytosol O
of O
the O
cells O
. O

Treatment O
of O
the O
cells O
with O
ionomycin O
resulted O
in O
a O
decrease O
in O
the O
molecular O
weight O
of O
NFATp B-protein
and O
a O
loss O
of O
32P O
, O
consistent O
with O
NFATp B-protein
dephosphorylation O
. O

The O
dephosphorylation O
of O
NFATp B-protein
was O
accompanied O
by O
localization O
of O
the O
protein O
to O
the O
nuclear O
fraction O
. O

Both O
of O
these O
events O
were O
blocked O
by O
preincubation O
of O
the O
cells O
with O
FK506 O
, O
a O
calcineurin B-protein
inhibitor O
, O
consistent O
with O
the O
hypothesis O
that O
NFATp B-protein
is O
a O
calcineurin B-protein
substrate O
in O
cells O
. O

Activation O
and O
expression O
of O
the O
nuclear B-protein
factors I-protein
of O
activated O
T O
cells O
, O
NFATp B-protein
and O
NFATc B-protein
, O
in O
human O
natural O
killer O
cells O
: O
regulation O
upon O
CD16 B-protein
ligand O
binding O
. O

The O
putative O
factors O
that O
couple O
the O
signal O
transduction O
from O
surface O
receptors O
to O
the O
activation O
of O
cytokine B-protein
synthesis O
in O
natural O
killer O
( O
NK O
) O
cells O
have O
not O
been O
elucidated O
. O

We O
report O
here O
that O
the O
nuclear B-protein
factor I-protein
of O
activated O
T O
cells O
( O
NFATp B-protein
) O
, O
a O
cyclosporin B-protein
A I-protein
( I-protein
CsA I-protein
) I-protein
- I-protein
sensitive I-protein
factor I-protein
that O
regulates O
the O
transcription O
of O
several O
cytokines B-protein
, O
mediates O
CD16 B-protein
- O
induced O
activation O
of O
cytokine B-protein
genes I-protein
in O
human O
NK O
cells O
. O

CD16 B-protein
( O
Fc B-protein
gamma I-protein
RIIIA I-protein
) O
- O
induced O
expression O
of O
cytokine O
mRNA O
in O
NK O
cells O
occurs O
via O
a O
CsA O
- O
sensitive O
and O
Ca O
( O
2 O
+ O
) O
- O
dependent O
mechanism O
. O

Stimulation O
of O
NK O
cells O
with O
CD16 B-protein
ligands O
induces O
NFAT B-protein
- O
like O
DNA O
binding O
activity O
in O
the O
nuclear O
extracts O
from O
these O
cells O
, O
as O
detected O
in O
electrophoretic O
mobility O
shift O
assays O
. O

This O
occurs O
with O
fast O
kinetics O
after O
stimulation O
, O
via O
a O
CsA O
- O
sensitive O
and O
Ca O
( O
2 O
+ O
) O
- O
dependent O
mechanism O
that O
does O
not O
require O
de O
novo O
protein O
synthesis O
. O

NK B-protein
cell I-protein
NFAT I-protein
is O
present O
in O
the O
cytosol O
of O
nonstimulated O
cells O
, O
migrates O
to O
the O
nucleus O
upon O
stimulation O
, O
and O
can O
associate O
with O
AP B-protein
- I-protein
1 I-protein
. O

Two O
distinct O
molecules O
, O
NFATp B-protein
and O
NFATc B-protein
, O
have O
been O
reported O
to O
mediate O
NFAT B-protein
activity O
. O

The O
results O
of O
supershift O
assays O
using O
NFATp O
- O
and O
NFATc O
- O
specific O
antibodies O
indicate O
that O
NK O
cell O
activation O
early O
after O
CD16 B-protein
ligand O
binding O
involves O
primarily O
, O
if O
not O
exclusively O
, O
NFATp B-protein
, O
and O
Western O
blot O
analysis O
shows O
that O
this O
has O
the O
same O
electrophoretic O
mobility O
( O
approximately O
120 O
kD O
) O
as O
that O
of O
T O
lymphocytes O
. O

NK O
cells O
do O
not O
express O
NFATc B-protein
constitutively O
, O
but O
NFATc B-protein
mRNA O
accumulation O
is O
induced O
in O
these O
cells O
within O
2 O
h O
of O
stimulation O
with O
CD16 O
ligands O
. O

However O
, O
supershift O
assays O
using O
the O
available O
mAb B-protein
recognizing O
the O
T B-protein
cell I-protein
NFATc I-protein
revealed O
no O
detectable O
NFATc B-protein
protein O
in O
nuclear O
and O
cytoplasmic O
extracts O
from O
CD16 O
- O
or O
phorbol O
ester O
- O
stimulated O
cells O
at O
any O
time O
tested O
, O
up O
to O
4 O
h O
. O

These O
results O
provide O
the O
first O
direct O
evidence O
that O
both O
CsA O
- O
sensitive O
transcription B-protein
factors I-protein
, O
NFATp B-protein
and O
NFATc B-protein
, O
are O
expressed O
in O
human O
NK O
cells O
, O
and O
that O
their O
activation O
and O
/ O
or O
expression O
can O
be O
regulated O
in O
primary O
cells O
by O
a O
single O
stimulus O
, O
that O
, O
in O
the O
case O
of O
CD16 O
in O
NK O
cells O
, O
results O
in O
early O
activation O
of O
NFATp B-protein
and O
subsequently O
induced O
expression O
of O
NFATc B-protein
mRNA O
. O

Interleukin O
2 O
signaling O
involves O
the O
phosphorylation O
of O
Stat B-protein
proteins I-protein
. O

One O
of O
the O
most O
important O
cytokines B-protein
involved O
in O
immune O
response O
regulation O
is O
interleukin O
2 O
( O
IL O
- O
2 O
) O
, O
a O
potent O
activator O
of O
the O
proliferation O
and O
function O
of O
T O
lymphocytes O
and O
natural O
killer O
cells O
. O

The O
mechanisms O
by O
which O
the O
effects O
of O
IL B-protein
- I-protein
2 I-protein
are O
propagated O
within O
cells O
are O
not O
understood O
. O

While O
the O
binding O
of O
IL B-protein
- I-protein
2 I-protein
to O
its O
receptor O
was O
recently O
shown O
to O
lead O
to O
the O
activation O
of O
two O
kinases B-protein
, O
Jak B-protein
- I-protein
1 I-protein
and O
Jak B-protein
- I-protein
3 I-protein
, O
subsequent O
steps O
in O
the O
signaling O
pathway O
to O
the O
nucleus O
that O
lead O
to O
the O
activation O
of O
specific O
genes O
had O
not O
been O
characterized O
. O

Since O
many O
cytokines B-protein
that O
activate O
Jak B-protein
kinases I-protein
also O
lead O
to O
the O
tyrosine O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Stat B-protein
family I-protein
of O
transcription B-protein
factors I-protein
, O
the O
ability O
of O
IL B-protein
- I-protein
2 I-protein
to O
trigger O
Stat O
phosphorylation O
was O
examined O
. O

Exposure O
of O
activated O
human O
T O
lymphocytes O
or O
of O
a O
natural O
killer O
cell O
line O
( O
NKL O
) O
to O
IL B-protein
- I-protein
2 I-protein
leads O
to O
the O
phosphorylation O
of O
Stat1 B-protein
alpha I-protein
, O
Stat1 B-protein
beta I-protein
, O
and O
Stat3 B-protein
, O
as O
well O
as O
of O
two O
Stat B-protein
- I-protein
related I-protein
proteins I-protein
, O
p94 B-protein
and O
p95 B-protein
. O

p94 B-protein
and O
p95 B-protein
share O
homology O
with O
Stat1 B-protein
at O
the O
phosphorylation B-protein
site I-protein
and O
in O
the O
Src B-protein
homology I-protein
2 I-protein
( I-protein
SH2 I-protein
) I-protein
domain I-protein
, O
but O
otherwise O
are O
immunologically O
distinct O
from O
Stat1 B-protein
. O

These O
Stat B-protein
proteins I-protein
were O
found O
to O
translocate O
to O
the O
nucleus O
and O
to O
bind O
to O
a O
specific O
DNA O
sequence O
. O

These O
findings O
suggest O
a O
mechanism O
by O
which O
IL B-protein
- I-protein
2 I-protein
binding O
to O
its O
receptor O
may O
activate O
specific O
genes O
involved O
in O
immune O
cell O
function O
. O

Expression O
of O
c O
- O
fos O
correlates O
with O
IFN B-protein
- I-protein
alpha I-protein
responsiveness O
in O
Philadelphia O
chromosome O
positive O
chronic O
myelogenous O
leukemia O
. O

This O
study O
evaluates O
( O
i O
) O
constitutive O
levels O
of O
oncogene O
and O
p53 O
transcripts O
in O
chronic O
phase O
CML O
patients O
and O
( O
ii O
) O
their O
modulations O
subsequent O
to O
in O
vivo O
therapy O
with O
rIFN B-protein
- I-protein
alpha I-protein
2c I-protein
. O

Peripheral O
blood O
mononuclear O
cells O
( O
pbmc O
) O
and O
bone O
marrow O
cells O
of O
26 O
patients O
were O
examined O
for O
c O
- O
fos O
, O
c O
- O
myc O
, O
p53 O
and O
the O
hybrid O
bcr O
/ O
abl O
mRNA O
levels O
. O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c O
- O
fos O
transcript O
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN B-protein
- I-protein
alpha I-protein
therapy O
( O
p O
< O
0 O
. O
01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes O
( O
r O
= O
0 O
. O
6895 O
, O
p O
< O
0 O
. O
01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature O
cells O
( O
r O
= O
- O
0 O
. O
568 O
, O
p O
< O
0 O
. O
01 O
) O
contained O
in O
the O
pbmc O
preparations O
tested O
, O
( O
ii O
) O
constitutive O
mRNA O
levels O
of O
the O
hybrid O
bcr O
/ O
abl O
, O
c O
- O
myc O
and O
p53 O
are O
positively O
correlated O
with O
each O
other O
, O
but O
failed O
to O
relate O
to O
disease O
parameters O
, O
and O
( O
iii O
) O
acute O
and O
chronic O
in O
vivo O
exposure O
to O
IFN B-protein
- I-protein
alpha I-protein
is O
accompanied O
by O
upregulation O
of O
c O
- O
fos O
and O
downregulation O
of O
c O
- O
myc O
mRNA O
levels O
in O
responder O
patients O
. O

Menopause O
is O
associated O
with O
a O
significant O
increase O
in O
blood O
monocyte O
number O
and O
a O
relative O
decrease O
in O
the O
expression O
of O
estrogen B-protein
receptors I-protein
in O
human O
peripheral O
monocytes O
. O

PROBLEM O
: O
The O
clinical O
significance O
of O
the O
differential O
expression O
of O
estrogen B-protein
receptor I-protein
( O
ER B-protein
) O
in O
human O
monocytes O
was O
evaluated O
. O

METHOD O
: O
Two O
color O
flow O
cytometry O
analysis O
was O
used O
on O
peripheral O
blood O
samples O
of O
young O
and O
postmenopausal O
females O
and O
postmenopausal O
females O
treated O
with O
estrogen O
replacement O
therapy O
. O

In O
addition O
, O
the O
monocyte O
and O
lymphocyte O
counts O
and O
the O
blood O
estrogen O
levels O
of O
each O
patient O
were O
determine O
. O

RESULTS O
: O
During O
menopause O
there O
is O
a O
significant O
decrease O
in O
the O
percentage O
of O
ER B-protein
positive O
monocytes O
, O
and O
an O
increase O
in O
blood O
monocyte O
number O
, O
which O
declines O
following O
estrogen O
replacement O
therapy O
to O
values O
of O
the O
young O
. O

CONCLUSIONS O
: O
These O
findings O
suggest O
that O
estrogen O
modulates O
the O
monocyte O
numbers O
and O
its O
effects O
may O
be O
mediated O
through O
the O
ER B-protein
in O
the O
monocytes O
. O

Staphylococcal B-protein
enterotoxins I-protein
modulate O
interleukin B-protein
2 I-protein
receptor I-protein
expression O
and O
ligand O
- O
induced O
tyrosine O
phosphorylation O
of O
the O
Janus B-protein
protein I-protein
- I-protein
tyrosine I-protein
kinase I-protein
3 I-protein
( O
Jak3 B-protein
) O
and O
signal B-protein
transducers I-protein
and I-protein
activators I-protein
of I-protein
transcription I-protein
( O
Stat B-protein
proteins I-protein
) O
. O

Staphylococcal B-protein
enterotoxins I-protein
( O
SE B-protein
) O
stimulate O
T O
cells O
expressing O
the O
appropriate O
variable B-protein
region I-protein
beta I-protein
chain I-protein
of I-protein
( I-protein
V I-protein
beta I-protein
) I-protein
T I-protein
- I-protein
cell I-protein
receptors I-protein
and O
have O
been O
implicated O
in O
the O
pathogenesis O
of O
several O
autoimmune O
diseases O
. O

Depending O
on O
costimulatory O
signals O
, O
SE B-protein
induce O
either O
proliferation O
or O
anergy O
in O
T O
cells O
. O

In O
addition O
, O
SE B-protein
can O
induce O
an O
interleukin B-protein
- I-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
nonresponsive O
state O
and O
apoptosis O
. O

Here O
, O
we O
show O
that O
SE B-protein
induce O
dynamic O
changes O
in O
the O
expression O
of O
and O
signal O
transduction O
through O
the O
IL O
- O
2 O
receptor O
( O
IL O
- O
2R O
) O
beta O
and O
gamma O
chains O
( O
IL B-protein
- I-protein
2R I-protein
beta I-protein
and O
IL B-protein
- I-protein
2R I-protein
gamma I-protein
) O
in O
human O
antigen O
- O
specific O
CD4 O
+ O
T O
- O
cell O
lines O
. O

Thus O
, O
after O
4 O
hr O
of O
exposure O
to O
SEA B-protein
and O
SEB B-protein
, O
the O
expression O
of O
IL B-protein
- I-protein
2R I-protein
beta I-protein
was O
down O
- O
regulated O
, O
IL B-protein
- I-protein
2R I-protein
gamma I-protein
was O
slightly O
up O
- O
regulated O
, O
while O
IL B-protein
- I-protein
2R I-protein
alpha I-protein
remained O
largely O
unaffected O
. O

The O
changes O
in O
the O
composition O
of O
IL B-protein
- I-protein
2Rs I-protein
were O
accompanied O
by O
inhibition O
of O
IL B-protein
- I-protein
2 I-protein
- O
induced O
tyrosine O
phosphorylation O
of O
the O
Janus B-protein
protein I-protein
- I-protein
tyrosine I-protein
kinase I-protein
3 I-protein
( O
Jak3 B-protein
) O
and O
signal B-protein
transducers I-protein
and I-protein
activators I-protein
of I-protein
transcription I-protein
called O
Stat3 B-protein
and O
Stat5 B-protein
. O

In O
parallel O
experiments O
, O
IL B-protein
- I-protein
2 I-protein
- O
driven O
proliferation O
was O
inhibited O
significantly O
. O

After O
16 O
hr O
of O
exposure O
to O
SE B-protein
, O
the O
expression O
of O
IL B-protein
- I-protein
2R I-protein
beta I-protein
remained O
low O
, O
while O
that O
of O
IL2R B-protein
alpha I-protein
and O
IL2R B-protein
gamma I-protein
was O
further O
up O
- O
regulated O
, O
and O
ligand O
- O
induced O
tyrosine O
phosphorylation O
of O
Jak3 B-protein
and O
Stat B-protein
proteins I-protein
was O
partly O
normalized O
. O

Yet O
, O
IL B-protein
- I-protein
2 I-protein
- O
driven O
proliferation O
remained O
profoundly O
inhibited O
, O
suggesting O
that O
signaling O
events O
other O
than O
Jak3 B-protein
/ B-protein
Stat I-protein
activation O
had O
also O
been O
changed O
following O
SE B-protein
stimulation O
. O

In O
conclusion O
, O
our O
data O
suggest O
that O
SE B-protein
can O
modulate O
IL B-protein
- I-protein
2R I-protein
expression O
and O
signal O
transduction O
involving O
the O
Jak B-protein
/ I-protein
Stat I-protein
pathway O
in O
CD4 O
+ O
T O
- O
cell O
lines O
. O

Constitutive O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
, O
enhanced O
granulopoiesis O
, O
and O
neonatal O
lethality O
in O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
- O
deficient O
mice O
. O

Transcription B-protein
factors I-protein
belonging O
to O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
family I-protein
are O
controlled O
by O
inhibitory B-protein
I I-protein
kappa I-protein
B I-protein
proteins I-protein
, O
mainly O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
and O
I B-protein
kappa I-protein
B I-protein
beta I-protein
. O

Apparently O
normal O
at O
birth O
, O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
- O
/ O
- O
mice O
exhibit O
severe O
runting O
, O
skin O
defects O
, O
and O
extensive O
granulopoiesis O
postnatally O
, O
typically O
dying O
by O
8 O
days O
. O

Hematopoietic O
tissues O
from O
these O
mice O
display O
elevated O
levels O
of O
both O
nuclear B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
and O
mRNAs O
of O
some O
, O
but O
not O
all O
, O
genes O
thought O
to O
be O
regulated O
by O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

NF B-protein
- I-protein
kappa I-protein
B I-protein
elevation O
results O
in O
these O
phenotypic O
abnormalities O
because O
mice O
lacking O
both O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
and O
the O
p50 B-protein
subunit I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
show O
a O
dramatically O
delayed O
onset O
of O
abnormalities O
. O

In O
contrast O
to O
hematopoietic O
cells O
, O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
- O
/ O
- O
embryonic O
fibroblasts O
show O
minimal O
constitutive B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
, O
as O
well O
as O
normal O
signal O
- O
dependent O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
that O
is O
concomitant O
with O
I B-protein
kappa I-protein
B I-protein
beta I-protein
degradation O
. O

Our O
results O
indicate O
that O
I O
kappa O
b O
beta O
, O
but O
not O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
, O
is O
required O
for O
the O
signal O
- O
dependent O
activation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
fibroblasts O
. O

However O
, O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
is O
required O
for O
the O
postinduction O
repression O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
fibroblasts O
. O

These O
results O
define O
distinct O
roles O
for O
the O
two O
forms O
of O
I B-protein
kappa I-protein
B I-protein
and O
demonstrate O
the O
necessity O
for O
stringent O
control O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

Interleukin B-protein
- I-protein
7 I-protein
can O
induce O
the O
activation O
of O
Jak B-protein
1 I-protein
, O
Jak B-protein
3 I-protein
and O
STAT B-protein
5 I-protein
proteins I-protein
in O
murine O
T O
cells O
. O

The O
activation O
of O
Janus B-protein
protein I-protein
tyrosine I-protein
kinases I-protein
( O
Jak B-protein
) O
and O
STAT B-protein
( I-protein
signal I-protein
transducer I-protein
and I-protein
activator I-protein
of I-protein
transcription I-protein
) I-protein
proteins I-protein
has O
recently O
been O
linked O
to O
the O
signal O
transduction O
mechanism O
of O
several O
cytokines B-protein
. O

IL B-protein
- I-protein
7 I-protein
was O
observed O
to O
induce O
a O
rapid O
and O
dose O
- O
dependent O
tyrosine O
phosphorylation O
of O
Jak B-protein
1 I-protein
and O
Jak B-protein
3 I-protein
and O
concomitantly O
, O
the O
tyrosine O
phosphorylation O
and O
DNA O
binding O
activity O
of O
multiple O
STAT B-protein
proteins I-protein
. O

The O
STAT B-protein
proteins I-protein
utilized O
by O
IL B-protein
- I-protein
7 I-protein
were O
identical O
to O
those O
induced O
by O
IL B-protein
- I-protein
2 I-protein
and O
could O
be O
identified O
as O
various O
STAT B-protein
5 I-protein
isoforms I-protein
. O

Moreover O
, O
the O
induction O
of O
both O
Jak O
1 O
and O
3 O
, O
and O
STAT B-protein
5 I-protein
activity O
strongly O
correlated O
with O
the O
growth O
- O
promoting O
effects O
of O
IL B-protein
- I-protein
7 I-protein
, O
suggesting O
that O
this O
signal O
transduction O
mechanism O
may O
play O
a O
key O
role O
in O
IL B-protein
- I-protein
7 I-protein
- O
induced O
proliferation O
. O

Cytokine B-protein
- O
modulating O
activity O
of O
tepoxalin O
, O
a O
new O
potential O
antirheumatic O
. O

Tepoxalin O
is O
a O
new O
dual O
cyclooxygenase O
/ O
5 O
- O
lipoxygenase O
anti O
- O
inflammatory O
compound O
currently O
under O
clinical O
investigation O
. O

It O
has O
been O
shown O
to O
possess O
anti O
- O
inflammatory O
activity O
in O
a O
variety O
of O
animal O
models O
and O
more O
recently O
to O
inhibit O
IL B-protein
- I-protein
2 I-protein
induced O
signal O
transduction O
. O

The O
current O
study O
was O
conducted O
to O
evaluate O
the O
cytokine B-protein
modulating O
activity O
of O
tepoxalin O
and O
the O
role O
of O
iron O
in O
these O
effects O
. O

In O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
stimulated O
with O
OKT3 O
/ O
PMA O
, O
tepoxalin O
inhibited O
lymphocyte O
proliferation O
with O
an O
IC50 O
of O
6 O
microM O
. O

Additionally O
, O
it O
inhibited O
the O
production O
of O
LTB4 B-protein
( O
IC50 O
= O
0 O
. O
5 O
microM O
) O
and O
the O
cytokines B-protein
IL B-protein
- I-protein
2 I-protein
, O
IL B-protein
- I-protein
6 I-protein
and O
TNF B-protein
alpha I-protein
( O
IC50 O
= O
10 O
- O
12 O
microM O
) O
. O

Cytotoxicity O
was O
not O
demonstrated O
at O
these O
concentrations O
. O

Add O
- O
back O
experiments O
with O
either O
cytokines B-protein
( O
IL B-protein
- I-protein
2 I-protein
or O
IL B-protein
- I-protein
6 I-protein
) O
, O
LTB4 B-protein
or O
conditioned O
media O
failed O
to O
restore O
the O
proliferative O
response O
in O
the O
presence O
of O
tepoxalin O
. O

However O
, O
the O
concurrent O
addition O
of O
iron O
( O
in O
the O
form O
of O
ferrous O
or O
ferric O
chloride O
and O
other O
iron O
salts O
) O
reversed O
the O
inhibition O
of O
proliferation O
caused O
by O
tepoxalin O
. O

Tepoxalin O
also O
inhibits O
the O
activation O
of O
NF B-protein
kappa I-protein
B I-protein
, O
a O
transcription B-protein
factor I-protein
which O
acts O
on O
several O
cytokine O
genes O
. O

Tepoxalin O
' O
s O
effect O
on O
NF B-protein
kappa I-protein
B I-protein
is O
also O
reversed O
by O
the O
addition O
of O
iron O
salts O
. O

These O
data O
suggest O
that O
the O
action O
of O
tepoxalin O
to O
inhibit O
proliferation O
in O
PBMC O
may O
be O
at O
least O
in O
part O
due O
to O
its O
ability O
to O
reduce O
the O
amount O
of O
available O
iron O
resulting O
in O
decreased O
activation O
of O
NF B-protein
kappa I-protein
B I-protein
and O
subsequent O
inhibition O
of O
cytokine B-protein
production O
. O

N B-protein
- I-protein
and I-protein
C I-protein
- I-protein
terminal I-protein
sequences I-protein
control O
degradation O
of O
MAD3 B-protein
/ I-protein
I I-protein
kappa I-protein
B I-protein
alpha I-protein
in O
response O
to O
inducers O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
. O

The O
proteolytic O
degradation O
of O
the O
inhibitory B-protein
protein I-protein
MAD3 B-protein
/ I-protein
I I-protein
kappa I-protein
B I-protein
alpha I-protein
in O
response O
to O
extracellular O
stimulation O
is O
a O
prerequisite O
step O
in O
the O
activation O
of O
the O
transcription B-protein
factor I-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

Analysis O
of O
the O
expression O
of O
human B-protein
I I-protein
kappa I-protein
B I-protein
alpha I-protein
protein I-protein
in O
stable O
transfectants O
of O
mouse O
70Z O
/ O
3 O
cells O
shows O
that O
, O
as O
for O
the O
endogenous O
murine O
protein O
, O
exogenous O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
is O
degraded O
in O
response O
to O
inducers O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
, O
such O
as O
phorbol O
myristate O
acetate O
or O
lipopolysaccharide O
. O

In O
addition O
, O
pretreatment O
of O
the O
cells O
with O
the O
proteasome B-protein
inhibitor O
N O
- O
Ac O
- O
Leu O
- O
Leu O
- O
norleucinal O
inhibits O
this O
ligand O
- O
induced O
degradation O
and O
, O
in O
agreement O
with O
previous O
studies O
, O
stabilizes O
a O
hyperphosphorylated O
form O
of O
the O
human B-protein
I I-protein
kappa I-protein
B I-protein
alpha I-protein
protein I-protein
. O

By O
expressing O
mutant O
forms O
of O
the O
human O
protein O
in O
this O
cell O
line O
, O
we O
have O
been O
able O
to O
delineate O
the O
sequences O
responsible O
for O
both O
the O
ligand O
- O
induced O
phosphorylation O
and O
the O
degradation O
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
. O

Our O
results O
show O
that O
deletion O
of O
the O
C B-protein
terminus I-protein
of O
the O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
molecule O
up O
to O
amino B-protein
acid I-protein
279 I-protein
abolishes O
constitutive O
but O
not O
ligand O
- O
inducible O
phosphorylation O
and O
inhibits O
ligand O
- O
inducible O
degradation O
. O

Further O
analysis O
reveals O
that O
the O
inducible O
phosphorylation O
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
maps O
to O
two O
serines O
in O
the O
N B-protein
terminus I-protein
of O
the O
protein O
( O
residues O
32 O
and O
36 O
) O
and O
that O
the O
mutation O
of O
either O
residue O
is O
sufficient O
to O
abolish O
ligand O
- O
induced O
degradation O
, O
whereas O
both O
residues O
must O
be O
mutated O
to O
abolish O
inducible O
phosphorylation O
of O
the O
protein O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Microtubules B-protein
mediate O
cellular O
25 O
- O
hydroxyvitamin O
D3 O
trafficking O
and O
the O
genomic O
response O
to O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
in O
normal O
human O
monocytes O
. O

The O
genomic O
actions O
of O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
1 O
, O
25 O
( O
OH O
) O
2D3 O
) O
are O
mediated O
by O
the O
intracellular O
vitamin B-protein
D I-protein
receptor I-protein
( O
VDR B-protein
) O
. O

Although O
immunocytochemistry O
has O
shown O
that O
disruption O
of O
microtubular O
assembly O
prevents O
nuclear O
access O
of O
the O
sterol B-protein
- I-protein
VDR I-protein
complex I-protein
, O
the O
role O
of O
microtubules B-protein
in O
the O
response O
to O
1 O
, O
25 O
( O
OH O
) O
2D3 O
has O
not O
been O
studied O
in O
viable O
cells O
. O

Our O
studies O
examined O
this O
interaction O
in O
normal O
human O
monocytes O
. O

Monocytes O
convert O
25 O
( O
OH O
) O
D3 O
to O
1 O
, O
25 O
( O
OH O
) O
2D3 O
and O
to O
24 O
- O
hydroxylated O
metabolites O
more O
polar O
than O
1 O
, O
25 O
( O
OH O
) O
2D3 O
. O

Microtubule O
disruption O
totally O
abolished O
the O
ability O
of O
exogenous O
1 O
, O
25 O
( O
OH O
) O
2D3 O
to O
suppress O
its O
own O
synthesis O
and O
to O
induce O
24 O
- O
hydroxylase O
mRNA O
and O
activity O
, O
without O
affecting O
either O
total O
1 O
, O
25 O
( O
OH O
) O
2D3 O
uptake O
or O
maximal O
1 O
, O
25 O
( O
OH O
) O
2D3 O
- B-protein
VDR I-protein
binding O
. O

Thus O
, O
intact O
microtubules B-protein
are O
essential O
for O
1 O
, O
25 O
( O
OH O
) O
2D3 O
- O
dependent O
modulation O
of O
gene O
transcription O
. O

Interestingly O
, O
microtubule B-protein
disruption O
also O
decreased O
monocyte O
1 O
, O
25 O
( O
OH O
) O
2D3 O
synthesis O
, O
not O
by O
decreasing O
the O
Vmax O
of O
monocyte B-protein
mitochondrial I-protein
1 I-protein
alpha I-protein
- I-protein
hydroxylase I-protein
but O
through O
an O
increase O
in O
the O
Km O
for O
25 O
( O
OH O
) O
2D3 O
. O

We O
examined O
25 O
( O
OH O
) O
D3 O
transport O
. O

Microtubule O
disruption O
did O
not O
affect O
total O
cellular O
25 O
( O
OH O
) O
D3 O
uptake O
but O
reduced O
its O
intracellular O
trafficking O
to O
the O
mitochondria O
. O

Thus O
, O
microtubules B-protein
participate O
in O
intracellular O
25 O
( O
OH O
) O
D3 O
transport O
, O
and O
their O
integrity O
determines O
normal O
1 O
, O
25 O
( O
OH O
) O
2D3 O
synthesis O
. O

Relationship O
between O
Rap1 B-protein
protein I-protein
phosphorylation O
and O
regulation O
of O
Ca2 O
+ O
transport O
in O
platelets O
: O
a O
new O
approach O
. O

Although O
the O
interrelationship O
between O
the O
two O
messengers O
Ca2 O
+ O
and O
cyclic O
AMP O
in O
platelet O
function O
is O
well O
documented O
, O
its O
mechanism O
of O
action O
still O
remains O
to O
be O
established O
. O

We O
investigated O
here O
the O
question O
of O
the O
regulation O
of O
platelet B-protein
Ca I-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
ATPases I-protein
by O
cyclic O
AMP O
through O
the O
phosphorylation O
of O
the O
Rap1 B-protein
protein I-protein
using O
a O
pathological O
model O
. O

We O
first O
found O
experimental O
conditions O
where O
Ca O
( O
2 O
+ O
) O
- O
transport O
by O
platelet O
membrane O
vesicles O
appeared O
to O
be O
dependent O
on O
the O
phosphorylation O
of O
the O
Rap1 B-protein
protein I-protein
. O

Then O
, O
we O
studied O
platelets O
of O
patients O
with O
congestive O
heart O
failure O
for O
their O
expression O
of O
the O
potential O
97 B-protein
kDa I-protein
Ca I-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
ATPase I-protein
target I-protein
of O
regulation O
through O
the O
Rap1 B-protein
protein I-protein
as O
well O
as O
the O
phosphorylation O
of O
the O
Rap1 B-protein
protein I-protein
using O
the O
catalytic B-protein
subunit I-protein
of O
the O
cyclic B-protein
AMP I-protein
- I-protein
dependent I-protein
protein I-protein
kinase I-protein
( O
C B-protein
. I-protein
Sub I-protein
. I-protein
) O
. O

In O
the O
first O
patients O
studied O
, O
we O
found O
no O
significant O
modification O
in O
the O
expression O
of O
the O
97 B-protein
kDa I-protein
Ca I-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
ATPase I-protein
by O
Western O
blotting O
using O
the O
PL B-protein
/ I-protein
IM I-protein
430 I-protein
monoclonal I-protein
antibody I-protein
which O
specifically O
recognized O
this O
isoform O
. O

In O
contrast O
, O
the O
Rap1 B-protein
protein I-protein
was O
differentially O
phosphorylated O
when O
using O
15 O
micrograms O
/ O
ml O
of O
the O
C O
. O
Sub O
. O

These O
results O
allowed O
us O
to O
use O
these O
pathological O
platelets O
to O
study O
the O
relationship O
between O
the O
expression O
of O
Rap1 B-protein
protein I-protein
and O
the O
regulation O
of O
Ca2 O
+ O
transport O
by O
selecting O
a O
patient O
with O
severe O
heart O
failure O
. O

We O
could O
show O
a O
decrease O
in O
the O
expression O
as O
well O
as O
in O
the O
phosphorylation O
of O
Rap1 B-protein
protein I-protein
and O
demonstrate O
a O
lower O
effect O
of O
C B-protein
. I-protein
Sub I-protein
. I-protein
on O
Ca2 O
+ O
transport O
. O

Finally O
, O
by O
studying O
a O
further O
series O
of O
patients O
, O
we O
could O
confirm O
that O
the O
decrease O
in O
Rap1 B-protein
protein I-protein
expression O
in O
heart O
failure O
, O
whatever O
its O
extent O
, O
was O
variable O
, O
and O
could O
strictly O
correlate O
the O
expression O
of O
Rap1 B-protein
protein I-protein
with O
the O
stimulatory O
effect O
of O
C B-protein
. I-protein
Sub I-protein
. I-protein
on O
Ca2 O
+ O
transport O
. O

Besides O
the O
evidence O
for O
regulation O
of O
the O
expression O
of O
the O
Rap1 B-protein
protein I-protein
in O
platelets O
from O
patients O
with O
heart O
failure O
, O
these O
findings O
constitute O
a O
new O
approach O
in O
favour O
of O
the O
regulation O
of O
platelet O
Ca2 O
+ O
transport O
through O
the O
phosphorylation O
of O
the O
Rap1 B-protein
protein I-protein
. O

An O
IRF B-protein
- I-protein
1 I-protein
- O
dependent O
pathway O
of O
DNA O
damage O
- O
induced O
apoptosis O
in O
mitogen O
- O
activated O
T O
lymphocytes O
. O

Lymphocytes O
are O
particularly O
susceptible O
to O
DNA O
damage O
- O
induced O
apoptosis O
, O
a O
response O
which O
may O
serve O
as O
a O
form O
of O
' O
altruistic O
suicide O
' O
to O
counter O
their O
intrinsic O
high O
potential O
for O
mutation O
and O
clonal O
expansion O
. O

The O
tumour B-protein
suppressor I-protein
p53 I-protein
has O
been O
shown O
to O
regulate O
this O
type O
of O
apoptosis O
in O
thymocytes O
, O
but O
an O
as O
yet O
unknown O
, O
p53 B-protein
- O
independent O
pathway O
( O
s O
) O
appears O
to O
mediate O
the O
same O
event O
in O
mitogen O
- O
activated O
mature O
T O
lymphocytes O
. O

Here O
we O
show O
DNA O
damage O
- O
induced O
apoptosis O
in O
these O
T O
lymphocytes O
is O
dependent O
on O
the O
antioncogenic B-protein
transcription I-protein
factor I-protein
interferon I-protein
regulatory I-protein
factor I-protein
( B-protein
IRF I-protein
) I-protein
- I-protein
1 I-protein
. O

Thus O
two O
different O
anti B-protein
- I-protein
onco I-protein
- I-protein
genic I-protein
transcription I-protein
factors I-protein
, O
p53 B-protein
and O
IRF B-protein
- I-protein
1 I-protein
, O
are O
required O
for O
distinct O
apoptotic O
pathways O
in O
T O
lymphocytes O
. O

We O
also O
show O
that O
mitogen O
induction O
of O
the O
interleukin B-protein
- I-protein
1 I-protein
beta I-protein
converting I-protein
enzyme I-protein
( O
ICE B-protein
) O
gene O
, O
a O
mammalian B-protein
homologue I-protein
of O
the O
Caenorhabditis O
elegans O
cell O
death O
gene O
ced O
- O
3 O
, O
is O
IRF B-protein
- I-protein
1 I-protein
- O
dependent O
. O

Ectopic O
overexpression O
of O
IRF B-protein
- I-protein
1 I-protein
results O
in O
the O
activation O
of O
the O
endogenous O
gene O
for O
ICE B-protein
and O
enhances O
the O
sensitivity O
of O
cells O
to O
radiation O
- O
induced O
apoptosis O
. O

Circadian O
rhythm O
of O
glucocorticoid B-protein
receptors I-protein
in O
human O
peripheral O
leukocytes O
and O
their O
reactivity O
to O
glucocorticoids O
. O

1 O
) O
There O
exists O
a O
CR O
of O
GR B-protein
in O
human O
leukocytes O
, O
PMN O
, O
and O
monocytes O
with O
the O
peak O
values O
from O
0400 O
to O
0800 O
hr O
and O
the O
trough O
values O
between O
2300 O
and O
0000 O
hr O
. O

The O
difference O
between O
them O
was O
significant O
statistically O
. O

2 O
) O
The O
FI O
of O
the O
chemotactic O
migration O
rate O
of O
PMN O
by O
cortisol O
also O
showed O
diurnal O
changes O
which O
were O
synchronous O
with O
that O
of O
GR B-protein
. O

This O
indicates O
that O
the O
CR O
of O
GR B-protein
may O
be O
of O
functional O
significance O
. O

3 O
) O
In O
Cushing O
' O
s O
syndrome O
, O
the O
CR O
of O
GR B-protein
was O
normal O
in O
spite O
of O
the O
fact O
that O
the O
CR O
of O
plasma O
cortisol O
was O
disturbed O
. O

This O
indicates O
the O
independency O
of O
the O
CR O
of O
GR B-protein
from O
that O
of O
cortisol O
. O

4 O
) O
In O
apoplexy O
caused O
by O
brain O
ischemia O
, O
the O
CR O
of O
GR B-protein
was O
abolished O
in O
patients O
with O
basal O
lesions O
but O
preserved O
when O
the O
lesions O
were O
located O
in O
the O
cerebral O
cortex O
. O

These O
results O
strongly O
suggest O
that O
the O
main O
" O
circadian O
pacemaker O
" O
of O
GR B-protein
is O
located O
in O
the O
basal O
brain O
, O
most O
probably O
in O
the O
suprachiasmatic O
nuclei O
as O
has O
been O
suggested O
for O
rodents O
. O

B O
- O
lymphoblastoid O
cell O
lines O
from O
multiple O
sclerosis O
patients O
and O
a O
healthy O
control O
producing O
a O
putative O
new O
human O
retrovirus O
and O
Epstein O
- O
Barr O
virus O
. O

On O
several O
occasions O
we O
have O
observed O
retrovirus O
- O
like O
particles O
( O
RVLPs O
) O
by O
transmission O
electron O
microscopy O
( O
EM O
) O
of O
cultured O
T O
cells O
from O
a O
patient O
with O
MS O
. O

Later O
we O
established O
spontaneously O
formed O
B O
- O
lymphoblastoid O
cell O
lines O
( O
LCLs O
) O
from O
a O
patient O
with O
an O
MS O
- O
like O
disease O
and O
from O
another O
patient O
with O
MS O
who O
had O
a O
reactivated O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
infection O
. O

Both O
LCLs O
were O
found O
by O
EM O
to O
produce O
RVLP O
and O
EBV O
particles O
. O

Reverse O
transcriptase O
( O
RT O
) O
assays O
were O
positive O
in O
purified O
viral O
material O
from O
both O
LCLs O
. O

To O
substantiate O
these O
findings O
we O
initiated O
an O
intensified O
culturing O
procedure O
and O
were O
able O
to O
establish O
LCLs O
from O
5 O
out O
of O
21 O
consecutive O
MS O
patients O
and O
1 O
out O
of O
13 O
consecutive O
healthy O
controls O
. O

All O
LCLs O
were O
found O
to O
produce O
both O
RVLP O
and O
EBV O
particles O
by O
EM O
. O

Whether O
the O
putative O
new O
retrovirus O
( O
es O
) O
and O
EBV O
have O
any O
causal O
relationship O
to O
MS O
is O
still O
not O
known O
, O
but O
the O
findings O
support O
this O
possibility O
. O

Identification O
of O
an O
ionomycin O
/ O
cyclosporin O
A O
- O
responsive O
element O
within O
the O
human O
T O
cell O
receptor O
gamma O
enhancer O
. O

Activation O
through O
the O
Ca2 O
+ O
/ O
calcineurin B-protein
pathway O
is O
essential O
to O
the O
transcription O
of O
many O
cytokine O
genes O
. O

The O
conserved O
cis O
- O
acting O
sequence O
, O
GGAAAA O
, O
and O
transcription B-protein
factors I-protein
binding O
to O
this O
sequence O
are O
involved O
in O
the O
response O
to O
increased O
intracellular O
Ca2 O
+ O
concentrations O
. O

Here O
we O
report O
the O
identification O
and O
importance O
of O
the O
same O
sequence O
in O
a O
non O
- O
cytokine O
gene O
, O
the O
human B-protein
T I-protein
cell I-protein
receptor I-protein
gamma I-protein
( O
TCRG B-protein
) O
enhancer O
. O

Results O
from O
site O
- O
directed O
mutations O
and O
electrophoretic O
mobility O
shift O
assays O
strongly O
suggest O
that O
this O
sequence O
mediates O
the O
ionomycin O
- O
induced O
activation O
of O
the O
TCRG O
enhancer O
. O

Our O
studies O
provide O
an O
explanation O
for O
a O
previous O
observation O
that O
TCRG O
mRNA O
levels O
, O
but O
not O
mRNA O
levels O
for O
T O
cell O
receptor O
alpha O
and O
- O
beta O
, O
are O
increased O
by O
ionomycin O
treatment O
. O

Coexpression O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
/ I-protein
Rel I-protein
and O
Sp1 B-protein
transcription B-protein
factors I-protein
in O
human O
immunodeficiency O
virus O
1 O
- O
induced O
, O
dendritic O
cell O
- O
T O
- O
cell O
syncytia O
. O

Productive O
infection O
of O
T O
cells O
with O
human O
immunodeficiency O
virus O
1 O
( O
HIV O
- O
1 O
) O
typically O
requires O
that O
the O
T O
cells O
be O
stimulated O
with O
antigens O
or O
mitogens O
. O

This O
requirement O
has O
been O
attributed O
to O
the O
activation O
of O
the O
transcription B-protein
factor I-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
which O
synergizes O
with O
the O
constitutive B-protein
transcription I-protein
factor I-protein
Sp1 B-protein
to O
drive O
the O
HIV O
- O
1 O
promoter O
. O

Recently O
, O
we O
have O
found O
that O
vigorous O
replication O
of O
HIV O
- O
1 O
takes O
place O
in O
nonactivated O
memory O
T O
cells O
after O
syncytium O
formation O
with O
dendritic O
cells O
( O
DCs O
) O
. O

These O
syncytia O
lack O
activated O
cells O
as O
determined O
by O
an O
absence O
of O
staining O
for O
Ki O
- O
67 O
cell O
cycle O
antigen O
. O

The O
expression O
and O
activity O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
Sp1 B-protein
were O
, O
therefore O
, O
analyzed O
in O
isolated O
T O
cells O
and O
DCs O
from O
humans O
and O
mice O
. O

We O
have O
used O
immunolabeling O
, O
Western O
blot O
analysis O
, O
and O
electrophoretic O
mobility O
shift O
and O
supershift O
assays O
. O

T O
cells O
lack O
active O
NF B-protein
- I-protein
kappa I-protein
B I-protein
but O
express O
Sp1 B-protein
as O
expected O
. O

DCs O
express O
high O
levels O
of O
all O
known O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
Rel B-protein
proteins I-protein
, O
with O
activity O
residing O
primarily O
within O
RelB B-protein
, O
p50 B-protein
, O
and O
p65 B-protein
. O

However O
, O
DCs O
lack O
Sp1 B-protein
, O
which O
may O
explain O
the O
failure O
of O
HIV O
- O
1 O
to O
replicate O
in O
purified O
DCs O
. O

Coexpression O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
Sp1 B-protein
occurs O
in O
the O
heterologous O
DC O
- O
T O
- O
cell O
syncytia O
that O
are O
induced O
by O
HIV O
- O
1 O
. O

Therefore O
, O
HIV O
- O
1 O
- O
induced O
cell O
fusion O
brings O
together O
factors O
that O
upregulate O
virus O
transcription O
. O

Since O
DCs O
and O
memory O
T O
cells O
frequently O
traffic O
together O
in O
situ O
, O
these O
unusual O
heterologous O
syncytia O
could O
develop O
in O
infected O
individuals O
and O
lead O
to O
chronic O
HIV O
- O
1 O
replication O
without O
ostensible O
immune O
stimulation O
. O

Cupric O
ion O
blocks O
NF B-protein
kappa I-protein
B I-protein
activation O
through O
inhibiting O
the O
signal O
- O
induced O
phosphorylation O
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
. O

A O
transcription B-protein
factor I-protein
NF B-protein
kappa I-protein
B I-protein
, O
which O
regulates O
expression O
of O
various O
cellular O
genes O
involved O
in O
immune O
responses O
and O
viral O
genes O
including O
HIV O
, O
is O
sequestered O
in O
the O
cytoplasm O
as O
a O
complex O
with O
an O
inhibitory B-protein
protein I-protein
I I-protein
kappa I-protein
B I-protein
. O

Various O
extracellular O
signals O
induce O
phosphorylation O
and O
rapid O
degradation O
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
to O
release O
NF B-protein
kappa I-protein
B I-protein
. O

Cu2 O
+ O
was O
found O
to O
inhibit O
the O
activation O
of O
NF B-protein
kappa I-protein
B I-protein
induced O
by O
TNF B-protein
- I-protein
alpha I-protein
, O
TPA O
, O
or O
H2O2 O
. O

Deoxycholate O
treatment O
of O
the O
cytoplasmic O
extract O
prepared O
from O
cells O
stimulated O
by O
TNF B-protein
- I-protein
alpha I-protein
in O
the O
presence O
of O
Cu2 O
+ O
resulted O
in O
the O
release O
of O
NF B-protein
kappa I-protein
B I-protein
from O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
, O
indicating O
that O
Cu2 O
+ O
interferes O
with O
the O
dissociation O
of O
the O
NF B-protein
kappa I-protein
B I-protein
- I-protein
I I-protein
kappa I-protein
B I-protein
complex I-protein
. O

Neither O
phosphorylation O
nor O
degradation O
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
was O
observed O
upon O
TNF B-protein
- I-protein
alpha I-protein
stimulation O
in O
the O
presence O
of O
Cu2 O
+ O
. O

These O
results O
indicate O
that O
Cu2 O
+ O
inhibits O
the O
release O
of O
NF B-protein
kappa I-protein
B I-protein
by O
blockade O
of O
a O
signal O
leading O
to O
the O
phosphorylation O
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
. O

Cloning O
a O
cDNA O
from O
human O
NK O
/ O
T O
cells O
which O
codes O
for O
a O
protein O
with O
high O
proline O
content O
. O

A O
cDNA O
clone O
, O
B4 O
- O
2 O
, O
was O
isolated O
from O
a O
natural O
killer O
( O
NK O
) O
minus O
T O
cell O
subtractive O
library O
. O

The O
B4 O
- O
2 O
clone O
coded O
for O
an O
mRNA O
of O
2061 O
bp O
in O
length O
. O

It O
encodes O
a O
deduced O
327 B-protein
aa I-protein
protein I-protein
with O
a O
calculated O
molecular O
mass O
of O
35 O
. O
2 O
kDa O
. O

Searching O
of O
B4 O
- O
2 O
DNA O
and O
protein O
sequences O
against O
various O
databases O
revealed O
no O
high O
homology O
to O
other O
sequences O
. O

However O
, O
B4 O
- O
2 O
has O
an O
unusually O
high O
proline O
content O
( O
13 O
% O
) O
, O
contains O
a O
putative O
nuclear B-protein
targeting I-protein
sequence I-protein
, O
and O
has O
several O
SPXX B-protein
motifs I-protein
which O
are O
frequently O
found O
in O
gene B-protein
regulatory I-protein
proteins I-protein
. O

One O
of O
the O
stretches O
of O
prolines O
in O
B4 O
- O
2 O
closely O
resembles O
the O
ligand O
for O
proteins O
with O
SH3 B-protein
domains I-protein
. O

Northern O
hybridization O
data O
showed O
that O
B4 O
- O
2 O
is O
not O
a O
lymphoid O
specific O
gene O
and O
is O
expressed O
in O
a O
hepatoma O
cell O
line O
and O
also O
weakly O
transcribed O
or O
absent O
in O
a O
variety O
of O
other O
cells O
. O

A O
polyclonal O
antiserum O
raised O
against O
recombinant B-protein
B4 I-protein
- I-protein
2 I-protein
recognizes O
a O
32 B-protein
- I-protein
34 I-protein
kDa I-protein
protein I-protein
in O
lymphocytes O
. O

Activation O
of O
JAK3 B-protein
, O
but O
not O
JAK1 B-protein
, O
is O
critical O
for O
IL B-protein
- I-protein
2 I-protein
- O
induced O
proliferation O
and O
STAT5 B-protein
recruitment O
by O
a O
COOH B-protein
- I-protein
terminal I-protein
region I-protein
of O
the O
IL B-protein
- I-protein
2 I-protein
receptor I-protein
beta I-protein
- I-protein
chain I-protein
. O

A O
number O
of O
cytokines B-protein
and O
growth B-protein
factors I-protein
use O
the O
JAK B-protein
- B-protein
STAT I-protein
pathway O
to O
signal O
from O
the O
cell O
membrane O
to O
the O
nucleus O
. O

While O
homodimerizing B-protein
cytokine I-protein
receptors I-protein
may O
transmit O
signal O
via O
a O
single O
form O
of O
JAK B-protein
( O
i O
. O
e O
. O
growth B-protein
hormone I-protein
receptors I-protein
) O
, O
several O
multicomponent B-protein
cytokine I-protein
receptors I-protein
have O
been O
shown O
to O
require O
simultaneous O
activation O
of O
pairs O
of O
different O
JAK B-protein
kinases I-protein
( O
i O
. O
e O
. O
interferon B-protein
receptors I-protein
) O
. O

Recent O
evidence O
for O
a O
preferential O
coupling O
of O
JAK3 B-protein
to O
interleukin B-protein
- I-protein
2 I-protein
receptor I-protein
- I-protein
gamma I-protein
( O
IL B-protein
- I-protein
2R I-protein
gamma I-protein
) O
and O
JAK1 B-protein
to O
IL B-protein
- I-protein
2R I-protein
beta I-protein
supports O
the O
concept O
of O
heterotrans O
- O
activation O
of O
JAK1 B-protein
and O
JAK3 B-protein
caused O
by O
IL B-protein
- I-protein
2 I-protein
- O
induced O
heterodimerization O
of O
their O
receptor O
partners O
. O

The O
present O
study O
verified O
the O
ability O
of O
IL B-protein
- I-protein
2 I-protein
to O
cause O
tyrosine O
phosphorylation O
and O
activation O
of O
JAK1 B-protein
and O
JAK3 B-protein
, O
but O
demonstrated O
that O
IL B-protein
- I-protein
2 I-protein
stimulated O
JAK3 B-protein
to O
a O
significantly O
larger O
extent O
than O
JAK1 B-protein
in O
human O
T O
lymphocytes O
and O
the O
YT O
cell O
line O
. O

This O
conclusion O
was O
based O
upon O
several O
independent O
criteria O
, O
including O
more O
vigorous O
tyrosine O
phosphorylation O
of O
JAK3 B-protein
, O
more O
marked O
enzymatic O
activation O
of O
JAK3 B-protein
as O
well O
as O
higher O
abundance O
of O
JAK3 B-protein
in O
activated O
IL B-protein
- I-protein
2 I-protein
receptor I-protein
complexes I-protein
. O

Furthermore O
, O
when O
human B-protein
IL I-protein
- I-protein
2R I-protein
beta I-protein
was O
stably O
expressed O
in O
murine O
BA O
/ O
F3 O
cells O
, O
robust O
IL B-protein
- I-protein
2 I-protein
- O
induced O
proliferation O
and O
JAK3 B-protein
activation O
occurred O
without O
detectable O
involvement O
of O
either O
JAK1 B-protein
, O
JAK2 B-protein
or O
TYK2 B-protein
. O

We O
therefore O
propose O
that O
IL B-protein
- I-protein
2 I-protein
receptor I-protein
signal O
transduction O
does O
not O
depend O
on O
equimolar O
heterodimerization O
of O
JAK1 B-protein
and O
JAK3 B-protein
following O
IL B-protein
- I-protein
2 I-protein
- O
induced O
heterodimerization O
of O
IL B-protein
- I-protein
2R I-protein
beta I-protein
and O
IL B-protein
- I-protein
2R I-protein
gamma I-protein
. O

Nonetheless O
, O
a O
membrane B-protein
- I-protein
proximal I-protein
region I-protein
of O
human O
IL B-protein
- I-protein
2R I-protein
beta I-protein
( O
Asn240 B-protein
- I-protein
Leu335 I-protein
) O
was O
critical O
for O
JAK3 B-protein
activation O
, O
and O
the O
amount O
of O
JAK3 B-protein
present O
in O
activated O
IL B-protein
- I-protein
2 I-protein
receptor I-protein
complexes I-protein
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B-protein
binding O
to O
the O
receptor B-protein
complex I-protein
relies O
on O
both O
IL B-protein
- I-protein
2R I-protein
beta I-protein
and O
IL B-protein
- I-protein
2R I-protein
gamma I-protein
. O

Moreover O
, O
STAT5 B-protein
was O
found O
to O
be O
the O
predominant O
STAT B-protein
transcription I-protein
factor I-protein
used O
by O
IL B-protein
- I-protein
2 I-protein
in O
human O
T O
cells O
, O
and O
specifically O
required O
a O
COOH B-protein
- I-protein
terminal I-protein
region I-protein
of O
IL B-protein
- I-protein
2R I-protein
beta I-protein
( O
Ser386 B-protein
- I-protein
Val525 I-protein
) O
, O
while O
STAT5 B-protein
recruitment O
was O
not O
correlated O
to O
activation O
of O
IL B-protein
- I-protein
2R I-protein
gamma I-protein
or O
JAK3 B-protein
. O

Up O
- O
regulation O
of O
high O
- O
affinity O
dehydroepiandrosterone O
binding O
activity O
by O
dehydroepiandrosterone O
in O
activated O
human O
T O
lymphocytes O
. O

Although O
evidence O
indicates O
that O
dehydroepiandrosterone O
( O
DHEA O
) O
exerts O
direct O
physiological O
effects O
, O
its O
mechanism O
of O
action O
remains O
unknown O
. O

DHEA O
binding O
sites O
were O
examined O
using O
a O
whole O
- O
cell O
binding O
assay O
in O
a O
human O
T O
lymphoid O
cell O
line O
, O
PEER O
, O
revealing O
that O
a O
single O
class O
of O
high O
- O
affinity O
binding O
sites O
for O
DHEA O
( O
dissociation O
constant O
= O
7 O
. O
4 O
+ O
/ O
- O
0 O
. O
53 O
nmol O
/ O
L O
, O
mean O
+ O
/ O
- O
SE O
, O
n O
= O
4 O
) O
was O
greatly O
increased O
when O
treated O
with O
DHEA O
, O
phorbol O
- O
12 O
- O
myristate O
- O
13 O
- O
acetate O
, O
and O
the O
Ca2 O
+ O
ionophore O
A23187 O
. O

Bound O
[ O
3H O
] O
DHEA O
was O
displaced O
sensitively O
by O
DHEA O
and O
secondarily O
by O
dihydrotestosterone O
, O
but O
not O
effectively O
by O
other O
steroids O
, O
including O
DHEA O
sulfate O
. O

These O
results O
not O
only O
indicate O
the O
existence O
of O
a O
DHEA B-protein
receptor I-protein
, O
but O
also O
suggest O
that O
T O
cells O
become O
susceptible O
to O
regulation O
by O
DHEA O
during O
the O
process O
of O
signal O
- O
induced O
activation O
. O

Ubiquitin O
- O
mediated O
processing O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
transcriptional B-protein
activator I-protein
precursor I-protein
p105 B-protein
. O

Reconstitution O
of O
a O
cell O
- O
free O
system O
and O
identification O
of O
the O
ubiquitin B-protein
- I-protein
carrier I-protein
protein I-protein
, O
E2 B-protein
, O
and O
a O
novel O
ubiquitin B-protein
- I-protein
protein I-protein
ligase I-protein
, O
E3 B-protein
, O
involved O
in O
conjugation O
. O

In O
most O
cases O
, O
the O
transcriptional B-protein
factor I-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
is O
a O
heterodimer B-protein
consisting O
of O
two O
subunits O
, O
p50 B-protein
and O
p65 B-protein
, O
which O
are O
encoded O
by O
two O
distinct O
genes O
of O
the O
Rel O
family O
. O

p50 B-protein
is O
translated O
as O
a O
precursor O
of O
105 B-protein
kDa I-protein
. O

The O
C B-protein
- I-protein
terminal I-protein
domain I-protein
of O
the O
precursor O
is O
rapidly O
degraded O
, O
forming O
the O
mature B-protein
p50 I-protein
subunit I-protein
consisted O
of O
the O
N B-protein
- I-protein
terminal I-protein
region I-protein
of O
the O
molecule O
. O

The O
mechanism O
of O
generation O
of O
p50 B-protein
is O
not O
known O
. O

It O
has O
been O
suggested O
that O
the O
ubiquitin B-protein
- B-protein
proteasome I-protein
system O
is O
involved O
in O
the O
process O
; O
however O
, O
the O
specific O
enzymes B-protein
involved O
and O
the O
mechanism O
of O
limited O
proteolysis O
, O
in O
which O
half O
of O
the O
molecule O
is O
spared O
, O
have O
been O
obscure O
. O

Palombella O
and O
colleagues O
( O
Palombella O
, O
V O
. O
J O
. O
, O
Rando O
, O
O O
. O
J O
. O
, O
Goldberg O
, O
A O
. O
L O
. O
, O
and O
Maniatis O
, O
T O
. O
( O
1994 O
) O
Cell O
78 O
, O
773 O
- O
785 O
) O
have O
shown O
that O
ubiquitin B-protein
is O
required O
for O
the O
processing O
in O
a O
cell O
- O
free O
system O
of O
a O
truncated O
, O
artificially O
constructed O
, O
60 B-protein
- I-protein
kDa I-protein
precursor I-protein
. O

They O
have O
also O
shown O
that O
proteasome B-protein
inhibitors O
block O
the O
processing O
both O
in O
vitro O
and O
in O
vivo O
. O

In O
this O
study O
, O
we O
demonstrate O
reconstitution O
of O
a O
cell O
- O
free O
processing O
system O
and O
demonstrate O
directly O
that O
: O
( O
a O
) O
the O
ubiquitin B-protein
- B-protein
proteasome I-protein
system O
is O
involved O
in O
processing O
of O
the O
intact O
p105 B-protein
precursor O
, O
( O
b O
) O
conjugation O
of O
ubiquitin B-protein
to O
the O
precursor O
is O
an O
essential O
intermediate O
step O
in O
the O
processing O
, O
( O
c O
) O
the O
recently O
discovered O
novel O
species O
of O
the O
ubiquitin B-protein
- I-protein
carrier I-protein
protein I-protein
, O
E2 B-protein
- I-protein
F1 I-protein
, O
that O
is O
involved O
in O
the O
conjugation O
and O
degradation O
of O
p53 B-protein
, O
is O
also O
required O
for O
the O
limited O
processing O
of O
the O
p105 B-protein
precursor I-protein
, O
and O
( O
d O
) O
a O
novel O
, O
approximately O
320 B-protein
- I-protein
kDa I-protein
species I-protein
of O
ubiquitin B-protein
- I-protein
protein I-protein
ligase I-protein
, O
is O
involved O
in O
the O
process O
. O

This O
novel O
enzyme O
is O
distinct O
from O
E6 B-protein
- I-protein
AP I-protein
, O
the O
p53 B-protein
- I-protein
conjugating I-protein
ligase I-protein
, O
and O
from O
E3 B-protein
alpha I-protein
, O
the O
" B-protein
N I-protein
- I-protein
end I-protein
rule I-protein
" I-protein
ligase I-protein
. O

Flutamide O
in O
the O
treatment O
of O
hirsutism O
: O
long O
- O
term O
clinical O
effects O
, O
endocrine O
changes O
, O
and O
androgen B-protein
receptor I-protein
behavior O
. O

OBJECTIVE O
: O
To O
investigate O
the O
long O
- O
term O
effects O
of O
treatment O
with O
low O
doses O
of O
flutamide O
on O
clinical O
and O
hormonal O
parameters O
, O
as O
well O
as O
on O
the O
androgen B-protein
receptor I-protein
status O
, O
in O
hirsute O
women O
. O

DESIGN O
: O
Eighteen O
hirsute O
patients O
with O
regular O
menses O
were O
studied O
basally O
and O
during O
treatment O
with O
125 O
mg O
flutamide O
, O
three O
times O
per O
day O
for O
12 O
months O
. O

Barrier O
or O
intrauterine O
contraception O
was O
used O
during O
the O
study O
in O
sexually O
active O
women O
. O

Safety O
parameters O
were O
assessed O
throughout O
the O
study O
. O

Hirsutism O
, O
graded O
by O
the O
modified O
Ferriman O
- O
Gallwey O
score O
, O
and O
hormonal O
parameters O
were O
evaluated O
basally O
and O
at O
4 O
- O
month O
intervals O
during O
treatment O
. O

Gonadotropin O
- O
releasing O
hormone O
and O
ACTH O
stimulation O
tests O
were O
performed O
before O
and O
after O
3 O
to O
4 O
months O
of O
therapy O
. O

In O
addition O
, O
the O
concentration O
of O
androgen B-protein
receptors I-protein
in O
mononuclear O
leukocytes O
was O
measured O
, O
in O
both O
the O
follicular O
and O
luteal O
phases O
of O
the O
menstrual O
cycle O
, O
basally O
and O
after O
4 O
months O
of O
flutamide O
treatment O
. O

RESULTS O
: O
Flutamide O
was O
well O
tolerated O
in O
all O
women O
, O
with O
the O
noticeable O
exception O
of O
one O
patient O
who O
presented O
increased O
serum B-protein
transaminase I-protein
after O
8 O
months O
of O
therapy B-protein
. O

Hirsutism O
markedly O
improved O
in O
all O
women O
during O
the O
treatment O
( O
Ferriman O
- O
Gallwey O
score O
after O
1 O
year O
: O
4 O
. O
1 O
+ O
/ O
- O
0 O
. O
5 O
versus O
14 O
. O
1 O
+ O
/ O
- O
0 O
. O
9 O
) O
. O

A O
reduction O
of O
serum O
androgens O
was O
found O
, O
whereas O
no O
change O
was O
observed O
in O
either O
basal O
or O
GnRH O
- O
stimulated O
gonadotropins O
or O
in O
the O
cortisol O
and O
17 O
alpha O
- O
hydroxyprogesterone O
response O
to O
ACTH O
. O

Cycles O
remained O
ovulatory O
. O

Before O
treatment O
, O
the O
number O
of O
androgen B-protein
receptors I-protein
was O
higher O
in O
the O
luteal O
than O
in O
the O
follicular O
phase O
. O

This O
rhythmic O
differentiation O
disappeared O
after O
the O
patients O
had O
been O
given O
the O
antiandrogen O
drug O
. O

CONCLUSIONS O
: O
Flutamide O
is O
effective O
in O
the O
treatment O
of O
hirsutism O
but O
requires O
constant O
surveillance O
of O
liver O
function O
. O

Androgen O
receptor O
blockade O
might O
be O
potentiated O
by O
a O
reduction O
of O
serum O
androgens O
. O

Flutamide O
affects O
androgen B-protein
receptor I-protein
behavior O
during O
the O
menstrual O
cycle O
. O

The O
meaning O
of O
this O
finding O
remains O
to O
be O
elucidated O
. O

Constitutive O
expression O
of O
HIV B-protein
- I-protein
1 I-protein
tat I-protein
protein I-protein
in O
human O
Jurkat O
T O
cells O
using O
a O
BK O
virus O
vector O
. O

The O
production O
and O
characterization O
of O
Jurkat O
cell O
lines O
that O
constitutively O
express O
functional O
human O
immune O
deficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
tat B-protein
protein I-protein
, O
using O
a O
BK O
virus O
plasmid O
expression O
vector O
and O
HIV O
- O
1 O
tat O
cDNA O
, O
is O
described O
. O

An O
increased O
growth O
rate O
of O
these O
Jurkat O
- O
tat O
cell O
lines O
as O
compared O
with O
control O
cell O
lines O
was O
observed O
. O

A O
PEBP2 B-protein
alpha I-protein
/ I-protein
AML I-protein
- I-protein
1 I-protein
- I-protein
related I-protein
factor I-protein
increases O
osteocalcin O
promoter O
activity O
through O
its O
binding O
to O
an O
osteoblast O
- O
specific O
cis O
- O
acting O
element O
. O

To O
identify O
osteoblast O
- O
specific O
cis O
- O
acting O
elements O
and O
trans B-protein
- I-protein
acting I-protein
factors I-protein
, O
we O
initiated O
an O
analysis O
of O
the O
promoter O
of O
a O
mouse O
osteocalcin O
gene O
, O
an O
osteoblast O
- O
specific O
gene O
. O

In O
this O
promoter O
, O
we O
identified O
two O
osteoblast O
- O
specific O
cis O
- O
acting O
elements O
( O
Ducy O
, O
P O
. O
and O
Karsenty O
, O
G O
. O
( O
1995 O
) O
Mol O
. O
Cell O
. O
Biol O
. O
15 O
, O
1858 O
- O
1869 O
) O
. O

The O
sequence O
of O
one O
of O
these O
elements O
, O
OSE2 O
, O
is O
identical O
to O
the O
DNA O
- O
binding O
site O
of O
the O
PEBP2 B-protein
alpha I-protein
/ I-protein
AML I-protein
- I-protein
1 I-protein
transcription I-protein
factors I-protein
, O
the O
mammalian B-protein
homologues I-protein
of O
the O
Drosophila B-protein
Runt I-protein
protein I-protein
. O

Here O
we O
show O
, O
using O
nuclear O
extracts O
, O
recombinant B-protein
protein I-protein
, O
and O
a O
specific O
antiserum O
against O
AML B-protein
- I-protein
1 I-protein
proteins I-protein
in O
DNA O
- O
binding O
assays O
, O
that O
one O
member O
of O
this O
family O
, O
AML B-protein
- I-protein
1B I-protein
, O
binds O
specifically O
to O
OSE2 O
and O
is O
immunologically O
related O
to O
OSF2 B-protein
, O
the O
factor O
present O
in O
osteoblast O
nuclear O
extracts O
that O
binds O
to O
OSE2 O
. O

By O
DNA O
cotransfection O
experiments O
, O
we O
also O
demonstrate O
that O
AML B-protein
- I-protein
1B I-protein
can O
increase O
the O
activity O
of O
a O
short O
osteocalcin O
promoter O
through O
its O
binding O
to O
OSE2 O
. O

Lastly O
, O
the O
different O
mobilities O
of O
osteoblast B-protein
nuclear I-protein
extract I-protein
- I-protein
DNA I-protein
complexes I-protein
compared O
with O
T B-protein
- I-protein
cell I-protein
nuclear I-protein
extract I-protein
- I-protein
DNA I-protein
complexes I-protein
, O
along O
with O
the O
inability O
of O
OSF2 B-protein
to O
be O
upregulated O
by O
retinoic O
acid O
, O
unlike O
the O
other O
PEBP2 B-protein
alpha I-protein
factors I-protein
, O
suggest O
that O
OSF2 B-protein
is O
a O
new O
member O
of O
this O
family O
of O
transcription B-protein
factors I-protein
. O

Thus O
, O
this O
study O
demonstrates O
that O
AML B-protein
- I-protein
1B I-protein
can O
increase O
gene O
expression O
of O
an O
osteoblast O
- O
specific O
gene O
through O
its O
binding O
to O
an O
osteoblast O
- O
specific O
cis O
- O
acting O
element O
and O
presents O
evidence O
that O
OSF2 B-protein
is O
a O
member O
of O
the O
PEBP2 B-protein
alpha I-protein
/ I-protein
AML I-protein
- I-protein
1 I-protein
family I-protein
of O
transcription B-protein
factors I-protein
. O

Initiation B-protein
binding I-protein
repressor I-protein
, O
a O
factor O
that O
binds O
to O
the O
transcription O
initiation O
site O
of O
the O
histone B-protein
h5 I-protein
gene O
, O
is O
a O
glycosylated B-protein
member I-protein
of O
a O
family O
of O
cell B-protein
growth I-protein
regulators I-protein
[ O
corrected O
] O
[ O
published O
erratum O
appears O
in O
Mol O
Cell O
Biol O
1996 O
Feb O
; O
16 O
( O
2 O
) O
: O
735 O
] O
. O

Initiation B-protein
binding I-protein
repressor I-protein
[ O
corrected O
] O
( O
IBR B-protein
) O
is O
a O
chicken B-protein
erythrocyte I-protein
factor I-protein
( O
apparent O
molecular O
mass O
, O
70 O
to O
73 O
kDa O
) O
that O
binds O
to O
the O
sequences O
spanning O
the O
transcription O
initiation O
site O
of O
the O
histone B-protein
h5 I-protein
gene O
, O
repressing O
its O
transcription O
. O

A O
variety O
of O
other O
cells O
, O
including O
transformed O
erythroid O
precursors O
, O
do O
not O
have O
IBR B-protein
but O
a O
factor O
referred O
to O
as O
IBF B-protein
( O
68 O
to O
70 O
kDa O
) O
that O
recognizes O
the O
same O
IBR B-protein
sites O
. O

We O
have O
cloned O
the O
IBR B-protein
cDNA O
and O
studied O
the O
relationship O
of O
IBR B-protein
and O
IBF B-protein
. O

IBR B-protein
is O
a O
503 B-protein
- I-protein
amino I-protein
- I-protein
acid I-protein
- I-protein
long I-protein
acidic I-protein
protein I-protein
which O
is O
99 O
. O
0 O
% O
identical O
to O
the O
recently O
reported O
human B-protein
NRF I-protein
- I-protein
1 I-protein
/ I-protein
alpha I-protein
- I-protein
Pal I-protein
factor I-protein
and O
highly O
related O
to O
the O
invertebrate O
transcription B-protein
factors I-protein
P3A2 B-protein
and O
erected B-protein
wing I-protein
gene I-protein
product I-protein
( O
EWG B-protein
) O
. O

We O
present O
evidence O
that O
IBR B-protein
and O
IBF B-protein
are O
most O
likely O
identical O
proteins O
, O
differing O
in O
their O
degree O
of O
glycosylation O
. O

We O
have O
analyzed O
several O
molecular O
aspects O
of O
IBR B-protein
/ I-protein
F I-protein
and O
shown O
that O
the O
factor O
associates O
as O
stable O
homodimers B-protein
and O
that O
the O
dimer B-protein
is O
the O
relevant B-protein
DNA I-protein
- I-protein
binding I-protein
species I-protein
. O

The O
evolutionarily O
conserved O
N B-protein
- I-protein
terminal I-protein
half I-protein
of O
IBR B-protein
/ I-protein
F I-protein
harbors O
the O
DNA B-protein
- I-protein
binding I-protein
/ I-protein
dimerization I-protein
domain I-protein
( O
outer O
limits O
, O
127 O
to O
283 O
) O
, O
one O
or O
several O
casein B-protein
kinase I-protein
II I-protein
sites I-protein
( O
37 O
to O
67 O
) O
, O
and O
a O
bipartite B-protein
nuclear I-protein
localization I-protein
signal I-protein
( O
89 O
to O
106 O
) O
which O
appears O
to O
be O
necessary O
for O
nuclear O
targeting O
. O

Binding O
site O
selection O
revealed O
that O
the O
alternating B-protein
RCGCRYGCGY I-protein
consensus I-protein
constitutes O
high O
- O
affinity O
IBR B-protein
/ I-protein
F I-protein
binding O
sites O
and O
that O
the O
direct O
- O
repeat O
palindrome O
TGCGCATGCGCA O
is O
the O
optimal O
site O
. O

A O
survey O
of O
genes O
potentially O
regulated O
by O
this O
family O
of O
factors B-protein
primarily O
revealed O
genes O
involved O
in O
growth O
- O
related O
metabolism O
. O

Triggering O
of O
the O
human O
interleukin O
- O
6 O
gene O
by O
interferon O
- O
gamma O
and O
tumor O
necrosis O
factor O
- O
alpha O
in O
monocytic O
cells O
involves O
cooperation O
between O
interferon B-protein
regulatory I-protein
factor I-protein
- I-protein
1 I-protein
, O
NF B-protein
kappa I-protein
B I-protein
, O
and O
Sp1 B-protein
transcription B-protein
factors I-protein
. O

We O
investigated O
the O
molecular O
basis O
of O
the O
synergistic O
induction O
by O
interferon B-protein
- I-protein
gamma I-protein
( O
IFN B-protein
- I-protein
gamma I-protein
) O
/ O
tumor B-protein
necrosis I-protein
factor I-protein
- I-protein
alpha I-protein
( O
TNF B-protein
- I-protein
alpha I-protein
) O
of O
human O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
gene O
in O
THP O
- O
1 O
monocytic O
cells O
, O
and O
compared O
it O
with O
the O
basis O
of O
this O
induction O
by O
lipopolysaccharide O
( O
LPS O
) O
. O

Functional O
studies O
with O
IL O
- O
6 O
promoter O
demonstrated O
that O
three O
regions O
are O
the O
targets O
of O
the O
IFN B-protein
- I-protein
gamma I-protein
and O
/ O
or O
TNF B-protein
- I-protein
alpha I-protein
action O
, O
whereas O
only O
one O
of O
these O
regions O
seemed O
to O
be O
implicated O
in O
LPS O
activation O
. O

The O
three O
regions O
concerned O
are O
: O
1 O
) O
a O
region O
between O
- O
73 O
and O
- O
36 O
, O
which O
is O
the O
minimal O
element O
inducible O
by O
LPS O
or O
TNF B-protein
- I-protein
alpha I-protein
; O
2 O
) O
an O
element O
located O
between O
- O
181 O
and O
- O
73 O
, O
which O
appeared O
to O
regulate O
the O
response O
to O
IFN B-protein
- I-protein
gamma I-protein
and O
TNF B-protein
- I-protein
alpha I-protein
negatively O
; O
and O
3 O
) O
a O
distal O
element O
upstream O
of O
- O
224 O
, O
which O
was O
inducible O
by O
IFN B-protein
- I-protein
gamma I-protein
alone O
. O

LPS O
signaling O
was O
found O
to O
involve O
NF B-protein
kappa I-protein
B I-protein
activation O
by O
the O
p50 B-protein
/ I-protein
p65 I-protein
heterodimers I-protein
. O

Synergistic O
induction O
of O
the O
IL B-protein
- I-protein
6 I-protein
gene O
by O
IFN B-protein
- I-protein
gamma I-protein
and O
TNF B-protein
- I-protein
alpha I-protein
, O
in O
monocytic O
cells O
, O
involved O
cooperation O
between O
the O
IRF B-protein
- I-protein
1 I-protein
and O
NF B-protein
kappa I-protein
B I-protein
p65 I-protein
homodimers I-protein
with O
concomitant O
removal O
of O
the O
negative O
effect O
of O
the O
retinoblastoma O
control O
element O
present O
in O
the O
IL O
- O
6 O
promoter O
. O

This O
removal O
occurred O
by O
activation O
of O
the O
constitutive B-protein
Sp1 I-protein
factor I-protein
, O
whose O
increased O
binding O
activity O
and O
phosphorylation O
were O
mediated O
by O
IFN B-protein
- I-protein
gamma I-protein
. O

Mutation O
of O
Jak3 B-protein
in O
a O
patient O
with O
SCID O
: O
essential O
role O
of O
Jak3 B-protein
in O
lymphoid O
development O
. O

Males O
with O
X O
- O
linked O
severe O
combined O
immunodeficiency O
( O
XSCID O
) O
have O
defects O
in O
the O
common O
cytokine B-protein
receptor I-protein
gamma I-protein
chain I-protein
( O
gamma B-protein
c I-protein
) O
gene O
that O
encodes O
a O
shared O
, O
essential O
component O
of O
the O
receptors O
of O
interleukin B-protein
- I-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
, O
IL B-protein
- I-protein
4 I-protein
, O
IL B-protein
- I-protein
7 I-protein
, O
IL B-protein
- I-protein
9 I-protein
, O
and O
IL B-protein
- I-protein
15 I-protein
. O

The O
Janus B-protein
family I-protein
tyrosine I-protein
kinase I-protein
Jak3 B-protein
is O
the O
only O
signaling O
molecule O
known O
to O
be O
associated O
with O
gamma B-protein
c I-protein
, O
so O
it O
was O
hypothesized O
that O
defects O
in O
Jak3 B-protein
might O
cause O
an O
XSCID O
- O
like O
phenotype O
. O

A O
girl O
with O
immunological O
features O
indistinguishable O
from O
those O
of O
XSCID O
was O
therefore O
selected O
for O
analysis O
. O

An O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
- O
transformed O
cell O
line O
derived O
from O
her O
lymphocytes O
had O
normal O
gamma B-protein
c I-protein
expression O
but O
lacked O
Jak3 B-protein
protein I-protein
and O
had O
greatly O
diminished O
Jak3 B-protein
messenger O
RNA O
. O

Sequencing O
revealed O
a O
different O
mutation O
on O
each O
allele O
: O
a O
single O
nucleotide O
insertion O
resulting O
in O
a O
frame O
shift O
and O
premature O
termination O
in O
the O
Jak3 B-protein
JH4 I-protein
domain I-protein
and O
a O
nonsense O
mutation O
in O
the O
Jak3 B-protein
JH2 O
domain O
. O

The O
lack O
of O
Jak3 B-protein
expression O
correlated O
with O
impaired O
B O
cell O
signaling O
, O
as O
demonstrated O
by O
the O
inability O
of O
IL B-protein
- I-protein
4 I-protein
to O
activate O
Stat6 B-protein
in O
the O
EBV O
- O
transformed O
cell O
line O
from O
the O
patient O
. O
These O
observations O
indicate O
that O
the O
functions O
of O
gamma B-protein
c I-protein
are O
dependent O
on O
Jak3 B-protein
and O
that O
Jak3 B-protein
is O
essential O
for O
lymphoid O
development O
and O
signaling O
. O

Constitutive O
overexpression O
of O
the O
L B-protein
- I-protein
selectin I-protein
gene O
in O
fresh O
leukemic O
cells O
of O
adult O
T O
- O
cell O
leukemia O
that O
can O
be O
transactivated O
by O
human B-protein
T I-protein
- I-protein
cell I-protein
lymphotropic I-protein
virus I-protein
type I-protein
1 I-protein
Tax I-protein
. O

L B-protein
- I-protein
selectin I-protein
is O
an O
adhesion O
molecule O
of O
the O
selectin O
family O
that O
mediates O
the O
initial O
step O
of O
leukocyte O
adhesion O
to O
vascular O
endothelium O
. O

Upon O
cellular O
activation O
, O
expression O
of O
the O
L B-protein
- I-protein
selectin I-protein
gene O
is O
downregulated O
at O
both O
the O
protein O
and O
mRNA O
levels O
. O

To O
understand O
the O
mechanism O
of O
leukemic O
cell O
infiltration O
into O
organs O
, O
we O
studied O
the O
expression O
and O
regulation O
of O
L B-protein
- I-protein
selectin I-protein
mRNA O
in O
fresh O
leukemic O
cells O
of O
adult O
T O
- O
cell O
leukemia O
( O
ATL O
) O
patients O
and O
investigated O
the O
response O
of O
the O
L B-protein
- I-protein
selectin I-protein
promoter O
to O
human B-protein
T I-protein
- I-protein
cell I-protein
lymphotropic I-protein
virus I-protein
type I-protein
1 I-protein
( I-protein
HTLV I-protein
- I-protein
1 I-protein
) I-protein
Tax I-protein
, O
which O
is O
a O
viral B-protein
transcriptional I-protein
transactivator I-protein
. O

Flow O
cytometry O
showed O
that O
L B-protein
- I-protein
selectin I-protein
was O
expressed O
on O
fresh O
ATL O
cells O
along O
with O
other O
activation B-protein
antigens I-protein
. O

Northern O
blot O
analysis O
showed O
that O
ATL O
cells O
overexpressed O
that O
L B-protein
- I-protein
selectin I-protein
mRNA O
and O
that O
the O
level O
was O
aberrantly O
upregulated O
after O
PMA O
stimulation O
. O

Studies O
using O
in O
situ O
hybridization O
showed O
expression O
of O
the O
L B-protein
- I-protein
selectin I-protein
mRNA O
in O
the O
infiltrating O
leukemic O
cells O
in O
the O
liver O
of O
two O
ATL O
patients O
. O

Intravenous O
injection O
of O
a O
rat O
T O
- O
cell O
line O
that O
overexpresses O
L B-protein
- I-protein
selectin I-protein
showed O
increased O
organ O
infiltration O
. O

The O
induction O
of O
Tax B-protein
expression O
in O
JPX9 O
cells O
resulted O
in O
about O
a O
twofold O
increase O
in O
the O
mRNA O
expression O
levels O
compared O
with O
the O
basal O
level O
. O

Chloramphenicol B-protein
acetyltransferase I-protein
( O
CAT B-protein
) O
assay O
after O
transient O
cotransfection O
showed O
about O
a O
fivefold O
transactivation O
of O
the O
L O
- O
selectin O
promoter O
by O
Tax B-protein
. O

The O
serum O
level O
of O
the O
shed O
form O
of O
L B-protein
- I-protein
selectin I-protein
was O
significantly O
increased O
in O
ATL O
patients O
( O
mean O
+ O
/ O
- O
SD O
, O
4 O
, O
215 O
. O
4 O
+ O
/ O
- O
4 O
, O
111 O
ng O
/ O
mL O
) O
compared O
with O
those O
of O
asymptomatic O
carriers O
and O
healthy O
blood O
donors O
( O
mean O
+ O
/ O
- O
SD O
, O
1 O
, O
148 O
. O
0 O
+ O
/ O
- O
269 O
. O
0 O
ng O
/ O
mL O
and O
991 O
. O
9 O
+ O
/ O
- O
224 O
ng O
/ O
mL O
, O
respectively O
) O
. O

These O
results O
indicated O
that O
ATL O
cells O
constitutively O
overexpress O
the O
L B-protein
- I-protein
selectin I-protein
gene O
that O
can O
be O
transactivated O
by O
HTLV O
- O
1 O
Tax B-protein
. O

The O
overexpression O
of O
L B-protein
- I-protein
selectin I-protein
, O
as O
well O
as O
of O
inflammatory B-protein
cytokines I-protein
, O
by O
ATL O
cells O
may O
provide O
a O
basis O
for O
ATL O
cells O
to O
attach O
the O
vascular O
endothelium O
, O
leading O
to O
transmigration O
and O
organ O
infitration O
. O

Human O
herpesvirus O
6 O
variant O
A O
, O
but O
not O
variant O
B O
, O
infects O
EBV O
- O
positive O
B O
lymphoid O
cells O
, O
activating O
the O
latent O
EBV O
genome O
through O
a O
BZLF B-protein
- I-protein
1 I-protein
- O
dependent O
mechanism O
. O

Human O
herpesvirus O
6 O
, O
a O
predominantly O
T O
lymphotropic O
virus O
, O
has O
been O
recently O
shown O
to O
infect O
some O
EBV O
- O
positive O
B O
cell O
lines O
, O
and O
to O
induce O
in O
them O
the O
activation O
of O
the O
EBV O
lytic O
cycle O
. O

Here O
we O
have O
confirmed O
and O
extended O
such O
observations O
, O
showing O
that O
( O
1 O
) O
this O
phenomenon O
is O
restricted O
to O
the O
variant O
A O
of O
HHV O
- O
6 O
: O
in O
fact O
two O
isolates O
belonging O
to O
the O
HHV O
- O
6 O
variant O
B O
( O
BA92 O
and O
Z29 O
) O
were O
neither O
able O
to O
infect O
any O
B O
cell O
line O
, O
independently O
of O
the O
EBV O
status O
, O
nor O
to O
induce O
the O
EBV O
genome O
expression O
. O

The O
only O
exception O
is O
represented O
by O
the O
P3HR1 O
cells O
, O
in O
which O
, O
however O
, O
the O
infection O
by O
the O
variant O
B O
does O
not O
determine O
induction O
of O
EBV B-protein
antigens I-protein
; O
( O
2 O
) O
the O
presence O
of O
the O
EBV O
genome O
contributes O
to O
the O
susceptibility O
of O
the O
B O
cell O
lines O
to O
HHV O
- O
6 O
infection O
, O
increasing O
the O
binding O
sites O
and O
the O
percentage O
of O
infectable O
cells O
, O
as O
detected O
by O
immunoelectron O
microscopy O
; O
and O
( O
3 O
) O
HHV O
- O
6 O
infected O
T O
cells O
, O
transfected O
with O
plasmids O
bearing O
the O
promoter O
regions O
of O
the O
EBV O
early O
genes O
BZLF1 O
and O
BMRF1 O
, O
show O
a O
strong O
transactivation O
of O
these O
promoters O
. O

Evidence O
for O
normal O
vitamin B-protein
D I-protein
receptor I-protein
messenger O
ribonucleic O
acid O
and O
genotype O
in O
absorptive O
hypercalciuria O
. O

Absorptive O
hypercalciuria O
( O
a O
stone O
- O
forming O
condition O
) O
is O
characterized O
by O
gut O
hyperabsorption O
of O
calcium O
, O
hypercalciuria O
, O
and O
reduced O
bone O
density O
. O

Inasmuch O
as O
these O
features O
implicate O
enhanced O
calcitriol O
action O
in O
gut O
and O
bone O
, O
we O
analyzed O
the O
vitamin B-protein
D I-protein
receptor I-protein
( O
VDR B-protein
) O
gene O
to O
ascertain O
whether O
an O
abnormality O
of O
this O
gene O
marks O
patients O
with O
intestinal O
hyperabsorption O
of O
calcium O
. O

We O
have O
compared O
the O
frequency O
of O
a O
restriction O
fragment O
length O
polymorphism O
( O
Bsm O
I O
) O
associated O
with O
different O
alleles O
of O
the O
VDR B-protein
gene O
in O
a O
group O
of O
33 O
well O
characterized O
absorptive O
hypercalciuric O
patients O
and O
a O
group O
of O
36 O
normal O
race O
- O
and O
age O
- O
matched O
control O
subjects O
. O

There O
was O
no O
difference O
between O
the O
distribution O
of O
the O
VDR B-protein
alleles O
in O
the O
patient O
population O
when O
compared O
with O
the O
normal O
population O
. O

The O
coding O
region O
of O
VDR B-protein
messenger O
RNA O
was O
also O
normal O
, O
as O
determined O
by O
both O
DNA O
sequence O
analysis O
and O
chemical O
mismatch O
cleavage O
analysis O
of O
copy O
DNA O
from O
11 O
index O
absorptive O
hypercalciuric O
patients O
. O

On O
the O
basis O
of O
these O
results O
, O
we O
propose O
that O
the O
enhanced O
intestinal O
calcium O
absorption O
invariably O
seen O
in O
absorptive O
hypercalciuria O
and O
attendant O
symptoms O
of O
this O
disorder O
are O
not O
attributable O
to O
mutations O
of O
the O
VDR B-protein
and O
are O
not O
linked O
to O
a O
common O
VDR B-protein
genotype O
. O

Transcriptional O
regulation O
of O
the O
gene O
encoding O
the O
human B-protein
C I-protein
- I-protein
type I-protein
lectin I-protein
leukocyte I-protein
receptor I-protein
AIM B-protein
/ I-protein
CD69 I-protein
and O
functional O
characterization O
of O
its O
tumor B-protein
necrosis I-protein
factor I-protein
- I-protein
alpha I-protein
- O
responsive O
elements O
. O

The O
human B-protein
activation I-protein
antigen I-protein
CD69 B-protein
is O
a O
member O
of O
the O
C B-protein
- I-protein
type I-protein
animal I-protein
lectin I-protein
superfamily I-protein
that O
functions O
as O
a O
signal B-protein
- I-protein
transmitting I-protein
receptor I-protein
. O

Although O
the O
expression O
of O
CD69 B-protein
can O
be O
induced O
in O
vitro O
on O
cells O
of O
most O
hematopoietic O
lineages O
with O
a O
wide O
variety O
of O
stimuli O
, O
in O
vivo O
it O
is O
mainly O
expressed O
by O
T O
- O
lymphocytes O
located O
in O
the O
inflammatory O
infiltrates O
of O
several O
human O
diseases O
. O

To O
elucidate O
the O
mechanisms O
that O
regulate O
the O
constitutive O
and O
inducible O
expression O
of O
CD69 B-protein
by O
leukocytes O
, O
we O
isolated O
the O
promoter O
region O
of O
the O
CD69 B-protein
gene O
and O
carried O
out O
its O
functional O
characterization O
. O

Sequence O
analysis O
of O
the O
5 O
' O
- O
flanking O
region O
of O
the O
CD69 B-protein
gene O
revealed O
the O
presence O
of O
a O
potential O
TATA O
element O
30 O
base O
pairs O
upstream O
of O
the O
major O
transcription O
initiation O
site O
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B-protein
factors I-protein
( O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
Egr B-protein
- I-protein
1 I-protein
, O
AP B-protein
- I-protein
1 I-protein
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

Transient O
expression O
of O
CD69 B-protein
promoter O
- O
based O
reporter O
gene O
constructs O
in O
K562 O
cells O
indicated O
that O
the O
proximal O
promoter O
region O
spanning O
positions O
- O
78 O
to O
+ O
16 O
contained O
the O
cis O
- O
acting O
sequences O
necessary O
for O
basal O
and O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
- O
inducible O
transcription O
of O
the O
CD69 B-protein
gene O
. O

Removal O
of O
the O
upstream O
sequences O
located O
between O
positions O
- O
78 O
and O
- O
38 O
resulted O
in O
decreased O
promoter O
strength O
and O
abolished O
the O
response O
to O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
. O

We O
also O
found O
that O
tumor B-protein
necrosis I-protein
factor I-protein
- I-protein
alpha I-protein
( O
TNF B-protein
- I-protein
alpha I-protein
) O
is O
capable O
of O
inducing O
the O
surface O
expression O
of O
the O
CD69 B-protein
molecule O
as O
well O
as O
the O
promoter O
activity O
of O
fusion O
plasmids O
that O
contain O
5 O
' O
- O
flanking O
sequences O
of O
the O
CD69 B-protein
gene O
, O
suggesting O
that O
this O
cytokine O
may O
regulate O
in O
vivo O
the O
expression O
of O
CD69 B-protein
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Characterization O
of O
5 O
' O
end O
of O
human O
thromboxane O
receptor O
gene O
. O

Organizational O
analysis O
and O
mapping O
of O
protein O
kinase O
C O
- O
- O
responsive O
elements O
regulating O
expression O
in O
platelets O
. O

Platelet B-protein
thromboxane I-protein
receptors I-protein
are O
acutely O
and O
reversibly O
upregulated O
after O
acute O
myocardial O
infarction O
. O

To O
determine O
if O
platelet O
thromboxane B-protein
receptors I-protein
are O
under O
transcriptional O
control O
, O
we O
isolated O
and O
characterized O
human O
genomic O
DNA O
clones O
containing O
the O
5 O
' O
flanking O
region O
of O
the O
thromboxane O
receptor O
gene O
. O

The O
exon O
- O
intron O
structure O
of O
the O
5 O
' O
portion O
of O
the O
thromboxane B-protein
receptor I-protein
gene O
was O
determined O
initially O
by O
comparing O
the O
nucleotide O
sequence O
of O
the O
5 O
' O
flanking O
genomic O
clone O
with O
that O
of O
a O
novel O
human O
uterine O
thromboxane B-protein
receptor I-protein
cDNA O
that O
extended O
the O
mRNA O
141 O
bp O
further O
upstream O
than O
the O
previously O
identified O
human O
placental O
cDNA O
. O

A O
major O
transcription O
initiation O
site O
was O
located O
in O
three O
human O
tissues O
approximately O
560 O
bp O
upstream O
from O
the O
translation O
initiation O
codon O
and O
380 O
bp O
upstream O
from O
any O
previously O
identified O
transcription O
initiation O
site O
. O

The O
thromboxane B-protein
receptor I-protein
gene O
has O
neither O
a O
TATA O
nor O
a O
CAAT O
consensus O
site O
. O

Promoter O
function O
of O
the O
5 O
' O
flanking O
region O
of O
the O
thromboxane B-protein
receptor I-protein
gene O
was O
evaluated O
by O
transfection O
of O
thromboxane B-protein
receptor I-protein
gene O
promoter O
/ O
chloramphenicol B-protein
acetyltransferase I-protein
( O
CAT B-protein
) O
chimera O
plasmids O
into O
platelet O
- O
like O
K562 O
cells O
. O

Thromboxane O
receptor O
promoter O
activity O
, O
as O
assessed O
by O
CAT B-protein
expression O
, O
was O
relatively O
weak O
but O
was O
significantly O
enhanced O
by O
phorbol O
ester O
treatment O
. O

Functional O
analysis O
of O
5 O
' O
deletion O
constructs O
in O
transfected O
K562 O
cells O
and O
gel O
mobility O
shift O
localized O
the O
major O
phorbol O
ester O
- O
responsive O
motifs O
in O
the O
thromboxane B-protein
receptor I-protein
gene O
promoter O
to O
a O
cluster O
of O
activator B-protein
protein I-protein
- I-protein
2 I-protein
( O
AP B-protein
- I-protein
2 I-protein
) O
binding O
consensus O
sites O
located O
approximately O
1 O
. O
8 O
kb O
5 O
' O
from O
the O
transcription O
initiation O
site O
. O

These O
studies O
are O
the O
first O
to O
determine O
the O
structure O
and O
organization O
of O
the O
5 O
' O
end O
of O
the O
thromboxane B-protein
receptor I-protein
gene O
and O
demonstrate O
that O
thromboxane B-protein
receptor I-protein
gene O
expression O
can O
be O
regulated O
by O
activation O
of O
protein B-protein
kinase I-protein
C I-protein
via O
induction O
of O
an O
AP B-protein
- I-protein
2 I-protein
- I-protein
like I-protein
nuclear I-protein
factor I-protein
binding O
to O
upstream O
promoter O
elements O
. O

These O
findings O
strongly O
suggest O
that O
the O
mechanism O
for O
previously O
described O
upregulation O
of O
platelet B-protein
thromboxane I-protein
receptors I-protein
after O
acute O
myocardial O
infarction O
is O
increased O
thromboxane B-protein
receptor I-protein
gene O
transcription O
in O
platelet O
- O
progenitor O
cells O
. O

Estrogen B-protein
receptor I-protein
concentration O
and O
social O
factors O
as O
predictors O
of O
natural O
killer O
cell O
activity O
in O
early O
- O
stage O
breast O
cancer O
patients O
. O

Confirmation O
of O
a O
model O
. O

Previous O
work O
of O
ours O
has O
demonstrated O
that O
a O
significant O
amount O
of O
natural O
killer O
( O
NK O
) O
activity O
variance O
after O
surgery O
in O
stage O
I O
and O
II O
breast O
cancer O
patients O
could O
be O
accounted O
for O
by O
both O
the O
estrogen B-protein
receptor I-protein
( O
ER B-protein
) O
status O
of O
the O
tumor O
and O
by O
social O
factors O
, O
namely O
, O
perceived O
social O
support O
and O
seeking O
social O
support O
as O
a O
general O
coping O
strategy O
. O

As O
considerable O
evidence O
has O
accumulated O
that O
social O
support O
in O
both O
animal O
and O
human O
populations O
may O
have O
survival O
value O
, O
we O
sought O
to O
test O
the O
reliability O
of O
this O
regression O
model O
, O
using O
coping O
and O
perceived O
support O
factor O
values O
obtained O
at O
3 O
months O
after O
surgery O
to O
account O
for O
concurrent O
follow O
- O
up O
NK O
activity O
in O
this O
serially O
assessed O
group O
of O
patients O
. O

It O
was O
found O
that O
the O
most O
significant O
variable O
predicting O
NK O
activity O
at O
follow O
- O
up O
was O
tumor O
ER B-protein
concentration O
, O
with O
higher O
NK O
activity O
associated O
with O
ER B-protein
- O
status O
. O

In O
addition O
, O
seeking O
social O
support O
as O
a O
coping O
strategy O
, O
as O
well O
as O
the O
perceived O
quality O
of O
support O
, O
also O
entered O
the O
model O
to O
account O
for O
a O
significant O
amount O
of O
NK O
activity O
variance O
( O
multivariate O
F O
= O
5 O
. O
25 O
, O
p O
less O
than O
0 O
. O
001 O
) O
. O

If O
, O
as O
the O
literature O
suggests O
, O
NK O
activity O
is O
relevant O
to O
breast O
cancer O
control O
, O
and O
since O
ER B-protein
- O
tumors O
have O
a O
worse O
prognosis O
, O
we O
suggest O
here O
that O
perhaps O
such O
tumors O
are O
resistant O
to O
control O
by O
NK O
cells O
because O
they O
lack O
the O
ability O
to O
attract O
an O
accumulation O
of O
effector O
cells O
to O
the O
tumor O
site O
, O
or O
because O
blocking O
factors O
at O
the O
site O
of O
the O
tumor O
prevent O
local O
tumor O
control O
at O
the O
site O
of O
action O
. O

The O
finding O
related O
to O
social O
support O
also O
replicates O
results O
from O
an O
independent O
sample O
of O
breast O
cancer O
patients O
. O

This O
finding O
, O
taken O
together O
with O
other O
evidence O
that O
this O
social O
variable O
is O
associated O
with O
longer O
survival O
in O
breast O
cancer O
populations O
, O
underscores O
the O
potential O
importance O
of O
this O
social O
support O
variable O
. O

Our O
findings O
also O
suggest O
one O
possible O
immunological O
variable O
involved O
, O
with O
potential O
clinical O
significance O
, O
for O
this O
patient O
population O
. O

Solution O
structure O
of O
the O
sequence O
- O
specific O
HMG O
box O
of O
the O
lymphocyte B-protein
transcriptional I-protein
activator I-protein
Sox B-protein
- I-protein
4 I-protein
. O

Two O
groups O
of O
HMG B-protein
box I-protein
proteins I-protein
are O
distinguished O
. O

Proteins O
in O
the O
first O
group O
contain O
multiple O
HMG B-protein
boxes I-protein
, O
are O
non O
- O
sequence O
- O
specific O
, O
and O
recognize O
structural O
features O
as O
found O
in O
cruciform O
DNA O
and O
cross O
- O
over O
DNA O
. O

The O
abundant O
chromosomal B-protein
protein I-protein
HMG B-protein
- I-protein
1 I-protein
belongs O
to O
this O
subgroup O
. O

Proteins O
in O
the O
second O
group O
carry O
a O
single B-protein
HMG I-protein
box I-protein
with O
affinity O
for O
the O
minor O
groove O
of O
the O
heptamer O
motif O
AACAAAG O
or O
variations O
thereof O
. O

A O
solution O
structure O
for O
the O
non O
- O
sequence O
- O
specific O
C B-protein
- I-protein
terminal I-protein
HMG I-protein
box I-protein
of O
HMG B-protein
- I-protein
1 I-protein
has O
recently O
been O
proposed O
. O

Now O
, O
we O
report O
the O
solution O
structure O
of O
the O
sequence B-protein
- I-protein
specific I-protein
HMG I-protein
- I-protein
box I-protein
of O
the O
SRY B-protein
- I-protein
related I-protein
protein I-protein
Sox B-protein
- I-protein
4 I-protein
. O

NMR O
analysis O
demonstrated O
the O
presence O
of O
three O
alpha B-protein
- I-protein
helices I-protein
( O
Val10 B-protein
- I-protein
Gln22 I-protein
, O
Glu30 B-protein
- I-protein
Leu41 I-protein
and O
Phe50 B-protein
- I-protein
Tyr65 I-protein
) O
connected O
by O
loop B-protein
regions I-protein
( O
Ser23 B-protein
- I-protein
Ala49 I-protein
and O
Leu42 B-protein
- I-protein
Pro49 I-protein
) O
. O

Helices O
I O
and O
II O
are O
positioned O
in O
an O
antiparallel B-protein
mode I-protein
and O
form O
one O
arm O
of O
the O
HMG B-protein
box I-protein
. O

Helix B-protein
III I-protein
is O
less O
rigid O
, O
makes O
an O
average O
angle O
of O
about O
90 O
degrees O
with O
helices O
I O
and O
II O
, O
and O
constitutes O
the O
other O
arm O
of O
the O
molecule O
. O

As O
in O
HMG1B B-protein
, O
the O
overall O
structure O
of O
the O
Sox B-protein
- I-protein
4 I-protein
HMG B-protein
box I-protein
is O
L O
- O
shaped O
and O
is O
maintained O
by O
a O
cluster O
of O
conserved O
, O
mainly O
aromatic O
residues O
. O

Nuclear B-protein
factor I-protein
- I-protein
IL6 I-protein
activates O
the O
human O
IL O
- O
4 O
promoter O
in O
T O
cells O
. O

Positive O
regulatory O
element O
I O
( O
PRE O
- O
I O
) O
is O
a O
strong O
enhancer O
element O
essential O
for O
expression O
of O
the O
human O
IL O
- O
4 O
gene O
. O

To O
identify O
transcription B-protein
factors I-protein
binding O
to O
PRE O
- O
I O
, O
we O
screened O
a O
cDNA O
expression O
library O
from O
Jurkat O
T O
cells O
and O
isolated O
a O
cDNA O
encoding O
nuclear B-protein
factor I-protein
( B-protein
NF I-protein
) I-protein
- I-protein
IL6 I-protein
( O
also O
known O
as O
C B-protein
/ I-protein
EBP I-protein
beta I-protein
) O
. O

NF O
- O
IL6 O
mRNA O
was O
found O
in O
human O
Jurkat O
T O
cells O
and O
in O
the O
mouse O
Th2 O
clone O
D10 O
, O
but O
not O
in O
Th1 O
clone O
29 O
. O

rNF B-protein
- I-protein
IL6 I-protein
expressed O
in O
bacteria O
was O
shown O
to O
specifically O
bind O
to O
PRE O
- O
I O
. O

PRE O
- O
I O
forms O
multiple B-protein
DNA I-protein
- I-protein
protein I-protein
complexes I-protein
with O
nuclear O
extracts O
from O
Jurkat O
cells O
. O

Some O
of O
these O
complexes O
were O
demonstrated O
to O
contain O
NF B-protein
- I-protein
IL6 I-protein
by O
using O
anti B-protein
- I-protein
C I-protein
/ I-protein
EBP I-protein
beta I-protein
Abs I-protein
. O

Overexpression O
of O
NF B-protein
- I-protein
IL6 I-protein
enhanced O
expression O
of O
the O
chloramphenicol B-protein
acetyl I-protein
transferase I-protein
reporter O
gene O
linked O
to O
the O
PRE B-protein
- I-protein
I I-protein
- I-protein
thymidine I-protein
kinase I-protein
or O
the O
human B-protein
IL I-protein
- I-protein
4 I-protein
promoter O
more O
than O
10 O
- O
fold O
in O
Jurkat O
cells O
. O

Promoter O
deletion O
studies O
revealed O
two O
additional O
NF B-protein
- I-protein
IL6 I-protein
binding O
sites O
located O
at O
positions O
- O
44 O
to O
- O
36 O
( O
C B-protein
/ I-protein
EBP I-protein
proximal I-protein
) O
and O
- O
87 O
to O
- O
79 O
( O
C B-protein
/ I-protein
EBP I-protein
medial I-protein
) O
, O
respectively O
. O

Our O
results O
demonstrate O
that O
NF B-protein
- I-protein
IL6 I-protein
is O
involved O
in O
transcriptional O
activation O
of O
the O
human B-protein
IL I-protein
- I-protein
4 I-protein
promoter O
in O
T O
cells O
. O

Identification O
of O
an O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
- I-protein
associated I-protein
protein I-protein
kinase I-protein
in O
a O
human O
monocytic O
cell O
line O
and O
determination O
of O
its O
phosphorylation B-protein
sites I-protein
on O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
. O

Nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
( O
NF B-protein
- I-protein
kappa I-protein
B I-protein
) O
is O
stored O
in O
the O
cytoplasm O
as O
an O
inactive O
form O
through O
interaction O
with O
I B-protein
kappa I-protein
B I-protein
. O

Stimulation O
of O
cells O
leads O
to O
a O
rapid O
phosphorylation O
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
, O
which O
is O
presumed O
to O
be O
important O
for O
the O
subsequent O
degradation O
. O

We O
have O
recently O
reported O
the O
establishment O
of O
a O
lipopolysaccharide O
( O
LPS O
) O
- O
dependent O
cell O
- O
free O
activation O
system O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
association O
with O
the O
induction O
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
phosphorylation O
. O

In O
this O
study O
, O
we O
have O
identified O
a O
kinase B-protein
in O
cell O
extracts O
from O
the O
LPS O
- O
stimulated O
human O
monocytic O
cell O
line O
, O
THP O
- O
1 O
, O
that O
specifically O
binds O
and O
phosphorylates O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
. O

LPS O
stimulation O
transiently O
enhanced O
the O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
- B-protein
bound I-protein
kinase I-protein
activity O
in O
THP O
- O
1 O
cells O
. O

Mutational O
analyses O
of O
I B-protein
kappa I-protein
B I-protein
alpha O
and O
competition O
experiments O
with O
the O
synthetic O
peptides O
identified O
major O
phosphorylation B-protein
sites I-protein
by O
the O
bound O
kinase B-protein
as O
Ser O
and O
Thr O
residues O
in O
the O
C B-protein
- I-protein
terminal I-protein
acidic I-protein
domain I-protein
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
. O

Moreover O
, O
we O
show O
that O
the O
peptide O
, O
corresponding O
to O
the O
C B-protein
- I-protein
terminal I-protein
acidic I-protein
domain I-protein
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
, O
blocked O
the O
LPS O
- O
induced O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
as O
well O
as O
inducible O
phosphorylation O
of O
endogenous O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
in O
a O
cell O
- O
free O
system O
using O
THP O
- O
1 O
cells O
. O

These O
results O
suggested O
that O
the O
bound B-protein
kinase I-protein
is O
involved O
in O
the O
signaling O
pathway O
of O
LPS O
by O
inducing O
the O
phosphorylation O
of O
the O
C B-protein
- I-protein
terminal I-protein
region I-protein
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
and O
subsequent O
dissociation O
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
complex I-protein
. O

Bik B-protein
, O
a O
novel O
death B-protein
- I-protein
inducing I-protein
protein I-protein
shares O
a O
distinct O
sequence O
motif O
with O
Bcl B-protein
- I-protein
2 I-protein
family I-protein
proteins I-protein
and O
interacts O
with O
viral O
and O
cellular B-protein
survival I-protein
- I-protein
promoting I-protein
proteins I-protein
. O

The O
survival O
- O
promoting O
activity O
of O
the O
Bcl B-protein
- I-protein
2 I-protein
family I-protein
of O
proteins O
appears O
to O
be O
modulated O
by O
interactions O
between O
various O
cellular B-protein
proteins I-protein
. O

We O
have O
identified O
a O
novel O
cellular B-protein
protein I-protein
, O
Bik B-protein
, O
that O
interacts O
with O
the O
cellular B-protein
survival I-protein
- I-protein
promoting I-protein
proteins I-protein
, O
Bcl B-protein
- I-protein
2 I-protein
and O
Bcl B-protein
- I-protein
xL I-protein
, O
as O
well O
as O
the O
viral B-protein
survival I-protein
- I-protein
promoting I-protein
proteins I-protein
, O
Epstein B-protein
Barr I-protein
virus I-protein
- I-protein
BHRF1 I-protein
and O
adenovirus B-protein
E1B I-protein
- I-protein
19 I-protein
kDa I-protein
. O

In O
transient O
transfection O
assays O
, O
Bik B-protein
promotes O
cell O
death O
in O
a O
manner O
similar O
to O
the O
death B-protein
- I-protein
promoting I-protein
members I-protein
of O
the O
Bcl B-protein
- I-protein
2 I-protein
family I-protein
, O
Bax B-protein
and O
Bak B-protein
. O

This O
death O
- O
promoting O
activity O
of O
Bik B-protein
can O
be O
suppressed O
by O
coexpression O
of O
Bcl B-protein
- I-protein
2 I-protein
, O
Bcl B-protein
- I-protein
XL I-protein
, O
EBV B-protein
- I-protein
BHRF1 I-protein
and O
E1B B-protein
- I-protein
19 I-protein
kDa I-protein
proteins O
suggesting O
that O
Bik B-protein
may O
be O
a O
common O
target O
for O
both O
cellular O
and O
viral O
anti O
- O
apoptotic O
proteins O
. O

While O
Bik B-protein
does O
not O
show O
overt O
homology O
to O
the O
BH1 B-protein
and O
BH2 B-protein
conserved O
domains O
characteristic O
of O
the O
Bcl B-protein
- I-protein
2 I-protein
family I-protein
, O
it O
does O
share O
a O
9 O
amino B-protein
acid I-protein
domain I-protein
( O
BH3 B-protein
) O
with O
Bax B-protein
and O
Bak B-protein
which O
may O
be O
a O
critical O
determinant O
for O
the O
death O
- O
promoting O
activity O
of O
these O
proteins O
. O

The O
human O
TCF O
- O
1 O
gene O
encodes O
a O
nuclear B-protein
DNA I-protein
- I-protein
binding I-protein
protein I-protein
uniquely O
expressed O
in O
normal O
and O
neoplastic O
T O
- O
lineage O
lymphocytes O
. O

The O
TCF B-protein
- I-protein
1 I-protein
gene O
encodes O
a O
putative B-protein
transcription I-protein
factor I-protein
with O
affinity O
for O
a O
sequence O
motif O
occurring O
in O
a O
number O
of O
T O
- O
cell O
enhancers O
. O

TCF B-protein
- I-protein
1 I-protein
mRNA O
was O
originally O
found O
to O
be O
expressed O
in O
a O
T O
cell O
- O
specific O
fashion O
within O
a O
set O
of O
human O
and O
mouse O
cell O
lines O
. O

In O
contrast O
, O
expression O
reportedly O
occurs O
in O
multiple O
nonlymphoid O
tissues O
during O
murine O
embryogenesis O
. O

We O
have O
now O
raised O
a O
monoclonal B-protein
antibody I-protein
to O
document O
expression O
and O
biochemistry O
of O
the O
human B-protein
TCF I-protein
- I-protein
1 I-protein
protein I-protein
. O

As O
expected O
, O
the O
TCF B-protein
- I-protein
1 I-protein
protein I-protein
was O
detectable O
only O
in O
cell O
lines O
of O
T O
lineage O
. O

Its O
expression O
was O
always O
restricted O
to O
the O
nucleus O
. O

Immunohistochemistry O
on O
a O
panel O
of O
human O
tissues O
revealed O
that O
the O
TCF B-protein
- I-protein
1 I-protein
protein I-protein
was O
found O
exclusively O
in O
thymocytes O
and O
in O
CD3 O
+ O
T O
cells O
in O
peripheral O
lymphoid O
tissues O
. O

Western O
blotting O
yielded O
a O
set O
of O
bands O
ranging O
from O
25 O
kD O
to O
55 O
kD O
, O
resulting O
from O
extensive O
alternative O
splicing O
. O

The O
TCF B-protein
- I-protein
1 I-protein
protein O
was O
detectable O
in O
all O
samples O
of O
a O
set O
of O
22 O
T O
- O
cell O
malignancies O
of O
various O
stages O
of O
maturation O
, O
but O
was O
absent O
from O
a O
large O
number O
of O
other O
hematologic O
neoplasms O
. O

These O
observations O
imply O
a O
T O
cell O
- O
specific O
function O
for O
TCF B-protein
- I-protein
1 I-protein
, O
a O
notion O
corroborated O
by O
recent O
observations O
on O
Tcf O
- O
1 O
knock O
- O
out O
mice O
. O

In O
addition O
, O
these O
results O
indicate O
that O
nuclear O
TCF B-protein
- I-protein
1 I-protein
expression O
can O
serve O
as O
a O
pan O
- O
T O
- O
lineage O
marker O
in O
the O
diagnosis O
of O
lymphoid O
malignancies O
. O

Cross O
- O
linking O
of O
Fc B-protein
gamma I-protein
receptors I-protein
activates O
HIV O
- O
1 O
long O
terminal O
repeat O
- O
driven O
transcription O
in O
human O
monocytes O
. O

Elevation O
of O
the O
levels O
of O
circulating B-protein
immune I-protein
complexes I-protein
frequently O
accompanies O
HIV O
- O
1 O
infection O
and O
is O
a O
prognostic O
indicator O
of O
clinical O
progression O
from O
asymptomatic O
infection O
to O
AIDS O
. O

Here O
we O
report O
that O
cross O
- O
linking O
of O
Fc B-protein
gamma I-protein
RI I-protein
or O
Fc B-protein
gamma I-protein
RII I-protein
by O
adherent B-protein
human I-protein
IgG I-protein
or O
by O
specific O
anti B-protein
- I-protein
Fc I-protein
gamma I-protein
R I-protein
mAb I-protein
activates O
HIV O
- O
1 O
gene O
expression O
in O
the O
human O
monocytic O
cell O
line O
BF24 O
and O
increased O
HIV O
RNA O
expression O
in O
monocytes O
from O
HIV O
infected O
patients O
as O
assayed O
by O
reverse O
transcription O
- O
PCR O
. O

In O
THP O
- O
1 O
cells O
, O
Fc B-protein
gamma I-protein
R I-protein
cross O
- O
linking O
induced O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
which O
is O
known O
to O
bind O
to O
the O
regulatory O
region O
of O
the O
long O
terminal O
repeat O
( O
LTR O
) O
of O
HIV O
- O
1 O
and O
to O
activate O
HIV O
- O
1 O
transcription O
. O
Anti B-protein
- I-protein
TNF I-protein
- I-protein
alpha I-protein
antibody I-protein
but O
not O
anti B-protein
- I-protein
IL I-protein
- I-protein
1 I-protein
beta I-protein
antibody I-protein
strongly O
inhibited O
both O
the O
induction O
of O
HIV O
- O
1 O
- O
LTR O
- O
driven O
transcription O
and O
the O
induction O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
by O
Fc B-protein
gamma I-protein
R I-protein
cross O
- O
linking O
. O

These O
results O
indicate O
that O
Fc B-protein
gamma I-protein
R I-protein
can O
mediate O
a O
TNF B-protein
- I-protein
alpha I-protein
- O
dependent O
induction O
of O
HIV O
- O
1 O
gene O
transcription O
and O
suggest O
that O
immune B-protein
complexes I-protein
may O
contribute O
to O
the O
pathophysiology O
of O
HIV O
- O
1 O
infection O
by O
augmenting O
viral O
replication O
in O
monocytes O
. O

Signalling O
via O
CD28 B-protein
of O
human O
naive O
neonatal O
T O
lymphocytes O
. O

Accessory O
molecules O
play O
a O
crucial O
role O
in O
the O
development O
of O
the O
T O
cell O
response O
to O
antigenic O
challenge O
. O

We O
have O
examined O
the O
role O
of O
CD28 B-protein
in O
modulating O
the O
' O
naive O
' O
neonatal O
T O
cell O
response O
to O
anti B-protein
- I-protein
CD2 I-protein
- O
mediated O
activation O
. O

To O
compare O
the O
role O
of O
CD28 B-protein
, O
neonatal O
and O
adult O
T O
cells O
were O
stimulated O
with O
a O
pair O
of O
mitogenic B-protein
anti I-protein
- I-protein
CD2 I-protein
antibodies I-protein
in O
the O
presence O
or O
absence O
of O
anti B-protein
- I-protein
CD28 I-protein
MoAb I-protein
. O

With O
anti B-protein
- I-protein
CD2 I-protein
alone O
, O
neonatal O
T O
cells O
proliferated O
slightly O
but O
produced O
no O
detectable O
IL B-protein
- I-protein
2 I-protein
, O
whereas O
adult O
T O
cells O
proliferated O
vigorously O
, O
with O
significant O
IL B-protein
- I-protein
2 I-protein
production O
. O

Costimulation O
with O
anti B-protein
- I-protein
CD28 I-protein
MoAb I-protein
greatly O
enhanced O
the O
proliferative O
response O
of O
neonatal O
T O
cells O
to O
levels O
equivalent O
to O
those O
of O
adult O
T O
cells O
, O
whereas O
adult O
T O
cells O
showed O
only O
slight O
increases O
. O

Although O
IL B-protein
- I-protein
2 I-protein
secretion O
was O
increased O
in O
the O
presence O
of O
anti B-protein
- I-protein
CD28 I-protein
MoAb I-protein
, O
neonatal O
T O
cell O
IL B-protein
- I-protein
2 I-protein
production O
remained O
lower O
than O
in O
adults O
. O

In O
contrast O
, O
enhancement O
of O
IL B-protein
- I-protein
2 I-protein
mRNA O
expression O
in O
neonates O
was O
similar O
to O
adult O
levels O
. O

Anti O
- O
CD28 B-protein
MoAb I-protein
costimulation O
increased O
NF B-protein
kappa I-protein
B I-protein
levels O
in O
neonates O
, O
albeit O
to O
levels O
lower O
than O
that O
of O
adults O
. O

The O
cellular O
mechanism O
governing O
the O
diminished O
proliferative O
response O
of O
neonatal O
T O
lymphocytes O
to O
anti B-protein
- I-protein
CD2 I-protein
may O
therefore O
be O
due O
to O
decreased O
NF B-protein
kappa I-protein
B I-protein
induction O
, O
reduced O
IL B-protein
- I-protein
2 I-protein
mRNA O
expression O
and O
deficient O
IL B-protein
- I-protein
2 I-protein
production O
. O

Although O
anti B-protein
- I-protein
CD28 I-protein
MoAb I-protein
costimulation O
enhances O
all O
of O
the O
above O
signals O
, O
NF O
kappa O
B O
and O
IL O
- O
2 O
levels O
remain O
lower O
than O
in O
adults O
, O
suggesting O
the O
need O
for O
further O
activation O
requirements O
in O
the O
neonate O
. O

TCL1 O
oncogene O
activation O
in O
preleukemic O
T O
cells O
from O
a O
case O
of O
ataxia O
- O
telangiectasia O
. O

The O
TCL1 O
oncogene O
on O
human O
chromosome O
14q32 O
. O
1 O
is O
involved O
in O
chromosome O
translocations O
[ O
t O
( O
14 O
; O
14 O
) O
( O
q11 O
; O
q32 O
. O
1 O
) O
and O
t O
( O
7 O
; O
14 O
) O
( O
q35 O
; O
q32 O
. O
1 O
) O
] O
and O
inversions O
[ O
inv14 O
( O
q11 O
; O
q32 O
. O
1 O
) O
] O
with O
TCR O
alpha O
/ O
beta O
loci O
in O
T O
- O
cell O
leukemias O
, O
such O
as O
T O
- O
prolymphocytic O
( O
T O
- O
PLL O
) O
. O

It O
is O
also O
involved O
in O
T O
- O
acute O
and O
- O
chronic O
leukemias O
arising O
in O
cases O
of O
ataxia O
- O
telangiectasia O
( O
AT O
) O
, O
an O
immunodeficiency O
syndrome O
. O

Similar O
chromosomal O
rearrangements O
occur O
also O
in O
the O
clonally O
expanded O
T O
cells O
in O
AT O
patients O
before O
the O
appearance O
of O
the O
overt O
leukemia O
. O

We O
have O
analyzed O
the O
expression O
of O
TCL1 O
mRNA O
and O
protein B-protein
in O
peripheral O
blood O
lymphocytes O
( O
PBLs O
) O
from O
four O
AT O
cases O
and O
from O
healthy O
controls O
. O

We O
found O
that O
the O
TCL1 O
gene O
was O
overexpressed O
in O
the O
PBLs O
of O
an O
AT O
patient O
with O
a O
large O
clonal O
T O
- O
cell O
population O
exhibiting O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
but O
not O
in O
the O
lymphocytes O
of O
the O
other O
cases O
. O

Fluorescence O
in O
situ O
hybridization O
of O
the O
TCL1 O
genomic O
locus O
to O
lymphocyte O
metaphases O
from O
the O
AT O
patient O
with O
the O
T O
- O
cell O
clonal O
expansion O
showed O
that O
the O
breakpoint O
of O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
lies O
within O
the O
TCL1 O
locus O
and O
is O
accompanied O
by O
an O
inverted O
duplication O
of O
the O
distal O
part O
of O
chromosome O
14 O
. O

These O
data O
indicate O
that O
TCL1 O
is O
activated O
in O
preleukemic O
clonal O
cells O
as O
a O
consequence O
of O
chromosome O
translocation O
involving O
sequences O
from O
the O
TCR O
locus O
at O
14q11 O
. O

Deregulation O
of O
TCL1 O
is O
the O
first O
event O
in O
the O
initiation O
of O
malignancy O
in O
these O
types O
of O
leukemias O
and O
represents O
a O
potential O
tool O
for O
clinical O
evaluation O
. O

C B-protein
/ I-protein
EBP I-protein
proteins I-protein
activate O
transcription O
from O
the O
human O
immunodeficiency O
virus O
type O
1 O
long O
terminal O
repeat O
in O
macrophages O
/ O
monocytes O
. O

Three O
binding O
sites O
for O
C B-protein
/ I-protein
EBP I-protein
proteins I-protein
are O
found O
in O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
long O
terminal O
repeat O
( O
LTR O
) O
( O
V O
. O
M O
. O
Tesmer O
, O
A O
. O
Rajadhyaksha O
, O
J O
. O
Babin O
, O
and O
M O
. O
Bina O
, O
Proc O
. O
Natl O
. O
Acad O
. O
Sci O
. O
USA O
90 O
: O
7298 O
- O
7302 O
, O
1993 O
) O
. O

We O
have O
determined O
the O
functional O
role O
of O
C B-protein
/ I-protein
EBP I-protein
proteins I-protein
and O
C O
/ O
EBP O
sites O
in O
regulating O
transcription O
from O
the O
HIV O
- O
1 O
LTR O
in O
monocytes O
/ O
macrophages O
. O

Inhibition O
of O
endogenous B-protein
C I-protein
/ I-protein
EBP I-protein
proteins I-protein
, O
using O
either O
an O
excess O
of O
C O
/ O
EBP O
binding O
sites O
or O
a O
trans O
- O
dominant O
negative O
inhibitor O
, O
demonstrated O
that O
C B-protein
/ I-protein
EBP I-protein
proteins I-protein
are O
required O
for O
basal O
and O
activated O
levels O
of O
HIV O
- O
1 O
LTR O
transcription O
in O
the O
promonocytic O
cell O
line O
U937 O
. O

Northern O
( O
RNA O
) O
blots O
and O
binding O
assays O
showed O
that O
NF B-protein
- I-protein
IL6 I-protein
is O
the O
only O
known O
C B-protein
/ I-protein
EBP I-protein
family I-protein
member I-protein
which O
is O
increased O
when O
U937 O
cells O
are O
activated O
. O

Mutational O
analyses O
of O
the O
HIV O
- O
1 O
LTR O
showed O
that O
one O
C O
/ O
EBP O
site O
is O
required O
for O
normal O
LTR O
transcription O
both O
before O
and O
after O
cellular O
activation O
and O
that O
the O
two O
3 O
' O
C O
/ O
EBP O
sites O
are O
functionally O
equivalent O
. O

However O
, O
transcription O
from O
crippled O
HIV O
- O
1 O
LTRs O
lacking O
C O
/ O
EBP O
sites O
can O
still O
be O
induced O
following O
activation O
of O
U937 O
cells O
. O

Several O
models O
are O
suggested O
for O
how O
elevated O
NF B-protein
- I-protein
IL6 I-protein
may O
participate O
in O
an O
autostimulatory O
loop O
involving O
HIV O
infection O
, O
macrophage O
activation O
, O
cytokine B-protein
expression O
, O
and O
HIV O
replication O
. O

Human O
immunodeficiency O
virus O
type O
- O
2 O
gene O
expression O
: O
two O
enhancers O
and O
their O
activation O
by O
T O
- O
cell O
activators O
. O

The O
human O
immunodeficiency O
viruses O
( O
HIVs O
) O
may O
include O
a O
spectrum O
of O
retroviruses O
with O
varying O
potential O
to O
infect O
their O
host O
, O
undergo O
long O
periods O
of O
latent O
infection O
, O
and O
induce O
pathology O
. O

Since O
expression O
of O
the O
viruses O
is O
in O
large O
part O
regulated O
by O
the O
sequence O
elements O
in O
their O
long O
terminal O
repeats O
( O
LTRs O
) O
, O
this O
study O
was O
directed O
to O
an O
analysis O
of O
the O
regulatory O
elements O
in O
the O
HIV O
- O
2 O
LTR O
. O

The O
HIV O
- O
2 O
LTR O
was O
found O
to O
contain O
two O
enhancers O
. O

One O
of O
these O
enhancers O
is O
, O
in O
part O
, O
identical O
to O
the O
HIV O
- O
1 O
enhancer O
. O

This O
enhancer O
in O
HIV O
- O
1 O
is O
the O
T O
- O
cell O
activation O
response O
element O
; O
in O
HIV O
- O
2 O
, O
however O
, O
it O
is O
the O
second O
enhancer O
that O
is O
mainly O
responsible O
for O
activation O
in O
response O
to O
T O
- O
cell O
activators O
. O

The O
second O
enhancer O
interacts O
with O
two O
nuclear B-protein
binding I-protein
proteins I-protein
( O
85 O
kD O
and O
27 O
kD O
mobility O
) O
that O
appear O
to O
be O
required O
for O
optimal O
enhancer O
function O
and O
activation O
. O

Observations O
such O
as O
these O
encourage O
the O
speculation O
that O
there O
may O
be O
subtle O
differences O
in O
the O
regulation O
of O
HIV O
- O
1 O
and O
HIV O
- O
2 O
expression O
that O
may O
be O
relevant O
to O
the O
possible O
longer O
latency O
and O
reduced O
pathogenicity O
of O
HIV O
- O
2 O
. O

NF B-protein
- I-protein
M I-protein
( O
chicken B-protein
C I-protein
/ I-protein
EBP I-protein
beta I-protein
) O
induces O
eosinophilic O
differentiation O
and O
apoptosis O
in O
a O
hematopoietic O
progenitor O
cell O
line O
. O

CAAT B-protein
/ I-protein
enhancer I-protein
binding I-protein
proteins I-protein
( O
C B-protein
/ I-protein
EBPs I-protein
) O
are O
transcriptional O
activators O
implicated O
in O
the O
differentiation O
processes O
of O
various O
cell O
lineages O
. O

We O
have O
shown O
earlier O
that O
NF B-protein
- I-protein
M I-protein
, O
the O
chicken B-protein
homolog I-protein
of O
C B-protein
/ I-protein
EBP I-protein
beta I-protein
, O
is O
specifically O
expressed O
in O
myelomonocytic O
and O
eosinophilic O
cells O
of O
the O
hematopoietic O
system O
. O

To O
investigate O
the O
role O
of O
NF B-protein
- I-protein
M I-protein
in O
hematopoietic O
cell O
lineage O
commitment O
, O
we O
constructed O
a O
conditional O
form O
of O
the O
protein O
by O
fusing O
it O
to O
the O
hormone B-protein
binding I-protein
domain I-protein
of O
the O
human B-protein
estrogen I-protein
receptor I-protein
. O

This O
construct O
was O
stably O
expressed O
in O
a O
multipotent O
progenitor O
cell O
line O
transformed O
by O
the O
Myb B-protein
- I-protein
Ets I-protein
oncoprotein I-protein
. O

We O
report O
here O
that O
both O
NF B-protein
- I-protein
M I-protein
- O
dependent O
promoter O
constructs O
and O
resident O
genes O
could O
be O
activated O
by O
addition O
of O
beta O
- O
estradiol O
to O
the O
NF B-protein
- I-protein
M I-protein
- I-protein
estrogen I-protein
receptor I-protein
expressing O
progenitors O
. O

At O
the O
same O
time O
, O
we O
observed O
a O
down O
- O
regulation O
of O
progenitor B-protein
- I-protein
specific I-protein
surface I-protein
markers I-protein
and O
the O
up O
- O
regulation O
of O
differentiation B-protein
markers I-protein
restricted O
to O
the O
eosinophil O
and O
myeloid O
lineages O
. O

In O
addition O
to O
the O
onset O
of O
differentiation O
, O
cell O
death O
was O
induced O
with O
typical O
apoptotic O
features O
. O

Our O
results O
suggest O
that O
NF B-protein
- I-protein
M I-protein
plays O
an O
important O
role O
in O
commitment O
along O
the O
eosinophil O
lineage O
and O
in O
the O
induction O
of O
apoptosis O
. O

Prolactin B-protein
and O
interleukin B-protein
- I-protein
2 I-protein
receptors I-protein
in O
T O
lymphocytes O
signal O
through O
a O
MGF B-protein
- I-protein
STAT5 I-protein
- I-protein
like I-protein
transcription I-protein
factor I-protein
. O

The O
cell O
surface O
receptors O
for O
PRL B-protein
and O
interleukin B-protein
- I-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
are O
structurally O
distinct O
, O
but O
share O
regulatory O
tasks O
in O
T O
lymphocytes O
. O

They O
can O
stimulate O
proliferation O
and O
activate O
transcription O
of O
over O
- O
lapping O
sets O
of O
genes O
of O
T O
cells O
. O

PRL B-protein
and O
IL B-protein
- I-protein
2 I-protein
receptor O
activation O
are O
both O
linked O
to O
the O
Jak B-protein
/ I-protein
Stat I-protein
( O
signal B-protein
transducer I-protein
and I-protein
activator I-protein
of I-protein
transcription I-protein
) O
pathway O
. O

We O
investigated O
the O
ability O
of O
PRL B-protein
and O
IL B-protein
- I-protein
2 I-protein
to O
activate O
Stat B-protein
proteins I-protein
in O
different O
T O
cell O
lines O
. O

The O
DNA O
binding O
specificities O
, O
the O
reactivities O
toward O
Stat O
- O
specific O
antisera O
, O
and O
the O
mol O
wt O
of O
IL B-protein
- I-protein
2 I-protein
- O
and O
PRL B-protein
- I-protein
induced I-protein
DNA I-protein
- I-protein
binding I-protein
proteins I-protein
in O
Nb2 O
and O
C196 O
T O
cell O
lines O
were O
investigated O
. O

A O
comparison O
with O
the O
Stat B-protein
proteins I-protein
induced O
by O
interferon B-protein
- I-protein
gamma I-protein
, O
PRL B-protein
, O
and O
IL B-protein
- I-protein
6 I-protein
in O
T47D O
mammary O
tumor O
cells O
was O
made O
. O

We O
found O
that O
these O
parameters O
were O
indistinguishable O
for O
one O
of O
the O
PRL O
- O
and O
IL O
- O
2 O
- O
induced O
factors O
. O

A O
transcription O
factor O
closely O
related O
to O
mammary B-protein
gland I-protein
factor I-protein
- I-protein
Stat5 I-protein
is O
rapidly O
activated O
upon O
interaction O
of O
IL B-protein
- I-protein
2 I-protein
and O
PRL B-protein
with O
their O
respective O
receptors O
. O

Activation O
of O
a O
second O
protein O
related O
to O
Stat1 B-protein
was O
also O
observed O
. O

Our O
results O
emphasize O
the O
role O
of O
PRL B-protein
as O
a O
regulator O
of O
the O
immune O
response O
and O
indicate O
that O
the O
Stat B-protein
factors I-protein
mammary B-protein
gland I-protein
factor I-protein
- I-protein
Stat5 I-protein
and O
Stat1 B-protein
play O
a O
role O
in O
the O
regulation O
of O
gene O
expression O
during O
T O
cell O
development O
. O

ETS1 B-protein
transactivates O
the O
human O
GM O
- O
CSF O
promoter O
in O
Jurkat O
T O
cells O
stimulated O
with O
PMA O
and O
ionomycin O
. O

Activation O
of O
T O
helper O
cells O
results O
in O
coordinate O
expression O
of O
a O
number O
of O
cytokines B-protein
involved O
in O
differentiation O
, O
proliferation O
and O
activation O
of O
the O
haematopoietic O
system O
. O

Granulocyte B-protein
- I-protein
macrophage I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
( O
GM B-protein
- I-protein
CSF I-protein
) O
is O
one O
such O
cytokine B-protein
whose O
increased O
expression O
results O
partly O
from O
increases O
in O
transcription O
. O

Cis O
- O
acting O
elements O
with O
NF O
kappa O
B O
, O
AP O
- O
1 O
and O
ETS O
- O
like O
motifs O
have O
been O
identified O
in O
the O
promoter O
region O
of O
the O
GM B-protein
- I-protein
CSF I-protein
gene O
, O
which O
are O
important O
for O
transcriptional O
activity O
following O
PMA O
and O
ionomycin O
stimulation O
. O

A O
number O
of O
the O
ETS B-protein
family I-protein
of O
transcription B-protein
factors I-protein
are O
expressed O
in O
T O
cells O
, O
including O
ETS1 B-protein
and O
ELF1 B-protein
. O

Here O
we O
describe O
the O
ability O
of O
these O
factors O
to O
interact O
with O
a O
site O
( O
GM5 O
) O
, O
located O
within O
the O
CLE0 O
element O
, O
- O
47 O
to O
- O
40 O
upstream O
of O
the O
GM B-protein
- I-protein
CSF I-protein
transcription O
initiation O
site O
. O

Exogenous O
ETS1 B-protein
, O
but O
not O
ELF1 B-protein
, O
can O
transactivate O
GM B-protein
- I-protein
CSF I-protein
, O
through O
the O
GM5 O
site O
, O
in O
a O
PMA O
/ O
ionomycin O
dependent O
manner O
. O

Other O
unidentified O
ETS B-protein
- I-protein
like I-protein
factors I-protein
present O
in O
Jurkat O
cells O
are O
also O
capable O
of O
binding O
GM5 O
. O

Mutation O
of O
the O
core O
ETS O
binding O
site O
from O
- O
GGAA O
- O
to O
- O
GGAT O
- O
prevents O
the O
binding O
of O
ETS B-protein
- I-protein
like I-protein
factors I-protein
with O
the O
exception O
of O
ETS1 B-protein
. O

The O
GM B-protein
- I-protein
CSF I-protein
promoter O
, O
modified O
in O
this O
way O
to O
be O
ETS1 B-protein
specific O
, O
is O
fully O
responsive O
to O
PMA O
/ O
ionomycin O
induction O
, O
in O
addition O
to O
ETS1 B-protein
transactivation O
in O
the O
presence O
of O
PMA O
and O
ionomycin O
. O

Together O
these O
data O
suggest O
that O
ETS1 B-protein
may O
be O
involved O
in O
mediating O
the O
increased O
GM B-protein
- I-protein
CSF I-protein
production O
associated O
with O
T O
cell O
activation O
. O

Quantitation O
of O
beta B-protein
1 I-protein
triiodothyronine I-protein
receptor I-protein
mRNA O
in O
human O
tissues O
by O
competitive O
reverse O
transcription O
polymerase O
chain O
reaction O
. O

Thyroid O
hormones O
act O
by O
binding O
to O
nuclear B-protein
receptor I-protein
proteins I-protein
, O
the O
thyroid B-protein
hormone I-protein
receptors I-protein
( O
TR B-protein
) O
alpha O
and O
beta O
. O

Data O
from O
cell O
culture O
and O
animal O
studies O
indicate O
that O
TR B-protein
expression O
may O
be O
regulated O
to O
modulate O
target O
organ O
responsiveness O
to O
thyroid O
hormone O
. O

To O
investigate O
whether O
such O
adaptive O
changes O
in O
TR B-protein
expression O
occur O
in O
humans O
, O
we O
determined O
the O
mRNA O
levels O
of O
the O
hTR B-protein
beta I-protein
1 I-protein
in O
various O
thyroid O
states O
. O

Patients O
with O
overt O
hypo O
- O
or O
hyperthyroidism O
were O
enrolled O
in O
the O
study O
. O

Total O
RNA O
was O
isolated O
from O
peripheral O
blood O
mononuclear O
cells O
and O
hTR B-protein
beta I-protein
1 I-protein
mRNA O
levels O
determined O
by O
quantitative O
competitive O
reverse O
transcription O
PCR O
. O

For O
comparison O
, O
hTR B-protein
beta I-protein
1 I-protein
mRNA O
levels O
were O
determined O
in O
lymphocytes O
and O
normal O
thyroid O
tissue O
of O
euthyroid O
patients O
. O

Human B-protein
TR I-protein
beta I-protein
1 I-protein
mRNA O
levels O
in O
lymphocytes O
were O
1 O
. O
8 O
+ O
/ O
- O
0 O
. O
4 O
, O
1 O
. O
9 O
+ O
/ O
- O
0 O
. O
5 O
, O
1 O
. O
1 O
+ O
/ O
- O
0 O
. O
4 O
10 O
( O
- O
18 O
) O
mol O
/ O
microgram O
RNA O
in O
hypo O
- O
, O
eu O
- O
and O
hyperthyroid O
patients O
, O
respectively O
, O
corresponding O
to O
an O
estimated O
0 O
. O
5 O
- O
2 O
molecules O
per O
cell O
. O

Although O
the O
mean O
hTR B-protein
beta I-protein
1 I-protein
mRNA O
levels O
were O
40 O
% O
lower O
in O
hyperthyroid O
than O
in O
euthyroid O
subjects O
, O
this O
difference O
did O
not O
reach O
statistical O
significance O
. O

Similar O
levels O
of O
hTR B-protein
beta I-protein
1 I-protein
mRNA O
levels O
were O
detected O
in O
thyroid O
gland O
from O
euthyroid O
patients O
. O

In O
summary O
, O
we O
developed O
an O
assay O
for O
the O
quantitative O
determination O
of O
hTR B-protein
beta I-protein
1 I-protein
mRNA O
levels O
in O
small O
human O
tissue O
samples O
, O
containing O
as O
little O
as O
50 O
ng O
of O
total O
RNA O
. O

Absolute O
hTR B-protein
beta I-protein
1 I-protein
mRNA O
levels O
are O
very O
low O
with O
an O
estimated O
one O
molecule O
of O
mRNA O
being O
present O
in O
a O
mononuclear O
blood O
cell O
or O
thyrocyte O
. O

No O
up O
- O
regulation O
of O
hTR B-protein
beta I-protein
1 I-protein
was O
seen O
in O
hypothyroid O
relative O
to O
euthyroid O
patients O
. O

However O
, O
there O
is O
a O
non O
- O
significant O
trend O
towards O
a O
down O
- O
regulation O
of O
hTR B-protein
beta I-protein
1 I-protein
mRNA O
levels O
in O
hyperthyroid O
patients O
. O

Multiple O
proteins B-protein
interact O
with O
the O
nuclear O
inhibitory O
protein O
repressor O
element O
in O
the O
human O
interleukin O
- O
3 O
promoter O
. O

T O
cell O
expression O
of O
interleukin B-protein
3 I-protein
( O
IL B-protein
- I-protein
3 I-protein
) O
is O
directed O
by O
positive O
and O
negative O
cis O
- O
acting O
DNA O
elements O
clustered O
within O
300 O
base O
pairs O
of O
the O
transcriptional O
start O
site O
. O

A O
strong O
repressor B-protein
element I-protein
, O
termed O
nuclear B-protein
inhibitory I-protein
protein I-protein
( O
NIP B-protein
) O
, O
was O
previously O
mapped O
to O
a O
segment O
of O
the O
IL O
- O
3 O
promoter O
between O
nucleotides O
- O
271 O
and O
- O
250 O
. O

Functional O
characterization O
of O
this O
element O
demonstrates O
that O
it O
can O
mediate O
repression O
when O
linked O
in O
cis O
to O
a O
heterologous O
promoter O
. O

DNA O
binding O
experiments O
were O
carried O
out O
to O
characterize O
the O
repressor O
activity O
. O

Using O
varying O
conditions O
, O
three O
distinct O
complexes O
were O
shown O
to O
interact O
specifically O
with O
the O
NIP B-protein
region O
, O
although O
only O
one O
correlates O
with O
repressor O
activity O
. O

Complex B-protein
1 I-protein
results O
from O
binding O
of O
a O
ubiquitous O
polypeptide O
that O
recognizes O
the O
3 O
' O
portion O
of O
this O
sequence O
and O
is O
not O
required O
for O
repression O
. O

Complex B-protein
2 I-protein
corresponds O
to O
binding O
of O
transcription B-protein
factor I-protein
( O
upstream B-protein
stimulatory I-protein
factor I-protein
) O
to O
an O
E O
- O
box O
motif O
in O
the O
5 O
' O
portion O
of O
the O
NIP B-protein
region O
. O

DNA O
binding O
specificity O
of O
complex O
3 O
overlaps O
with O
that O
of O
upstream B-protein
stimulatory I-protein
factor I-protein
but O
is O
clearly O
distinct O
. O

To O
determine O
which O
of O
the O
latter O
two O
complexes O
represents O
NIP B-protein
activity O
, O
we O
incorporated O
small O
alterations O
into O
the O
NIP B-protein
site O
of O
an O
IL O
- O
3 O
promoter O
- O
linked O
reporter O
construct O
and O
examined O
their O
effects O
on O
NIP B-protein
- O
mediated O
repression O
. O

Functional O
specificity O
for O
repression O
matches O
the O
DNA O
binding O
specificity O
of O
complex B-protein
3 I-protein
; O
both O
repressor O
activity O
and O
complex B-protein
3 I-protein
binding O
require O
the O
consensus O
sequence O
CTCACNTNC O
. O

The O
hematopoietic B-protein
transcription I-protein
factor I-protein
PU B-protein
. I-protein
1 I-protein
is O
downregulated O
in O
human O
multiple O
myeloma O
cell O
lines O
. O

PU B-protein
. I-protein
1 I-protein
is O
a O
hematopoietic B-protein
transcription I-protein
factor I-protein
belonging O
to O
the O
Ets B-protein
- I-protein
family I-protein
. O

It O
is O
identical O
to O
the O
Spi O
- O
1 O
oncogene O
, O
which O
is O
implicated O
in O
spleen O
focus O
- O
forming O
virus O
- O
induced O
murine O
erythroleukemias O
. O

PU B-protein
. I-protein
1 I-protein
seems O
to O
be O
required O
for O
early O
development O
of O
multiple O
hematopoietic O
lineages O
, O
but O
its O
expression O
in O
mature O
cells O
is O
preferentially O
observed O
in O
cells O
of O
the O
B O
- O
cell O
- O
and O
monocyte O
/ O
macrophage O
- O
differentiation O
lineage O
. O

It O
binds O
the O
so O
- O
called O
Pu O
box O
, O
an O
important O
tissue O
- O
specific O
regulatory O
DNA O
element O
present O
in O
a O
number O
of O
genes O
expressed O
in O
these O
cell O
lineages O
. O

We O
have O
analyzed O
the O
expression O
and O
activity O
of O
PU B-protein
. I-protein
1 I-protein
during O
human O
B O
- O
cell O
development O
using O
a O
panel O
of O
B O
- O
cell O
lines O
representing O
different O
stages O
of O
maturation O
, O
from O
early O
precursors O
to O
differentiated O
plasma O
cells O
. O

PU B-protein
. I-protein
1 I-protein
mRNA O
expression O
and O
PU B-protein
. I-protein
1 I-protein
DNA O
binding O
activity O
, O
as O
measured O
by O
Northern O
blot O
analysis O
and O
electrophoretic O
mobility O
shift O
assay O
, O
respectively O
, O
were O
evident O
in O
cell O
lines O
representing O
pro O
- O
B O
, O
pre O
- O
B O
, O
and O
mature O
B O
cells O
. O

We O
could O
also O
show O
Pu O
box O
- O
dependent O
transactivation O
of O
a O
reporter O
gene O
in O
transient O
transfections O
in O
these O
cell O
lines O
. O

In O
contrast O
, O
in O
a O
number O
of O
multiple O
myeloma O
cell O
lines O
, O
representing O
differentiated O
, O
plasma O
cell O
- O
like O
B O
cells O
, O
PU B-protein
. I-protein
1 I-protein
DNA O
binding O
activity O
, O
mRNA O
expression O
, O
and O
Pu O
box O
- O
dependent O
transactivation O
were O
absent O
or O
detectable O
at O
a O
very O
low O
level O
. O

In O
lymphoblastoid O
cell O
lines O
, O
which O
exemplify O
an O
intermediate O
stage O
of O
B O
- O
cell O
differentiation O
, O
a O
reduced O
expression O
and O
activity O
were O
observed O
. O

The O
findings O
in O
the O
human O
multiple O
myeloma O
cell O
lines O
represent O
the O
first O
examples O
of O
B O
cells O
with O
downregulated O
PU B-protein
. I-protein
1 I-protein
expression O
and O
apparently O
contradict O
observations O
in O
the O
murine O
system O
in O
which O
PU B-protein
. I-protein
1 I-protein
is O
expressed O
and O
active O
in O
plasmacytoma O
cell O
lines O
. O

At O
present O
, O
it O
is O
unclear O
whether O
the O
lack O
of O
PU B-protein
. I-protein
1 I-protein
expression O
and O
activity O
in O
human O
multiple O
myeloma O
cell O
lines O
represents O
a O
malignancy O
- O
associated O
defect O
in O
these O
cells O
or O
exemplifies O
a O
normal O
developmental O
regulation O
in O
terminally O
differentiated O
B O
cells O
. O

Regulation O
of O
granulocyte B-protein
- I-protein
macrophage I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
and O
E B-protein
- I-protein
selectin I-protein
expression O
in O
endothelial O
cells O
by O
cyclosporin O
A O
and O
the O
T B-protein
- I-protein
cell I-protein
transcription I-protein
factor I-protein
NFAT B-protein
. O

Nuclear B-protein
factor I-protein
of I-protein
activated I-protein
T I-protein
cells I-protein
( O
NFAT B-protein
) O
was O
originally O
described O
as O
a O
T B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
athat O
supported O
the O
activation O
of O
cytokine B-protein
gene O
expression O
and O
mediated O
the O
immunoregulatory B-protein
effects O
of O
cyclosporin O
A O
( O
CsA O
) O
. O

As O
we O
observed O
that O
activated O
endothelial O
cells O
also O
expressed O
NFAT B-protein
, O
we O
tested O
the O
antiinflammatory O
properties O
of O
CsA O
in O
endothelial O
cells O
. O

Significantly O
, O
CsA O
completely O
suppressed O
the O
induction O
of O
NFAT B-protein
in O
endothelial O
cells O
and O
inhibited O
the O
activity O
of O
granulocyte B-protein
- I-protein
macrophage I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
( O
GM B-protein
- I-protein
CSF I-protein
) O
gene O
regulatory O
elements O
that O
use O
NFAT B-protein
by O
60 O
% O
. O

CsA O
similarly O
mediated O
a O
reduction O
of O
up O
to O
65 O
% O
in O
GM B-protein
- I-protein
CSF I-protein
mRNA O
and O
protein O
expression O
in O
activated O
endothelial O
cells O
. O

CsA O
also O
suppressed O
E B-protein
- I-protein
selectin I-protein
, O
but O
not O
vascular B-protein
cell I-protein
adhesion I-protein
molecule I-protein
- I-protein
1 I-protein
( O
VCAM B-protein
- I-protein
1 I-protein
) O
expression O
in O
endothelial O
cells O
, O
even O
though O
the O
E B-protein
- I-protein
selectin I-protein
promoter O
is O
activated O
by O
NF B-protein
- I-protein
kappa I-protein
B I-protein
rather O
than O
NFAT B-protein
. O

Hence O
, O
induction O
of O
cell O
surface O
expression O
of O
this O
leukocyte B-protein
adhesion I-protein
molecule I-protein
by O
tumor B-protein
necrosis I-protein
factor I-protein
( I-protein
TNF I-protein
) I-protein
- I-protein
alpha I-protein
was O
reduced O
by O
40 O
% O
in O
the O
presence O
of O
CsA O
, O
and O
this O
was O
reflected O
by O
a O
29 O
% O
decrease O
in O
neutrophil O
adhesion O
. O

The O
effects O
of O
CsA O
on O
endothelial O
cells O
were O
also O
detected O
at O
the O
chromatin O
structure O
level O
, O
as O
DNasel B-protein
hypersensitive O
sites O
within O
both O
the O
GM B-protein
- I-protein
CSF I-protein
enhancer O
and O
the O
E B-protein
- I-protein
selectin I-protein
promoter O
were O
suppressed O
by O
CsA O
. O

This O
represents O
the O
first O
report O
of O
NFAT B-protein
in O
endothelial O
cells O
and O
suggests O
mechanisms O
by O
which O
CsA O
could O
function O
as O
an O
antiinflammatory O
agent O
. O

Costimulation O
requirement O
for O
AP B-protein
- I-protein
1 I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
transcription O
factor O
activation O
in O
T O
cells O
. O

The O
transcriptional O
activity O
of O
the O
IL B-protein
- I-protein
2 I-protein
promoter O
requires O
T O
- O
cell O
costimulation O
delivered O
by O
the O
TCR B-protein
and O
the O
auxiliary B-protein
receptor I-protein
CD28 I-protein
. O

Several O
transcription B-protein
factors I-protein
participate O
in O
IL B-protein
- I-protein
2 I-protein
promoter O
activation O
, O
among O
which O
are O
AP B-protein
- I-protein
1 I-protein
- I-protein
like I-protein
factors I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

Protein O
phosphorylation O
has O
an O
important O
role O
in O
the O
regulation O
of O
these O
two O
factors O
: O
( O
1 O
) O
it O
induces O
the O
transactivating O
capacity O
of O
the O
AP B-protein
- I-protein
1 I-protein
protein I-protein
c B-protein
- I-protein
Jun I-protein
; O
and O
( O
2 O
) O
it O
is O
involved O
in O
the O
release O
of O
the O
cytoplasmic B-protein
inhibitor I-protein
, O
I B-protein
kappa I-protein
B I-protein
, O
from O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
allowing O
translocation O
of O
the O
latter O
into O
the O
nucleus O
. O

We O
have O
recently O
shown O
that O
both O
phosphorylation O
processes O
require O
T O
- O
cell O
costimulation O
. O

Furthermore O
, O
in O
activated O
T O
cells O
, O
the O
kinetics O
of O
the O
two O
phosphorylation O
events O
are O
essentially O
similar O
. O

According O
to O
our O
results O
, O
however O
, O
the O
kinases O
responsible O
for O
the O
two O
processes O
are O
distinct O
entities O
. O

Whereas O
TPCK B-protein
inhibits O
phosphorylation O
of O
I B-protein
kappa I-protein
B I-protein
and O
, O
consequently O
, O
activation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
it O
markedly O
enhances O
the O
activity O
of O
JNK B-protein
, O
the O
MAP B-protein
kinase I-protein
- I-protein
related I-protein
kinase I-protein
that O
phosphorylates O
the O
transactivation B-protein
domain I-protein
of O
c B-protein
- I-protein
Jun I-protein
. O

We O
, O
therefore O
, O
propose O
the O
activation O
scheme O
presented O
in O
FIGURE O
3 O
for O
T O
- O
cell O
costimulation O
. O

Costimulation O
results O
in O
the O
activation O
of O
a O
signaling O
pathway O
that O
leads O
to O
the O
simultaneous O
induction O
of O
the O
two O
transcription B-protein
factors I-protein
, O
AP B-protein
- I-protein
1 I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

Integration O
of O
the O
signals O
generated O
by O
TCR B-protein
and O
CD28 B-protein
engagement O
occurs O
along O
this O
pathway O
, O
which O
then O
bifurcates O
to O
induce O
I B-protein
kappa I-protein
B I-protein
phosphorylation O
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
on O
the O
one O
hand O
, O
and O
JNK B-protein
activation O
and O
c B-protein
- I-protein
Jun I-protein
phosphorylation O
on O
the O
other O
. O

We O
are O
currently O
engaged O
in O
defining O
where O
the O
two O
signals O
integrate O
along O
the O
AP B-protein
- I-protein
1 I-protein
/ O
NF B-protein
- I-protein
kappa I-protein
B I-protein
pathway O
. O

Regulation O
of O
human O
immunodeficiency O
virus O
type O
1 O
and O
cytokine O
gene O
expression O
in O
myeloid O
cells O
by O
NF B-protein
- I-protein
kappa I-protein
B I-protein
/ I-protein
Rel I-protein
transcription B-protein
factors I-protein
. O

CD4 O
+ O
macrophages O
in O
tissues O
such O
as O
lung O
, O
skin O
, O
and O
lymph O
nodes O
, O
promyelocytic O
cells O
in O
bone O
marrow O
, O
and O
peripheral O
blood O
monocytes O
serve O
as O
important O
targets O
and O
reservoirs O
for O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
replication O
. O

HIV O
- O
1 O
- O
infected O
myeloid O
cells O
are O
often O
diminished O
in O
their O
ability O
to O
participate O
in O
chemotaxis O
, O
phagocytosis O
, O
and O
intracellular O
killing O
. O

HIV O
- O
1 O
infection O
of O
myeloid O
cells O
can O
lead O
to O
the O
expression O
of O
surface B-protein
receptors I-protein
associated O
with O
cellular O
activation O
and O
/ O
or O
differentiation O
that O
increase O
the O
responsiveness O
of O
these O
cells O
to O
cytokines B-protein
secreted O
by O
neighboring O
cells O
as O
well O
as O
to O
bacteria O
or O
other O
pathogens O
. O

Enhancement O
of O
HIV O
- O
1 O
replication O
is O
related O
in O
part O
to O
increased O
DNA O
- O
binding O
activity O
of O
cellular B-protein
transcription I-protein
factors I-protein
such O
as O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

NF B-protein
- I-protein
kappa I-protein
B I-protein
binds O
to O
the O
HIV O
- O
1 O
enhancer O
region O
of O
the O
long O
terminal O
repeat O
and O
contributes O
to O
the O
inducibility O
of O
HIV O
- O
1 O
gene O
expression O
in O
response O
to O
multiple O
activating O
agents O
. O

Phosphorylation O
and O
degradation O
of O
the O
cytoplasmic B-protein
inhibitor I-protein
I B-protein
kappa I-protein
B I-protein
alpha O
are O
crucial O
regulatory O
events O
in O
the O
activation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
DNA O
- O
binding O
activity O
. O

Both O
N O
- O
and O
C O
- O
terminal O
residues O
of O
I B-protein
kappa I-protein
B I-protein
alpha O
are O
required O
for O
inducer O
- O
mediated O
degradation O
. O

Chronic O
HIV O
- O
1 O
infection O
of O
myeloid O
cells O
leads O
to O
constitutive O
NF B-protein
- I-protein
kappa I-protein
B I-protein
DNA O
- O
binding O
activity O
and O
provides O
an O
intranuclear O
environment O
capable O
of O
perpetuating O
HIV O
- O
1 O
replication O
. O

Increased O
intracellular O
stores O
of O
latent B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
may O
also O
result O
in O
rapid O
inducibility O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
dependent O
cytokine B-protein
gene O
expression O
. O

In O
response O
to O
secondary O
pathogenic O
infections O
or O
antigenic O
challenge O
, O
cytokine B-protein
gene O
expression O
is O
rapidly O
induced O
, O
enhanced O
, O
and O
sustained O
over O
prolonged O
periods O
in O
HIV O
- O
1 O
- O
infected O
myeloid O
cells O
compared O
with O
uninfected O
cells O
. O

Elevated O
levels O
of O
several O
inflammatory B-protein
cytokines I-protein
have O
been O
detected O
in O
the O
sera O
of O
HIV O
- O
1 O
- O
infected O
individuals O
. O

Secretion O
of O
myeloid B-protein
cell I-protein
- I-protein
derived I-protein
cytokines I-protein
may O
both O
increase O
virus O
production O
and O
contribute O
to O
AIDS O
- O
associated O
disorders O
. O

Steroid O
mediated O
lysis O
of O
lymphoblasts O
requires O
the O
DNA O
binding O
region O
of O
the O
steroid O
hormone O
receptor O
. O

Glucocorticoids O
kill O
certain O
types O
of O
lymphoblasts O
, O
but O
the O
mechanisms O
are O
unknown O
. O

It O
is O
clear O
that O
sufficient O
numbers O
of O
functional O
glucocorticoid B-protein
receptors I-protein
are O
required O
to O
mediate O
lysis O
, O
but O
whether O
they O
do O
so O
through O
the O
classical O
model O
of O
steroid O
hormone O
activation O
and O
modulation O
of O
gene O
expression O
has O
not O
been O
established O
. O

In O
this O
report O
we O
have O
asked O
which O
region O
( O
s O
) O
of O
the O
steroid B-protein
receptor I-protein
are O
important O
for O
mediating O
lysis O
in O
leukemic O
T O
lymphoblasts O
. O

CEM O
- O
ICR O
27 O
leukemic O
lymphoblasts O
, O
a O
clone O
of O
CEM O
cells O
which O
lack O
functional O
glucocorticoid B-protein
receptors I-protein
and O
therefore O
are O
neither O
lysed O
by O
dexamethasone O
nor O
capable O
of O
showing O
glutamine B-protein
synthetase I-protein
induction O
, O
were O
provided O
with O
steroid B-protein
receptors I-protein
by O
DNA O
transfections O
of O
various O
receptor O
gene O
constructs O
. O

We O
measured O
steroid O
mediated O
lysis O
, O
receptor O
number O
and O
induction O
of O
glutamine B-protein
synthetase I-protein
in O
the O
transfected O
cells O
. O

Our O
results O
provide O
evidence O
that O
the O
lysis O
mechanism O
in O
the O
ICR27 O
lymphoblasts O
is O
restored O
when O
functional O
receptor O
number O
is O
restored O
. O

The O
DNA B-protein
binding I-protein
region I-protein
specifying O
high O
affinity O
for O
GRE O
sites O
is O
required O
. O

Lysis O
is O
mediated O
by O
any O
steroid O
that O
allows O
for O
activation O
of O
the O
receptor O
containing O
such O
a O
region O
. O

Our O
data O
support O
the O
view O
that O
steroid O
- O
mediated O
cell O
death O
occurs O
by O
a O
process O
requiring O
direct O
interaction O
of O
steroid B-protein
- I-protein
receptor I-protein
complexes I-protein
with O
the O
genome O
. O

Functional O
characterization O
of O
the O
murine B-protein
homolog I-protein
of O
the O
B B-protein
cell I-protein
- I-protein
specific I-protein
coactivator I-protein
BOB B-protein
. I-protein
1 I-protein
/ I-protein
OBF I-protein
. I-protein
1 I-protein
. O

B O
cell O
- O
specific O
transcriptional O
promoter O
activity O
mediated O
by O
the O
octamer O
motif O
requires O
the O
Oct1 B-protein
or O
Oct2 B-protein
protein I-protein
and O
additional O
B B-protein
cell I-protein
- I-protein
restricted I-protein
cofactors I-protein
. O

One O
such O
cofactor B-protein
, O
BOB B-protein
. I-protein
1 I-protein
/ I-protein
OBF I-protein
. I-protein
1 I-protein
, O
was O
recently O
isolated O
from O
human O
B O
cells O
. O

Here O
, O
we O
describe O
the O
isolation O
and O
detailed O
characterization O
of O
the O
murine B-protein
homolog I-protein
. O

Full O
- O
length O
cDNAs O
and O
genomic O
clones O
were O
isolated O
, O
and O
the O
gene O
structure O
was O
determined O
. O
Comparison O
of O
the O
deduced O
amino O
acids O
shows O
88 O
% O
sequence O
identity O
between O
mouse O
and O
human O
BOB O
. O
1 O
/ O
OBF O
. O
1 O
. O

The O
NH2 B-protein
- I-protein
terminal I-protein
126 I-protein
amino I-protein
acids I-protein
of O
BOB B-protein
. I-protein
1 I-protein
/ I-protein
OBF I-protein
. I-protein
1 I-protein
are O
both O
essential O
and O
sufficient O
for O
interaction O
with O
the O
POU B-protein
domains I-protein
of O
either O
Oct1 B-protein
or O
Oct2 B-protein
. O

This O
protein O
- O
protein O
interaction O
does O
not O
require O
the O
simultaneous O
binding O
of O
Oct B-protein
proteins I-protein
to O
DNA O
, O
and O
high O
resolution O
footprinting O
of O
the O
Oct O
- O
DNA O
interaction O
reveals O
that O
binding O
of O
BOB B-protein
. I-protein
1 I-protein
/ I-protein
OBF I-protein
. I-protein
1 I-protein
to O
Oct1 B-protein
or O
Oct2 B-protein
does O
not O
alter O
the O
interaction O
with O
DNA O
. O

BOB B-protein
. I-protein
1 I-protein
/ I-protein
OBF I-protein
. I-protein
1 I-protein
can O
efficiently O
activate O
octamer O
- O
dependent O
promoters O
in O
fibroblasts O
; O
however O
, O
it O
fails O
to O
stimulate O
octamer O
- O
dependent O
enhancer O
activity O
. O

Fusion O
of O
subdomains O
of O
BOB B-protein
. I-protein
1 I-protein
/ I-protein
OBF I-protein
. I-protein
1 I-protein
with O
the O
GAL4 B-protein
DNA I-protein
binding I-protein
domain I-protein
reveals O
that O
both O
NH2 O
- O
and O
COOH O
- O
terminal O
domains O
of O
BOB B-protein
. I-protein
1 I-protein
/ I-protein
OBF I-protein
. I-protein
1 I-protein
contribute O
to O
full O
transactivation O
function O
, O
the O
COOH B-protein
- I-protein
terminal I-protein
domain I-protein
is O
more O
efficient O
in O
this O
transactivation O
assay O
. O

Consistent O
with O
the O
failure O
of O
full B-protein
- I-protein
length I-protein
BOB I-protein
. I-protein
1 I-protein
/ I-protein
OBF I-protein
. I-protein
1 I-protein
to O
stimulate O
octamer O
- O
dependent O
enhancer O
elements O
in O
non O
B O
cells O
, O
the O
GAL4 B-protein
fusions I-protein
likewise O
only O
stimulate O
from O
a O
promoter O
- O
proximal O
position O
. O

Anti B-protein
- I-protein
immunoglobulin I-protein
M I-protein
activates O
nuclear B-protein
calcium I-protein
/ I-protein
calmodulin I-protein
- I-protein
dependent I-protein
protein I-protein
kinase I-protein
II I-protein
in O
human O
B O
lymphocytes O
. O

We O
and O
others O
have O
previously O
shown O
that O
the O
nuclear B-protein
protein I-protein
, O
Ets B-protein
- I-protein
1 I-protein
, O
is O
phosphorylated O
in O
a O
calcium O
- O
dependent O
manner O
after O
ligation O
of O
immunoglobulin B-protein
( I-protein
Ig I-protein
) I-protein
M I-protein
on O
B O
lymphocytes O
. O

As O
this O
phosphorylation O
was O
independent O
of O
protein B-protein
kinase I-protein
C I-protein
activity O
, O
we O
tested O
whether O
a O
calcium B-protein
/ I-protein
calmodulin I-protein
- I-protein
dependent I-protein
protein I-protein
kinase I-protein
( O
CaM B-protein
kinase I-protein
) O
might O
phosphorylate O
the O
Ets B-protein
- I-protein
1 I-protein
protein I-protein
after O
elevation O
of O
intracellular O
free O
calcium O
concentrations O
. O

The O
dephosphorylated O
form O
of O
Ets B-protein
- I-protein
1 I-protein
has O
been O
shown O
to O
bind O
to O
chromatin O
, O
suggesting O
that O
the O
operative B-protein
kinase I-protein
should O
be O
detectable O
in O
the O
nucleus O
. O

We O
prepared O
nuclear O
extracts O
from O
two O
human O
B O
cell O
lines O
in O
which O
increased O
intracellular O
free O
calcium O
levels O
correlated O
with O
increased O
phosphorylation O
of O
the O
Ets B-protein
- I-protein
1 I-protein
protein O
. O

Activity O
of O
the O
CaM B-protein
kinases I-protein
was O
determined O
using O
a O
synthetic O
peptide O
substrate O
both O
in O
the O
absence O
and O
presence O
of O
an O
inhibitor O
specific O
for O
the O
CaM B-protein
kinase I-protein
family I-protein
, O
KN O
- O
62 O
. O

Stimulation O
of O
cells O
with O
anti B-protein
- I-protein
IgM I-protein
led O
to O
increased O
activity O
of O
a O
nuclear B-protein
kinase I-protein
that O
could O
phosphorylate O
the O
peptide O
, O
and O
this O
activity O
was O
reduced O
by O
10 O
microM O
KN O
- O
62 O
. O

Kinase O
activity O
was O
reduced O
in O
lysates O
preadsorbed O
using O
an O
antibody B-protein
specific O
for O
CaM B-protein
kinase I-protein
II I-protein
. O

Two O
- O
dimensional O
phosphopeptide O
maps O
of O
the O
Ets B-protein
- I-protein
1 I-protein
protein O
from O
cells O
incubated O
with O
ionomycin O
or O
anti B-protein
- I-protein
IgM I-protein
contained O
two O
unique O
phosphopeptides O
that O
were O
absent O
in O
untreated O
cells O
. O

Incubation O
of O
isolated B-protein
Ets I-protein
- I-protein
1 I-protein
protein I-protein
with O
purified O
CaM B-protein
kinase I-protein
II I-protein
produced O
phosphorylation O
of O
peptides O
that O
migrated O
identically O
to O
those O
found O
in O
cells O
incubated O
with O
either O
anti B-protein
- I-protein
IgM I-protein
or O
ionomycin O
. O

These O
data O
suggest O
a O
model O
of O
signal O
transduction O
by O
the O
antigen B-protein
receptor I-protein
on O
B O
lymphocytes O
in O
which O
increased O
intracellular O
free O
calcium O
can O
rapidly O
activate O
nuclear B-protein
CaM I-protein
kinase I-protein
II I-protein
, O
potentially O
resulting O
in O
phosphorylation O
and O
regulation O
of O
DNA B-protein
- I-protein
binding I-protein
proteins I-protein
. O

Transcriptional O
activation O
and O
repression O
, O
two O
properties O
of O
the O
lymphoid B-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
Oct B-protein
- I-protein
2a I-protein
. O

The O
lymphoid B-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
Oct B-protein
- I-protein
2a I-protein
contains O
two O
transcriptional B-protein
activation I-protein
domains I-protein
which O
are O
located O
within O
the O
N B-protein
- I-protein
terminal I-protein
and O
C B-protein
- I-protein
terminal I-protein
regions I-protein
. O

To O
study O
their O
differential B-protein
activation I-protein
properties I-protein
, O
we O
linked O
the O
isolated O
effector B-protein
domains I-protein
to O
the O
GAL4 B-protein
DNA I-protein
- I-protein
binding I-protein
domain I-protein
. O

We O
have O
shown O
that O
both O
activating O
regions O
of O
Oct B-protein
- I-protein
2a I-protein
, O
isolated O
from O
their O
natural O
context O
, O
can O
activate O
transcription O
as O
promoter B-protein
factors I-protein
. O

In O
contrast O
to O
the O
C B-protein
- I-protein
terminus I-protein
, O
activation O
by O
the O
N B-protein
- I-protein
terminal I-protein
domain I-protein
is O
dependent O
on O
a O
yet O
unidentified O
factor O
( O
s O
) O
binding O
to O
the O
simian O
virus O
40 O
enhancer O
. O

The O
results O
obtained O
by O
duplication O
of O
activation B-protein
domains I-protein
or O
their O
mixed O
combination O
suggest O
that O
the O
domains O
are O
functionally O
independent O
. O

However O
, O
activation O
from O
a O
remote O
position O
could O
only O
be O
achieved O
with O
the O
C B-protein
- I-protein
terminus I-protein
of O
Oct B-protein
- I-protein
2a I-protein
in O
B O
cells O
. O

In O
lymphoid O
cells O
, O
higher O
activation O
levels O
were O
observed O
, O
suggesting O
that O
distinct O
B B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
cofactors I-protein
in O
concert O
with O
the O
effector B-protein
domains I-protein
of O
Oct B-protein
- I-protein
2a I-protein
might O
be O
involved O
in O
mediating O
transcription O
from O
proximal O
and O
remote O
positions O
. O

Furthermore O
, O
we O
identified O
a O
repression O
domain O
at O
the O
N O
- O
terminus O
of O
Oct B-protein
- I-protein
2a I-protein
. O

When O
transferred O
to O
a O
potent O
activator O
, O
transcriptional O
stimulation O
was O
inhibited O
efficiently O
. O

These O
results O
underscore O
the O
modular O
structure O
of O
Oct B-protein
- I-protein
2a I-protein
with O
separable O
domains O
for O
activation O
and O
repression O
and O
suggest O
that O
Oct B-protein
- I-protein
2a I-protein
might O
have O
complex O
regulatory O
functions O
in O
vivo O
. O

Nonopsonic O
phagocytosis O
of O
Pseudomonas O
aeruginosa O
by O
macrophages O
and O
polymorphonuclear O
leukocytes O
requires O
the O
presence O
of O
the O
bacterial O
flagellum O
. O

Whereas O
the O
mechanism O
of O
nonopsonic O
phagocytosis O
of O
Pseudomonas O
aeruginosa O
has O
been O
described O
, O
the O
bacterial O
ligands O
required O
are O
poorly O
understood O
. O

To O
identify O
the O
requisite O
bacterial O
ligands O
, O
studies O
with O
isogenic O
mutants O
of O
P O
. O
aeruginosa O
PAK O
lacking O
pili O
, O
flagella O
, O
and O
the O
RpoN B-protein
sigma I-protein
factor I-protein
were O
undertaken O
. O

The O
RpoN O
mutant O
, O
lacking O
pili O
, O
flagella O
, O
and O
nonpilus B-protein
adhesins I-protein
, O
bound O
poorly O
and O
was O
resistant O
to O
ingestion O
by O
both O
macrophages O
and O
neutrophils O
. O

Pili O
were O
not O
absolutely O
required O
for O
binding O
or O
phagocytosis O
of O
P O
. O
aeruginosa O
. O

The O
presence O
of O
a O
flagellum O
was O
not O
required O
for O
binding O
of O
P O
. O
aeruginosa O
to O
macrophages O
but O
was O
critical O
for O
the O
subsequent O
internalization O
of O
the O
bacterium O
, O
suggesting O
that O
this O
factor O
or O
a O
surface O
ligand O
associated O
with O
its O
assembly O
was O
responsible O
for O
stimulation O
of O
nonopsonic O
phagocytosis O
. O

Identification O
of O
essential O
GATA O
and O
Ets O
binding O
motifs O
within O
the O
promoter O
of O
the O
platelet O
glycoprotein O
Ib O
alpha O
gene O
. O

Platelet B-protein
glycoprotein I-protein
( O
GP B-protein
) O
Ib B-protein
- I-protein
IX I-protein
- I-protein
V I-protein
is O
a O
multisubunit B-protein
adhesion I-protein
receptor I-protein
that O
supports O
platelet O
attachment O
to O
thrombogenic O
surfaces O
at O
sites O
of O
vascular O
injury O
. O

The O
congenital O
absence O
of O
the O
receptor O
results O
in O
a O
bleeding O
disorder O
associated O
with O
" O
giant O
" O
platelets O
, O
a O
condition O
linking O
the O
expression O
of O
the O
complex O
to O
platelet O
morphogenesis O
. O

To O
understand O
better O
the O
expression O
of O
the O
GP B-protein
Ib I-protein
- I-protein
IX I-protein
- I-protein
V I-protein
complex I-protein
, O
studies O
were O
undertaken O
to O
define O
the O
essential O
genetic O
elements O
supporting O
the O
expression O
of O
the O
alpha B-protein
- I-protein
subunit I-protein
of O
the O
complex O
( O
GP B-protein
Ib I-protein
alpha I-protein
) O
. O

GP B-protein
Ib O
alpha O
promoter O
activity O
was O
evaluated O
by O
transfection O
of O
human O
erythroleukemia O
cells O
with O
reporter O
plasmids O
coding O
for O
the O
enzyme B-protein
, O
luciferase B-protein
. O

Studies O
were O
initiated O
with O
a O
fragment O
extending O
2 O
, O
738 O
nucleotides O
5 O
' O
to O
the O
transcription O
start O
site O
and O
lead O
to O
the O
identification O
of O
253 O
nucleotides O
retaining O
full O
promoter O
activity O
in O
human O
erythroleukemia O
cells O
. O

In O
cells O
of O
nonhematopoietic O
lineage O
, O
human O
endothelial O
and O
HeLa O
cells O
, O
the O
GP B-protein
Ib I-protein
alpha I-protein
promoter O
activity O
was O
no O
greater O
than O
background O
levels O
obtained O
with O
promoterless O
constructs O
. O

Gel O
shift O
assays O
and O
site O
- O
directed O
mutagenesis O
studies O
defined O
essential O
GATA O
and O
Ets O
binding O
motifs O
93 O
and O
150 O
nucleotides O
upstream O
of O
the O
transcription O
start O
site O
, O
a O
finding O
which O
further O
substantiates O
these O
elements O
as O
important O
determinants O
of O
megakaryocytic O
gene O
expression O
. O

The O
results O
define O
essential O
cis O
- O
acting O
elements O
responsible O
for O
the O
expression O
of O
GP B-protein
Ib I-protein
alpha I-protein
and O
provide O
insights O
into O
molecular O
events O
coinciding O
with O
the O
release O
of O
normal O
platelets O
into O
the O
bloodstream O
. O

CD30 B-protein
ligation O
induces O
nuclear B-protein
factor I-protein
- I-protein
kappa I-protein
B I-protein
activation O
in O
human O
T O
cell O
lines O
. O

CD30 B-protein
is O
a O
recently O
described O
member O
of O
the O
tumor B-protein
necrosis I-protein
factor I-protein
/ I-protein
nerve I-protein
growth I-protein
factor I-protein
receptor I-protein
superfamily I-protein
. O

In O
this O
report O
, O
we O
show O
that O
following O
incubation O
of O
L540 O
cells O
( O
Hodgkin O
' O
s O
disease O
- O
derived O
, O
T O
cell O
- O
like O
, O
CD30 B-protein
+ O
cells O
) O
with O
the O
agonistic B-protein
anti I-protein
- I-protein
CD30 I-protein
monoclonal I-protein
antibodies I-protein
( O
mAb B-protein
) O
M44 B-protein
and O
M67 B-protein
, O
two O
nuclear B-protein
factor I-protein
( I-protein
NF I-protein
) I-protein
- I-protein
kappa I-protein
B I-protein
DNA O
binding O
activities O
were O
induced O
in O
nuclear O
extracts O
, O
as O
determined O
in O
gel O
retardation O
assays O
. O

The O
effect O
of O
the O
mAb B-protein
towards O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
was O
rapid O
, O
as O
it O
occurred O
within O
20 O
min O
, O
and O
was O
sustained O
for O
up O
to O
6 O
h O
. O

By O
comparison O
, O
an O
isotype B-protein
- I-protein
matched I-protein
antibody I-protein
had O
no O
effect O
on O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
. O

Moreover O
, O
in O
human O
T O
helper O
( O
Th O
) O
clones O
functionally O
characterized O
as O
being O
of O
the O
type O
0 O
, O
type O
1 O
and O
type O
2 O
( O
28 O
% O
, O
< O
1 O
% O
und O
93 O
% O
CD30 O
+ O
, O
respectively O
) O
, O
the O
extent O
of O
CD30 B-protein
- O
mediated O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
correlated O
with O
the O
proportion O
of O
CD30 O
+ O
cells O
. O

In O
all O
cell O
lines O
investigated O
, O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
complexes I-protein
induced O
following O
CD30 B-protein
engagement O
were O
shown O
to O
contain O
p50 B-protein
NF I-protein
- I-protein
kappa I-protein
B1 I-protein
, O
p65 B-protein
RelA I-protein
, O
and O
possibly O
other O
transcription B-protein
factors I-protein
. O

Collectively O
, O
our O
results O
demonstrate O
that O
nuclear O
translocation O
and O
activation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
rank O
among O
the O
short O
- O
term O
cellular O
responses O
elicited O
following O
CD30 B-protein
ligation O
. O

Pathogenesis O
of O
atherosclerosis O
. O

The O
earliest O
lesion O
in O
the O
development O
of O
an O
atherosclerotic O
plaque O
is O
the O
fatty O
streak O
. O

This O
chronic O
inflammatory O
reaction O
results O
from O
a O
sequence O
of O
events O
that O
begins O
with O
the O
trapping O
of O
low O
density O
lipoprotein O
( O
LDL O
) O
in O
the O
subendothelial O
space O
of O
the O
artery O
wall O
. O

The O
trapped O
LDL O
is O
seeded O
with O
oxidative O
species O
released O
by O
the O
overlying O
endothelium O
, O
and O
lipid O
oxidation O
is O
initiated O
within O
the O
LDL O
particle O
. O
Some O
of O
the O
lipids O
that O
result O
lead O
to O
the O
activation O
of O
NFkB B-protein
- I-protein
like I-protein
transcription I-protein
factors I-protein
that O
cause O
the O
expression O
of O
genes O
whose O
protein B-protein
products I-protein
mediate O
monocyte O
binding O
, O
monocyte O
chemotaxis O
into O
the O
subendothelial O
space O
, O
and O
conversion O
into O
macrophages O
. O

At O
least O
1 O
major O
gene O
modulates O
the O
oxidation O
of O
LDL O
lipids O
and O
/ O
or O
the O
biologic O
response O
to O
these O
lipids O
. O

The O
inverse O
relation O
between O
high O
density O
lipoprotein O
( O
HDL O
) O
and O
atherosclerotic O
events O
may O
in O
part O
be O
due O
to O
enzymes B-protein
associated O
with O
HDL O
that O
destroy O
the O
biologically O
active O
lipids O
generated O
in O
LDL O
. O

Estrogen B-protein
and O
progesterone B-protein
receptors I-protein
in O
vernal O
keratoconjunctivitis O
. O

PURPOSE O
: O
Sex O
- O
related O
influences O
have O
been O
implicated O
in O
the O
pathogenesis O
of O
vernal O
keratoconjunctivitis O
( O
VKC O
) O
, O
an O
allergic O
eosinophilic O
disease O
. O

METHODS O
: O
The O
authors O
evaluated O
tarsal O
and O
bulbar O
conjunctival O
biopsies O
from O
seven O
patients O
with O
severe O
and O
symptomatic O
VKC O
for O
the O
presence O
of O
estrogen O
and O
progesterone B-protein
receptors I-protein
by O
using O
monoclonal B-protein
antibodies I-protein
with O
a O
peroxidase O
- O
antiperoxidase O
technique O
. O

RESULTS O
: O
Both O
the O
epithelium O
and O
subepithelium O
of O
the O
tarsal O
and O
bulbar O
conjunctiva O
of O
patients O
with O
VKC O
, O
but O
not O
those O
of O
four O
nonatopic O
control O
subjects O
, O
showed O
intense O
positive O
staining O
for O
estrogen O
and O
progesterone B-protein
receptors I-protein
. O

Immunofluorescence O
colocalization O
of O
both O
estrogen B-protein
and O
progesterone B-protein
receptors I-protein
with O
eosinophil B-protein
cationic I-protein
protein I-protein
showed O
that O
approximately O
70 O
% O
of O
positive O
cells O
were O
eosinophils O
. O

CONCLUSIONS O
: O
Sexual O
hormones O
, O
through O
their O
receptors B-protein
, O
may O
influence O
the O
activity O
of O
eosinophils O
in O
patients O
with O
VKC O
. O

CIITA B-protein
activates O
the O
expression O
of O
MHC O
class O
II O
genes O
in O
mouse O
T O
cells O
. O

It O
has O
long O
been O
a O
puzzle O
that O
MHC B-protein
class I-protein
II I-protein
molecules I-protein
are O
expressed O
in O
human O
T O
cells O
after O
activation O
but O
not O
in O
mouse O
T O
cells O
; O
this O
expression O
is O
believed O
to O
play O
a O
role O
in O
the O
cell O
mediated O
immune O
response O
. O

Recently O
the O
MHC B-protein
class I-protein
II I-protein
transactivator I-protein
( O
CIITA B-protein
) O
has O
been O
reported O
to O
be O
a O
major B-protein
regulatory I-protein
factor I-protein
for O
both O
the O
constitutive O
and O
IFN O
inducible O
expression O
of O
MHC O
class O
II O
genes O
. O

Here O
we O
show O
that O
human O
T O
cells O
expressing O
MHC O
class O
II O
have O
CIITA B-protein
transcripts O
while O
MHC O
class O
II O
- O
negative O
human O
T O
cells O
and O
mouse O
T O
cells O
do O
not O
. O

The O
expression O
of O
MHC O
class O
II O
genes O
in O
mouse O
T O
cells O
can O
be O
reconstituted O
upon O
transfection O
with O
the O
human O
CIITA B-protein
cDNA O
. O

These O
data O
indicate O
that O
the O
expression O
of O
CIITA B-protein
explains O
the O
expression O
or O
lack O
of O
expression O
of O
MHC B-protein
class I-protein
II I-protein
in O
human O
and O
mouse O
T O
cells O
respectively O
. O

Anti B-protein
- I-protein
Ro I-protein
( I-protein
SSA I-protein
) I-protein
autoantibodies I-protein
are O
associated O
with O
T O
cell O
receptor O
beta O
genes O
in O
systemic O
lupus O
erythematosus O
patients O
. O

Several O
of O
the O
heterogeneous O
clinical O
manifestations O
of O
systemic O
lupus O
erythematosus O
have O
been O
associated O
with O
specific O
autoantibodies B-protein
. O

Associations O
between O
HLA B-protein
class I-protein
II I-protein
antigens I-protein
and O
autoantibodies B-protein
to O
the O
ribonucleoproteins B-protein
Ro B-protein
( I-protein
SSA I-protein
) I-protein
and O
La B-protein
( I-protein
SSB I-protein
) I-protein
have O
been O
reported O
in O
these O
patients O
. O

Because O
HLA B-protein
class I-protein
II I-protein
molecules I-protein
present O
antigen O
to O
T B-protein
cell I-protein
receptors I-protein
( O
TCRs B-protein
) O
, O
we O
have O
searched O
for O
a O
TCR O
gene O
associated O
with O
the O
production O
of O
anti B-protein
- I-protein
Ro I-protein
( I-protein
SSA I-protein
) I-protein
antibodies I-protein
. O

A O
pair O
of O
restriction O
fragment O
length O
polymorphisms O
( O
RFLPs O
) O
, O
one O
of O
which O
hybridizes O
to O
the O
TCR O
constant O
region O
C O
beta O
1 O
and O
the O
other O
to O
the O
C O
beta O
2 O
gene O
, O
has O
been O
identified O
, O
suggesting O
these O
may O
be O
genotypic O
markers O
for O
an O
extended O
region O
of O
the O
TCR O
beta O
locus O
. O

This O
RFLP O
pair O
occurs O
in O
76 O
% O
of O
patients O
with O
Ro B-protein
( I-protein
SSA I-protein
) I-protein
precipitins O
, O
84 O
% O
of O
anti O
- O
Ro B-protein
( I-protein
SSA I-protein
) I-protein
- O
positive O
patients O
lacking O
La B-protein
( I-protein
SSB I-protein
) I-protein
precipitins B-protein
, O
but O
only O
41 O
% O
of O
the O
patients O
lacking O
both O
precipitins B-protein
( O
P O
= O
0 O
. O
0004 O
) O
. O

This O
disproportionate O
occurrence O
in O
a O
subset O
of O
lupus O
patients O
indicates O
that O
these O
RFLPs O
are O
not O
disease O
susceptibility O
markers O
, O
but O
rather O
are O
important O
markers O
for O
TCR O
genes O
whose O
products O
are O
involved O
in O
the O
production O
of O
anti B-protein
- I-protein
Ro I-protein
( I-protein
SSA I-protein
) I-protein
antibodies I-protein
. O

The O
majority O
of O
patients O
who O
have O
these O
RFLPs O
and O
HLA B-protein
class I-protein
II I-protein
antigens I-protein
previously O
associated O
with O
the O
anti O
- O
Ro B-protein
( I-protein
SSA I-protein
) I-protein
response O
make O
this O
antibody O
, O
suggesting O
that O
interactions O
between O
products O
of O
these O
loci O
occur O
in O
response O
to O
Ro B-protein
( I-protein
SSA I-protein
) I-protein
. O

Inhibition O
of O
NF B-protein
- I-protein
AT I-protein
- O
dependent O
transcription O
by O
NF B-protein
- I-protein
kappa I-protein
B I-protein
: O
implications O
for O
differential O
gene O
expression O
in O
T O
helper O
cell O
subsets O
. O

Activation O
of O
individual O
CD4 O
+ O
T O
cells O
results O
in O
differential O
lymphokine B-protein
expression O
: O
interleukin B-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
is O
preferentially O
produced O
by O
T O
helper O
type O
1 O
( O
TH1 O
) O
cells O
, O
which O
are O
involved O
in O
cell O
- O
mediated O
immune O
responses O
, O
whereas O
IL B-protein
- I-protein
4 I-protein
is O
synthesized O
by O
TH2 O
cells O
, O
which O
are O
essential O
for O
humoral O
immunity O
. O

The O
Ca B-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
dependent I-protein
factor I-protein
NF B-protein
- I-protein
ATp I-protein
plays O
a O
key O
role O
in O
the O
inducible O
transcription O
of O
both O
these O
lymphokine O
genes O
. O

However O
, O
while O
IL2 B-protein
expression O
requires O
the O
contribution O
of O
Ca O
( O
2 O
+ O
) O
- O
and O
protein B-protein
kinase I-protein
C I-protein
- O
dependent O
signals O
, O
we O
report O
that O
activation O
of O
human B-protein
IL4 I-protein
transcription O
through O
the O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathway O
is O
diminished O
by O
protein B-protein
kinase I-protein
C I-protein
stimulation O
in O
Jurkat O
T O
cells O
. O

This O
phenomenon O
is O
due O
to O
mutually O
exclusive O
binding O
of O
NF B-protein
- I-protein
ATp I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
to O
the O
P O
sequence O
, O
an O
element O
located O
69 O
bp O
upstream O
of O
the O
IL4 O
transcription O
initiation O
site O
. O

Human O
IL4 O
promoter O
- O
mediated O
transcription O
is O
downregulated O
in O
Jurkat O
cells O
stimulated O
with O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- I-protein
activating I-protein
cytokine I-protein
tumor B-protein
necrosis I-protein
factor I-protein
alpha I-protein
and O
suppressed O
in O
RelA B-protein
- O
overexpressing O
cells O
. O

In O
contrast O
, O
protein B-protein
kinase I-protein
C I-protein
stimulation O
or O
RelA B-protein
overexpression O
does O
not O
affect O
the O
activity O
of O
a O
human B-protein
IL4 I-protein
promoter O
containing O
a O
mouse O
P O
sequence O
, O
which O
is O
a O
higher O
- O
affinity O
site O
for O
NF B-protein
- I-protein
ATp I-protein
and O
a O
lower O
- O
affinity O
site O
for O
RelA B-protein
. O

Thus O
, O
competition O
between O
two O
general O
transcriptional B-protein
activators I-protein
, O
RelA B-protein
and O
NF B-protein
- I-protein
ATp I-protein
, O
mediates O
the O
inhibitory O
effect O
of O
protein B-protein
kinase I-protein
C I-protein
stimulation O
on O
IL4 B-protein
expression O
and O
may O
contribute O
to O
differential O
gene O
expression O
in O
TH O
cells O
. O

Regulation O
of O
the O
balance O
of O
cytokine B-protein
production O
and O
the O
signal O
transducer O
and O
activator O
of O
transcription O
( O
STAT B-protein
) O
transcription O
factor O
activity O
by O
cytokines B-protein
and O
inflammatory O
synovial O
fluids O
. O

The O
balance O
between O
type O
1 O
and O
2 O
T O
helper O
cell O
cytokine O
production O
plays O
an O
important O
role O
in O
several O
animal O
models O
of O
autoimmunity O
, O
and O
skewed O
patterns O
of O
cytokine B-protein
expression O
have O
been O
described O
in O
human O
inflammatory O
diseases O
. O

Many O
cytokines B-protein
activate O
signal B-protein
transducer I-protein
and I-protein
activation I-protein
of I-protein
transcription I-protein
( I-protein
STAT I-protein
) I-protein
transcription I-protein
factors I-protein
, O
which O
, O
in O
turn O
, O
activate O
transcription O
of O
inflammatory O
effector O
genes O
. O

We O
used O
mononuclear O
cell O
priming O
cultures O
and O
inflammatory O
synovial O
fluids O
( O
SFs O
) O
derived O
from O
arthritis O
patients O
to O
examine O
the O
regulation O
of O
cytokine B-protein
production O
and O
STAT B-protein
activity O
by O
an O
inflammatory O
synovial O
microenvironment O
. O

Exposure O
to O
SFs O
during O
priming O
resulted O
in O
an O
81 O
% O
inhibition O
of O
interferon B-protein
( I-protein
IFN I-protein
) I-protein
- I-protein
gamma I-protein
, O
but O
not O
interleukin B-protein
( I-protein
IL I-protein
) I-protein
4 I-protein
, O
production O
by O
effector O
cells O
generated O
in O
priming O
cultures O
. O

SF O
suppression O
was O
mediated O
by O
IL B-protein
- I-protein
4 I-protein
and O
IL B-protein
- I-protein
10 I-protein
and O
inhibition O
of O
IL B-protein
- I-protein
12 I-protein
expression O
, O
and O
it O
was O
reversed O
in O
a O
dominant O
fashion O
by O
exogenous O
IL O
- O
12 O
. O

SFs O
blocked O
the O
sustained O
activity O
of O
transcription B-protein
factor I-protein
Stat1 I-protein
, O
but O
not O
Stat3 B-protein
, O
during O
the O
priming O
period O
, O
and O
Stat1 B-protein
activity O
was O
differentially O
regulated O
by O
cytokines B-protein
in O
parallel O
with O
their O
positive O
or O
negative O
regulation O
of O
IFN B-protein
- I-protein
gamma I-protein
production O
. O

Active O
Stat3 B-protein
, O
but O
not O
Stat1 B-protein
, O
was O
detected O
in O
cells O
from O
inflamed O
joints O
. O

These O
results O
suggest O
a O
role O
for O
altered O
balance O
of O
Stat1 O
and O
Stat3 O
transcriptional O
activity O
in O
the O
regulation O
of O
T O
cell O
differentiation O
and O
in O
the O
pathogenesis O
of O
inflammatory O
synovitis O
. O

Triggering O
of O
complement B-protein
receptors I-protein
CR1 B-protein
( O
CD35 B-protein
) O
and O
CR3 B-protein
( O
CD11b B-protein
/ I-protein
CD18 I-protein
) O
induces O
nuclear O
translocation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
( O
p50 B-protein
/ I-protein
p65 I-protein
) O
in O
human O
monocytes O
and O
enhances O
viral O
replication O
in O
HIV O
- O
infected O
monocytic O
cells O
. O

Monocyte O
/ O
macrophages O
may O
harbor O
HIV O
in O
a O
nonproductive O
fashion O
for O
prolonged O
periods O
of O
time O
. O

Viral O
gene O
expression O
may O
be O
reactivated O
by O
stimulation O
of O
the O
cells O
with O
LPS O
or O
cytokines B-protein
such O
as O
TNF B-protein
- I-protein
alpha I-protein
in O
vitro O
. O

The O
effect O
of O
LPS O
and O
TNF B-protein
- I-protein
alpha I-protein
is O
mediated O
by O
their O
ability O
to O
induce O
nuclear O
translocation O
of O
the O
DNA B-protein
- I-protein
binding I-protein
heterodimer I-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
( O
p50 B-protein
/ I-protein
p65 I-protein
) O
, O
which O
binds O
to O
a O
specific O
sequence O
in O
the O
HIV O
- O
long O
terminal O
repeat O
. O

The O
present O
study O
demonstrates O
that O
triggering O
of O
complement B-protein
receptors I-protein
CR1 B-protein
( O
CD35 B-protein
) O
and O
CR3 B-protein
( O
CD11b B-protein
/ I-protein
CD18 I-protein
) O
enhances O
viral O
replication O
in O
HIV O
- O
infected O
human O
monocytic O
cells O
. O

Monocytic O
cell O
lines O
and O
normal O
peripheral O
blood O
monocytes O
were O
infected O
with O
HIV O
- O
1 O
in O
vitro O
and O
cultured O
in O
the O
presence O
or O
absence O
of O
F B-protein
( I-protein
ab I-protein
' I-protein
) I-protein
2 I-protein
fragments I-protein
of O
monoclonal B-protein
anti I-protein
- I-protein
CR1 I-protein
or O
anti B-protein
- I-protein
CR3 I-protein
Abs I-protein
or O
with O
C3 B-protein
fragments I-protein
. O

Stimulation O
of O
CR1 B-protein
or O
CR3 B-protein
induces O
a O
two O
- O
to O
fourfold O
increase O
in O
the O
amount O
of O
cell O
- O
associated O
and O
released O
p24 B-protein
Ag I-protein
in O
cell O
cultures O
that O
was O
equivalent O
to O
that O
observed O
in O
control O
cultures O
triggered O
with O
LPS O
. O

We O
further O
observed O
that O
stimulation O
of O
CR1 B-protein
or O
CR3 B-protein
induces O
the O
nuclear O
translocation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p50 B-protein
/ I-protein
p65 I-protein
in O
infected O
cells O
. O

Translocation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p50 B-protein
/ I-protein
p65 I-protein
was O
also O
observed O
following O
stimulation O
of O
CR1 B-protein
or O
CR3 B-protein
of O
uninfected O
peripheral O
blood O
monocytes O
from O
HIV O
- O
seronegative O
donors O
. O

The O
amount O
of O
protein O
translocated O
was O
similar O
to O
that O
observed O
when O
cells O
were O
stimulated O
with O
rhTNF B-protein
- I-protein
alpha I-protein
. O

TNF B-protein
- I-protein
alpha I-protein
did O
not O
mediate O
the O
translocation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p50 B-protein
/ I-protein
p65 I-protein
induced O
by O
triggering O
of O
complement B-protein
receptors I-protein
. O

Taken O
together O
, O
these O
observations O
suggest O
that O
HIV O
gene O
expression O
may O
be O
activated O
in O
infected O
monocytes O
through O
interaction O
of O
the O
cells O
with O
complement B-protein
- I-protein
opsonized I-protein
particles I-protein
and O
that O
enhanced O
viral O
replication O
is O
associated O
with O
C3 B-protein
receptor I-protein
- O
mediated O
nuclear O
translocation O
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
complex I-protein
. O

Attenuation O
of O
gamma B-protein
interferon I-protein
- O
induced O
tyrosine O
phosphorylation O
in O
mononuclear O
phagocytes O
infected O
with O
Leishmania O
donovani O
: O
selective O
inhibition O
of O
signaling O
through O
Janus B-protein
kinases I-protein
and O
Stat1 B-protein
. O

The O
induction O
of O
gene O
transcription O
in O
response O
to O
gamma B-protein
interferon I-protein
is O
impaired O
in O
mononuclear O
phagocytes O
infected O
with O
Leishmania O
donovani O
, O
and O
the O
mechanisms O
involved O
are O
not O
fully O
understood O
. O

The O
changes O
in O
gene O
expression O
brought O
about O
by O
gamma B-protein
interferon I-protein
are O
thought O
to O
involve O
transient O
increases O
in O
the O
activities O
of O
cellular B-protein
protein I-protein
tyrosine I-protein
kinases I-protein
, O
including O
the O
Janus B-protein
kinases I-protein
Jak1 B-protein
and O
Jak2 B-protein
, O
leading O
to O
tyrosine O
phosphorylation O
of O
the O
transcription B-protein
factor I-protein
Stat1 I-protein
. O

To O
investigate O
the O
mechanisms O
accounting O
for O
the O
impaired O
responses O
to O
gamma B-protein
interferon I-protein
, O
a O
model O
system O
for O
examining O
overall O
changes O
in O
protein O
tyrosine O
phosphorylation O
, O
activation O
of O
Jak1 B-protein
and O
Jak2 B-protein
and O
phosphorylation O
of O
Stat1 B-protein
was O
developed O
in O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
- O
differentiated O
U O
- O
937 O
cells O
. O

Analysis O
of O
whole O
- O
cell O
lysates O
by O
antiphosphotyrosine O
immunoblotting O
showed O
that O
incubation O
with O
gamma B-protein
interferon I-protein
brought O
about O
specific O
increases O
in O
phosphotyrosine O
labeling O
of O
several O
proteins O
. O

Increased O
labeling O
of O
these O
proteins O
occurred O
to O
similar O
extents O
in O
control O
cells O
and O
in O
cells O
that O
had O
been O
infected O
with O
L O
. O
donovani O
for O
16 O
h O
. O

Jak1 B-protein
, O
Jak2 B-protein
, O
and O
Stat1 B-protein
were O
immunoprecipitated O
from O
control O
and O
interferon O
- O
treated O
cells O
, O
and O
tyrosine O
phosphorylation O
of O
these O
proteins O
, O
detected O
by O
antiphosphotyrosine O
immunoblotting O
was O
used O
to O
measured O
their O
activation O
. O

Tyrosine O
phosphorylation O
of O
Jak1 B-protein
, O
Jak2 B-protein
, O
and O
Stat1 B-protein
increased O
markedly O
, O
in O
a O
dose O
- O
dependent O
manner O
, O
in O
U O
- O
937 O
cells O
incubated O
with O
gamma B-protein
interferon I-protein
. O

In O
contrast O
, O
in O
cells O
infected O
with O
L O
. O
donovani O
, O
tyrosine O
phosphorylation O
of O
Jak1 B-protein
, O
Jak2 B-protein
, O
and O
Stat1 B-protein
was O
markedly O
impaired O
. O

This O
effect O
was O
dependent O
upon O
the O
duration O
of O
exposure O
to O
L O
. O
donovani O
and O
was O
maximal O
and O
complete O
at O
16 O
h O
. O

Results O
similar O
to O
those O
observed O
with O
U O
- O
937 O
cells O
were O
also O
obtained O
with O
human O
peripheral O
blood O
monocytes O
. O

These O
findings O
indicate O
that O
infection O
of O
human O
mononuclear O
phagocytes O
with O
L O
. O
donovani O
leads O
to O
impaired O
gamma B-protein
interferon I-protein
- O
mediated O
tyrosine O
phosphorylation O
and O
selective O
effects O
on O
the O
Jak O
- O
Stat1 B-protein
pathway O
. O

Unresponsiveness O
to O
gamma B-protein
interferon I-protein
for O
activation O
of O
this O
pathway O
may O
explain O
impaired O
transcriptional O
responses O
in O
leishmania O
- O
infected O
cells O
. O

Mutually O
exclusive O
interaction O
of O
a O
novel O
matrix B-protein
attachment I-protein
region I-protein
binding I-protein
protein I-protein
and O
the O
NF B-protein
- I-protein
muNR I-protein
enhancer I-protein
repressor I-protein
. O

Implications O
for O
regulation O
of O
immunoglobulin B-protein
heavy I-protein
chain I-protein
expression O
. O

The O
immunoglobulin B-protein
heavy I-protein
chain I-protein
( O
IgH B-protein
) O
intronic O
enhancer O
stimulates O
transcription O
from O
functional O
promoters O
in O
B O
lymphocytes O
but O
not O
other O
cell O
types O
. O

The O
observation O
that O
binding O
sites O
for O
the O
nuclear B-protein
factor I-protein
- I-protein
mu I-protein
negative I-protein
regulator I-protein
( O
NF B-protein
- I-protein
muNR I-protein
) O
enhancer O
repressor O
overlap O
nuclear B-protein
matrix I-protein
attachment I-protein
regions I-protein
( O
MARs B-protein
) O
in O
this O
enhancer O
has O
lead O
to O
the O
hypothesis O
that O
the O
cell O
type O
specificity O
of O
the O
enhancer O
might O
be O
controlled O
by O
regulating O
nuclear O
matrix O
attachment O
( O
Scheuermann O
, O
R O
. O
H O
. O
, O
and O
Chen O
, O
U O
. O
( O
1989 O
) O
Genes O
& O
Dev O
. O
3 O
, O
1255 O
- O
1266 O
) O
. O

To O
understand O
the O
role O
of O
MARs B-protein
in O
IgH B-protein
enhancer O
regulation O
, O
we O
have O
identified O
a O
novel O
MAR B-protein
- I-protein
binding I-protein
protein I-protein
, O
MAR B-protein
- I-protein
BP1 I-protein
, O
from O
soluble O
nuclear O
matrix O
preparations O
based O
on O
its O
ability O
to O
bind O
to O
the O
MARs B-protein
associated O
with O
the O
IgH B-protein
enhancer O
. O

Purified O
MAR B-protein
- I-protein
BP1 I-protein
migrates O
as O
a O
33 B-protein
- I-protein
kDa I-protein
protein I-protein
, O
and O
it O
can O
be O
found O
in O
nuclear O
matrix O
preparations O
from O
a O
number O
of O
different O
types O
of O
lymphoid O
cell O
lines O
. O

Although O
specific O
binding O
sites O
have O
been O
difficult O
to O
localize O
by O
chemical O
or O
enzymatic O
footprinting O
procedures O
, O
NF B-protein
- I-protein
muNR I-protein
binding O
sites O
are O
critical O
for O
efficient O
MAR B-protein
- I-protein
BP1 I-protein
binding O
. O

Indeed O
, O
binding O
of O
the O
IgH B-protein
enhancer O
to O
either O
intact O
nuclear O
matrix O
preparations O
or O
to O
MAR B-protein
- I-protein
BP1 I-protein
is O
mutually O
exclusive O
to O
NF B-protein
- I-protein
muNR I-protein
binding O
. O

These O
results O
are O
consistent O
with O
a O
model O
for O
cell O
- O
type O
specific O
regulation O
in O
which O
binding O
of O
the O
NF B-protein
- I-protein
muNR I-protein
repressor I-protein
to O
the O
IgH B-protein
enhancer O
prevents O
nuclear O
matrix O
attachment O
in O
inappropriate O
cells O
by O
interfering O
with O
MAR B-protein
- I-protein
BP1 I-protein
/ O
enhancer O
interaction O
. O

PU B-protein
. I-protein
1 I-protein
( O
Spi B-protein
- I-protein
1 I-protein
) O
and O
C B-protein
/ I-protein
EBP I-protein
alpha I-protein
regulate O
expression O
of O
the O
granulocyte B-protein
- I-protein
macrophage I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
receptor I-protein
alpha O
gene O
. O

Growth B-protein
factor I-protein
receptors I-protein
play O
an O
important O
role O
in O
hematopoiesis O
. O

In O
order O
to O
further O
understand O
the O
mechanisms O
directing O
the O
expression O
of O
these O
key O
regulators O
of O
hematopoiesis O
, O
we O
initiated O
a O
study O
investigating O
the O
transcription B-protein
factors I-protein
activating O
the O
expression O
of O
the O
granulocyte B-protein
- I-protein
macrophage I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
( O
GM B-protein
- I-protein
CSF I-protein
) O
receptor O
alpha O
gene O
. O

Here O
, O
we O
demonstrate O
that O
the O
human O
GM B-protein
- I-protein
CSF I-protein
receptor I-protein
alpha I-protein
promoter O
directs O
reporter O
gene O
activity O
in O
a O
tissue O
- O
specific O
fashion O
in O
myelomonocytic O
cells O
, O
which O
correlates O
with O
its O
expression O
pattern O
as O
analyzed O
by O
reverse O
transcription O
PCR O
. O

The O
GM B-protein
- I-protein
CSF I-protein
receptor I-protein
alpha I-protein
promoter O
contains O
an O
important O
functional O
site O
between O
positions O
- O
53 O
and O
- O
41 O
as O
identified O
by O
deletion O
analysis O
of O
reporter O
constructs O
. O

We O
show O
that O
the O
myeloid O
and O
B B-protein
cell I-protein
transcription I-protein
factor I-protein
PU B-protein
. I-protein
1 I-protein
binds O
specifically O
to O
this O
site O
. O

Furthermore O
, O
we O
demonstrate O
that O
a O
CCAAT O
site O
located O
upstream O
of O
the O
PU B-protein
. I-protein
1 I-protein
site O
between O
positions O
- O
70 O
and O
- O
54 O
is O
involved O
in O
positive O
- O
negative O
regulation O
of O
the O
GM B-protein
- I-protein
CSF I-protein
receptor I-protein
alpha I-protein
promoter O
activity O
. O

C B-protein
/ I-protein
EBP I-protein
alpha I-protein
is O
the O
major O
CCAAT B-protein
/ I-protein
enhancer I-protein
- I-protein
binding I-protein
protein I-protein
( O
C B-protein
/ I-protein
EBP I-protein
) O
form O
binding O
to O
this O
site O
in O
nuclear O
extracts O
of O
U937 O
cells O
. O

Point O
mutations O
of O
either O
the O
PU B-protein
. I-protein
1 I-protein
site O
or O
the O
C B-protein
/ I-protein
EBP I-protein
site O
that O
abolish O
the O
binding O
of O
the O
respective O
factors O
result O
in O
a O
significant O
decrease O
of O
GM B-protein
- I-protein
CSF I-protein
receptor I-protein
alpha I-protein
promoter O
activity O
in O
myelomonocytic O
cells O
only O
. O

Furthermore O
, O
we O
demonstrate O
that O
in O
myeloid O
and O
B O
cell O
extracts O
, O
PU B-protein
. I-protein
1 I-protein
forms O
a O
novel O
, O
specific O
, O
more O
slowly O
migrating O
complex O
( O
PU B-protein
- I-protein
SF I-protein
) O
when O
binding O
the O
GM B-protein
- I-protein
CSF I-protein
receptor I-protein
alpha I-protein
promoter O
PU B-protein
. I-protein
1 I-protein
site O
. O

This O
is O
the O
first O
demonstration O
of O
a O
specific O
interaction O
with O
PU B-protein
. I-protein
1 I-protein
on O
a O
myeloid O
PU B-protein
. I-protein
1 I-protein
binding O
site O
. O

The O
novel O
complex O
is O
distinct O
from O
that O
described O
previously O
as O
binding O
to O
B O
cell O
enhancer O
sites O
and O
can O
be O
formed O
by O
addition O
of O
PU B-protein
. I-protein
1 I-protein
to O
extracts O
from O
certain O
nonmyeloid O
cell O
types O
which O
do O
not O
express O
PU B-protein
. I-protein
1 I-protein
, O
including O
T O
cells O
and O
epithelial O
cells O
, O
but O
not O
from O
erythroid O
cells O
. O

Furthermore O
, O
we O
demonstrate O
that O
the O
PU B-protein
- I-protein
SF I-protein
complex I-protein
binds O
to O
PU B-protein
. I-protein
1 I-protein
sites O
found O
on O
a O
number O
of O
myeloid O
promoters O
, O
and O
its O
formation O
requires O
an O
intact O
PU B-protein
. I-protein
1 I-protein
site O
adjacent O
to O
a O
single O
- O
stranded O
region O
. O

Expression O
of O
PU B-protein
. I-protein
1 I-protein
in O
nonmyeloid O
cells O
can O
activate O
the O
GM B-protein
- I-protein
CSF I-protein
receptor O
alpha O
promoter O
. O

Deletion O
of O
the O
amino B-protein
- I-protein
terminal I-protein
region I-protein
of O
PU B-protein
. I-protein
1 I-protein
results O
in O
a O
failure O
to O
form O
the O
PU B-protein
- I-protein
SF I-protein
complex O
and O
in O
a O
concomitant O
loss O
of O
transactivation O
, O
suggesting O
that O
formation O
of O
the O
PU B-protein
- I-protein
SF I-protein
complex I-protein
is O
of O
functional O
importance O
for O
the O
activity O
of O
the O
GM B-protein
- I-protein
CSF I-protein
receptor O
alpha O
promoter O
. O

Finally O
, O
we O
demonstrate O
that O
C B-protein
/ I-protein
EBP I-protein
alpha I-protein
can O
also O
active O
the O
GM B-protein
- I-protein
CSF I-protein
receptor I-protein
alpha I-protein
promoter O
in O
nonmyeloid O
cells O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
400 O
WORDS O
) O
. O

HMG B-protein
- I-protein
I I-protein
binds O
to O
GATA O
motifs O
: O
implications O
for O
an O
HPFH O
syndrome O
. O

We O
have O
examined O
binding O
of O
the O
nuclear B-protein
protein I-protein
HMG B-protein
- I-protein
I I-protein
to O
the O
human O
gamma O
- O
globin O
promoter O
. O

We O
find O
that O
HMG B-protein
- I-protein
I I-protein
binds O
preferentially O
to O
the O
more O
3 O
' O
of O
a O
pair O
of O
GATA O
motifs O
in O
the O
gamma O
- O
globin O
promoter O
; O
this O
paired O
motif O
is O
bound O
by O
the O
erythroid B-protein
factor I-protein
GATA I-protein
- I-protein
1 I-protein
. O

A O
naturally O
occurring O
mutation O
( O
- O
175 O
T O
- O
C O
) O
in O
the O
area O
bound O
by O
HMG B-protein
- I-protein
I I-protein
results O
in O
overexpression O
of O
gamma B-protein
- I-protein
globin I-protein
in O
adult O
red O
blood O
cells O
( O
HPFH O
) O
and O
up O
- O
regulation O
of O
the O
gamma B-protein
- I-protein
globin I-protein
promoter O
in O
in O
vitro O
expression O
assays O
; O
HMG B-protein
- I-protein
I I-protein
does O
not O
bind O
to O
this O
mutant O
sequence O
. O

A O
survey O
of O
GATA O
motifs O
from O
other O
globin O
cis O
- O
elements O
demonstrates O
HMG B-protein
- I-protein
I I-protein
binding O
to O
most O
of O
them O
. O

These O
findings O
implicate O
HMG B-protein
- I-protein
I I-protein
in O
the O
HPFH O
phenotype O
; O
we O
speculate O
that O
it O
may O
participate O
in O
the O
formation O
of O
multiprotein B-protein
complexes I-protein
that O
regulate O
globin O
gene O
expression O
. O

Constitutive O
activation O
of O
different O
Jak B-protein
tyrosine I-protein
kinases I-protein
in O
human B-protein
T I-protein
cell I-protein
leukemia I-protein
virus I-protein
type I-protein
1 I-protein
( I-protein
HTLV I-protein
- I-protein
1 I-protein
) I-protein
tax I-protein
protein I-protein
or O
virus O
- O
transformed O
cells O
. O

HTLV O
- O
1 O
infection O
causes O
an O
adult O
T O
cell O
leukemia O
in O
humans O
. O

The O
viral B-protein
encoded I-protein
protein I-protein
tax B-protein
, O
is O
thought O
to O
play O
an O
important O
role O
in O
oncogenesis O
. O

Our O
previous O
data O
obtained O
from O
a O
tax B-protein
transgenic O
mouse O
model O
revealed O
that O
tax B-protein
transforms O
mouse O
fibroblasts O
but O
not O
thymocytes O
, O
despite O
comparable O
levels O
of O
tax B-protein
expression O
in O
both O
tissues O
. O

Constitutive O
tyrosine O
phosphorylation O
of O
a O
130 B-protein
- I-protein
kD I-protein
protein I-protein
( O
s O
) O
was O
observed O
in O
the O
tax B-protein
transformed O
fibroblast O
B O
line O
and O
in O
HTLV O
- O
1 O
transformed O
human O
lymphoid O
lines O
, O
but O
not O
in O
thymocytes O
from O
Thy O
- O
tax O
transgenic O
mice O
. O

Phosphotyrosine O
immunoprecipitation O
followed O
by O
Western O
blot O
analysis O
with O
a O
set O
of O
Jak B-protein
kinase I-protein
specific I-protein
antibodies I-protein
, O
identified O
p130 O
as O
Jak2 B-protein
in O
the O
tax B-protein
transformed O
mouse O
fibroblastic O
cell O
line O
and O
Jak3 B-protein
in O
HTLV O
- O
1 O
transformed O
human O
T O
cell O
lines O
. O

Phosphorylation O
of O
Jak2 B-protein
in O
tax B-protein
transformed O
cells O
resulted O
from O
high O
expression O
of O
IL B-protein
- I-protein
6 I-protein
. O

Tyrosine O
phosphorylation O
of O
this O
protein O
could O
also O
be O
induced O
in O
Balb O
/ O
c3T3 O
cells O
using O
a O
supernatant O
from O
the O
B O
line O
, O
which O
was O
associated O
with O
induction O
of O
cell O
proliferation O
. O

Both O
phosphorylation O
and O
proliferation O
were O
inhibited O
by O
IL B-protein
- I-protein
6 I-protein
neutralizing I-protein
antibodies I-protein
. O

Constitutive O
phosphorylation O
of O
Jak B-protein
kinases I-protein
may O
facilitate O
tumor O
growth O
in O
both O
HTLV O
- O
1 O
infected O
human O
T O
cells O
and O
the O
transgenic O
mouse O
model O
. O

Regulation O
of O
c O
- O
jun O
mRNA O
expression O
by O
hydroxyurea O
in O
human O
K562 O
cells O
during O
erythroid O
differentiation O
[ O
published O
erratum O
appears O
in O
Biochim O
Biophys O
Acta O
1995 O
Dec O
27 O
; O
1264 O
( O
3 O
) O
: O
409 O
] O
. O

Hydroxyurea O
( O
HU O
) O
is O
an O
antitumor O
agent O
which O
also O
induces O
hemoglobinization O
during O
erythroid O
differentiation O
. O

In O
addition O
, O
HU O
stimulates O
the O
synthesis O
of O
fetal B-protein
hemoglobin I-protein
in O
sickle O
cell O
anemia O
patients O
. O

To O
further O
understand O
its O
mechanism O
of O
action O
, O
we O
investigated O
the O
effects O
of O
HU O
on O
regulation O
of O
c O
- O
jun O
expression O
prior O
to O
the O
onset O
of O
erythroid O
differentiation O
of O
K562 O
cells O
. O

HU O
induced O
a O
dose O
- O
dependent O
stimulation O
of O
c O
- O
jun O
synthesis O
. O

The O
levels O
of O
c O
- O
jun O
mRNA O
was O
elevated O
4 O
to O
7 O
. O
5 O
- O
fold O
by O
HU O
within O
2 O
h O
. O

This O
was O
followed O
by O
a O
gradual O
decline O
to O
the O
basal O
level O
by O
24 O
h O
. O

Both O
nuclear O
run O
- O
on O
and O
actinomycin O
D O
pulse O
experiments O
strongly O
indicate O
that O
HU O
regulates O
c O
- O
jun O
mRNA O
expression O
by O
increasing O
the O
rate O
of O
synthesis O
as O
well O
as O
stabilizing O
the O
c O
- O
jun O
mRNA O
. O

In O
addition O
, O
the O
level O
of O
jun B-protein
protein I-protein
was O
elevated O
by O
2 O
to O
5 O
- O
fold O
within O
4 O
h O
in O
HU O
treated O
cells O
. O

Furthermore O
, O
concentrations O
of O
HU O
below O
250 O
microM O
slightly O
increased O
the O
5X O
AP B-protein
- I-protein
1 I-protein
/ B-protein
CAT I-protein
activity O
. O

These O
results O
strongly O
suggest O
that O
HU O
induces O
both O
transcriptional O
and O
post O
- O
transcription O
regulation O
of O
c O
- O
jun O
during O
erythroid O
differentiation O
. O

In O
vivo O
and O
in O
vitro O
effects O
of O
glucocorticoids O
on O
lymphocyte O
proliferation O
in O
man O
: O
relationship O
to O
glucocorticoid B-protein
receptors I-protein
. O

Interrelations O
between O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
system O
( O
HPA O
) O
and O
the O
immune O
system O
represent O
a O
well O
- O
documented O
biological O
phenomenon O
. O

While O
in O
vitro O
administration O
of O
glucocorticoids O
may O
inhibit O
concanavalin O
A O
( O
Con O
A O
) O
- O
and O
phytohemagglutinin O
( O
PHA O
) O
- O
induced O
T O
- O
cell O
proliferation O
, O
pokeweed B-protein
mitogen I-protein
( O
PWM B-protein
) O
- O
driven O
B O
- O
cell O
mitogenesis O
is O
relatively O
resistant O
to O
glucocorticoids O
. O

To O
further O
explore O
the O
link O
between O
the O
HPA O
and O
the O
immune O
system O
in O
relation O
to O
glucocorticoid B-protein
receptor I-protein
function O
, O
dose O
- O
response O
curves O
were O
obtained O
for O
Con O
A O
- O
and O
PHA B-protein
- O
induced O
T O
- O
cell O
mitogenesis O
, O
PWM B-protein
- O
generated O
B O
- O
cell O
mitogenesis O
and O
spontaneous O
lymphocyte O
proliferation O
in O
13 O
healthy O
controls O
. O

Glucocorticoid O
effects O
were O
assessed O
in O
vivo O
by O
depletion O
of O
endogenous O
glucocorticoids O
after O
oral O
administration O
of O
1 O
. O
5 O
g O
metyrapone O
( O
MET O
) O
and O
subsequent O
glucocorticoid O
replacement O
, O
and O
in O
vitro O
by O
incubation O
of O
the O
cells O
with O
different O
doses O
of O
dexamethasone O
( O
DEX O
) O
. O

There O
was O
a O
significant O
decrease O
in O
PWM B-protein
- O
induced O
B O
- O
cell O
mitogenesis O
and O
a O
more O
pronounced O
effect O
of O
DEX O
administered O
in O
vitro O
on O
spontaneous O
lymphocyte O
proliferation O
after O
MET O
treatment O
when O
compared O
with O
the O
DEX O
plus O
MET O
pretreated O
condition O
in O
vivo O
. O

These O
data O
suggest O
that O
the O
inhibition O
of O
spontaneous O
lymphocyte O
proliferation O
by O
glucocorticoids O
in O
vitro O
is O
related O
to O
glucocorticoid B-protein
receptor I-protein
function O
. O

The O
decrease O
in O
PWM B-protein
- O
generated O
B O
- O
cell O
proliferation O
following O
cortisol O
depletion O
by O
MET O
may O
be O
seen O
in O
connection O
with O
impaired O
glucocorticoid O
- O
mediated O
induction O
of O
interleukin B-protein
- I-protein
1 I-protein
receptor I-protein
synthesis O
. O

Transcription O
specific O
differences O
visualized O
by O
fluorescence O
in O
situ O
hybridization O
pattern O
on O
interphase O
nuclei O
of O
different O
cell O
types O
. O

Application O
of O
a O
" O
formamide O
free O
" O
and O
thus O
" O
material O
preserving O
" O
in O
situ O
hybridization O
technique O
using O
the O
cDNA O
of O
the O
myf3 O
gene O
revealed O
the O
following O
results O
: O
Human O
rhabdomyosarcoma O
cells O
, O
characterized O
by O
a O
high O
expression O
of O
myf3 O
show O
intensive O
hybridization O
signals O
in O
their O
interphase O
. O

RNase B-protein
treatment O
prior O
to O
hybridization O
considerably O
reduces O
the O
size O
of O
this O
signals O
. O

In O
comparison O
, O
isolated O
nuclei O
of O
human O
lymphocytes O
in O
which O
no O
need O
for O
the O
expression O
of O
this O
gene O
exists O
, O
show O
barely O
hybridization O
signals O
. O

Correspondingly O
, O
RNase B-protein
treatment O
had O
no O
effect O
on O
hybridization O
pattern O
at O
all O
. O

In O
conclusion O
an O
increased O
transcription O
efficiency O
of O
a O
cell O
type O
specific O
gene O
is O
accompanied O
by O
a O
higher O
hybridization O
accessibility O
in O
the O
corresponding O
cell O
nuclei O
. O

Oncogenicity O
of O
human O
papillomavirus O
- O
or O
adenovirus O
- O
transformed O
cells O
correlates O
with O
resistance O
to O
lysis O
by O
natural O
killer O
cells O
. O

The O
reasons O
for O
the O
dissimilar O
oncogenicities O
of O
human O
adenoviruses O
and O
human O
papillomaviruses O
( O
HPV O
) O
in O
humans O
are O
unknown O
but O
may O
relate O
to O
differences O
in O
the O
capacities O
of O
the O
E1A B-protein
and O
E7 B-protein
proteins I-protein
to O
target O
cells O
for O
rejection O
by O
the O
host O
natural O
killer O
( O
NK O
) O
cell O
response O
. O

As O
one O
test O
of O
this O
hypothesis O
, O
we O
compared O
the O
abilities O
of O
E1A B-protein
- O
and O
E7 B-protein
- O
expressing O
human O
fibroblastic O
or O
keratinocyte O
- O
derived O
human O
cells O
to O
be O
selectively O
killed O
by O
either O
unstimulated O
or O
interferon O
( O
IFN O
) O
- O
activated O
NK O
cells O
. O

Cells O
expressing O
the O
E1A B-protein
oncoprotein I-protein
were O
selectively O
killed O
by O
unstimulated O
NK O
cells O
, O
while O
the O
same O
parental O
cells O
but O
expressing O
the O
HPV O
type O
16 O
( O
HPV O
- O
16 O
) O
or O
HPV O
- O
18 O
E7 B-protein
oncoprotein I-protein
were O
resistant O
to O
NK O
cell O
lysis O
. O

The O
ability O
of O
IFN O
- O
activated O
NK O
cells O
to O
selectively O
kill O
virally O
transformed O
cells O
depends O
on O
IFN B-protein
' O
s O
ability O
to O
induce O
resistance O
to O
NK O
cell O
lysis O
in O
normal O
( O
i O
. O
e O
. O
, O
non O
- O
viral O
oncogene O
- O
expressing O
) O
but O
not O
virally O
transformed O
cells O
. O

E1A B-protein
blocked O
IFN B-protein
' O
s O
induction O
of O
cytolytic O
resistance O
, O
resulting O
in O
the O
selective O
lysis O
of O
adenovirus O
- O
transformed O
cells O
by O
IFN B-protein
- O
activated O
NK O
cells O
. O

The O
extent O
of O
IFN B-protein
- O
induced O
NK O
cell O
killing O
of O
E1A B-protein
- O
expressing O
cells O
was O
proportional O
to O
the O
level O
of O
E1A B-protein
expression O
and O
correlated O
with O
the O
ability O
of O
E1A B-protein
to O
block O
IFN B-protein
- O
stimulated O
gene O
expression O
in O
target O
cells O
. O

In O
contrast O
, O
E7 B-protein
blocked O
neither O
IFN B-protein
- O
stimulated O
gene O
expression O
nor O
IFN B-protein
' O
s O
induction O
of O
cytolytic O
resistance O
, O
thereby O
precluding O
the O
selective O
lysis O
of O
HPV O
- O
transformed O
cells O
by O
IFN B-protein
- O
activated O
NK O
cells O
. O

In O
conclusion O
, O
E1A B-protein
expression O
marks O
cells O
for O
destruction O
by O
the O
host O
NK O
cell O
response O
, O
whereas O
the O
E7 B-protein
oncoprotein I-protein
lacks O
this O
activity O
. O

Regulation O
of O
IkB B-protein
alpha I-protein
phosphorylation O
by O
PKC O
- O
and O
Ca O
( O
2 O
+ O
) O
- O
dependent O
signal O
transduction O
pathways O
. O

The O
Ca B-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
dependent I-protein
phosphatase I-protein
calcineurin B-protein
, O
a O
target O
of O
FK506 O
and O
CsA O
, O
synergizes O
with O
PKC B-protein
- O
induced O
activation O
of O
nuclear B-protein
factor I-protein
( I-protein
NF I-protein
) I-protein
- I-protein
kappa I-protein
B I-protein
in O
T O
cell O
lines O
. O

We O
have O
investigated O
whether O
this O
synergy O
is O
present O
in O
other O
cell O
types O
and O
the O
mechanism O
( O
s O
) O
by O
which O
these O
two O
pathways O
lead O
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
. O

While O
this O
synergy O
is O
present O
in O
other O
cell O
types O
, O
in O
the O
monocytic O
cell O
line O
U937 O
calcineurin B-protein
is O
also O
sufficient O
to O
activate O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

Having O
previously O
shown O
that O
Ca O
( O
2 O
+ O
) O
- O
and O
PKC O
- O
dependent O
pathways O
synergize O
by O
accelerating O
the O
degradation O
of O
IkB B-protein
alpha I-protein
, O
we O
focused O
on O
the O
regulation O
of O
IkB B-protein
alpha I-protein
phosphorylation O
. O

While O
PKC B-protein
- O
dependent O
pathways O
sequentially O
result O
in O
the O
phosphorylation O
and O
in O
an O
incomplete O
degradation O
of O
IkB B-protein
alpha I-protein
in O
T O
cell O
lines O
, O
co O
- O
activation O
of O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathways O
accelerates O
the O
rate O
of O
IkB B-protein
alpha I-protein
phosphorylation O
and O
results O
in O
its O
complete O
degradation O
. O

Activation O
of O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathways O
alone O
do O
not O
result O
in O
the O
phosphorylation O
and O
/ O
or O
degradation O
of O
IkB B-protein
alpha I-protein
in O
Jurkat O
T O
or O
in O
U937 O
cells O
. O

Treatment O
of O
T O
cells O
with O
the O
selective O
PKC B-protein
inhibitor O
GF109203X O
abrogates O
the O
PMA O
- O
induced O
IkB B-protein
alpha I-protein
phosphorylation O
/ O
degradation O
irrespective O
of O
activation O
of O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathways O
, O
but O
not O
the O
phosphorylation O
and O
degradation O
of O
IkB B-protein
alpha I-protein
induced O
by O
TNF B-protein
- I-protein
alpha I-protein
, O
a O
PKC B-protein
- O
independent O
stimulus O
. O

Contrary O
to O
the O
interaction O
with O
PKC B-protein
, O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathways O
synergize O
with O
TNF B-protein
- I-protein
alpha I-protein
not O
at O
the O
level O
of O
IkB B-protein
alpha I-protein
phosphorylation O
, O
but O
at O
the O
level O
of O
its O
degradation O
. O

These O
results O
indicate O
that O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathways O
, O
including O
the O
phosphatase B-protein
calcineurin B-protein
, O
participate O
in O
the O
regulation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
a O
cell O
specific O
fashion O
and O
synergize O
with O
PKC B-protein
- O
dependent O
and O
- O
independent O
pathways O
at O
the O
level O
of O
IkB B-protein
alpha I-protein
phosphorylation O
and O
degradation O
. O

Vitamin O
E O
therapy O
of O
acute O
CCl4 O
- O
induced O
hepatic O
injury O
in O
mice O
is O
associated O
with O
inhibition O
of O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
binding O
. O

Oxidative O
stress O
, O
with O
reactive O
oxygen O
intermediate O
formation O
, O
may O
represent O
a O
common O
mechanism O
by O
which O
liver O
injury O
is O
induced O
by O
diverse O
etiologies O
. O

Oxidative O
stress O
enhances O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
( O
NF B-protein
- I-protein
kappa I-protein
B I-protein
) O
activity O
, O
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
has O
been O
shown O
to O
enhance O
the O
expression O
of O
cytotoxic B-protein
cytokines I-protein
. O

Acute O
hepatic O
injury O
caused O
by O
reactive O
oxygen O
intermediate O
production O
was O
induced O
by O
an O
intraperitoneal O
injection O
of O
CCl4 O
in O
mice O
. O

This O
injury O
was O
significantly O
inhibited O
by O
intravenous O
pretreatment O
of O
the O
mice O
with O
a O
water O
- O
soluble O
emulsion O
of O
alpha O
- O
tocopherol O
. O

Alpha O
- O
tocopherol O
treatment O
of O
the O
mice O
given O
the O
CCl4 O
also O
reduced O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
to O
levels O
approaching O
those O
found O
in O
normal O
mice O
. O

In O
vitro O
treatment O
of O
a O
monocyte O
/ O
macrophage O
cell O
line O
with O
CCl4 O
led O
to O
enhanced O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
and O
an O
increase O
in O
tumor B-protein
necrosis I-protein
factor I-protein
- I-protein
alpha I-protein
( O
TNF B-protein
- I-protein
alpha I-protein
) O
messenger O
RNA O
levels O
. O

Liver O
specimens O
taken O
from O
patients O
with O
acute O
fulminant O
hepatitis O
had O
markedly O
increased O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
activity O
in O
comparison O
with O
the O
binding O
of O
normal O
livers O
. O

These O
data O
demonstrate O
that O
abolishing O
acute O
hepatic O
injury O
with O
alpha O
- O
tocopherol O
, O
a O
free O
radical O
scavenger O
, O
also O
eliminated O
increased O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
. O

It O
is O
tempting O
to O
speculate O
that O
enhanced O
NF B-protein
- I-protein
kappa I-protein
B I-protein
expression O
caused O
by O
free O
radical O
production O
/ O
oxidative O
stress O
may O
modulate O
liver O
injury O
, O
perhaps O
through O
an O
effect O
on O
cytotoxic B-protein
cytokine I-protein
synthesis O
. O

Immunosuppression O
by O
glucocorticoids O
: O
inhibition O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
through O
induction O
of O
I B-protein
kappa I-protein
B I-protein
synthesis O
[ O
see O
comments O
] O
. O

Glucocorticoids O
are O
among O
the O
most O
potent O
anti O
- O
inflammatory O
and O
immunosuppressive O
agents O
. O

They O
inhibit O
synthesis O
of O
almost O
all O
known O
cytokines B-protein
and O
of O
several O
cell B-protein
surface I-protein
molecules I-protein
required O
for O
immune O
function O
, O
but O
the O
mechanism O
underlying O
this O
activity O
has O
been O
unclear O
. O
Here O
it O
is O
shown O
that O
glucocorticoids O
are O
potent O
inhibitors O
of O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
( O
NF B-protein
- I-protein
kappa I-protein
B I-protein
) O
activation O
in O
mice O
and O
cultured O
cells O
. O

This O
inhibition O
is O
mediated O
by O
induction O
of O
the O
I B-protein
kappa I-protein
B I-protein
alpha O
inhibitory O
protein O
, O
which O
traps O
activated O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
inactive B-protein
cytoplasmic I-protein
complexes I-protein
. O

Because O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activates O
many O
immunoregulatory O
genes O
in O
response O
to O
pro O
- O
inflammatory O
stimuli O
, O
the O
inhibition O
of O
its O
activity O
can O
be O
a O
major O
component O
of O
the O
anti O
- O
inflammatory O
activity O
of O
glucocorticoids O
. O

Transcriptional O
repression O
of O
the O
interleukin O
- O
2 O
gene O
by O
vitamin O
D3 O
: O
direct O
inhibition O
of O
NFATp B-protein
/ I-protein
AP I-protein
- I-protein
1 I-protein
complex I-protein
formation O
by O
a O
nuclear B-protein
hormone I-protein
receptor I-protein
. O

T O
- O
lymphocyte O
proliferation O
is O
suppressed O
by O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
[ O
1 O
, O
25 O
( O
OH O
) O
2D3 O
] O
, O
the O
active O
metabolite O
of O
vitamin O
D3 O
, O
and O
is O
associated O
with O
a O
decrease O
in O
interleukin O
2 O
( O
IL O
- O
2 O
) O
, O
gamma O
interferon O
, O
and O
granulocyte O
- O
macrophage O
colony O
- O
stimulating O
factor O
mRNA O
levels O
. O

We O
report O
here O
that O
1 O
, O
25 O
( O
OH O
) O
2D3 O
- O
mediated O
repression O
in O
Jurkat O
cells O
is O
cycloheximide O
resistant O
, O
suggesting O
that O
it O
is O
a O
direct O
transcriptional O
repressive O
effect O
on O
IL B-protein
- I-protein
2 I-protein
expression O
by O
the O
vitamin B-protein
D3 I-protein
receptor I-protein
( O
VDR B-protein
) O
. O

We O
therefore O
examined O
vitamin O
D3 O
- O
mediated O
repression O
of O
activated O
IL B-protein
- I-protein
2 I-protein
expression O
by O
cotransfecting O
Jurkat O
cells O
with O
IL B-protein
- I-protein
2 I-protein
promoter O
/ O
reporter O
constructs O
and O
a O
VDR B-protein
overexpression O
vector O
and O
by O
DNA O
binding O
. O

We O
delineated O
an O
element O
conferring O
both O
DNA O
binding O
by O
the O
receptor O
in O
vitro O
and O
1 O
, O
25 O
( O
OH O
) O
2D3 O
- O
mediated O
repression O
in O
vivo O
to O
a O
short O
40 O
- O
bp O
region O
encompassing O
an O
important O
positive O
regulatory O
element O
, O
NF O
- O
AT O
- O
1 O
, O
which O
is O
bound O
by O
a O
T B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
, O
NFATp B-protein
, O
as O
well O
as O
by O
AP B-protein
- I-protein
1 I-protein
. O

VDR B-protein
DNA I-protein
- I-protein
binding I-protein
mutants I-protein
were O
unable O
to O
either O
bind O
to O
this O
element O
in O
vitro O
or O
repress O
in O
vivo O
; O
the O
VDR B-protein
DNA I-protein
- I-protein
binding I-protein
domain I-protein
alone O
, O
however O
, O
bound O
the O
element O
but O
also O
could O
not O
repress O
IL B-protein
- I-protein
2 I-protein
expression O
. O

These O
results O
indicate O
that O
DNA O
binding O
by O
VDR B-protein
is O
necessary O
but O
not O
sufficient O
to O
mediate O
IL B-protein
- I-protein
2 I-protein
repression O
. O

By O
combining O
partially B-protein
purified I-protein
proteins I-protein
in O
vitro O
, O
we O
observed O
the O
loss O
of O
the O
bound O
NFATp B-protein
/ I-protein
AP I-protein
- I-protein
1 I-protein
- I-protein
DNA I-protein
complex I-protein
upon O
inclusion O
of O
VDR B-protein
or O
VDR B-protein
- I-protein
retinoid I-protein
X I-protein
receptor I-protein
. O

Order O
of O
addition O
and O
off O
- O
rate O
experiments O
indicate O
that O
the O
VDR B-protein
- I-protein
retinoid I-protein
X I-protein
receptor I-protein
heterodimer I-protein
blocks O
NFATp B-protein
/ I-protein
AP I-protein
- I-protein
1 I-protein
complex I-protein
formation O
and O
then O
stably O
associates O
with O
the O
NF O
- O
AT O
- O
1 O
element O
. O

This O
direct O
inhibition O
by O
a O
nuclear O
hormone O
receptor O
of O
transcriptional B-protein
activators I-protein
of O
the O
IL B-protein
- I-protein
2 I-protein
gene O
may O
provide O
a O
mechanistic O
explanation O
of O
how O
vitamin O
derivatives O
can O
act O
as O
potent O
immunosuppressive O
agents O
. O

Tissue O
- O
specific O
regulation O
of O
the O
rabbit O
15 B-protein
- I-protein
lipoxygenase I-protein
gene O
in O
erythroid O
cells O
by O
a O
transcriptional O
silencer O
. O

The O
15 O
- O
lipoxygenase O
( O
lox O
) O
gene O
is O
expressed O
in O
a O
tissue O
- O
specific O
manner O
, O
predominantly O
in O
erythroid O
cells O
but O
also O
in O
airway O
epithelial O
cells O
and O
eosinophils O
. O

We O
demonstrate O
in O
this O
report O
that O
the O
5 O
' O
flanking O
DNA O
of O
the O
15 O
- O
lox O
gene O
contains O
sequences O
which O
down O
- O
regulate O
its O
activity O
in O
a O
variety O
of O
non O
- O
erythroid O
cell O
lines O
but O
not O
in O
two O
erythroid O
cell O
lines O
. O

The O
element O
has O
characteristics O
of O
a O
transcriptional O
' O
silencer O
' O
since O
it O
functions O
in O
both O
orientations O
. O

The O
main O
activity O
of O
the O
silencer O
has O
been O
mapped O
to O
the O
first O
900 O
bp O
of O
5 O
' O
flanking O
DNA O
, O
which O
contains O
nine O
binding O
sites O
for O
a O
nuclear B-protein
factor I-protein
present O
in O
non O
- O
erythroid O
cells O
but O
not O
in O
erythroid O
cells O
. O

These O
binding O
sites O
have O
similar O
sequences O
and O
multiple O
copies O
of O
the O
binding O
sites O
confer O
tissue O
- O
specific O
down O
- O
regulation O
when O
attached O
to O
a O
minimal O
lox O
promoter O
fragment O
. O

The O
5 O
' O
flanking O
DNA O
also O
contains O
a O
cluster O
of O
three O
binding O
sites O
for O
the O
GATA B-protein
family I-protein
of O
transcription B-protein
factors I-protein
. O

Phosphorylation O
of O
the O
transcription B-protein
factor I-protein
NFATp B-protein
inhibits O
its O
DNA O
binding O
activity O
in O
cyclosporin O
A O
- O
treated O
human O
B O
and O
T O
cells O
. O

Cyclosporin O
A O
( O
CsA O
) O
exerts O
its O
immunosuppressive O
effect O
by O
inhibiting O
the O
activity O
of O
nuclear B-protein
factor I-protein
of O
activated O
T O
cells O
( O
NFAT B-protein
) O
, O
thus O
preventing O
transcriptional O
induction O
of O
several O
cytokine O
genes O
. O

This O
effect O
is O
thought O
to O
be O
largely O
mediated O
through O
inactivation O
of O
the O
phosphatase O
calcineurin B-protein
, O
which O
in O
turn O
inhibits O
translocation O
of O
an O
NFAT B-protein
component O
to O
the O
nucleus O
. O

Here O
we O
report O
that O
CsA O
treatment O
of O
Raji O
B O
and O
Jurkat O
T O
cell O
lines O
yields O
a O
phosphorylated O
form O
of O
NFATp B-protein
that O
is O
inhibited O
in O
DNA O
- O
binding O
and O
in O
its O
ability O
to O
form O
an O
NFAT B-protein
complex I-protein
with O
Fos B-protein
and O
Jun B-protein
. O

Immunoblot O
analyses O
and O
metabolic O
labeling O
with O
[ O
32P O
] O
orthophosphate O
show O
that O
CsA O
alters O
NFATp B-protein
migration O
on O
SDS O
- O
polyacrylamide O
gel O
electrophoresis O
by O
increasing O
its O
phosphorylation O
level O
without O
affecting O
subcellular O
distribution O
. O

Dephosphorylation O
by O
in O
vitro O
treatment O
with O
calcineurin B-protein
or O
alkaline B-protein
phosphatase I-protein
restores O
NFATp B-protein
DNA O
binding O
activity O
and O
its O
ability O
to O
reconstitute O
an O
NFAT B-protein
complex I-protein
with O
Fos B-protein
and O
Jun B-protein
proteins O
. O

These O
data O
point O
to O
a O
new O
mechanism O
for O
CsA O
- O
sensitive O
regulation O
of O
NFATp B-protein
in O
which O
dephosphorylation O
is O
critical O
for O
DNA O
binding O
. O

Transcription B-protein
factors I-protein
as O
targets O
for O
oxidative O
signalling O
during O
lymphocyte O
activation O
. O

We O
previously O
have O
demonstrated O
a O
requirement O
for O
oxidative O
events O
during O
cell O
cycle O
entry O
in O
T O
lymphocytes O
and O
have O
hypothesised O
that O
reactive O
oxygen O
species O
may O
act O
as O
intracellular O
signalling O
agents O
during O
lymphocyte O
activation O
. O

In O
the O
current O
study O
, O
cysteamine O
, O
an O
aminothiol O
compound O
with O
antioxidant O
activity O
, O
has O
been O
used O
to O
further O
investigate O
the O
role O
of O
oxidative O
signalling O
during O
lymphocyte O
activation O
. O

Treatment O
of O
normal O
human O
peripheral O
blood O
lymphocytes O
with O
cysteamine O
in O
vitro O
was O
found O
to O
inhibit O
proliferation O
in O
a O
dose O
- O
dependent O
manner O
, O
with O
essentially O
complete O
inhibition O
occurring O
at O
a O
dose O
of O
400 O
microM O
. O

This O
inhibitory O
effect O
was O
limited O
to O
the O
first O
2 O
h O
after O
mitogenic O
activation O
, O
localizing O
the O
time O
- O
frame O
of O
action O
of O
cysteamine O
to O
within O
the O
commitment O
period O
. O

It O
therefore O
was O
of O
interest O
to O
establish O
which O
, O
if O
any O
, O
commitment O
events O
were O
affected O
by O
oxidative O
signalling O
during O
cell O
cycle O
entry O
. O

Taking O
the O
IL B-protein
- I-protein
2 I-protein
gene O
as O
a O
candidate O
, O
we O
examined O
the O
effect O
of O
cysteamine O
treatment O
on O
early O
gene O
expression O
during O
lymphocyte O
activation O
, O
and O
on O
the O
activity O
of O
transcription B-protein
factors I-protein
AP B-protein
- I-protein
1 I-protein
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
NF B-protein
- I-protein
AT I-protein
and O
Oct1 B-protein
, O
whose O
functions O
are O
required O
for O
expression O
of O
the O
IL B-protein
- I-protein
2 I-protein
mRNA O
. O

Cysteamine O
treatment O
inhibited O
both O
expression O
of O
the O
IL B-protein
- I-protein
2 I-protein
mRNA O
and O
secretion O
of O
IL B-protein
- I-protein
2 I-protein
into O
the O
culture O
medium O
. O

The O
inhibitory O
effect O
of O
cysteamine O
may O
be O
mediated O
at O
least O
in O
part O
by O
an O
effect O
on O
transcription B-protein
factor I-protein
function O
, O
as O
the O
DNA O
binding O
activities O
of O
AP B-protein
- I-protein
1 I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
extracted O
from O
mitogen O
- O
stimulated O
cells O
were O
significantly O
inhibited O
by O
cysteamine O
treatment O
. O

Interestingly O
, O
Oct1 O
and O
NF O
- O
AT O
DNA O
binding O
activity O
were O
not O
affected O
by O
cysteamine O
treatment O
, O
suggesting O
that O
oxidative O
signalling O
processes O
operate O
in O
a O
selective O
manner O
. O

The O
identification O
of O
regulatory B-protein
proteins I-protein
, O
such O
as O
transcription B-protein
factors I-protein
, O
as O
molecular O
targets O
for O
oxidative O
signalling O
provides O
further O
evidence O
to O
implicate O
oxidative O
signalling O
as O
being O
intimately O
involved O
in O
the O
G0 O
to O
G1 O
phase O
transition O
in O
T O
lymphocytes O
. O

Sex O
and O
age O
distribution O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptors I-protein
in O
peripheral O
blood O
mononuclear O
cells O
from O
normal O
human O
subjects O
. O

Specific O
receptors O
for O
1 O
, O
25 O
Dihydroxyvitamin O
D3 O
have O
been O
described O
in O
human O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
. O

We O
have O
tried O
to O
find O
out O
whether O
these O
receptors O
could O
show O
any O
difference O
in O
sex O
or O
age O
distribution O
. O

Twenty O
two O
healthy O
men O
aged O
21 O
- O
66 O
yr O
( O
mean O
+ O
/ O
- O
SD O
41 O
. O
0 O
+ O
/ O
- O
13 O
. O
6 O
) O
and O
nineteen O
healthy O
women O
aged O
22 O
- O
60 O
yr O
( O
38 O
. O
9 O
+ O
/ O
- O
13 O
. O
9 O
) O
have O
been O
studied O
. O

The O
mean O
dissociation O
constant O
( O
Kd O
) O
was O
similar O
in O
both O
sexes O
( O
1 O
. O
35 O
+ O
/ O
- O
0 O
. O
70 O
x O
10 O
( O
- O
10 O
) O
M O
in O
males O
, O
1 O
. O
13 O
+ O
/ O
- O
0 O
. O
66 O
x O
10 O
( O
- O
10 O
) O
M O
in O
females O
) O
, O
but O
the O
concentration O
of O
binding O
sites O
( O
Nmax O
) O
was O
significantly O
lower O
in O
females O
( O
2 O
. O
32 O
+ O
/ O
- O
0 O
. O
92 O
fmol O
/ O
10 O
( O
7 O
) O
PBMC O
vs O
4 O
. O
43 O
+ O
/ O
- O
1 O
. O
38 O
fmol O
/ O
10 O
( O
7 O
) O
PBMC O
in O
males O
; O
p O
= O
0 O
. O
0001 O
) O
. O

Neither O
Kd O
nor O
Nmax O
were O
significantly O
correlated O
with O
age O
. O

No O
difference O
was O
found O
between O
pre O
and O
postmenopausal O
women O
. O

Further O
studies O
are O
needed O
to O
elucidate O
if O
this O
sex O
difference O
in O
PBMC B-protein
receptors I-protein
for O
1 O
. O
25 O
Dihydroxyvitamin O
D3 O
is O
of O
any O
pathophysiological O
relevance O
. O

Expression O
of O
Id2 O
and O
Id3 O
mRNA O
in O
human O
lymphocytes O
. O

Helix B-protein
- I-protein
loop I-protein
- I-protein
helix I-protein
( I-protein
HLH I-protein
) I-protein
transcription I-protein
factors I-protein
are O
involved O
in O
cellular O
growth O
and O
differentiation O
. O

The O
Id B-protein
( O
inhibitor O
of O
DNA O
binding O
and O
differentiation O
) O
HLH B-protein
proteins I-protein
, O
in O
a O
dominantly O
negative O
fashion O
, O
regulate O
transcriptional O
activities O
of O
basic B-protein
HLH I-protein
proteins I-protein
. O

We O
examined O
by O
northern O
hybridization O
the O
expression O
of O
Id2 O
and O
Id3 O
mRNA O
in O
human O
leukemia O
/ O
lymphoma O
lines O
and O
patient O
samples O
, O
as O
well O
as O
resting O
and O
activated O
normal O
human O
lymphocytes O
from O
peripheral O
blood O
( O
PBL O
) O
. O

The O
Id2 B-protein
mRNA O
was O
abundantly O
expressed O
in O
5 O
/ O
12 O
T O
- O
cell O
and O
3 O
/ O
4 O
B O
- O
cell O
lines O
, O
and O
Id3 B-protein
mRNA O
was O
detected O
in O
4 O
/ O
12 O
T O
- O
cell O
and O
3 O
/ O
4 O
B O
- O
cell O
lines O
. O

Interestingly O
, O
Id2 B-protein
, O
but O
not O
Id3 B-protein
, O
mRNA O
was O
strongly O
expressed O
in O
4 O
/ O
5 O
T O
- O
cell O
lines O
infected O
with O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
( O
ATL O
- O
1k O
, O
MT O
- O
2 O
, O
S O
- O
LB1 O
) O
and O
type O
II O
( O
Mo O
) O
. O

Another O
unexpected O
finding O
was O
that O
T O
- O
cell O
leukemias O
and O
T O
- O
cell O
lines O
often O
expressed O
either O
Id2 B-protein
or O
Id3 B-protein
mRNA O
. O

In O
addition O
, O
resting O
PBL O
constitutively O
expressed O
prominent O
levels O
of O
Id2 B-protein
mRNA O
, O
but O
not O
Id3 B-protein
mRNA O
. O

Upon O
PHA B-protein
- O
stimulation O
, O
Id2 B-protein
expression O
decreased O
and O
Id3 B-protein
levels O
increased O
with O
biphasic O
kinetics O
. O

Taken O
together O
, O
our O
studies O
revealed O
three O
unexpected O
findings O
which O
require O
further O
analysis O
: O
( O
1 O
) O
expression O
of O
Id2 B-protein
mRNA O
is O
often O
associated O
with O
lymphocytic O
transformation O
by O
HTLV O
- O
I O
or O
- O
II O
; O
( O
2 O
) O
T O
- O
cells O
usually O
express O
either O
Id2 B-protein
or O
Id3 B-protein
mRNA O
, O
but O
B O
- O
cells O
often O
express O
both O
simultaneously O
; O
( O
3 O
) O
non O
- O
dividing O
, O
normal O
PBL O
express O
high O
levels O
of O
Id2 B-protein
and O
no O
Id3 B-protein
mRNA O
; O
and O
with O
the O
onset O
of O
cellular O
proliferation O
, O
levels O
of O
Id2 B-protein
mRNA O
decrease O
while O
levels O
of O
Id3 B-protein
mRNA O
increase O
, O
suggesting O
that O
regulation O
of O
expression O
of O
these O
closely O
related O
genes O
is O
disparate O
. O

Salicylates O
inhibit O
lipopolysaccharide O
- O
induced O
transcriptional O
activation O
of O
the O
tissue O
factor O
gene O
in O
human O
monocytic O
cells O
. O

Binding O
of O
plasma B-protein
Factor I-protein
VII I-protein
/ I-protein
VIIa I-protein
to O
the O
tissue B-protein
factor I-protein
( I-protein
TF I-protein
) I-protein
receptor I-protein
initiates O
the O
coagulation B-protein
protease I-protein
cascades O
. O

TF O
expression O
by O
circulating O
monocytes O
is O
associated O
with O
thrombotic O
and O
inflammatory O
complications O
in O
a O
variety O
of O
diseases O
. O

Transcriptional O
activation O
of O
the O
human O
TF O
gene O
in O
monocytic O
cells O
exposed O
to O
bacterial O
lipopolysaccharide O
( O
LPS O
) O
is O
mediated O
by O
binding O
of O
c B-protein
- I-protein
Rel I-protein
/ I-protein
p65 I-protein
heterodimers I-protein
to O
a O
kappa O
B O
site O
in O
the O
TF O
promoter O
. O

Here O
, O
we O
report O
that O
a O
family O
of O
anti O
- O
inflammatory O
agents O
, O
known O
as O
the O
salicylates O
, O
inhibited O
LPS O
induction O
of O
TF O
activity O
and O
TF O
gene O
transcription O
in O
human O
monocytes O
and O
monocytic O
THP O
- O
1 O
cells O
at O
clinically O
relevant O
doses O
. O

Furthermore O
, O
sodium O
salicylate O
blocked O
the O
LPS O
- O
induced O
proteolytic O
degradation O
of O
I B-protein
kappa I-protein
B I-protein
alpha I-protein
, O
which O
prevented O
the O
nuclear O
translocation O
of O
c B-protein
- I-protein
Rel I-protein
/ I-protein
p65 I-protein
heterodimers I-protein
. O

In O
contrast O
, O
two O
other O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
, O
ibuprofen O
and O
indomethacin O
, O
did O
not O
inhibit O
LPS O
induction O
of O
the O
TF O
gene O
. O

These O
results O
indicated O
that O
salicylates O
inhibited O
LPS O
induction O
of O
TF O
gene O
transcription O
in O
monocytic O
cells O
by O
preventing O
nuclear O
translocation O
of O
c B-protein
- I-protein
Rel I-protein
/ I-protein
p65 I-protein
heterodimers I-protein
. O

The O
clinical O
benefits O
of O
salicylates O
in O
the O
treatment O
of O
several O
diseases O
, O
including O
atherosclerosis O
and O
rheumatoid O
arthritis O
, O
may O
be O
related O
to O
their O
ability O
to O
reduce O
monocyte O
gene O
expression O
. O

Activation O
of O
the O
signal O
transducer O
and O
transcription O
( O
STAT B-protein
) O
signaling O
pathway O
in O
a O
primary O
T O
cell O
response O
. O

Critical O
role O
for O
IL B-protein
- I-protein
6 I-protein
. O

The O
T O
cell O
activation O
is O
initiated O
by O
interaction O
of O
specific O
Ags B-protein
with O
TCR B-protein
, O
followed O
by O
activation O
of O
intracellular O
biochemical O
events O
leading O
to O
activation O
of O
several O
genes O
. O

The O
activation O
of O
signal O
transducer O
and O
activator O
of O
transcription B-protein
( I-protein
STAT I-protein
) I-protein
proteins I-protein
in O
a O
primary O
TCR B-protein
- O
mediated O
activation O
of O
T O
cells O
have O
been O
explored O
. O

In O
purified O
human O
peripheral O
blood O
T O
cells O
, O
nuclear B-protein
STAT I-protein
proteins I-protein
were O
activated O
approximately O
3 O
h O
after O
activation O
by O
cross O
- O
linked O
anti B-protein
- I-protein
CD3 I-protein
Abs I-protein
. O

These O
STAT B-protein
proteins I-protein
were O
detected O
by O
using O
the O
IFN O
- O
gamma O
- O
activated O
sequence O
( O
GAS O
) O
and O
related O
oligonucleotides O
as O
probes O
in O
electrophoretic O
mobility O
shift O
assay O
. O

Analysis O
of O
the O
nuclear O
extracts O
with O
anti B-protein
- I-protein
STAT I-protein
Abs I-protein
indicated O
that O
they O
contained O
STAT B-protein
- I-protein
3 I-protein
and O
additional O
proteins O
crossreactive O
with O
the O
STAT B-protein
family I-protein
. O

The O
induction O
of O
STAT B-protein
activity O
was O
inhibited O
completely O
by O
pretreatment O
with O
either O
cycloheximide O
or O
cyclosporin O
A O
, O
thus O
indicating O
that O
the O
induction O
was O
due O
to O
a O
secondary B-protein
factor I-protein
produced O
by O
the O
activated O
T O
cells O
. O

As O
neutralizing B-protein
anti I-protein
- I-protein
IL I-protein
- I-protein
6 I-protein
Abs I-protein
effectively O
down O
- O
regulated O
the O
early O
induction O
of O
STAT B-protein
proteins I-protein
and O
as O
exogenously O
added O
IL B-protein
- I-protein
6 I-protein
rapidly O
activated O
DNA O
binding O
similar O
to O
TCR B-protein
- O
mediated O
bindings O
, O
it O
can O
be O
concluded O
that O
IL B-protein
- I-protein
6 I-protein
is O
the O
factor O
responsible O
for O
the O
activation O
of O
STAT B-protein
proteins I-protein
in O
a O
primary O
T O
cell O
response O
. O

The O
normal O
cell O
cycle O
activation O
program O
is O
exploited O
during O
the O
infection O
of O
quiescent O
B O
lymphocytes O
by O
Epstein O
- O
Barr O
virus O
. O

B O
lymphocytes O
in O
the O
peripheral O
circulation O
are O
maintained O
in O
a O
non O
- O
proliferative O
state O
. O

Antigen O
recognition O
stimulates O
limited O
proliferation O
, O
whereas O
infection O
with O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
results O
in O
continual O
proliferation O
and O
the O
outgrowth O
of O
immortal O
cell O
lines O
. O

Because O
it O
is O
not O
clear O
at O
which O
point O
in O
cell O
cycle O
the O
peripheral O
B O
lymphocytes O
are O
arrested O
, O
we O
characterized O
the O
expression O
of O
several O
cell O
cycle O
- O
associated O
genes O
in O
quiescent O
and O
stimulated O
cells O
. O

We O
show O
that O
the O
expression O
of O
four O
cell O
genes O
, O
cdc O
- O
2 O
, O
cyclin O
E O
, O
CD23 O
, O
and O
cyclin O
D2 O
, O
are O
up O
- O
regulated O
approximately O
100 O
- O
fold O
as O
a O
result O
of O
EBV O
- O
mediated O
immortalization O
. O

Because O
these O
genes O
play O
a O
positive O
role O
in O
cell O
proliferation O
, O
we O
suggest O
that O
this O
regulatory O
switch O
contributes O
to O
controlling O
entry O
into O
the O
cell O
cycle O
. O

Transient O
stimulation O
of O
quiescent O
B O
lymphocytes O
with O
either O
a O
cocktail O
of O
anti B-protein
- I-protein
CD40 I-protein
, O
anti B-protein
- I-protein
IgM I-protein
, O
and O
IL4 B-protein
, O
or O
EBV O
results O
in O
the O
rapid O
expression O
of O
the O
same O
four O
genes O
, O
suggesting O
that O
, O
after O
infection O
, O
EBV O
exploits O
the O
normal O
program O
of O
B O
- O
lymphocyte O
cell O
cycle O
activation O
. O

Expression O
of O
the O
chemokine B-protein
receptor I-protein
BLR2 B-protein
/ I-protein
EBI1 I-protein
is O
specifically O
transactivated O
by O
Epstein B-protein
- I-protein
Barr I-protein
virus I-protein
nuclear I-protein
antigen I-protein
2 I-protein
. O

In O
our O
attempt O
to O
identify O
chemokine B-protein
receptors I-protein
that O
are O
related O
to O
Burkitt B-protein
' I-protein
s I-protein
lymphoma I-protein
receptor I-protein
1 I-protein
( O
BLR1 B-protein
) O
and O
are O
expressed O
in O
activated O
lymphocytes O
we O
used O
RT O
- O
PCR O
resulting O
in O
the O
isolation O
of O
a O
cDNA O
encoding O
a O
seven B-protein
transmembrane I-protein
receptor I-protein
termed O
BLR2 B-protein
. O

The O
protein O
shows O
significant O
sequence O
similarities O
to O
the O
family O
of O
G B-protein
- I-protein
protein I-protein
coupled O
chemokine B-protein
receptors I-protein
and O
turned O
out O
to O
be O
identical O
to O
the O
recently O
described O
receptor B-protein
EBI1 I-protein
. O

Northern O
blot O
analysis O
revealed O
that O
BLR2 B-protein
mRNA O
could O
be O
highly O
stimulated O
in O
mitogen O
- O
and O
anti O
- O
CD3 O
- O
treated O
peripheral O
blood O
lymphocytes O
. O

BLR2 B-protein
- O
specific O
mRNA O
could O
be O
detected O
in O
all O
Epstein O
- O
Barr O
virus O
positive O
B O
cell O
lines O
. O

We O
show O
that O
transcription O
of O
the O
BLR2 B-protein
gene O
could O
be O
specifically O
induced O
in O
Epstein O
- O
Barr O
virus O
negative O
BL O
41 O
cells O
via O
estrogen O
- O
mediated O
activation O
of O
Epstein B-protein
- I-protein
Barr I-protein
virus I-protein
nuclear I-protein
antigen I-protein
2 I-protein
, O
a O
key O
regulator O
of O
viral O
and O
cellular O
genes O
in O
immortalized O
B O
cells O
. O

Our O
data O
suggest O
an O
involvement O
of O
BLR2 B-protein
in O
the O
regulation O
of O
migration O
in O
activated O
lymphocytes O
and O
in O
viral O
pathogenesis O
. O

A O
central O
role O
for O
a O
single O
c O
- O
Myb O
binding O
site O
in O
a O
thymic O
locus O
control O
region O
. O

Locus O
control O
regions O
( O
LCRs O
) O
are O
powerful O
assemblies O
of O
cis O
elements O
that O
organize O
the O
actions O
of O
cell B-protein
- I-protein
type I-protein
- I-protein
specific I-protein
trans I-protein
- I-protein
acting I-protein
factors I-protein
. O

A O
2 B-protein
. I-protein
3 I-protein
- I-protein
kb I-protein
LCR I-protein
in O
the O
human O
adenosine O
deaminase O
( O
ADA O
) O
gene O
first O
intron O
, O
which O
controls O
expression O
in O
thymocytes O
, O
is O
composed O
of O
a O
200 O
- O
bp O
enhancer O
domain O
and O
extended O
flanking O
sequences O
that O
facilitate O
activation O
from O
within O
chromatin O
. O

Prior O
analyses O
have O
demonstrated O
that O
the O
enhancer O
contains O
a O
28 O
- O
bp O
core O
region O
and O
local O
adjacent O
augmentative O
cis O
elements O
. O

We O
now O
show O
that O
the O
core O
contains O
a O
single O
critical O
c O
- O
Myb O
binding O
site O
. O

In O
both O
transiently O
cotransfected O
human O
cells O
and O
stable O
chromatin O
- O
integrated O
yeast O
cells O
, O
c B-protein
- I-protein
Myb I-protein
strongly O
transactivated O
reporter O
constructs O
that O
contained O
polymerized O
core O
sequences O
. O

c B-protein
- I-protein
Myb I-protein
protein I-protein
was O
strongly O
evident O
in O
T O
lymphoblasts O
in O
which O
the O
enhancer O
was O
active O
and O
was O
localized O
within O
discrete O
nuclear O
structures O
. O

Fetal O
murine O
thymus O
exhibited O
a O
striking O
concordance O
of O
endogenous O
c O
- O
myb O
expression O
with O
that O
of O
mouse O
ADA O
and O
human O
ADA O
LCR O
- O
directed O
transgene O
expression O
. O

Point O
mutation O
of O
the O
c B-protein
- I-protein
Myb I-protein
site O
within O
the O
intact O
2 B-protein
. I-protein
3 I-protein
- I-protein
kb I-protein
LCR I-protein
severely O
attenuated O
enhancer O
activity O
in O
transfections O
and O
LCR O
activity O
in O
transgenic O
thymocytes O
. O

Within O
the O
context O
of O
a O
complex O
enhancer O
and O
LCR O
, O
c B-protein
- I-protein
Myb I-protein
can O
act O
as O
an O
organizer O
of O
thymocyte O
- O
specific O
gene O
expression O
via O
a O
single O
binding O
site O
. O

A O
regulatory O
element O
in O
the O
human O
interleukin O
2 O
gene O
promoter O
is O
a O
binding O
site O
for O
the O
zinc B-protein
finger I-protein
proteins I-protein
Sp1 B-protein
and O
EGR B-protein
- I-protein
1 I-protein
. O

Activation O
of O
the O
interleukin B-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
gene O
after O
antigen O
recognition O
is O
a O
critical O
event O
for O
T O
cell O
proliferation O
and O
effector O
function O
. O

Prior O
studies O
have O
identified O
several O
transcription B-protein
factors I-protein
that O
contribute O
to O
the O
activity O
of O
the O
IL B-protein
- I-protein
2 I-protein
promoter O
in O
stimulated O
T O
lymphocytes O
. O

Here O
we O
describe O
a O
novel O
regulatory O
element O
within O
the O
IL O
- O
2 O
promoter O
located O
immediately O
upstream O
of O
the O
nuclear B-protein
factor I-protein
of I-protein
activated I-protein
T I-protein
cell I-protein
( O
NFAT B-protein
) O
domain O
. O

This O
region O
( O
termed O
the O
zinc O
finger O
protein O
binding O
region O
( O
ZIP O
) O
) O
serves O
as O
binding O
site O
for O
two O
differently O
regulated O
zinc B-protein
finger I-protein
proteins I-protein
: O
the O
constitutively B-protein
expressed I-protein
transcription I-protein
factor I-protein
Sp1 B-protein
and O
the O
inducible B-protein
early I-protein
growth I-protein
response I-protein
protein I-protein
EGR B-protein
- I-protein
1 I-protein
. O

In O
unstimulated O
cells O
which O
do O
not O
secrete O
IL B-protein
- I-protein
2 I-protein
, O
only O
Sp1 B-protein
binds O
to O
this O
region O
, O
while O
in O
stimulated O
IL B-protein
- I-protein
2 I-protein
secreting O
cells O
the O
inducible B-protein
EGR I-protein
- I-protein
1 I-protein
protein I-protein
recognizes O
this O
element O
. O

In O
Jurkat O
T O
cells O
, O
the O
ZIP O
site O
serves O
as O
an O
activator O
for O
IL B-protein
- I-protein
2 I-protein
gene O
expression O
, O
and O
a O
combination O
of O
ZIP O
and O
NFAT B-protein
binding O
sites O
is O
required O
for O
maximal O
IL B-protein
- I-protein
2 I-protein
promoter O
activity O
. O

These O
results O
suggest O
a O
critical O
role O
of O
the O
ZIP O
site O
for O
IL B-protein
- I-protein
2 I-protein
promoter O
activity O
. O

Activation O
of O
the O
HIV O
- O
1 O
enhancer O
by O
the O
LEF B-protein
- I-protein
1 I-protein
HMG I-protein
protein I-protein
on O
nucleosome O
- O
assembled O
DNA O
in O
vitro O
. O

Lymphoid B-protein
enhancer I-protein
- I-protein
binding I-protein
factor I-protein
1 I-protein
( O
LEF B-protein
- I-protein
1 I-protein
) O
is O
a O
regulatory B-protein
high I-protein
mobility I-protein
group I-protein
( I-protein
HMG I-protein
) I-protein
protein I-protein
that O
activates O
the O
T B-protein
cell I-protein
receptor I-protein
alpha I-protein
( O
TCR B-protein
alpha I-protein
) O
enhancer O
in O
a O
context O
- O
restricted O
manner O
in O
T O
cells O
. O

In O
this O
paper O
we O
demonstrate O
that O
the O
distal O
region O
of O
the O
human O
immunodeficiency O
virus O
- O
1 O
( O
HIV O
- O
1 O
) O
enhancer O
, O
which O
contains O
DNA O
- O
binding O
sites O
for O
LEF B-protein
- I-protein
1 I-protein
and O
Ets O
- O
1 O
, O
also O
provides O
a O
functional O
context O
for O
activation O
by O
LEF B-protein
- I-protein
1 I-protein
. O

First O
, O
we O
show O
that O
mutations O
in O
the O
LEF B-protein
- I-protein
1 I-protein
- O
binding O
site O
inhibit O
the O
activity O
of O
multimerized O
copies O
of O
the O
HIV O
- O
1 O
enhancer O
in O
Jurkat O
T O
cells O
, O
and O
that O
LEF B-protein
- I-protein
1 I-protein
/ I-protein
GAL4 I-protein
can O
activate O
a O
GAL4 O
- O
substituted O
HIV O
- O
1 O
enhancer O
80 O
- O
to O
100 O
- O
fold O
in O
vivo O
. O

Second O
, O
recombinant B-protein
LEF I-protein
- I-protein
1 I-protein
is O
shown O
to O
activate O
HIV O
- O
1 O
transcription O
on O
chromatin O
- O
assembled O
DNA O
in O
vitro O
. O

By O
using O
a O
nucleosome B-protein
- O
assembly O
system O
derived O
from O
Drosophila O
embryos O
, O
we O
find O
that O
the O
packaging O
of O
DNA O
into O
chromatin O
in O
vitro O
strongly O
represses O
HIV O
- O
1 O
transcription O
and O
that O
repression O
can O
be O
counteracted O
efficiently O
by O
preincubation O
of O
the O
DNA O
with O
LEF B-protein
- I-protein
1 I-protein
( O
or O
LEF B-protein
- I-protein
1 I-protein
and O
Ets B-protein
- I-protein
1 I-protein
) O
supplemented O
with O
fractions O
containing O
the O
promoter B-protein
- I-protein
binding I-protein
protein I-protein
, O
Sp1 B-protein
. O

Addition O
of O
TFE B-protein
- I-protein
3 I-protein
, O
which O
binds O
to O
an O
E O
- O
box O
motif O
upstream O
of O
the O
LEF O
- O
1 O
and O
Ets O
- O
1 O
sites O
, O
further O
augments O
transcription O
in O
this O
system O
. O

Individually O
or O
collectively O
, O
none O
of O
the O
three O
enhancer B-protein
- I-protein
binding I-protein
proteins I-protein
( O
LEF B-protein
- I-protein
1 I-protein
, O
Ets B-protein
- I-protein
1 I-protein
, O
and O
TFE B-protein
- I-protein
3 I-protein
) O
could O
activate O
transcription O
in O
the O
absence O
of O
Sp1 B-protein
. O

A O
truncation B-protein
mutant I-protein
of O
LEF B-protein
- I-protein
1 I-protein
( O
HMG B-protein
- I-protein
88 I-protein
) O
, O
which O
contains O
the O
HMG B-protein
box I-protein
but O
lacks O
the O
trans B-protein
- I-protein
activation I-protein
domain I-protein
, O
did O
not O
activate O
transcription O
from O
nucleosomal O
DNA O
, O
indicating O
that O
bending O
of O
DNA O
by O
the O
HMG B-protein
domain I-protein
is O
not O
sufficient O
to O
activate O
transcription O
in O
vitro O
. O

We O
conclude O
that O
transcription O
activation O
by O
LEF B-protein
- I-protein
1 I-protein
in O
vitro O
is O
a O
chromatin O
- O
dependent O
process O
that O
requires O
a O
functional O
trans B-protein
- I-protein
activation I-protein
domain I-protein
in O
addition O
to O
the O
HMG B-protein
domain I-protein
. O

HIV B-protein
- I-protein
1 I-protein
envelope I-protein
glycoproteins I-protein
induce O
activation O
of O
activated O
protein B-protein
- I-protein
1 I-protein
in O
CD4 O
+ O
T O
cells O
[ O
published O
erratum O
appears O
in O
J O
Biol O
Chem O
1995 O
Dec O
1 O
; O
270 O
( O
48 O
) O
: O
29038 O
] O
. O

Activation O
of O
CD4 O
positive O
T O
cells O
is O
a O
primary O
requirement O
for O
human O
immunodeficiency O
virus O
( O
HIV O
) O
entry O
, O
efficient O
HIV O
replication O
, O
and O
progression O
to O
AIDS O
, O
Utilizing O
CD4 O
positive O
T O
cell O
lines O
and O
purified O
T O
cells O
from O
normal O
individuals O
, O
we O
have O
demonstrated O
that O
native B-protein
envelope I-protein
glycoproteins I-protein
of O
HIV O
, O
gp B-protein
160 I-protein
, O
can O
induce O
activation O
of O
transcription B-protein
factor I-protein
, I-protein
activated I-protein
protein I-protein
- I-protein
1 I-protein
( O
AP B-protein
- I-protein
1 I-protein
) O
. O

The O
stimulatory O
effects O
of O
gp160 B-protein
are O
mediated O
through O
the O
CD4 B-protein
molecule I-protein
, O
since O
treatment O
of O
gp160 B-protein
with O
soluble O
CD4 B-protein
- I-protein
IgG I-protein
abrogates O
its O
activity O
, O
and O
CD4 O
negative O
T O
cell O
lines O
fail O
to O
be O
stimulated O
with O
gp160 B-protein
. O

Immunoprecipitation O
of O
the O
gp B-protein
160 I-protein
- O
induced O
nuclear O
extracts O
with O
polyclonal B-protein
antibodies I-protein
to O
Fos B-protein
and O
Jun B-protein
proteins I-protein
indicates O
that O
AP B-protein
- I-protein
1 I-protein
complex I-protein
is O
comprised O
of O
members O
of O
these O
family O
of O
proteins O
. O

The O
gp160 B-protein
- I-protein
induced I-protein
AP I-protein
- I-protein
1 I-protein
complex I-protein
is O
dependent O
upon O
protein O
tyrosine O
phosphorylation O
and O
is O
protein O
synthesis O
- O
independent O
. O

This O
stimulation O
can O
also O
be O
abolished O
by O
inhibitors O
of O
protein B-protein
kinase I-protein
C I-protein
, O
but O
it O
is O
unaffected O
by O
calcium O
channel O
blocker O
or O
cyclosporine O
A O
. O

This O
gp160 B-protein
treatment O
adversely O
affects O
the O
functional O
capabilities O
of O
T O
cells O
: O
pre O
- O
treatment O
of O
CD4 O
+ O
T O
cells O
with O
gp160 B-protein
for O
4 O
h O
at O
37 O
degrees O
C O
inhibited O
anti B-protein
- I-protein
CD3 I-protein
- O
induced O
interleukin B-protein
- I-protein
2 I-protein
secretion O
. O

Effects O
similar O
to O
gp160 B-protein
were O
seen O
with O
anti B-protein
- I-protein
CD4 I-protein
mAb I-protein
. O

The O
aberrant O
activation O
of O
AP B-protein
- I-protein
1 I-protein
by O
gp160 B-protein
in O
CD4 O
positive O
T O
cells O
could O
result O
in O
up O
- O
regulation O
of O
cytokines B-protein
containing O
AP B-protein
- I-protein
1 I-protein
sites O
, O
e O
. O
g O
. O
interleukin B-protein
- I-protein
3 I-protein
and O
granulocyte B-protein
macrophage I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
, O
and O
concurrently O
lead O
to O
T O
cell O
unresponsiveness O
by O
inhibiting O
interleukin B-protein
- I-protein
2 I-protein
secretion O
. O
